<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Cells</journal-id><journal-id journal-id-type="iso-abbrev">Cells</journal-id><journal-id journal-id-type="pmc-domain-id">2106</journal-id><journal-id journal-id-type="pmc-domain">cells</journal-id><journal-id journal-id-type="publisher-id">cells</journal-id><journal-title-group><journal-title>Cells</journal-title></journal-title-group><issn pub-type="epub">2073-4409</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7564019</article-id><article-id pub-id-type="pmcid-ver">PMC7564019.1</article-id><article-id pub-id-type="pmcaid">7564019</article-id><article-id pub-id-type="pmcaiid">7564019</article-id><article-id pub-id-type="pmid">32917034</article-id><article-id pub-id-type="doi">10.3390/cells9092061</article-id><article-id pub-id-type="publisher-id">cells-09-02061</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Nucleic Acid-Based Approaches for Tumor Therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3572-7205</contrib-id><name name-style="western"><surname>Hager</surname><given-names initials="S">Simone</given-names></name><xref ref-type="aff" rid="af1-cells-09-02061">1</xref><xref rid="c1-cells-09-02061" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fittler</surname><given-names initials="FJ">Frederic Julien</given-names></name><xref ref-type="aff" rid="af2-cells-09-02061">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8413-0934</contrib-id><name name-style="western"><surname>Wagner</surname><given-names initials="E">Ernst</given-names></name><xref ref-type="aff" rid="af1-cells-09-02061">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bros</surname><given-names initials="M">Matthias</given-names></name><xref ref-type="aff" rid="af2-cells-09-02061">2</xref><xref rid="c1-cells-09-02061" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-cells-09-02061"><label>1</label>Department of Chemistry and Pharmacy, Ludwig-Maximilians-University (LMU), 81377 Munich, Germany; <email>ernst.wagner@cup.uni-muenchen.de</email></aff><aff id="af2-cells-09-02061"><label>2</label>Department of Dermatology, University Medical Center, 55131 Mainz, Germany; <email>ffittler@students.uni-mainz.de</email></aff><author-notes><corresp id="c1-cells-09-02061"><label>*</label>Correspondence: <email>simone.hager@cup.uni-muenchen.de</email> (S.H.); <email>mbros@uni-mainz.de</email> (M.B.); Tel.: +49-89218077454 (S.H.); +49-6131179846 (M.B.)</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>9</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2020</year></pub-date><volume>9</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">367021</issue-id><elocation-id>2061</elocation-id><history><date date-type="received"><day>03</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>07</day><month>9</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>27</day><month>10</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-30 16:25:15.757"><day>30</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cells-09-02061.pdf"/><abstract><p>Within the last decade, the introduction of checkpoint inhibitors proposed to boost the patients&#8217; anti-tumor immune response has proven the efficacy of immunotherapeutic approaches for tumor therapy. Furthermore, especially in the context of the development of biocompatible, cell type targeting nano-carriers, nucleic acid-based drugs aimed to initiate and to enhance anti-tumor responses have come of age. This review intends to provide a comprehensive overview of the current state of the therapeutic use of nucleic acids for cancer treatment on various levels, comprising (i) mRNA and DNA-based vaccines to be expressed by antigen presenting cells evoking sustained anti-tumor T cell responses, (ii) molecular adjuvants, (iii) strategies to inhibit/reprogram tumor-induced regulatory immune cells e.g., by RNA interference (RNAi), (iv) genetically tailored T cells and natural killer cells to directly recognize tumor antigens, and (v) killing of tumor cells, and reprograming of constituents of the tumor microenvironment by gene transfer and RNAi. Aside from further improvements of individual nucleic acid-based drugs, the major perspective for successful cancer therapy will be combination treatments employing conventional regimens as well as immunotherapeutics like checkpoint inhibitors and nucleic acid-based drugs, each acting on several levels to adequately counter-act tumor immune evasion.</p></abstract><kwd-group><kwd>nucleic acids</kwd><kwd>nanoparticle</kwd><kwd>transgene</kwd><kwd>antigen</kwd><kwd>adjuvant</kwd><kwd>dendritic cell</kwd><kwd>tumor</kwd><kwd>immunotherapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-cells-09-02061"><title>1. Introduction</title><p>Cancer is a serious and life-threatening disease with increasing incidence in today&#8217;s world [<xref rid="B1-cells-09-02061" ref-type="bibr">1</xref>,<xref rid="B2-cells-09-02061" ref-type="bibr">2</xref>,<xref rid="B3-cells-09-02061" ref-type="bibr">3</xref>,<xref rid="B4-cells-09-02061" ref-type="bibr">4</xref>,<xref rid="B5-cells-09-02061" ref-type="bibr">5</xref>]. Depending on the tumor type, stage, and location, cancer therapy can be very challenging. Conventional treatments (surgery, chemotherapy, and irradiation) are often inefficient, resulting in recurrence and even death. The main reasons for therapy failure are chemoresistance as well as metastasis [<xref rid="B6-cells-09-02061" ref-type="bibr">6</xref>,<xref rid="B7-cells-09-02061" ref-type="bibr">7</xref>]. Moreover, the patients often suffer from severe side-effects [<xref rid="B8-cells-09-02061" ref-type="bibr">8</xref>]. In the last 20&#8211;30 years, however, cancer treatment regimens have changed remarkably, based on the gained knowledge about molecular biology as well as tumor pathobiology and pathophysiology [<xref rid="B9-cells-09-02061" ref-type="bibr">9</xref>,<xref rid="B10-cells-09-02061" ref-type="bibr">10</xref>,<xref rid="B11-cells-09-02061" ref-type="bibr">11</xref>]. As a consequence of a better understanding of the tumor as a heterogeneous tissue with different types of cells, new strategies for cancer therapy have been developed, which are also applicable in combination with classical therapies [<xref rid="B12-cells-09-02061" ref-type="bibr">12</xref>,<xref rid="B13-cells-09-02061" ref-type="bibr">13</xref>,<xref rid="B14-cells-09-02061" ref-type="bibr">14</xref>,<xref rid="B15-cells-09-02061" ref-type="bibr">15</xref>,<xref rid="B16-cells-09-02061" ref-type="bibr">16</xref>,<xref rid="B17-cells-09-02061" ref-type="bibr">17</xref>,<xref rid="B18-cells-09-02061" ref-type="bibr">18</xref>,<xref rid="B19-cells-09-02061" ref-type="bibr">19</xref>,<xref rid="B20-cells-09-02061" ref-type="bibr">20</xref>,<xref rid="B21-cells-09-02061" ref-type="bibr">21</xref>,<xref rid="B22-cells-09-02061" ref-type="bibr">22</xref>,<xref rid="B23-cells-09-02061" ref-type="bibr">23</xref>,<xref rid="B24-cells-09-02061" ref-type="bibr">24</xref>]. However, still only a limited number of patients respond to the already approved immunotherapies, and toxicity as well as induction of resistance towards treatment are often a problem [<xref rid="B25-cells-09-02061" ref-type="bibr">25</xref>,<xref rid="B26-cells-09-02061" ref-type="bibr">26</xref>,<xref rid="B27-cells-09-02061" ref-type="bibr">27</xref>,<xref rid="B28-cells-09-02061" ref-type="bibr">28</xref>,<xref rid="B29-cells-09-02061" ref-type="bibr">29</xref>]. Nanotechnology-based strategies, and in particular therapeutic nucleic acids, as well as combined immunotherapies may improve the therapeutic outcome in more patients for a broad range of tumors, even in late stage. In this regard, nucleic acid-based immunotherapeutic approaches have received growing interest [<xref rid="B24-cells-09-02061" ref-type="bibr">24</xref>,<xref rid="B30-cells-09-02061" ref-type="bibr">30</xref>,<xref rid="B31-cells-09-02061" ref-type="bibr">31</xref>].</p><p>This review aims to present a comprehensive overview of the current state of nucleic acid-based anti-tumor therapeutics, and associated optimization strategies. As depicted in <xref ref-type="fig" rid="cells-09-02061-f001">Figure 1</xref>, such strategies aim (i) to deliver tumor-related antigen plus adjuvant to antigen presenting cells (APC) like dendritic cells (DC) that induce tumor-specific immune responses, (ii) to either deplete or reprogram tumor-induced/expanded immunoregulatory cell types, especially regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC), which collectively inhibit the induction of adaptive immune reactions in the periphery, (iii) to generate tumor-specific T cells and natural killer (NK) cells by genetic introduction of synthetic antigen receptors, termed CARs (chimeric antigen receptors), and (iv) at the tumor site itself to yield direct tumor cell killing, and to inhibit the tumor-promoting function of the tumor microenvironment (TEM). It is worth mentioning that the first clinical trial ever using in vivo gene transfer was conducted by Nabel et al. in 1993 with an intratumorally applied liposomal formulation of immunotherapeutic DNA encoding for HLA (human leukocyte antigen)-B7 [<xref rid="B32-cells-09-02061" ref-type="bibr">32</xref>].</p></sec><sec id="sec2-cells-09-02061"><title>2. Nucleic Acid-Based Strategies to Induce Adaptive Anti-Tumor Responses</title><p>In the last decades, the potential to exploit the patients&#180; immune system to induce and shape anti-tumor responses has gained increasing interest [<xref rid="B33-cells-09-02061" ref-type="bibr">33</xref>]. The induction of tumor antigen-specific adaptive immune responses requires co-delivery of the antigen and of an immunostimulatory compound to evoke activation of a professional antigen presenting cell (APC) [<xref rid="B34-cells-09-02061" ref-type="bibr">34</xref>]. In this regard, DC that are considered the most potent APC population at stimulated state are in the focus of interest [<xref rid="B35-cells-09-02061" ref-type="bibr">35</xref>]. In conventional vaccination approaches, the antigen is applied as a peptide/protein in combination with a structurally different adjuvant that specifically triggers a danger receptor expressed by DC (and other APC) [<xref rid="B36-cells-09-02061" ref-type="bibr">36</xref>]. According vaccination approaches need to overcome several obstacles like (i) unwanted uncoupling of antigen and adjuvant in vivo, which may contribute to unwanted immune reactions, (ii) binding/uptake of the vaccine by non-APC, including regulatory immune cells like tumor-associated macrophages (TAM) and tumor-induced myeloid-derived suppressor cells (MDSC), which may result in the induction of tumor immune tolerance, and (iii) limited presentation of the exogenous antigen via major histocompatibility complex class I (MHCI), yielding limited activation of CD8<sup>+</sup> T cells, and thereby insufficient induction of cytotoxic tumor lymphocytes (CTL). As outlined in the following, nucleic acids encoding for antigens (plasmid DNA (pDNA) or mRNA) and nucleic acid-based adjuvants, especially when encapsulated in APC-targeting nanoparticles (NP), provide an interesting alternative to conventional vaccination approaches.</p><p>So far, nucleic acid-based vaccines have been delivered largely by intramuscular, intradermal, as well as subcutaneous injections, resulting in predominant transfection of myocytes [<xref rid="B37-cells-09-02061" ref-type="bibr">37</xref>] and keratinocytes [<xref rid="B38-cells-09-02061" ref-type="bibr">38</xref>], respectively. Whereas mRNA-based transgenes are expressed directly in the cytoplasm of the transfected cell [<xref rid="B39-cells-09-02061" ref-type="bibr">39</xref>], pDNA needs to translocate to the nucleus for transcription, followed by translation in the cytoplasm [<xref rid="B40-cells-09-02061" ref-type="bibr">40</xref>]. In case of intramuscular [<xref rid="B41-cells-09-02061" ref-type="bibr">41</xref>] as well as cutaneous [<xref rid="B42-cells-09-02061" ref-type="bibr">42</xref>] administration, directly transfected cells may express the antigen. Antigen may be transferred to regional APC by the release of exosomes [<xref rid="B43-cells-09-02061" ref-type="bibr">43</xref>] or apoptotic bodies [<xref rid="B44-cells-09-02061" ref-type="bibr">44</xref>]. In either case, antigen of exogenous origin is presented largely on MHCII, resulting in the activation of antigen-specific CD4<sup>+</sup> T helper cells (Th) [<xref rid="B45-cells-09-02061" ref-type="bibr">45</xref>]. Only subpopulations of DC are characterized by so-called cross priming activity, which means that antigen is shuttled/processed in such a manner that MHCI is loaded, resulting in CD8<sup>+</sup> T cell activation [<xref rid="B46-cells-09-02061" ref-type="bibr">46</xref>]. In case of direct APC transfection [<xref rid="B47-cells-09-02061" ref-type="bibr">47</xref>], the antigen is expressed and processed like an endogenous gene, resulting in parallel loading onto MHCI and MHCII molecules [<xref rid="B48-cells-09-02061" ref-type="bibr">48</xref>]. APC that are sufficiently stimulated by pathogen-derived molecular patterns (PAMP) or endogenous danger signals, mimicked by the adjuvant, upregulate expression of MHC molecules, of costimulators, and of soluble mediators (i.e., cytokines), and migrate into the secondary lymphoid organs (draining lymph nodes, spleen) to prime antigen-specific T cells [<xref rid="B49-cells-09-02061" ref-type="bibr">49</xref>]. Activated CD4<sup>+</sup> T cells are required for full activation of CD8<sup>+</sup> T cells to yield CTL [<xref rid="B50-cells-09-02061" ref-type="bibr">50</xref>], and to confer so-called B cell help [<xref rid="B51-cells-09-02061" ref-type="bibr">51</xref>]. Depending largely on the composition of cytokines released by activated APC, CD4<sup>+</sup> T cells polarize into various types of Th [<xref rid="B52-cells-09-02061" ref-type="bibr">52</xref>]. In case of tumor responses, the induction of Th1 cells, depending largely on IL-12, is paramount for CTL activation [<xref rid="B53-cells-09-02061" ref-type="bibr">53</xref>].</p><sec id="sec2dot1-cells-09-02061"><title>2.1. Clinical Trials Using Nucleic Acid-Based Vaccines for Tumor Therapy</title><sec id="sec2dot1dot1-cells-09-02061"><title>2.1.1. pDNA Vaccines</title><p>In an early clinical phase I trial, stage IV melanoma patients were intranodally infused with pDNA encoding for melanoma-associated tyrosinase every two weeks for a total of four times [<xref rid="B54-cells-09-02061" ref-type="bibr">54</xref>]. This trial confirmed tolerability of pDNA administration, and some activation of tyrosinase-specific T cells, but no clinical responses were observed. In subsequent clinical trials DC were differentiated in vitro from peripheral blood monocytes of patients using GM-CSF (granulocyte macrophage colony-stimulating factor) plus interleukin (IL)-4, pulsed with tumor lysate/proteins, matured, and reinfused [<xref rid="B55-cells-09-02061" ref-type="bibr">55</xref>]. In order to evaluate the suitability of nucleic acid-based vaccination, in a clinical phase I/II trial that enrolled stage IV melanoma patients, monocyte-derived DC were transfected in vitro with pDNA encoding melanoma-associated antigens melan A and gp100 using a cationic peptide for pDNA transfer, and chloroquine to promote endosomal escape, and were stimulated with TNF (tumor necrosis factor)-&#945; and IL-1&#946; [<xref rid="B56-cells-09-02061" ref-type="bibr">56</xref>]. Patients were vaccinated every three weeks for a total of three months. Whereas antigen-specific T cell responses were observed, the clinical response rate was only in the range of 10%, and not sustained. So far, similar results have been obtained in most clinical studies on APC-focused pDNA vaccination (tabulated in [<xref rid="B57-cells-09-02061" ref-type="bibr">57</xref>]).</p><p>Only a few clinical trials have demonstrated therapeutic efficacy of pDNA vaccination. In a clinical phase I/II study, patients with carcinoembryonic antigen (CEA)-positive tumors (in most cases colorectal cancer) were repetitively treated with a pDNA vaccine that encoded for a MHCI-restricted CEA-derived peptide fused to an immunostimulatory domain derived from tetanus toxin fragment C as an adjuvant by intramuscular injection for three months [<xref rid="B58-cells-09-02061" ref-type="bibr">58</xref>]. About half of the patients developed diarrhea due to a break in tolerance towards CEA, which is also expressed by colonic mucosa. The group of patients that developed autoimmunity showed a prolonged overall survival over the 16 months observation period.</p><p>Several reports have shown that combined treatment with a pDNA vaccine and a second drug exerted improved anti-tumor responses. In a clinical phase I trial, progression of metastatic prostate cancer was attenuated in more than half of the patients vaccinated for three months with a prostate acid phosphatase encoding pDNA plus recombinant GM-CSF as an adjuvant, co-applied intradermally, in combination with the programmed cell death protein (PD-)1 blocking antibody pembrolizumab [<xref rid="B59-cells-09-02061" ref-type="bibr">59</xref>]. This effect was not observed in case of sequential treatment with the antigen encoding vector/GM-CSF for three months followed by pembrolizumab application. In a phase IIB/III trial, treatment of non-small-cell lung cancer patients with a vaccinia virus encoding the tumor-associated antigen (TAA) Mucin-1, and IL-2 to stimulate T cells (TG4010) by repetitive subcutaneous injections yielded longer overall survival of patients upon co-treatment with first line chemotherapy (different drugs) as compared to patients that received chemotherapy only [<xref rid="B60-cells-09-02061" ref-type="bibr">60</xref>]. The efficacy of TG4010 in combination with checkpoint inhibitors is evaluated in ongoing phase II trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02823990">NCT02823990</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03353675">NCT03353675</ext-link>).</p><p>Due to the overall low efficacy of pDNA vaccination in clinical trials observed so far, pDNA vaccines need to be improved to yield stronger immunogenicity. In the following various parameters that are important for the optimization of the design of pDNA vaccines as well as their delivery are discussed.</p></sec><sec id="sec2dot1dot2-cells-09-02061"><title>2.1.2. mRNA Vaccines</title><p>Until a few years ago, mRNA-based anti-tumor vaccines were largely evaluated in clinical studies using patient-derived autologous DC electroporated in vitro with TAA-encoding mRNA either alone, in combination with adjuvant-encoding mRNA or followed by stimulation with soluble mediators, followed by intradermal administration. In most of these trials, adaptive antigen-specific immune responses were detectable, but only some reached clinical responses (the outcome of these clinical trials is listed in [<xref rid="B61-cells-09-02061" ref-type="bibr">61</xref>]).</p><p>In an early phase II clinical trial, acute myeloid leukemia patients were vaccinated by intradermal injection with autologous DC electroporated in vitro with mRNA, encoding Wilms&#180; tumor 1 (WT1) antigen in bi-weekly intervals for four cycles [<xref rid="B62-cells-09-02061" ref-type="bibr">62</xref>]. About a third of the patients displayed complete remission after more than a year after the first vaccination. Therapeutic efficacy of vaccination with WT1-mRNA transfected DC was increased by including the lysosomal targeting signal of lysosomal-associated membrane protein (LAMP) [<xref rid="B63-cells-09-02061" ref-type="bibr">63</xref>], which previously demonstrated to achieve improved loading of antigen onto MHCII [<xref rid="B64-cells-09-02061" ref-type="bibr">64</xref>]. Similar results were achieved in another clinical phase II trial on patients with acute myeloid leukemia (AML) using human telomerase reverse transcriptase (hTERT) encoding mRNA for ex vivo electroporation of DC, followed by intradermal application [<xref rid="B65-cells-09-02061" ref-type="bibr">65</xref>]. The hTERT expression unit was fused to a LAMP minigene. Transfected DC were applied weekly for six weeks, followed by bi-weekly application for another six rounds. Recurrence-free survival of accordingly treated patients was prolonged as compared to historical controls.</p><p>Therapeutic efficacy of ex vivo mRNA-vaccinated DC was also demonstrated for glioblastoma, applied after surgical removal of the major tumor mass, and in combination with more conventional treatment regimens. In a phase II clinical trial, autologous DC were electroporated ex vivo with mRNA derived from surgically removed glioblastoma, and were maturated with a cocktail of proinflammatory mediators prior to intradermal application [<xref rid="B66-cells-09-02061" ref-type="bibr">66</xref>]. DC were applied six weeks after surgery and combined radiotherapy/chemotherapy (temozolomide), twice in the first week, and once per month afterwards (up to 18 treatments). All patients received chemotherapy throughout the vaccination period. The group of DC-treated patients showed prolonged progression-free survival. Strongly improved progression-free survival of glioblastoma patients vaccinated in a similar setting was also observed in a phase I clinical study using an mRNA encoding cytomegalovirus (CMV) pp-65 for DC transfection and GM-CSF as an adjuvant [<xref rid="B67-cells-09-02061" ref-type="bibr">67</xref>]. CMV pp-65 was chosen based on the fact that glioblastoma cells expressed this protein, but no other brain cells [<xref rid="B68-cells-09-02061" ref-type="bibr">68</xref>].</p><p>In melanoma therapy, efficacy of mRNA vaccines was observed in a study that enrolled stage III/IV melanoma patients after resection of metastases [<xref rid="B69-cells-09-02061" ref-type="bibr">69</xref>]. Autologous DC were co-transfected ex vivo with a mixture of four to six melanoma-associated antigen-encoding mRNAs (MAGE-A1/A3/C2, Melan A, gp100, tyrosinase) plus a mixture of adjuvants (either the toll-like receptor (TLR) 3 ligand polyriboinosinic:polyribocytidylic acid (poly(I:C)) plus CD40 ligand-mRNA, or mRNA coding for CD40L, CD70, and a constitutively active TLR4 mutant (TriMix-mRNA)). Transfected DC were applied intradermally in a bi-weekly cycle up to 12 times, and interferon (IFN)-&#945; 2b was administered concomitantly in most cases. Vaccinated patients showed an increased survival rate as compared to historical controls. In a follow-up study on stage III/IV melanoma patients, co-treatment of patients with DC co-electroporated with either of the melanoma antigen-mRNAs plus TriMix, and concomitant treatment with the checkpoint inhibitor ipilimumab (CTL-associated protein (CTLA-)4 blocking antibody), applied every three weeks for a total of four times yielded better long term survival rates than ipilimumab treatment alone [<xref rid="B70-cells-09-02061" ref-type="bibr">70</xref>].</p><p>Within the last few years also some clinical trials assessing the potency of systemically applied mRNA-based vaccines (e.g., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02410733">NCT02410733</ext-link>; Lipo-MERIT) have been initiated, using lipoplexes to prevent mRNA degradation. The mRNA vaccine tested in the Lipo-MERIT study aims to directly target DC for melanoma therapy [<xref rid="B71-cells-09-02061" ref-type="bibr">71</xref>], and is comprised of several mRNAs that encode four different TAA (MAGE-A3, NY-ESO-1, TPTE, and tyrosinase,) to be presented via MHCI and MHCII, and induce IFN type I driven immune responses due to intrinsic stimulatory activity. In a preclinical setting, a liposomal formulation that specifically addressed DC was identified by testing the biodistribution and cell binding properties of a library of cationic liposomes consisting of DOTMA (1,2-di-O-octadecenyl-3-trimethylammonium propane) and DOPE (dioleoyl phosphatidylethanolamine), which differed in their size and zeta potential [<xref rid="B72-cells-09-02061" ref-type="bibr">72</xref>]. mRNA-loaded lipoplexes with a negative net charge and a diameter of around 300 nm almost exclusively accumulated in the spleen and were shown to address splenic and lymph node DC.</p></sec></sec><sec id="sec2dot2-cells-09-02061"><title>2.2. Optimization Strategies for Nucleic Acid-Based Vaccines</title><sec id="sec2dot2dot1-cells-09-02061"><title>2.2.1. Antigen</title><p>For tumor therapy, nucleic acid-based vaccines need to encode tumor-specific immunogenic peptides, which allows to comprise antigen-encoding sequences of different proteins within one minigene aimed to activate a broader number of CD4<sup>+</sup> and CD8<sup>+</sup> T cells [<xref rid="B73-cells-09-02061" ref-type="bibr">73</xref>]. In general, TAA may either constitute tumor-specific shared or tumor-specific unique antigens [<xref rid="B74-cells-09-02061" ref-type="bibr">74</xref>]. Whereas shared TAAs are also presented by normal cell types, albeit at lower extent, unique tumor antigens, also called neo-antigens, are exclusively expressed by tumors [<xref rid="B75-cells-09-02061" ref-type="bibr">75</xref>]. Especially in older studies, sequences encoding shared TAAs have been used [<xref rid="B76-cells-09-02061" ref-type="bibr">76</xref>], but this may also result in autoimmune responses [<xref rid="B77-cells-09-02061" ref-type="bibr">77</xref>]. On the contrary, effector T cell responses towards neo-antigens, identified in a tumor-specific manner by mutagenome analysis, have been reported to be more potent [<xref rid="B78-cells-09-02061" ref-type="bibr">78</xref>,<xref rid="B79-cells-09-02061" ref-type="bibr">79</xref>]. Moreover, antigens with a prolonged half-life have been shown to induce stronger CTL responses, and thereby increased immunogenicity [<xref rid="B80-cells-09-02061" ref-type="bibr">80</xref>]. To improve the presentation of (tumor) antigens, epitope-specific changes have been shown to increase MHC affinity [<xref rid="B81-cells-09-02061" ref-type="bibr">81</xref>], including the use of xenogeneic antigens [<xref rid="B82-cells-09-02061" ref-type="bibr">82</xref>]. Loading of pDNA-encoded antigens onto MHCII was also demonstrated to be improved by inclusion of the coding sequence of the invariant chain [<xref rid="B83-cells-09-02061" ref-type="bibr">83</xref>]. mRNA-encoded antigens were shown to be presented at higher extent via MHCII when fused with the lysosomal targeting signal of LAMP [<xref rid="B64-cells-09-02061" ref-type="bibr">64</xref>].</p></sec><sec id="sec2dot2dot2-cells-09-02061"><title>2.2.2. Adjuvant</title><p>Conventional pDNA was reported to possess intrinsic immunostimulatory activity due to a CpG-rich motif located within the ampicillin-resistance gene that triggered TLR9 in endo/lysosomes [<xref rid="B84-cells-09-02061" ref-type="bibr">84</xref>]. Besides, pDNA was also shown to bind cytosolic DNA sensors that mediate activation of the stimulator of IFN genes (STING) signaling pathway [<xref rid="B85-cells-09-02061" ref-type="bibr">85</xref>]. Moreover, physical stress associated with vaccination may also exert adjuvant effects as observed for gene gun-mediated delivery of gold particle adsorbed pDNA into the skin [<xref rid="B86-cells-09-02061" ref-type="bibr">86</xref>].</p><p>However, nucleic acid-based vaccines normally contain an adjuvant, which is delivered as a separate unit, like the TLR3 agonist poly(I:C) [<xref rid="B69-cells-09-02061" ref-type="bibr">69</xref>] or CpG oligodeoxynucleotides (ODNs) that trigger TLR9 [<xref rid="B87-cells-09-02061" ref-type="bibr">87</xref>,<xref rid="B88-cells-09-02061" ref-type="bibr">88</xref>], or more conventional adjuvants like Alum [<xref rid="B89-cells-09-02061" ref-type="bibr">89</xref>]. Whereas these moieties trigger danger receptors, in several studies the efficacy of transgenes that encode constitutively active mutants of danger receptors like TLR4, and receptors with co-stimulatory activity like CD40L and CD70 [<xref rid="B69-cells-09-02061" ref-type="bibr">69</xref>] to confer APC activation has been evaluated. Additionally, minigenes encoding signaling adaptors and transcription factors have been assessed in this regard. For example, Shedlock and co-workers reported that co-transfection of an NF-&#954;B p65 expression plasmid and of a HIV protein encoding pDNA by in vivo electroporation of mice yielded stronger T cell responses [<xref rid="B90-cells-09-02061" ref-type="bibr">90</xref>]. Likewise, human monocyte-derived DC co-transfected in vitro with an mRNA encoding for a constitutively active form of IKK&#946; (inhibitor of nuclear factor kappa B kinase subunit beta) showed elevated upregulation of surface activation markers and cytokines like IL-12, and conferred stronger activation of co-cultured CD8<sup>+</sup> T cells [<xref rid="B91-cells-09-02061" ref-type="bibr">91</xref>] and NK cells [<xref rid="B92-cells-09-02061" ref-type="bibr">92</xref>]. Similarly, biolistic co-transfection of mice with an IRF-3 encoding pDNA enhanced T cell responses towards co-applied influenza antigen-encoding pDNA [<xref rid="B93-cells-09-02061" ref-type="bibr">93</xref>].</p><p>Further, the suitability of pDNA [<xref rid="B49-cells-09-02061" ref-type="bibr">49</xref>] or mRNA [<xref rid="B94-cells-09-02061" ref-type="bibr">94</xref>] encoding cytokines intended to activate APC and to modulate T cells (in a paracrine manner) has been evaluated. For example, Li and co-workers co-administered healthy volunteers a multigene HIV DNA vaccine plus an IL-12 encoding pDNA by intramuscular injection, which conferred increased Th1/CTL responses [<xref rid="B95-cells-09-02061" ref-type="bibr">95</xref>]. Bontkes et al. demonstrated that human DC co-transfected in vitro with a TAA, and IL-12 as well as IL-18 encoding mRNA induced increased activity of co-cultured CD8<sup>+</sup> T cells and NK cells [<xref rid="B94-cells-09-02061" ref-type="bibr">94</xref>]. Similar findings were made in a preclinical mouse study upon intramuscular administration of a pDNA encoding mycobacteria antigen and IL-15, known to activate both APC as well as T cells and NK cells [<xref rid="B96-cells-09-02061" ref-type="bibr">96</xref>]. Further, administration of IL-2 and IL-7 pDNA expression constructs aimed to promote T cell activation and proliferation have been tested in preclinical studies [<xref rid="B97-cells-09-02061" ref-type="bibr">97</xref>].</p></sec><sec id="sec2dot2dot3-cells-09-02061"><title>2.2.3. Inhibition of Regulatory Proteins in APC</title><p>In other studies, the potential of small interfering RNA (siRNA) to inhibit the expression of endogenous inhibitory key factors in APC has been tested. For example, Luo and co-workers boosted anti-tumor responses using NPs that co-delivered the TLR3 ligand poly(I:C) and a siRNA specific for the transcription factor STAT (signal transducer and activators of transcription) 3 [<xref rid="B98-cells-09-02061" ref-type="bibr">98</xref>], which induces expression of anti-inflammatory factors like IL-10. Likewise, NPs delivering siRNA specific for the co-inhibitory receptor programmed cell death (PD) ligand 1 (PD-L1) have been evaluated in tumor studies [<xref rid="B99-cells-09-02061" ref-type="bibr">99</xref>]. More recently, also micro-RNA (miRNA) species, which constitute endogenously expressed small RNA species that inhibit gene expression (<xref ref-type="fig" rid="cells-09-02061-f002">Figure 2</xref>), are considered interesting candidates to modulate the activation state of APC [<xref rid="B100-cells-09-02061" ref-type="bibr">100</xref>]. For example, delivery of a plasmid harboring multiple miRNA consensus bindings sites, termed miRNA sponge [<xref rid="B101-cells-09-02061" ref-type="bibr">101</xref>] and of anti-miRNA oligonucleotides [<xref rid="B102-cells-09-02061" ref-type="bibr">102</xref>], is intended to limit the inhibitory effect of miRNAs on activation-associated mRNA targets.</p></sec><sec id="sec2dot2dot4-cells-09-02061"><title>2.2.4. Structural Optimization of pDNA Vaccines</title><sec><title>Expression Units</title><p>In most of the aforementioned studies pDNA and mRNA species encoding antigen and adjuvant were applied as separate plasmids (in trans). However, the approach to integrate several transcription units into the same pDNA or mRNA in cis has received growing interest [<xref rid="B104-cells-09-02061" ref-type="bibr">104</xref>]. In case of pDNA, according vectors may either contain separate expression units each driven by another promoter, or a single promoter that regulates expression of the antigen and of molecular adjuvants. In case of the latter, which is also possible in case of mRNA vaccines, the different expression units may be separated either by an internal ribosomal entry site that confers cap-independent translation [<xref rid="B105-cells-09-02061" ref-type="bibr">105</xref>,<xref rid="B106-cells-09-02061" ref-type="bibr">106</xref>] or virus-derived recognition sites [<xref rid="B107-cells-09-02061" ref-type="bibr">107</xref>], which in the derived long peptide are recognized by a ubiquitously expressed protease [<xref rid="B108-cells-09-02061" ref-type="bibr">108</xref>].</p></sec><sec><title>Size Reduction</title><p>A large part of pDNA is of prokaryotic origin and is required only for propagation in bacteria. It has been shown that after transfection prokaryotic parts are silenced by formation of heterochromatin, which may spread into the eukaryotic expression unit(s), and thereby limit transgene expression [<xref rid="B109-cells-09-02061" ref-type="bibr">109</xref>]. Therefore, the strategy to flank the expression cassette comprised of the promoter and the transgene-encoding part with phage recombinase-recognition sites has received growing interest. This configuration allows deletion of the prokaryotic part in the late phase of plasmid propagation by inducing phage recombinase. In several studies the derived mini-circle DNA (mcDNA) was reported to yield a higher transfection efficiency as well as a longer duration of gene expression as compared to the full length parental construct [<xref rid="B110-cells-09-02061" ref-type="bibr">110</xref>].</p></sec><sec><title>Nuclear Transfer</title><p>Moreover, in case of a pDNA vaccine its nuclear translocation is necessary for transcription of the encoded transgene(s), which constitutes a hurdle in mitotically inactive APC [<xref rid="B111-cells-09-02061" ref-type="bibr">111</xref>]. It was shown that transcription factors may bind recognition sites within the gene regulatory regions of the pDNA, and mediate nuclear import of the pDNA by their nuclear localization signal (NLS) [<xref rid="B112-cells-09-02061" ref-type="bibr">112</xref>]. Especially the simian virus (SV)40 enhancer sequence was demonstrated to harbor several of these transcription factor binding sites, and inclusion of this region directly upstream or downstream of the transgene expression unit conferred enhanced nuclear import and elevated transfection efficiencies [<xref rid="B40-cells-09-02061" ref-type="bibr">40</xref>]. In a more controlled manner, viral peptides (e.g., SV40 large T antigen) coupled to pDNA can facilitate its nuclear entry via their NLS [<xref rid="B113-cells-09-02061" ref-type="bibr">113</xref>].</p></sec><sec><title>Transcriptional Regulation</title><p>Expression units of pDNA-based vaccines are often under transcriptional control of virus-derived promotors characterized by ubiquitous activity at high level, like the human intermediate/early CMV or the SV40 promoter [<xref rid="B114-cells-09-02061" ref-type="bibr">114</xref>]. Since viral promoters may be subjected to methylation-mediated inactivation, both eukaryotic promoters, like the human elongation factor (EF)1&#945; or beta-actin gene promoter, as well as viral/eukaryotic hybrid (e.g., CMV/beta-actin) promoters have been introduced that allow long term transgene expression [<xref rid="B115-cells-09-02061" ref-type="bibr">115</xref>]. These types of promoters are still widely used in preclinical and clinical studies. On the contrary, the potential of promoters that restrict gene expression to DC to avoid unwanted vaccine expression by regulatory immune cells (e.g., TAM, MDSC) has been assessed in a limited number of preclinical studies only. The promoter of DC-STAMP (dendrocyte-expressed seven transmembrane proteins) is active in unstimulated human and mouse DC as well as in macrophages, and is downregulated upon stimulation [<xref rid="B116-cells-09-02061" ref-type="bibr">116</xref>]. Mice transduced with a lentivirus containing the DC-STAMP promoter displayed reporter activity in DC, monocytes, B cells, and NK cells [<xref rid="B117-cells-09-02061" ref-type="bibr">117</xref>]. Biolistic transfection of mice with a pDNA containing the promoter of the Langerhans cell (LC)-specifically active Dectin-2 gene resulted in LC-specific reporter activity [<xref rid="B118-cells-09-02061" ref-type="bibr">118</xref>], and when employed in a lentiviral vector conferred both DC- and macrophage-restricted reporter expression [<xref rid="B119-cells-09-02061" ref-type="bibr">119</xref>]. In several studies the promoters of the evolutionarily conserved human [<xref rid="B120-cells-09-02061" ref-type="bibr">120</xref>,<xref rid="B121-cells-09-02061" ref-type="bibr">121</xref>] and mouse [<xref rid="B120-cells-09-02061" ref-type="bibr">120</xref>,<xref rid="B121-cells-09-02061" ref-type="bibr">121</xref>] fascin-1 genes were demonstrated to restrict gene expression to maturing DC. Biolistic transfection of mice with fascin-1 promoter driven antigen encoding pDNA yielded largely DC-restricted transgene expression, and conferred Th1-polarized immune responses in models of allergy [<xref rid="B122-cells-09-02061" ref-type="bibr">122</xref>], and multiple sclerosis [<xref rid="B123-cells-09-02061" ref-type="bibr">123</xref>]. Furthermore, pDNA encoding for anti-inflammatory transforming growth factor (TGF)-&#946; [<xref rid="B123-cells-09-02061" ref-type="bibr">123</xref>] and IDO [<xref rid="B124-cells-09-02061" ref-type="bibr">124</xref>] under transcriptional control of the fascin-1 promoter yielded tolerogenic effects.</p></sec></sec><sec id="sec2dot2dot5-cells-09-02061"><title>2.2.5. NPs for APC-Focused Delivery of Nucleic Acids</title><p>Biocompatible NPs are highly interesting for cellular transfer of nucleic acids [<xref rid="B125-cells-09-02061" ref-type="bibr">125</xref>] in the context of nucleic acid-based tumor therapy [<xref rid="B126-cells-09-02061" ref-type="bibr">126</xref>], since they offer protection against extracellular degradation by DNases [<xref rid="B127-cells-09-02061" ref-type="bibr">127</xref>] and RNases [<xref rid="B128-cells-09-02061" ref-type="bibr">128</xref>] either by dense complexation [<xref rid="B129-cells-09-02061" ref-type="bibr">129</xref>] or encapsulation [<xref rid="B130-cells-09-02061" ref-type="bibr">130</xref>] of nucleic acids. Especially in case of systemic application, NPs may confer either due to their intrinsic properties passive [<xref rid="B72-cells-09-02061" ref-type="bibr">72</xref>] or upon conjunction with surface receptor targeting moieties active [<xref rid="B46-cells-09-02061" ref-type="bibr">46</xref>] targeting of APC populations.</p><sec><title>NP Size and Surface Characteristics Affecting Biodistribution</title><p>With regard to the design of NPs it needs to be taken into account that DC as the often preferred target cell type internalize smaller particles (&lt;200 nm) more efficiently [<xref rid="B131-cells-09-02061" ref-type="bibr">131</xref>], whereas monocytes/macrophages preferably ingest larger ones (&lt;5 &#181;m) by means of receptor-mediated endocytosis and phagocytosis [<xref rid="B132-cells-09-02061" ref-type="bibr">132</xref>]. Besides size, also the shape of the NP may affect the efficacy of uptake as evaluated for gold-based NPs, which were engulfed by macrophages more efficiently in case of spherical as compared to e.g., elongated shape [<xref rid="B133-cells-09-02061" ref-type="bibr">133</xref>]. Both the cellular internalization of transfection complexes and the endosomal release of NP-complexed nucleic acids, can be increased by cell penetrating peptides (CPP) that are attached either e.g., to the pDNA [<xref rid="B134-cells-09-02061" ref-type="bibr">134</xref>] or to the NP [<xref rid="B135-cells-09-02061" ref-type="bibr">135</xref>].</p><p>Concerning the biodistribution of nucleic acid/NP transfection complexes, it was shown that small particles are easily transported into the lymph node, whereas larger particles remain longer at the site of administration [<xref rid="B136-cells-09-02061" ref-type="bibr">136</xref>]. Further, the route of administration can also account for the fate of NP delivery systems. After subcutaneous injection small PEGylated liposomes were found in a larger amount in the lymph node than after intravenous or intraperitoneal application [<xref rid="B137-cells-09-02061" ref-type="bibr">137</xref>]. Concerning NP clearance from the body, NPs that are smaller than 8 nm are cleared renally [<xref rid="B138-cells-09-02061" ref-type="bibr">138</xref>], and the extent of renal clearance was shown to correlate with the extent of negative charge [<xref rid="B139-cells-09-02061" ref-type="bibr">139</xref>]. Biliary clearance was observed especially for particles over 200 nm, and for strongly charged particles [<xref rid="B140-cells-09-02061" ref-type="bibr">140</xref>].</p></sec><sec><title>NP Types Suitable for APC Transfection</title><p>By now, a large variety of materials and structures has been evaluated for transfer of nucleic acids into APC, comprising inorganic materials like solid core gold [<xref rid="B141-cells-09-02061" ref-type="bibr">141</xref>] and iron oxide-based [<xref rid="B142-cells-09-02061" ref-type="bibr">142</xref>], mesoporous silica [<xref rid="B143-cells-09-02061" ref-type="bibr">143</xref>], and graphene oxide [<xref rid="B144-cells-09-02061" ref-type="bibr">144</xref>] based NPs. The latter have repetitively shown to confer endosomal escape of nucleic acids [<xref rid="B145-cells-09-02061" ref-type="bibr">145</xref>,<xref rid="B146-cells-09-02061" ref-type="bibr">146</xref>]. Polymer-based NPs bind nucleic acids by electrostatic interactions [<xref rid="B147-cells-09-02061" ref-type="bibr">147</xref>]. PLG (poly-D,L-lactide-co-glycolide) [<xref rid="B148-cells-09-02061" ref-type="bibr">148</xref>], PLGA (poly-D,L-lactic-co-glycolic acid) [<xref rid="B149-cells-09-02061" ref-type="bibr">149</xref>], and polyethylenimine (PEI) [<xref rid="B150-cells-09-02061" ref-type="bibr">150</xref>] are among the most intensely studied polymer-based NPs for delivery of nucleic acids. Of these, PEI by acting as a &#8217;proton sponge&#8217; conferred the most pronounced endosomal release of nucleic acids [<xref rid="B151-cells-09-02061" ref-type="bibr">151</xref>], but at the same time also mediated strong cytotoxicity [<xref rid="B152-cells-09-02061" ref-type="bibr">152</xref>]. Chitosan is a natural polysaccharide-based polymer, which has been evaluated for pDNA transfer [<xref rid="B153-cells-09-02061" ref-type="bibr">153</xref>] and similar to PLGA [<xref rid="B154-cells-09-02061" ref-type="bibr">154</xref>] was demonstrated to exert immunostimulatory activity [<xref rid="B155-cells-09-02061" ref-type="bibr">155</xref>]. Protein-based NPs offer the advantage of high biocompatibility [<xref rid="B156-cells-09-02061" ref-type="bibr">156</xref>]. For example, gelatin B (negatively charged) combined with protamine sulfate (positively charged) conferred DNA transfection, and mediated pDNA release under acidic conditions as apparent in endolysosomes [<xref rid="B157-cells-09-02061" ref-type="bibr">157</xref>]. Using endogenous proteins as nano-carriers may reduce potential immune reactions in response to repetitive application. In this regard, serum albumin coated with chitosan conferred DNA transfection [<xref rid="B158-cells-09-02061" ref-type="bibr">158</xref>]. NPs, consisting of albumin conjugated with cationic ethylenediamine complexed Bcl-2 specific siRNA, intravenously injected into mice with established melanoma lung metastases successfully inhibited further tumor progression [<xref rid="B159-cells-09-02061" ref-type="bibr">159</xref>]. Cationic lipids complex negatively charged nucleic acids by electrostatic interactions, and by interaction with the negatively charged cell membrane confer internalization of lipoplexes [<xref rid="B160-cells-09-02061" ref-type="bibr">160</xref>]. DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride) was the first lipid to be used for pDNA transfection [<xref rid="B161-cells-09-02061" ref-type="bibr">161</xref>], and is still used either as a single component for complexation of nucleic acids or in combinations with helper lipids. With regard to the latter, neutral helper lipids like cholesterol have been included resulting in much stronger transfection efficiency presumably due to elevated endosomal escape of passenger DNA [<xref rid="B162-cells-09-02061" ref-type="bibr">162</xref>]. Incorporation of coiled-coil lipopeptides into liposomes resulted in direct release of the payload into the cytosol [<xref rid="B163-cells-09-02061" ref-type="bibr">163</xref>].</p></sec><sec><title>Administration Routes</title><p>Direct transfection of APC in secondary lymphoid organs can be achieved by intravenous application [<xref rid="B164-cells-09-02061" ref-type="bibr">164</xref>], given that the nano-vaccine predominantly addresses APC by passive [<xref rid="B72-cells-09-02061" ref-type="bibr">72</xref>] or active [<xref rid="B165-cells-09-02061" ref-type="bibr">165</xref>] targeting. This would result in the induction of antigen-specific T effector cells, which can home to each tissue, and thereby also reach metastases irrespective of their location. However, as delineated in preclinical rodent biodistribution studies, systemically administered NPs of larger size (&#8805; 200 nm diameter) may accumulate e.g., in lung as reported e.g., for mesoporous silica particles [<xref rid="B166-cells-09-02061" ref-type="bibr">166</xref>] or chitosan NP [<xref rid="B167-cells-09-02061" ref-type="bibr">167</xref>]. Moreover, most NP formulations tested so far accumulate in the liver [<xref rid="B168-cells-09-02061" ref-type="bibr">168</xref>] as a consequence of the general clearance function of the liver [<xref rid="B169-cells-09-02061" ref-type="bibr">169</xref>], conferred by Kupffer cells (KC) as the major liver-resident macrophage population [<xref rid="B170-cells-09-02061" ref-type="bibr">170</xref>] and liver sinusoidal endothelial cells (LSEC) [<xref rid="B171-cells-09-02061" ref-type="bibr">171</xref>]. KC and LSEC are equipped with a number of danger receptors, including different C-type lectin receptors (CLR) as e.g., the mannose receptor CD206 [<xref rid="B172-cells-09-02061" ref-type="bibr">172</xref>,<xref rid="B173-cells-09-02061" ref-type="bibr">173</xref>], and scavenger receptors that broadly bind negatively charged ligands [<xref rid="B174-cells-09-02061" ref-type="bibr">174</xref>,<xref rid="B175-cells-09-02061" ref-type="bibr">175</xref>]. Besides, KC [<xref rid="B176-cells-09-02061" ref-type="bibr">176</xref>] and LSEC [<xref rid="B177-cells-09-02061" ref-type="bibr">177</xref>] express high affinity Fc receptors, and KC also express complement receptors [<xref rid="B178-cells-09-02061" ref-type="bibr">178</xref>]. Therefore, it is conceivable that NPs, depending on the characteristics of the protein corona formed in vivo [<xref rid="B179-cells-09-02061" ref-type="bibr">179</xref>], also including complement activation as shown for lectin-coated NP [<xref rid="B180-cells-09-02061" ref-type="bibr">180</xref>], may be internalized preferentially by KC and LSEC. The formation of a pronounced protein corona may be attenuated by PEGylation, shown to reduce unwanted binding to KC [<xref rid="B181-cells-09-02061" ref-type="bibr">181</xref>] and LSEC [<xref rid="B182-cells-09-02061" ref-type="bibr">182</xref>], and by conjugation with CD47, which serves as a &#8216;do not-eat-me&#8217; ignal for macrophages as evaluated for liposomes [<xref rid="B183-cells-09-02061" ref-type="bibr">183</xref>]. Furthermore, targeting moieties on NP may engage according receptors on either non-parenchymal liver cell population. An example is mannose, which has frequently been used to address CD206-expressing APC of myeloid origin [<xref rid="B184-cells-09-02061" ref-type="bibr">184</xref>,<xref rid="B185-cells-09-02061" ref-type="bibr">185</xref>].</p><p>NP delivery via the skin constitutes an interesting alternative to systemic NP delivery for several reasons: (i) topical application circumvents unwanted liver accumulation, (ii) cutaneous DC, comprising Langerhans cells (LC) as the epidermal DC population, which form a dense network (200&#8211;1000 LC/mm<sup>2</sup> [<xref rid="B186-cells-09-02061" ref-type="bibr">186</xref>]), and dermal DC are apparent at rather high numbers in skin, and (iii) targeting is not necessary since only DC, at activated state, are able to migrate to secondary lymphoid organs [<xref rid="B187-cells-09-02061" ref-type="bibr">187</xref>]. By now, several approaches for transfection of skin DC have been tested successfully in clinical trials concerning safety and tolerability and are used in preclinical studies to evaluate vaccines. These include conventional intradermal injection [<xref rid="B188-cells-09-02061" ref-type="bibr">188</xref>], biolistic transfection of nucleic acids pre-adsorbed onto particles applied by gene gun [<xref rid="B189-cells-09-02061" ref-type="bibr">189</xref>] and PMED (particle-mediated epidermal delivery) [<xref rid="B190-cells-09-02061" ref-type="bibr">190</xref>], patches with dissolvable microneedles [<xref rid="B191-cells-09-02061" ref-type="bibr">191</xref>,<xref rid="B192-cells-09-02061" ref-type="bibr">192</xref>], and tattooing devices [<xref rid="B193-cells-09-02061" ref-type="bibr">193</xref>]. All of these transdermal delivery methods can transfer NP-complexed nucleic acids [<xref rid="B194-cells-09-02061" ref-type="bibr">194</xref>]. In case of biolistic transfection the method-associated physical stress was sufficient to confer activation and consequently emigration of transfected DC [<xref rid="B86-cells-09-02061" ref-type="bibr">86</xref>]. Further, administration of an electrical pulse just after intradermal [<xref rid="B195-cells-09-02061" ref-type="bibr">195</xref>] and intramuscular [<xref rid="B196-cells-09-02061" ref-type="bibr">196</xref>] injection, was shown to induce local inflammation, which activated APC at the according site, and to enhance overall transfection rates [<xref rid="B197-cells-09-02061" ref-type="bibr">197</xref>]. Consequently, electroporation devices that are applied in the context of intradermal injection are currently tested in clinical phase I (e.g., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04336410">NCT04336410</ext-link>) and phase II (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03180684">NCT03180684</ext-link>) pDNA vaccination studies.</p><p>Other potential delivery routes for tumor vaccination comprise the respiratory system by applying nebulized pDNA or mRNA that largely transfect lung epithelia [<xref rid="B198-cells-09-02061" ref-type="bibr">198</xref>], which has predominantly been employed for treatment of lung diseases like cystic fibrosis [<xref rid="B199-cells-09-02061" ref-type="bibr">199</xref>], and oral vaccination approaches using attenuated bacteria (e.g., <italic toggle="yes">Salmonella typhimurium</italic>) for pDNA transfer to APC in Payer&#8217;s patches [<xref rid="B200-cells-09-02061" ref-type="bibr">200</xref>].</p></sec><sec><title>Targeting of APC</title><p>Passive targeting of DC and monocytes/macrophages in vivo may be a consequence of the protein corona formed in case of many types of NPs due to adsorption of serum factors, which may constitute genuine ligands for cell surface receptors [<xref rid="B179-cells-09-02061" ref-type="bibr">179</xref>]. The composition of the protein corona is determined by several factors including e.g., charge and hydrophobicity of the particle surface. Further, serum factors due to interaction with the particle surface may alter their state of conformation, and thereby are recognized as &#8216;new&#8217; ligands e.g., by scavenger receptors [<xref rid="B201-cells-09-02061" ref-type="bibr">201</xref>]. Finally, NPs may be recognized as pathogen-like by the innate immune system, e.g., in case of lectin surfaces intended to ensure biocompatibility of the NP, which however was found to trigger the lectin-dependent complement pathway [<xref rid="B202-cells-09-02061" ref-type="bibr">202</xref>]. This in turn resulted in adsorption of active complement C3 on the particle surface, and subsequent recognition of immune cells via complement receptors [<xref rid="B180-cells-09-02061" ref-type="bibr">180</xref>]. Unwanted adsorption of serum factors may be limited by conjugation with polyethylene glycol (PEG) [<xref rid="B203-cells-09-02061" ref-type="bibr">203</xref>]. However, concerning the repetitive application of vaccines potential adverse reactions as e.g., the induction of PEG-specific antibodies [<xref rid="B204-cells-09-02061" ref-type="bibr">204</xref>] need to be taken into account.</p><p>Active targeting of transfection complexes to DC and monocytes/macrophages can be achieved by conjugation of NPs with derivatives of natural ligands and antibodies that specifically bind endocytic surface receptors like C-type lectin receptors, which are expressed in a largely cell type-specific manner [<xref rid="B205-cells-09-02061" ref-type="bibr">205</xref>]. For example, the mannose receptor CD206 is highly expressed by macrophages (M2-like &gt; M1-like), and is apparent at some extent on conventional DC [<xref rid="B206-cells-09-02061" ref-type="bibr">206</xref>], whereas DC-SIGN is predominantly expressed by conventional DC populations, but only by a low fraction of macrophages [<xref rid="B207-cells-09-02061" ref-type="bibr">207</xref>]. In a preclinical study, intramuscular vaccination of mice with mannosylated cationic liposomes (distearoylphosphoethanolamine-polycarboxybetaine/DOTAP/cholesterol) that showed intrinsic DC stimulatory activity and complexed a HIV antigen-encoding pDNA improved HIV-specific T cell responses [<xref rid="B208-cells-09-02061" ref-type="bibr">208</xref>]. More recently, trimannosylated liposomes (1,2-bis(hexadecyl)glycerol/1,2-Dioleoyl-sn-glycero-3-phosphocholine/cholesterol) were shown to specifically address DC-SIGN, and to accumulate at highest extent in the spleen after intravenous application, addressing predominantly DC [<xref rid="B165-cells-09-02061" ref-type="bibr">165</xref>]. While these approaches aimed to directly transfect APC in vivo, in an alternative approach Wang and co-workers designed a pDNA that encoded a fusion protein consisting of a tumor antigen polypeptide and a single chain antibody fragment known to bind the murine DC-specific receptor CD11c [<xref rid="B209-cells-09-02061" ref-type="bibr">209</xref>]. Thereby, this pDNA was aimed to be expressed in non-APC, but the expressed fusion protein was meant to target DC. In a mouse breast cancer model intramuscular injection of this pDNA prevented tumor growth when applied protectively prior to subcutaneous tumor cell inoculation, and attenuated tumor progression in a therapeutic setting. As mentioned above, lipoplexes composed of DOTMA and DOPE loaded with mRNA with a negative net charge and a size of around 300 nm due to these characteristics predominantly targeted DC in secondary lymphoid organs [<xref rid="B72-cells-09-02061" ref-type="bibr">72</xref>].</p></sec></sec></sec></sec><sec id="sec3-cells-09-02061"><title>3. Inhibition of Regulatory Immune Cells</title><p>The success of vaccination to induce a sustained antigen-specific anti-tumor response is limited by regulatory immune cells that are induced and expanded by tumors as part of their evasion strategy [<xref rid="B210-cells-09-02061" ref-type="bibr">210</xref>]. Both MDSC [<xref rid="B211-cells-09-02061" ref-type="bibr">211</xref>] and Treg [<xref rid="B212-cells-09-02061" ref-type="bibr">212</xref>] can attenuate the T cell stimulatory activity of APC, the activation of T cells as well as the anti-tumor function of Teff, and effector functions of NK cells. To counteract the suppressive effect of regulatory immune cells the suitability of RNAi has been delineated [<xref rid="B213-cells-09-02061" ref-type="bibr">213</xref>,<xref rid="B214-cells-09-02061" ref-type="bibr">214</xref>]. Further, nucleic acids with immunostimulatory function were reported to reprogram MDSC to exert anti-tumor activity [<xref rid="B215-cells-09-02061" ref-type="bibr">215</xref>].</p><sec id="sec3dot1-cells-09-02061"><title>3.1. Inhibition of Treg by RNA Interference</title><p>Under homeostatic conditions Treg ensure tolerance towards self-antigens to prohibit autoimmunity [<xref rid="B216-cells-09-02061" ref-type="bibr">216</xref>], and against harmless antigens to prevent allergies [<xref rid="B217-cells-09-02061" ref-type="bibr">217</xref>]. Besides, as a negative feedback mechanism Treg are expanded and are also induced de novo in the course of immune reactions in order to limit immune responses and thereby to minimize tissue damages. Under healthy conditions Treg occur only in small numbers [<xref rid="B218-cells-09-02061" ref-type="bibr">218</xref>]. Depending on the place of origin Treg can be differentiated in thymic Treg (tTreg), alternatively termed natural Treg, [<xref rid="B219-cells-09-02061" ref-type="bibr">219</xref>] and in Treg that are induced in the periphery (iTreg) [<xref rid="B220-cells-09-02061" ref-type="bibr">220</xref>]. During thymopoiesis thymocytes, which express a T cell receptor (TCR) with intermediate affinity for self-peptides, differentiate into immunosuppressive tTreg [<xref rid="B221-cells-09-02061" ref-type="bibr">221</xref>]. iTreg derive from CD4<sup>+</sup>/CD8<sup>+</sup> T cells, whose TCR is not specific for self-antigens, but recognizes microbiota- and environmental antigens presented by DC in the periphery [<xref rid="B222-cells-09-02061" ref-type="bibr">222</xref>] in the context of low co-stimulation and/or Treg-promoting factors like retinoic acid, kynurenine, and TGF-&#946; [<xref rid="B223-cells-09-02061" ref-type="bibr">223</xref>,<xref rid="B224-cells-09-02061" ref-type="bibr">224</xref>]. In mice, tTreg and some iTreg populations can be identified by constitutive expression of the IL-2 receptor CD25 and by co-expression of the transcription factor FoxP3 [<xref rid="B225-cells-09-02061" ref-type="bibr">225</xref>], whereas other iTreg populations are Foxp3-deficient, but may express anti-inflammatory mediators like IL-10 and TGF-&#946; [<xref rid="B226-cells-09-02061" ref-type="bibr">226</xref>].</p><p>In cancer, constituents of the TME produce anti-inflammatory mediators, which promote Treg expansion/induction in the periphery [<xref rid="B218-cells-09-02061" ref-type="bibr">218</xref>], and release of chemokines as for example the C-C motif chemokine ligand (CCL) 22, to recruit Treg to the tumor [<xref rid="B227-cells-09-02061" ref-type="bibr">227</xref>]. Treg suppress anti-tumor responses on the level of APC activity, T cell activation, T effector cell functions, and the functions of NK cells by numerous mechanisms, as for example anti-inflammatory cytokines (e.g., IL-10, TGF-&#946;), surface receptor interactions (e.g., negative cross-talk via CTLA-4), IL-2 depletion, and transfer of cyclic adenosine monophosphate (cAMP) [<xref rid="B228-cells-09-02061" ref-type="bibr">228</xref>].</p><p>There are different approaches to overcome the obstacle of Treg-mediated suppression of anti-tumor responses, including strategies to deplete Treg or to reduce their suppressive activity [<xref rid="B229-cells-09-02061" ref-type="bibr">229</xref>]. Concerning nucleic acid-based approaches to attenuate Treg induction, silencing of tumor-derived TGF-&#946; in murine CT26 colon carcinoma cells by transfection with oligofectamine/TGF-&#946;1 siRNA complexes suppressed Treg induction [<xref rid="B230-cells-09-02061" ref-type="bibr">230</xref>]. Most recently, Masjedi et al. reported that ex vivo silencing of the adenosine A2A receptor (A2AR) with an A2AR-specific siRNA complexed with PEG-chitosan-lactate (PCL) NPs inhibited the differentiation of CD4<sup>+</sup>CD25<sup>&#8722;</sup> T cells derived from 4T1 breast tumor-bearing Balb/C mice toward Treg [<xref rid="B231-cells-09-02061" ref-type="bibr">231</xref>]. Alternative approaches have aimed to minimize the suppressive capability of Treg. For example, in vitro transfection of murine Treg with a Foxp3-specific siRNA resulted in profound inhibition of their suppressive capacity [<xref rid="B232-cells-09-02061" ref-type="bibr">232</xref>]. Another treatment option is to interfere with the recruitment of Treg to the tumor site. Kang and co-workers have demonstrated that tumor infiltration with Treg in athymic nude mice, inoculated with human breast cancer cells, can be prohibited by tail vein injection of Treg transfected with a siRNA specific for CCL22 [<xref rid="B233-cells-09-02061" ref-type="bibr">233</xref>]. Besides the use of synthetic siRNA for RNA interference, in recent years miRNA (over)expression intended to alter the genetic program of Treg has gained increasing interest. In this regard, lentiviral transduction of Treg in vitro with miR-9 and miR-155 encoding vectors resulted in reduced expression of CTLA-4, which is a key factor for the immunosuppressive activity of Treg [<xref rid="B234-cells-09-02061" ref-type="bibr">234</xref>]. Additionally, Jonuleit et al. reported that in a mouse melanoma model systemic delivery of CTLA-4 specific siRNA by cationic lipid-assisted PEG&#8211;poly(lactic acid (PLA))-based NP resulted in reduced Treg numbers, and inhibited tumor growth [<xref rid="B235-cells-09-02061" ref-type="bibr">235</xref>]. Administration of miR-141 and miR-200a mimics in multiple sclerosis patients shifted the differentiation of naive T cells towards Th17, and at the same time inhibited Treg differentiation [<xref rid="B236-cells-09-02061" ref-type="bibr">236</xref>]. In a mouse model of epithelial ovarian cancer (EOC) in vitro transfection of CD4<sup>+</sup> T cells with miRNA 29a-3p and miR-21-5p mimics, complexed with the commercially available X-tremeGENE siRNA transfection reagent, followed by adoptive transfer into tumor-burdened mice, tumor growth was attenuated [<xref rid="B237-cells-09-02061" ref-type="bibr">237</xref>]. This outcome was based on the inhibitory effects of both miRNA species on STAT3 expression, thereby favoring Th17 over Treg differentiation. In another study, transfection of Treg with miR-142-3p reduced the level of intracellular cAMP and adenylyl cyclase type 9 expression, which impaired their suppressive properties [<xref rid="B238-cells-09-02061" ref-type="bibr">238</xref>]. Treg-specific delivery of biologicals may be achieved by using IL-2-functionalized NPs as shown for hydroxyethyl starch nanocapsules that targeted Treg due to their constitutive high level expression of the IL-2 receptor CD25 [<xref rid="B239-cells-09-02061" ref-type="bibr">239</xref>].</p><p>Altogether, these studies demonstrate that nucleic acid-based strategies have a high potential to reduce overall Treg activity in cancer. However, it should be noted that Treg depletion may result in a compensatory induction of MDSC [<xref rid="B240-cells-09-02061" ref-type="bibr">240</xref>].</p></sec><sec id="sec3dot2-cells-09-02061"><title>3.2. Strategies for MDSC Reprograming and Depletion</title><p>MDSC derive from myeloid precursor cells during myelopoiesis [<xref rid="B241-cells-09-02061" ref-type="bibr">241</xref>]. Immunomodulatory factors generated by tumors like some cytokines, chemokines, or colony-stimulating factors (CSF) are capable of stimulating expansion of MDSC on the expansion of monocytes, conventional DC, and neutrophils [<xref rid="B242-cells-09-02061" ref-type="bibr">242</xref>], while chronic inflammations can lead to extramedullary myelopoiesis [<xref rid="B243-cells-09-02061" ref-type="bibr">243</xref>]. The expansion and activation of generated MDSC requires concerted interaction of several signaling pathways, like the NF-&#954;B, JAK-STAT, HIF-1&#945;, C/EBP&#946;, and CHOP pathway. Based on the expression of plasma membrane markers, the amount of immune suppressive molecules as well as by functional analysis [<xref rid="B244-cells-09-02061" ref-type="bibr">244</xref>], MDSC can be allocated to CD11b<sup>+</sup>Ly6G<sup>&#8722;</sup>Ly6C<sup>hi</sup> monocytic (m)MDSC and to CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>low</sup> granulocytic (g)MDSC [<xref rid="B245-cells-09-02061" ref-type="bibr">245</xref>]. MDSC exert potent immune-suppressive activity against T cells [<xref rid="B246-cells-09-02061" ref-type="bibr">246</xref>] and NK cells [<xref rid="B247-cells-09-02061" ref-type="bibr">247</xref>]. Accordingly, MDSC contribute to control autoimmunity [<xref rid="B248-cells-09-02061" ref-type="bibr">248</xref>] and infections [<xref rid="B249-cells-09-02061" ref-type="bibr">249</xref>]. After activation, MDSC migrate to the site of inflammation or to the tumor site in response to a variety of chemokines [<xref rid="B250-cells-09-02061" ref-type="bibr">250</xref>]. There, MDSC generate an immune-suppressive milieu, which is enhanced by different cytokines [<xref rid="B243-cells-09-02061" ref-type="bibr">243</xref>]. The infiltration of mMDSC into a tumor leads to a distribution of tumor cells from the place of origin by induction of epithelial&#8211;mesenchymal transition (EMT), which generates a cancer stem cell (CSC) phenotype [<xref rid="B251-cells-09-02061" ref-type="bibr">251</xref>]. Tumor infiltration of gMDSC withdraws the CSC phenotype and leads to tumor cell proliferation and promotes metastasis. In secondary lymphoid organs MDSC suppress APC, the activation of tumor antigen-specific T cells, and T effector cells by several mechanisms in an analogous manner as described for Treg [<xref rid="B252-cells-09-02061" ref-type="bibr">252</xref>].</p><p>In some approaches siRNA and miRNA have been applied to attenuate MDSC generation and their suppressive activity. For example, Boldin et al. have shown that miR-146a inhibited the proliferation of MDSC by targeting tumor necrosis factor receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated kinase 1 (IRAK1) [<xref rid="B253-cells-09-02061" ref-type="bibr">253</xref>]. Similarly, miR-424 was reported to interfere with MDSC differentiation [<xref rid="B214-cells-09-02061" ref-type="bibr">214</xref>]. In several mouse tumor models intravenous application of oligofectamine/miR-223 complexes inhibited tumor-conferred MDSC generation by targeting myocyte enhancer factor 2C (MEF2C) in bone marrow progenitor cells [<xref rid="B254-cells-09-02061" ref-type="bibr">254</xref>].</p><p>Moreover, some types of NPs as an intrinsic property have been reported to reprogram MDSC towards proinflammatory macrophages as shown e.g., for cationic dextran- and PEI-based NP [<xref rid="B215-cells-09-02061" ref-type="bibr">215</xref>] in vitro and for NP modified with a cationic polymer in vivo [<xref rid="B255-cells-09-02061" ref-type="bibr">255</xref>]. In addition, TLR agonists that address TLR7/8 (e.g., R848) and TLR9 (CpG ODN) were shown to exert similar effects both in vitro and in vivo [<xref rid="B256-cells-09-02061" ref-type="bibr">256</xref>], which may contribute to the overall immunostimulatory effect of these adjuvants.</p></sec><sec id="sec3dot3-cells-09-02061"><title>3.3. Inhibition of Treg and MDSC by Tumor-Directed Approaches</title><p>Besides direct targeting of Treg and MDSC via RNA interference, the induction/expansion and tumor infiltration of either regulatory cell type may also be controlled indirectly by affecting tumor gene expression and as a secondary effect in the course of inducing anti-tumor responses. Stem cell factor (SCF; c-kit ligand) is generated by tumors and confers MDSC infiltration [<xref rid="B257-cells-09-02061" ref-type="bibr">257</xref>]. In a mouse MCA26 colon tumor model adenoviral transfer of SCF-specific siRNA resulted in reduced accumulation of MDSC at the tumor site [<xref rid="B258-cells-09-02061" ref-type="bibr">258</xref>]. Injection of a TNFAIP3-specific siRNA into E.G7 or B16-F10 melanoma induced apoptosis in MDSC via activation of the c-Jun N-terminal kinase (JNK) pathway [<xref rid="B259-cells-09-02061" ref-type="bibr">259</xref>]. Injection of vascular endothelial growth factor (VEGF)-specific siRNA, complexed with nanogels, into renal tumors significantly reduced MDSC numbers in that area [<xref rid="B260-cells-09-02061" ref-type="bibr">260</xref>]. Injection of a Newcastle Disease Virus Hemagglutinin&#8211;Neuraminidase encoding pDNA into the ear pinna of DA3 tumor bearing Balb/c mice promoted innate anti-tumor responses and reduced MDSC infiltration into the tumor site [<xref rid="B261-cells-09-02061" ref-type="bibr">261</xref>]. In humans suffering from pancreatic ductal adenocarcinoma (PDA), in many cases antibodies and T cells specific for &#945;-enolase (ENO1) have been identified [<xref rid="B262-cells-09-02061" ref-type="bibr">262</xref>]. In a mouse model of autochthonous pancreatic cancer, injection/electroporation with a ENO1-encoding pDNA attenuated tumor growth and concomitantly also the expansion of Treg and MDSC [<xref rid="B263-cells-09-02061" ref-type="bibr">263</xref>].</p></sec></sec><sec id="sec4-cells-09-02061"><title>4. Generation of T Cells and NK Cells Expressing CARs for Tumor Therapy</title><p>CARs are synthetic antigen receptors, which comprise an extracellular antibody domain, a transmembrane domain, and an intracellular signaling domain, and recognize e.g., tumor-associated antigens [<xref rid="B264-cells-09-02061" ref-type="bibr">264</xref>]. So-called CAR T cells (CAR-T) and CAR natural killer cells (CAR-NK) are generated by transfection of either cell type with a CAR-encoding pDNA, mRNA, or are transduced with a CAR-encoding viral vector [<xref rid="B265-cells-09-02061" ref-type="bibr">265</xref>]. Therefore, CAR expressing cells are able to recognize antigens under tumor-induced immune-suppressive conditions and can exert a proper immune response. For CAR synthesis, the variable domains of an antibodies&#8217; light and heavy chain are fused, for example by short glycine-serine linkers, to yield a single chain fragment variable (scFv) [<xref rid="B266-cells-09-02061" ref-type="bibr">266</xref>]. The transmembrane domain is usually derived from CD28 or another membrane receptor [<xref rid="B267-cells-09-02061" ref-type="bibr">267</xref>]. In most cases CD3&#950;, which is a component of the endogenous TCR, serves as the signaling domain for CAR-T [<xref rid="B268-cells-09-02061" ref-type="bibr">268</xref>]. For CAR-NK the transmembrane immune signaling adaptor chain is employed as the signaling domain [<xref rid="B264-cells-09-02061" ref-type="bibr">264</xref>]. The signaling domain is often combined with one or more co-stimulatory motifs [<xref rid="B269-cells-09-02061" ref-type="bibr">269</xref>] like CD28 [<xref rid="B270-cells-09-02061" ref-type="bibr">270</xref>], CD137, CD357, CD278, or CD134 [<xref rid="B271-cells-09-02061" ref-type="bibr">271</xref>] for CAR-T, and CD28, CD137 [<xref rid="B272-cells-09-02061" ref-type="bibr">272</xref>], CD278, CD134 [<xref rid="B273-cells-09-02061" ref-type="bibr">273</xref>], or Dap10 [<xref rid="B270-cells-09-02061" ref-type="bibr">270</xref>] in case of CAR-NK. The first generation of CARs contained only CD3 (&#950; or &#947; chain) signaling motifs, which are able to activate murine CTL hybridoma cells, modified with chimeric genes for surface receptors, e.g., to trigger IL-2 secretion, but these may be inactivated by tumors [<xref rid="B274-cells-09-02061" ref-type="bibr">274</xref>]. The second generation of CARs was equipped in addition with a co-stimulatory domain, and the third generation possessed more than one co-stimulatory domain [<xref rid="B275-cells-09-02061" ref-type="bibr">275</xref>].</p><p>In an alternative approach, the signaling and the co-stimulatory domains are split between two different CARs, which is termed combinatorial targeting [<xref rid="B264-cells-09-02061" ref-type="bibr">264</xref>]. Until now, two CAR-T based immunotherapies have been approved by the United States Food and Drug Administration (FDA). Both are CD19-directed CAR-T immunotherapies, targeting the pan-B cell receptor CD19. They have shown significant results in the treatment of non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL) [<xref rid="B276-cells-09-02061" ref-type="bibr">276</xref>]. Of these, treatment with tisagenlecleucel (T cells from the patients&#8217; blood are lentivirally transduced with CD19-speciic CARs) yielded an overall remission rate of 81% after three months in patients suffering from relapsed or refractory ALL, but caused serious, mainly reversible toxic effects in children and young adults under 25 years [<xref rid="B277-cells-09-02061" ref-type="bibr">277</xref>]. In patients with NHL, axicabtagene ciloleucel (lentiviral transduction of patients&#8217; blood T cells with CD19-specific CARs) resulted in an objective response rate of 82%, and a complete response in 54% of cases [<xref rid="B278-cells-09-02061" ref-type="bibr">278</xref>]. However, treatment with either CAR-T treatment can lead to serious and even life-threatening side effects, like the tumor lysis syndrome, a disease which can result from a tumor therapy, causing hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia [<xref rid="B279-cells-09-02061" ref-type="bibr">279</xref>], and the cytokine release syndrome that is induced by a cytokine storm [<xref rid="B280-cells-09-02061" ref-type="bibr">280</xref>], leading to fever, hypotension, and respiratory insufficiency [<xref rid="B281-cells-09-02061" ref-type="bibr">281</xref>].</p><p>Another problem of CAR-Ts is the interaction of MDSC with CAR-Ts, which may lead to a reduction of CAR-T activation, to reduced proliferation after antigen stimulation, and lowered cytokine production [<xref rid="B282-cells-09-02061" ref-type="bibr">282</xref>]. MDSC in the liver for example suppress an anti-tumor response of CAR-Ts via binding of PD-L1 that engages PD-1 on T cells [<xref rid="B283-cells-09-02061" ref-type="bibr">283</xref>]. The expression of PD-L1 by MDSC in the liver is supported by GM-CSF and is largely regulated by the transcription factor STAT3. The negative effect of MDSC on CAR-T can be avoided by MDSC depletion, using therapeutic drugs like gemcitabine and 5-fluorouracil [<xref rid="B284-cells-09-02061" ref-type="bibr">284</xref>], neutralization of GM-CSF, e.g., by otilimab that is currently assessed in a clinical phase 3 study [<xref rid="B285-cells-09-02061" ref-type="bibr">285</xref>], and PD-L1 blockade, e.g., by checkpoint inhibitors like atezolizumab [<xref rid="B286-cells-09-02061" ref-type="bibr">286</xref>]. For example, Fultang and co-workers have recently shown that the activity of an anti-GD2-/mesothelin-/EGFRvIII-CAR-T was significantly enhanced when co-applied with the anti-MDSC drug gemtuzumab ozogamicin, an anti-CD33 antibody linked to cytostatic calicheamicin [<xref rid="B287-cells-09-02061" ref-type="bibr">287</xref>]. Altogether, due to the high potential of CARs for cancer treatment, improvement of CAR-based therapy is in the focus of research. For example, Wang et al. have recently generated CAR-T cells by electroporation-based transfection of T cells with non-viral mcDNA, which is considered much safer than virus-based chimeric antigen receptor-engineered CARs [<xref rid="B288-cells-09-02061" ref-type="bibr">288</xref>].</p></sec><sec id="sec5-cells-09-02061"><title>5. Manipulating the TME Using Therapeutic Nucleic Acids</title><p>The TME is a complex, very heterogeneous network of stromal and endothelial cells as well as recruited immune cells [<xref rid="B289-cells-09-02061" ref-type="bibr">289</xref>]. It is characterized by leaky blood vessels, a special tumor-specific extracellular matrix (ECM), immunomodulatory agents/cytokines, and growth factors [<xref rid="B18-cells-09-02061" ref-type="bibr">18</xref>,<xref rid="B289-cells-09-02061" ref-type="bibr">289</xref>,<xref rid="B290-cells-09-02061" ref-type="bibr">290</xref>,<xref rid="B291-cells-09-02061" ref-type="bibr">291</xref>]. The TME plays an important role during tumorigenesis as well as tumor progression and metastasis by supporting the tumor cells in evading the immune system [<xref rid="B19-cells-09-02061" ref-type="bibr">19</xref>,<xref rid="B292-cells-09-02061" ref-type="bibr">292</xref>] and by contributing to chemoresistance [<xref rid="B293-cells-09-02061" ref-type="bibr">293</xref>]. Different cell types like CAF [<xref rid="B294-cells-09-02061" ref-type="bibr">294</xref>], TAM (pro-tumoral phenotype) [<xref rid="B295-cells-09-02061" ref-type="bibr">295</xref>,<xref rid="B296-cells-09-02061" ref-type="bibr">296</xref>,<xref rid="B297-cells-09-02061" ref-type="bibr">297</xref>], MDSC, and Treg (see <xref ref-type="sec" rid="sec3-cells-09-02061">Section 3</xref>) [<xref rid="B18-cells-09-02061" ref-type="bibr">18</xref>] as well as tolerogenic DC [<xref rid="B18-cells-09-02061" ref-type="bibr">18</xref>,<xref rid="B298-cells-09-02061" ref-type="bibr">298</xref>] contribute to the establishment and maintenance of the immunosuppressive tumor surroundings. In addition, the TME inactivates effector functions of tumor-infiltrating lymphocytes (TIL) by various mechanisms, and thus undermines immunosurveillance [<xref rid="B292-cells-09-02061" ref-type="bibr">292</xref>,<xref rid="B299-cells-09-02061" ref-type="bibr">299</xref>,<xref rid="B300-cells-09-02061" ref-type="bibr">300</xref>].</p><p>Further characteristics of the tumor tissue comprise acidity (&#8776;pH 6.5) due to the Warburg effect [<xref rid="B301-cells-09-02061" ref-type="bibr">301</xref>,<xref rid="B302-cells-09-02061" ref-type="bibr">302</xref>], hypoxia [<xref rid="B303-cells-09-02061" ref-type="bibr">303</xref>], expression of distinct matrix enzymes like matrix metalloproteases (MMPs) [<xref rid="B304-cells-09-02061" ref-type="bibr">304</xref>], and an elevated redox potential [<xref rid="B305-cells-09-02061" ref-type="bibr">305</xref>] as well as increased levels of reactive oxygen species (ROS) [<xref rid="B306-cells-09-02061" ref-type="bibr">306</xref>]. These properties display barriers in the delivery process of anti-tumor drugs, but can be also exploited for bio-responsive targeting of therapeutics to the tumor tissue [<xref rid="B307-cells-09-02061" ref-type="bibr">307</xref>]. By this, tumor selectivity and overall biocompatibility might be enhanced. Besides, passive targeting via the enhanced permeation and retention (EPR) effect [<xref rid="B308-cells-09-02061" ref-type="bibr">308</xref>], and more effective tumor addressing via tumor homing peptides and CPPs can increase accumulation of (nano) formulations within the tumor [<xref rid="B309-cells-09-02061" ref-type="bibr">309</xref>,<xref rid="B310-cells-09-02061" ref-type="bibr">310</xref>,<xref rid="B311-cells-09-02061" ref-type="bibr">311</xref>]. In addition, active targeting mediated by ligands such as peptides, vitamins, or antibodies is often utilized to direct a therapeutic selectively to the target site [<xref rid="B312-cells-09-02061" ref-type="bibr">312</xref>].</p><p>Immunotherapeutic approaches often aim to evoke a switch from immunosuppression to immune permission within the tumor tissue. By this, the tumor becomes immune-sensitive again, and then can be effectively combated by the innate and adaptive immune system. In the following, a selection of diverse strategies for TME manipulation is presented with a focus on nucleic acid-based approaches.</p><sec id="sec5dot1-cells-09-02061"><title>5.1. Modulation of Intratumoral Signaling by Nucleic Acids</title><p>In the immunosuppressive TME a disproportion exists between soluble mediators (cytokines and growth factors) exerting pro- and anti-inflammatory properties, thereby promoting tumor immune escape and tumorigenesis [<xref rid="B313-cells-09-02061" ref-type="bibr">313</xref>]. There are two options to counteract this imbalance, resulting in effective anti-tumor activity [<xref rid="B313-cells-09-02061" ref-type="bibr">313</xref>]. On the one hand, the immune system can be stimulated by overexpression of pro-inflammatory cytokines. On the other hand, immunosuppression can be reduced by inhibition/neutralization of anti-inflammatory signals.</p><p>Cytokines are key mediators in the communication of immune cells and are crucially involved in controlling the intensity of an immune response [<xref rid="B314-cells-09-02061" ref-type="bibr">314</xref>,<xref rid="B315-cells-09-02061" ref-type="bibr">315</xref>,<xref rid="B316-cells-09-02061" ref-type="bibr">316</xref>]. Thus, it is not surprising that cytokine therapy has been pursued as a cancer immunotherapeutic approach for more than 30 years now. However, in clinical studies, such cytokine therapies have not met the expectations based on the results of preclinical studies, especially when applied as monotherapies [<xref rid="B313-cells-09-02061" ref-type="bibr">313</xref>]. Only IFN-&#945; [<xref rid="B317-cells-09-02061" ref-type="bibr">317</xref>] and IL-2 as high-dose therapy [<xref rid="B318-cells-09-02061" ref-type="bibr">318</xref>] have been approved for the systemic treatment of several cancers, based on moderate beneficial anti-tumor effects in clinical trials. Ongoing research is focused on increasing therapeutic efficacy and biocompatibility by developing recombinant cytokines with improved pharmacokinetics (e.g., PEGylated or fused with targeting antibodies), combinations with other immunotherapeutic approaches such as immune checkpoint inhibitors, and local or specifically targeted administration of (recombinant) cytokines [<xref rid="B313-cells-09-02061" ref-type="bibr">313</xref>]. Besides that, cytokine gene therapy (using gene encoding pDNA or viral vectors) and other nucleic acid-based approaches (like RNAi or genome editing) are promising concepts [<xref rid="B24-cells-09-02061" ref-type="bibr">24</xref>,<xref rid="B313-cells-09-02061" ref-type="bibr">313</xref>,<xref rid="B316-cells-09-02061" ref-type="bibr">316</xref>]. <xref rid="cells-09-02061-t001" ref-type="table">Table 1</xref> summarizes such nucleic acid-based approaches evaluated in clinical trials. In the following, important signaling molecules and strategies (especially therapeutic nucleic acids) to modulate their levels within the tumor tissue are outlined.</p><p>IL-2 stimulates T-lymphocytes and NK cells, but also controls the duration and intensity of their activation, regulates immune homeostasis, and balances the Teff/Treg ratio [<xref rid="B313-cells-09-02061" ref-type="bibr">313</xref>,<xref rid="B334-cells-09-02061" ref-type="bibr">334</xref>]. Various autologous/syngeneic as well as allogeneic IL-2 gene-modified tumor cell vaccines have been investigated in preclinical and clinical studies for their potential in prophylactic and therapeutic application for the treatment of advanced and metastatic cancers like melanoma [<xref rid="B319-cells-09-02061" ref-type="bibr">319</xref>,<xref rid="B320-cells-09-02061" ref-type="bibr">320</xref>,<xref rid="B321-cells-09-02061" ref-type="bibr">321</xref>,<xref rid="B322-cells-09-02061" ref-type="bibr">322</xref>,<xref rid="B335-cells-09-02061" ref-type="bibr">335</xref>,<xref rid="B336-cells-09-02061" ref-type="bibr">336</xref>,<xref rid="B337-cells-09-02061" ref-type="bibr">337</xref>]. In vitro transduction of tumor cells with the IL-2 gene was achieved using viral vectors (e.g., retro-viral or adenoviral) [<xref rid="B320-cells-09-02061" ref-type="bibr">320</xref>,<xref rid="B322-cells-09-02061" ref-type="bibr">322</xref>,<xref rid="B336-cells-09-02061" ref-type="bibr">336</xref>] or by employment of advanced methods like the adenovirus-enhanced transferrinfection (AVET) system [<xref rid="B319-cells-09-02061" ref-type="bibr">319</xref>,<xref rid="B335-cells-09-02061" ref-type="bibr">335</xref>,<xref rid="B337-cells-09-02061" ref-type="bibr">337</xref>,<xref rid="B338-cells-09-02061" ref-type="bibr">338</xref>]. The toxicity profile of systemic IL-2 gene therapy can be improved by transcriptional targeting of IL-2 to the tumor to ensure specific expression of the IL-2 gene within the tumor [<xref rid="B339-cells-09-02061" ref-type="bibr">339</xref>,<xref rid="B340-cells-09-02061" ref-type="bibr">340</xref>,<xref rid="B341-cells-09-02061" ref-type="bibr">341</xref>].</p><p>TNF-&#945; exhibits tumoricidal effects by inducing apoptosis and hemorrhagic necrosis of tumor cells [<xref rid="B323-cells-09-02061" ref-type="bibr">323</xref>]. GenVec&#8217;s TNFerade is a replication-deficient adenoviral vector encoding for TNF-&#945; under the control of a radiation-inducible promotor [<xref rid="B323-cells-09-02061" ref-type="bibr">323</xref>,<xref rid="B324-cells-09-02061" ref-type="bibr">324</xref>], applied by intratumoral injection. Phase III clinical trials have been terminated in 2010, as a study in locally advanced pancreatic cancer failed to show a significantly improved outcome of combination therapy with TNFerade in comparison to standard therapy alone [<xref rid="B342-cells-09-02061" ref-type="bibr">342</xref>]. Reduced transgene expression may be caused by (pre-existing) immune responses against the adenoviral vector, mainly mediated by antibodies, limiting the option of repeated application [<xref rid="B343-cells-09-02061" ref-type="bibr">343</xref>]. Besides viral vectors, non-viral carrier systems for TNF-&#945; delivery are subject of research as well. Kircheis et al. for example designed surface-shielded transferrin-PEI/DNA complexes for targeted TNF-&#945; gene delivery after intravenous application in tumor-bearing mice [<xref rid="B344-cells-09-02061" ref-type="bibr">344</xref>]. Significant and selective TNF-&#945; expression within the tumor without detectable serum levels could be demonstrated in three different tumor models. In a combination approach, Su et al. evaluated to which extent systemic TNF-&#945; gene therapy synergized with liposomal doxorubicin (Doxil<sup>&#174;</sup>) to enhance tumor endothelium permeability, and thus would promote accumulation of the chemotherapeutic drug within the tumor [<xref rid="B345-cells-09-02061" ref-type="bibr">345</xref>]. Synthetic polymers based on amino ethylene units [<xref rid="B346-cells-09-02061" ref-type="bibr">346</xref>,<xref rid="B347-cells-09-02061" ref-type="bibr">347</xref>] were used as pDNA carriers. The beneficial effect of TNF-&#945; expression on concomitant Doxil<sup>&#174;</sup> therapy was proven in all tested tumor models including metastases [<xref rid="B345-cells-09-02061" ref-type="bibr">345</xref>]. All in all, this combination approach offers great potential in treating metastases even with low doses of chemotherapeutic drugs. Quinn et al. achieved synergistic effects on tumor growth inhibition by combining systemic application of a previously evaluated RGD-targeted adeno-associated virus phage encoding for TNF-&#945; [<xref rid="B348-cells-09-02061" ref-type="bibr">348</xref>,<xref rid="B349-cells-09-02061" ref-type="bibr">349</xref>] with hypo-fractionated radiation for the therapy of disseminated melanoma [<xref rid="B350-cells-09-02061" ref-type="bibr">350</xref>].</p><p>Another interesting candidate for cancer immunotherapy is IL-12 because of its ability to activate both the innate and the adaptive immune system [<xref rid="B351-cells-09-02061" ref-type="bibr">351</xref>]. In addition, IL-12 has anti-angiogenic properties by inducing IFN-&#947;, which in turn inhibits VEGF and MMPs [<xref rid="B313-cells-09-02061" ref-type="bibr">313</xref>,<xref rid="B351-cells-09-02061" ref-type="bibr">351</xref>,<xref rid="B352-cells-09-02061" ref-type="bibr">352</xref>,<xref rid="B353-cells-09-02061" ref-type="bibr">353</xref>,<xref rid="B354-cells-09-02061" ref-type="bibr">354</xref>]. In early clinical trials, however, the anti-tumor activity of systemically applied IL-12 was found to be only moderate, and was accompanied by severe side effects [<xref rid="B351-cells-09-02061" ref-type="bibr">351</xref>,<xref rid="B355-cells-09-02061" ref-type="bibr">355</xref>]. IFN-&#947; as induced by IL-12 is mainly responsible for the dose-related and schedule-dependent toxicity [<xref rid="B353-cells-09-02061" ref-type="bibr">353</xref>,<xref rid="B356-cells-09-02061" ref-type="bibr">356</xref>]. New strategies focus on targeted and local delivery of IL-12 to minimize systemic toxicity and to improve specific tumor targeting by conjugating IL-12 to tumor antigen-specific monoclonal antibodies (so-called immunocytokines) [<xref rid="B357-cells-09-02061" ref-type="bibr">357</xref>,<xref rid="B358-cells-09-02061" ref-type="bibr">358</xref>]. Moreover, various IL-12 gene therapy approaches ex vivo and in vivo are pursued [<xref rid="B359-cells-09-02061" ref-type="bibr">359</xref>,<xref rid="B360-cells-09-02061" ref-type="bibr">360</xref>]. Different delivery methods comprise viral vectors like adeno- or retroviral vectors [<xref rid="B325-cells-09-02061" ref-type="bibr">325</xref>,<xref rid="B361-cells-09-02061" ref-type="bibr">361</xref>,<xref rid="B362-cells-09-02061" ref-type="bibr">362</xref>,<xref rid="B363-cells-09-02061" ref-type="bibr">363</xref>,<xref rid="B364-cells-09-02061" ref-type="bibr">364</xref>,<xref rid="B365-cells-09-02061" ref-type="bibr">365</xref>,<xref rid="B366-cells-09-02061" ref-type="bibr">366</xref>], and non-viral techniques such as electroporation [<xref rid="B367-cells-09-02061" ref-type="bibr">367</xref>,<xref rid="B368-cells-09-02061" ref-type="bibr">368</xref>,<xref rid="B369-cells-09-02061" ref-type="bibr">369</xref>,<xref rid="B370-cells-09-02061" ref-type="bibr">370</xref>,<xref rid="B371-cells-09-02061" ref-type="bibr">371</xref>,<xref rid="B372-cells-09-02061" ref-type="bibr">372</xref>,<xref rid="B373-cells-09-02061" ref-type="bibr">373</xref>] or synthetic carrier systems like (lipo)polymer-DNA complexes and liposomes [<xref rid="B374-cells-09-02061" ref-type="bibr">374</xref>,<xref rid="B375-cells-09-02061" ref-type="bibr">375</xref>,<xref rid="B376-cells-09-02061" ref-type="bibr">376</xref>,<xref rid="B377-cells-09-02061" ref-type="bibr">377</xref>]. In order to increase the specificity of local IL-12 expression within the tumor, an IL-12 transgene with a ligand-inducible expression switch was designed [<xref rid="B325-cells-09-02061" ref-type="bibr">325</xref>,<xref rid="B364-cells-09-02061" ref-type="bibr">364</xref>]. Another way to locally control in situ expression of IL-12 is to engineer CAR- T cells, which release IL-12 in an inducible or constitutive manner [<xref rid="B378-cells-09-02061" ref-type="bibr">378</xref>]. Moreover, the IL-12 gene may be inserted in the genome of oncolytic viruses as an immune stimulatory component (see <xref ref-type="sec" rid="sec5dot3-cells-09-02061">Section 5.3</xref>).</p><p>GM-CSF has been investigated as an adjuvant for different types of vaccines because of its stimulatory effect on myeloid cell types like conventional DC and macrophages [<xref rid="B313-cells-09-02061" ref-type="bibr">313</xref>]. Unfortunately, GM-CSF activates TAM and MDSC as well, thereby supporting tumor growth. These opposing effects are mainly responsible for its only moderate clinical efficacy [<xref rid="B316-cells-09-02061" ref-type="bibr">316</xref>]. Combination therapy is an option to overcome this issue; e.g., co-treatment with recombinant GM-CSF and immune checkpoint inhibitors led to prolonged survival of metastatic melanoma patients [<xref rid="B379-cells-09-02061" ref-type="bibr">379</xref>]. An example for a GM-CSF gene-based approach is the GVAX technology [<xref rid="B326-cells-09-02061" ref-type="bibr">326</xref>,<xref rid="B327-cells-09-02061" ref-type="bibr">327</xref>,<xref rid="B328-cells-09-02061" ref-type="bibr">328</xref>,<xref rid="B329-cells-09-02061" ref-type="bibr">329</xref>]. To this end, allogeneic pancreatic tumor cells have been transfected ex vivo with pDNA encoding GM-CSF. GVAX has been tested in combination with immune checkpoint inhibitors as well as with tumor vaccines. Moreover, oncolytic viruses often encode inter alia for GM-CSF (see <xref ref-type="sec" rid="sec5dot3-cells-09-02061">Section 5.3</xref>). GM-CSF is also addressed in strategies to improve the efficacy and to lower the toxicity of CAR-T cell therapies. However, in contrast to the aforementioned GM-CSF therapy concepts, here GM-CSF is not substituted, but knocked out for example via CRISPR/Cas9 technology [<xref rid="B380-cells-09-02061" ref-type="bibr">380</xref>].</p><p>The CXCL12/CXCR4 (C-X-C motif chemokine 12/C-X-C motif chemokine receptor 4) axis plays a crucial role in tumorigenesis, metastasis, and chemoresistance [<xref rid="B381-cells-09-02061" ref-type="bibr">381</xref>,<xref rid="B382-cells-09-02061" ref-type="bibr">382</xref>], and therefore is an ideal target for cancer immunotherapy. However, the toxicity of systemic anti-CXCL12 therapy approaches using small CXCR4 inhibitors like AMD3100 [<xref rid="B383-cells-09-02061" ref-type="bibr">383</xref>] and monoclonal antibodies targeting CXCL12 [<xref rid="B384-cells-09-02061" ref-type="bibr">384</xref>] is a serious issue. Transient and locally restricted expression of antibody-like trap proteins that bind and neutralize CXCL12 constitutes an option to increase systemic tolerability [<xref rid="B385-cells-09-02061" ref-type="bibr">385</xref>,<xref rid="B386-cells-09-02061" ref-type="bibr">386</xref>]. For this purpose, NPs are used for target site-selective delivery of pCXCL12-trap encoding pDNA [<xref rid="B18-cells-09-02061" ref-type="bibr">18</xref>], such as lipid NPs/liposomes [<xref rid="B385-cells-09-02061" ref-type="bibr">385</xref>,<xref rid="B386-cells-09-02061" ref-type="bibr">386</xref>,<xref rid="B387-cells-09-02061" ref-type="bibr">387</xref>].</p><p>VEGF is crucial for neoangiogenesis, which is essential for tumor progression and metastasis [<xref rid="B388-cells-09-02061" ref-type="bibr">388</xref>]. Moreover, VEGF contributes to immunosuppression within the TME [<xref rid="B389-cells-09-02061" ref-type="bibr">389</xref>]. Accordingly, several anti-VEGF therapeutics have already been clinically approved, and many pre-/clinical trials are currently carried out evaluating the VEGF trap protein aflibercept [<xref rid="B390-cells-09-02061" ref-type="bibr">390</xref>,<xref rid="B391-cells-09-02061" ref-type="bibr">391</xref>] or monoclonal antibodies that target either VEGF itself (bevacizumab) [<xref rid="B392-cells-09-02061" ref-type="bibr">392</xref>,<xref rid="B393-cells-09-02061" ref-type="bibr">393</xref>] and its receptor VEGFR (ramucirumab) [<xref rid="B394-cells-09-02061" ref-type="bibr">394</xref>] in combination with classical chemotherapeutics or immune checkpoint inhibitors [<xref rid="B389-cells-09-02061" ref-type="bibr">389</xref>,<xref rid="B395-cells-09-02061" ref-type="bibr">395</xref>]. Another potent strategy is RNAi aimed to knock-down VEGF or VEGFR, which showed good anti-tumor results in many preclinical studies. In this regard, CPPs [<xref rid="B396-cells-09-02061" ref-type="bibr">396</xref>,<xref rid="B397-cells-09-02061" ref-type="bibr">397</xref>,<xref rid="B398-cells-09-02061" ref-type="bibr">398</xref>,<xref rid="B399-cells-09-02061" ref-type="bibr">399</xref>], polymers like PEI [<xref rid="B400-cells-09-02061" ref-type="bibr">400</xref>,<xref rid="B401-cells-09-02061" ref-type="bibr">401</xref>,<xref rid="B402-cells-09-02061" ref-type="bibr">402</xref>,<xref rid="B403-cells-09-02061" ref-type="bibr">403</xref>] or chitosan [<xref rid="B404-cells-09-02061" ref-type="bibr">404</xref>], cationic liposomes [<xref rid="B405-cells-09-02061" ref-type="bibr">405</xref>,<xref rid="B406-cells-09-02061" ref-type="bibr">406</xref>], gold [<xref rid="B407-cells-09-02061" ref-type="bibr">407</xref>], and graphene oxide NPs [<xref rid="B408-cells-09-02061" ref-type="bibr">408</xref>], often modified with shielding and targeting units, have been used as delivery systems.</p><p>TGF-&#946; exhibits manifold functions regarding cell proliferation, differentiation, migration, and apoptosis [<xref rid="B409-cells-09-02061" ref-type="bibr">409</xref>,<xref rid="B410-cells-09-02061" ref-type="bibr">410</xref>,<xref rid="B411-cells-09-02061" ref-type="bibr">411</xref>]. In the context of cancer progression, an overexpression of TGF-&#946; has been observed within the TME, promoting EMT, immunosuppression, and metastasis. However, these tumor-promoting effects of TGF-&#946; occur only in late-stage tumors, while in early stages its anti-tumor activity is more pronounced. Thus, anti-TGF-&#946; therapy approaches aim to treat advanced cancers. A lot of preclinical and clinical research has been performed in the field of nucleic acid-based strategies ranging from siRNA [<xref rid="B412-cells-09-02061" ref-type="bibr">412</xref>] over miRNA [<xref rid="B413-cells-09-02061" ref-type="bibr">413</xref>,<xref rid="B414-cells-09-02061" ref-type="bibr">414</xref>,<xref rid="B415-cells-09-02061" ref-type="bibr">415</xref>] to antisense oligonucleotides (ASO) [<xref rid="B416-cells-09-02061" ref-type="bibr">416</xref>,<xref rid="B417-cells-09-02061" ref-type="bibr">417</xref>,<xref rid="B418-cells-09-02061" ref-type="bibr">418</xref>,<xref rid="B419-cells-09-02061" ref-type="bibr">419</xref>,<xref rid="B420-cells-09-02061" ref-type="bibr">420</xref>,<xref rid="B421-cells-09-02061" ref-type="bibr">421</xref>]. Belagenpneumatucel-L is an anti-TGF-&#946; allogeneic tumor cell vaccine, based on non-small cell lung cancer cells genetically engineered to express ASO directed against TGF-&#946; [<xref rid="B331-cells-09-02061" ref-type="bibr">331</xref>,<xref rid="B332-cells-09-02061" ref-type="bibr">332</xref>,<xref rid="B333-cells-09-02061" ref-type="bibr">333</xref>]. In a phase III clinical trial, however, no significant increase in the mean overall survival was achieved compared to placebo treatment, but e.g., prior treatment with radiation therapy was found to have a positive effect on therapeutic outcome [<xref rid="B333-cells-09-02061" ref-type="bibr">333</xref>]. Therefore, further investigation in clinical trials is necessary.</p><p>In addition to the mediators discussed above, many others can be addressed in immunotherapeutic approaches as well [<xref rid="B313-cells-09-02061" ref-type="bibr">313</xref>,<xref rid="B316-cells-09-02061" ref-type="bibr">316</xref>]. For example, intramuscular IL-27 and intratumoral IFN-&#945; gene delivery via viral vectors promoted Treg depletion in the TME [<xref rid="B422-cells-09-02061" ref-type="bibr">422</xref>,<xref rid="B423-cells-09-02061" ref-type="bibr">423</xref>,<xref rid="B424-cells-09-02061" ref-type="bibr">424</xref>]. This is favorable in view of the efficacy of cancer immunotherapy [<xref rid="B425-cells-09-02061" ref-type="bibr">425</xref>,<xref rid="B426-cells-09-02061" ref-type="bibr">426</xref>], suggesting that both approaches are valuable as adjuvant therapies. Moreover, IFN-&#945; showed strong anti-proliferative, anti-angiogenic, and immunomodulatory activity [<xref rid="B427-cells-09-02061" ref-type="bibr">427</xref>,<xref rid="B428-cells-09-02061" ref-type="bibr">428</xref>]. An IFN-&#945; encoding adenoviral vector (rAdIFN&#945;2b/Syn3, Instiladrin<sup>&#174;</sup>) has been investigated in advanced clinical trials for intravesical treatment of BCG (Bacillus Calmette&#8211;Guerin) unresponsive bladder cancer [<xref rid="B330-cells-09-02061" ref-type="bibr">330</xref>]. Results of a phase III clinical trial that has been completed in 2018 are still pending (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02773849">NCT02773849</ext-link>).</p></sec><sec id="sec5dot2-cells-09-02061"><title>5.2. Nucleic Acid-Mediated Immune Checkpoint Inhibition and T Cell Stimulation</title><p>Immune checkpoints regulate the intensity and the duration of immune responses [<xref rid="B429-cells-09-02061" ref-type="bibr">429</xref>,<xref rid="B430-cells-09-02061" ref-type="bibr">430</xref>]. By this, self-tolerance is preserved, and hence tissue damage is minimized. Tumors often abuse such pathways in order to create an immunosuppressive surrounding, e.g., by anergizing tumor-reactive Teff. Consequently, blockade of immune checkpoints presents a very promising method to restore immunity against the tumor and the TME. Among these CTLA-4 and PD-1 are the best characterized receptors [<xref rid="B431-cells-09-02061" ref-type="bibr">431</xref>,<xref rid="B432-cells-09-02061" ref-type="bibr">432</xref>]. Intensive research led to therapy concepts of immune checkpoint inhibition, which revolutionized treatment especially of advanced cancers [<xref rid="B433-cells-09-02061" ref-type="bibr">433</xref>]. Up to now, several antibodies addressing CTLA-4, PD-1, and its ligand PD-L1 have been implemented in cancer therapy regimens [<xref rid="B25-cells-09-02061" ref-type="bibr">25</xref>,<xref rid="B26-cells-09-02061" ref-type="bibr">26</xref>]. However, response rates are quite low, and relapse often occurs due to resistance development [<xref rid="B434-cells-09-02061" ref-type="bibr">434</xref>,<xref rid="B435-cells-09-02061" ref-type="bibr">435</xref>,<xref rid="B436-cells-09-02061" ref-type="bibr">436</xref>,<xref rid="B437-cells-09-02061" ref-type="bibr">437</xref>,<xref rid="B438-cells-09-02061" ref-type="bibr">438</xref>]. Moreover, immune checkpoint blockade is effective only if the number of tumor-reactive Teff is high enough at the beginning of treatment [<xref rid="B434-cells-09-02061" ref-type="bibr">434</xref>,<xref rid="B439-cells-09-02061" ref-type="bibr">439</xref>,<xref rid="B440-cells-09-02061" ref-type="bibr">440</xref>,<xref rid="B441-cells-09-02061" ref-type="bibr">441</xref>,<xref rid="B442-cells-09-02061" ref-type="bibr">442</xref>]. In this regard, the T cell number in a patient can be increased by ex vivo expansion of TIL that are subsequently reinfused, or by prior treatment with tumor vaccines [<xref rid="B438-cells-09-02061" ref-type="bibr">438</xref>]. Combinations of different immune checkpoint inhibitors as well as their combination with other (immuno)therapeutic approaches aim to overcome the resistance mechanisms [<xref rid="B436-cells-09-02061" ref-type="bibr">436</xref>,<xref rid="B437-cells-09-02061" ref-type="bibr">437</xref>,<xref rid="B442-cells-09-02061" ref-type="bibr">442</xref>].</p><p>Other major issues of checkpoint inhibitor therapy are immune-related adverse effects and toxicity [<xref rid="B443-cells-09-02061" ref-type="bibr">443</xref>,<xref rid="B444-cells-09-02061" ref-type="bibr">444</xref>]. Systemic toxicity can be reduced by targeted delivery of checkpoint inhibitors using NPs and by nucleic acid-based approaches [<xref rid="B442-cells-09-02061" ref-type="bibr">442</xref>]. Concerning the latter, mRNA encoding for an anti-CTLA-4 antibody [<xref rid="B445-cells-09-02061" ref-type="bibr">445</xref>], pDNA encoding for PD-L1 traps [<xref rid="B386-cells-09-02061" ref-type="bibr">386</xref>,<xref rid="B446-cells-09-02061" ref-type="bibr">446</xref>,<xref rid="B447-cells-09-02061" ref-type="bibr">447</xref>], siRNA specific for PD-L1 [<xref rid="B448-cells-09-02061" ref-type="bibr">448</xref>,<xref rid="B449-cells-09-02061" ref-type="bibr">449</xref>,<xref rid="B450-cells-09-02061" ref-type="bibr">450</xref>,<xref rid="B451-cells-09-02061" ref-type="bibr">451</xref>,<xref rid="B452-cells-09-02061" ref-type="bibr">452</xref>], and CRISPR/Cas9-mediated knock-out of the PD-1 gene in CAR-T cells [<xref rid="B453-cells-09-02061" ref-type="bibr">453</xref>,<xref rid="B454-cells-09-02061" ref-type="bibr">454</xref>] have been tested so far (<xref ref-type="fig" rid="cells-09-02061-f003">Figure 3</xref>).</p><p>For example, Pruitt et al. electroporated DC ex vivo with mRNA encoding heavy and light chains of blocking antibodies specific for CTLA-4 and glucocorticoid-induced TNFR-related protein [<xref rid="B445-cells-09-02061" ref-type="bibr">445</xref>], which are expressed by Treg at high level [<xref rid="B455-cells-09-02061" ref-type="bibr">455</xref>]. Transfected DC were co-administrated with tumor antigen-transfected DC via subcutaneous injection into B16/F10.9 melanoma bearing C57BL/6 mice [<xref rid="B445-cells-09-02061" ref-type="bibr">445</xref>]. Based on the encouraging results, a phase I clinical trial for treatment of metastatic melanoma has been initiated (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01216436">NCT01216436</ext-link>).</p><p>Transient local expression of PD-L1 trap was pursued by Huang and co-workers [<xref rid="B447-cells-09-02061" ref-type="bibr">447</xref>]. For this purpose, pDNA encoding for PD-L1 trap fusion protein was loaded into lipid-protamine-DNA NPs, consisting of a DNA-protamine core within pre-formed DOTAP-cholesterol liposomes. These were optionally equipped with 1,2-distearoylphosphatidylethanolamine (DSPE)-PEG or DSPE-PEG-AEAA for shielding and targeting. These nano formulations were applied intravenously in combination with intraperitoneally administered oxaliplatin, a chemotherapeutic drug inducing immunogenic cell death and thereby activating DC. By this approach, synergistic effects on tumor inhibition were achieved in a colorectal cancer mouse model.</p><p>A further combination approach was conducted by Zhou et al. by combined administration of doxorubicin and of PD-L1-specific siRNA delivered by stimuli-responsive NPs in a B16 melanoma tumor model [<xref rid="B452-cells-09-02061" ref-type="bibr">452</xref>]. These NPs were dually sensitive towards the extracellular slightly acidic pH of tumor cells (pH-triggered detachment of the PEG layer) and their elevated intracellular redox potential (reduction-sensitive polymer core of poly-L-lysine&#8211;lipoic acid). This combination therapy was superior to either monotherapy in terms of specificity, efficacy, and tolerability, proving once more the advantage of targeted combination therapies.</p></sec><sec id="sec5dot3-cells-09-02061"><title>5.3. Multi-Faceted Combat of Cancer by Oncolytic Virotherapy</title><p>Oncolytic viruses may constitute the next breakthrough in cancer immunotherapy [<xref rid="B456-cells-09-02061" ref-type="bibr">456</xref>]. They comprise DNA and RNA viruses, which can be wild-type (e.g., coxsackie virus, reovirus) or genetically modified (e.g., herpes simplex virus (HSV), adenovirus, vaccinia virus) [<xref rid="B457-cells-09-02061" ref-type="bibr">457</xref>]. Oncolytic viruses selectively replicate in tumor tissue while destroying it [<xref rid="B14-cells-09-02061" ref-type="bibr">14</xref>,<xref rid="B458-cells-09-02061" ref-type="bibr">458</xref>,<xref rid="B459-cells-09-02061" ref-type="bibr">459</xref>,<xref rid="B460-cells-09-02061" ref-type="bibr">460</xref>]. Moreover, they exhibit an immunostimulatory function. Infection and lysis of tumor cells lead to the release of ROS and proinflammatory cytokines as well as danger-associated molecular patterns and intracellular tumor antigens, stimulating both the innate and the adaptive immune system [<xref rid="B460-cells-09-02061" ref-type="bibr">460</xref>]. By this, even immunological memory can be induced, resulting in long-lasting anti-tumor effects [<xref rid="B14-cells-09-02061" ref-type="bibr">14</xref>,<xref rid="B461-cells-09-02061" ref-type="bibr">461</xref>].</p><p>In 1991, Martuza et al. succeeded in producing the first genetically modified HSV-1 characterized by a mutation in the thymidine kinase (TK) gene to ensure selective replication only in tumor cells [<xref rid="B462-cells-09-02061" ref-type="bibr">462</xref>]. This pioneer work opened a new way for cancer treatment. The first clinical trial with an oncolytic virus started in mid-1990 [<xref rid="B463-cells-09-02061" ref-type="bibr">463</xref>], followed quickly by many others [<xref rid="B464-cells-09-02061" ref-type="bibr">464</xref>]. However, the clinical efficacy fell short of the expectations, but safety and synergism with standard cancer treatments could be demonstrated [<xref rid="B464-cells-09-02061" ref-type="bibr">464</xref>]. Subsequent generations of oncolytic viruses have been developed by genetic engineering to enhance selectivity and efficiency while maintaining or even improving safety [<xref rid="B457-cells-09-02061" ref-type="bibr">457</xref>,<xref rid="B459-cells-09-02061" ref-type="bibr">459</xref>,<xref rid="B465-cells-09-02061" ref-type="bibr">465</xref>,<xref rid="B466-cells-09-02061" ref-type="bibr">466</xref>] (<xref ref-type="fig" rid="cells-09-02061-f004">Figure 4</xref>). Tumor selectivity can be enhanced at several levels (transduction, transcription, translation, post-translation) as well as via oncogenic targeting or insertion of miRNA targeting sequences [<xref rid="B465-cells-09-02061" ref-type="bibr">465</xref>,<xref rid="B467-cells-09-02061" ref-type="bibr">467</xref>]. Oncolytic and immunogenic efficacy can be increased by insertion of certain transgenes encoding (i) enzymes that convert pro-drugs to cytotoxic products (e.g., HSV-TK or cytosine deaminase), (ii) immunostimulatory cytokines (e.g., GM-CSF or IL-12), or (iii) TME/ECM-modifying peptides and enzymes (e.g., MMP-9 or the anti-angiogenic peptide angiostatin) [<xref rid="B468-cells-09-02061" ref-type="bibr">468</xref>]. Safety can be ensured by mutations in pathogenic and virulence genes as well as in genes required for viral replication in normal cells [<xref rid="B457-cells-09-02061" ref-type="bibr">457</xref>,<xref rid="B468-cells-09-02061" ref-type="bibr">468</xref>].</p><p>Nowadays, a large repertoire of oncolytic viruses is available and oncolytic virotherapy has been intensively investigated in numerous preclinical and clinical studies, also in combination with other cancer therapies like chemotherapy, radiation therapy, or other immunotherapies [<xref rid="B456-cells-09-02061" ref-type="bibr">456</xref>,<xref rid="B457-cells-09-02061" ref-type="bibr">457</xref>,<xref rid="B458-cells-09-02061" ref-type="bibr">458</xref>,<xref rid="B459-cells-09-02061" ref-type="bibr">459</xref>,<xref rid="B460-cells-09-02061" ref-type="bibr">460</xref>,<xref rid="B469-cells-09-02061" ref-type="bibr">469</xref>,<xref rid="B470-cells-09-02061" ref-type="bibr">470</xref>]. <xref rid="cells-09-02061-t002" ref-type="table">Table 2</xref> displays approved oncolytic virotherapies and those that have been or are currently tested in clinical trials.</p><p>RIGVIR<sup>&#174;</sup> was the first oncolytic virus being approved for therapy of melanoma in Latvia in 2004 [<xref rid="B471-cells-09-02061" ref-type="bibr">471</xref>]. This oncolytic virus, enteric cytopathogenic human orphan (ECHO)-7, is a wild-type virus. In 2005, the first genetically modified oncolytic virus (Oncorine<sup>&#174;</sup>, a recombinant oncolytic adenovirus H101) was approved in China for the treatment of nasopharyngeal carcinoma [<xref rid="B474-cells-09-02061" ref-type="bibr">474</xref>,<xref rid="B475-cells-09-02061" ref-type="bibr">475</xref>]. Ten years later, T-Vec (talminogene laherparepvec) achieved approval by the FDA and the European Medicines Agency (EMA) for treatment of advanced melanoma [<xref rid="B477-cells-09-02061" ref-type="bibr">477</xref>,<xref rid="B478-cells-09-02061" ref-type="bibr">478</xref>]. This oncolytic virus is derived from HSV-1 and was genetically modified to mitigate pathogenicity as well as to increase tumor-selective replication and lysis [<xref rid="B478-cells-09-02061" ref-type="bibr">478</xref>]. In addition, T-Vec expresses GM-CSF to enhance anti-tumor immunity.</p><p>Saha et al. conducted a preclinical study with a triple-mutated third generation oncolytic HSV-1 vector (G47&#916;-mIL12), in which the murine IL-12 gene was inserted [<xref rid="B483-cells-09-02061" ref-type="bibr">483</xref>]. This oncolytic virus was applied intratumorally, in combination with systemically applied immune checkpoint inhibitors. Only the triple combination of G47&#916;-mIL12, anti-CTLA-4, and anti-PD-1 antibodies successfully cured glioblastoma in an immune-competent glioblastoma mouse model.</p><p>Other oncolytic DNA viruses that are frequently used are genetically engineered adenovirus and vaccinia viruses [<xref rid="B484-cells-09-02061" ref-type="bibr">484</xref>,<xref rid="B485-cells-09-02061" ref-type="bibr">485</xref>]. CG0070, an oncolytic adenovirus type 5 with an inserted GM-CSF gene, is currently investigated in advanced clinical trials for treatment of non-muscle invasive bladder cancer (BOND, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01438112">NCT01438112</ext-link>; BOND2, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02365818">NCT02365818</ext-link>) [<xref rid="B456-cells-09-02061" ref-type="bibr">456</xref>]. The BOND study (phase II/III clinical trial) demonstrated that intravesically applied CG0070 evoked a durable response in a subset of high-risk patients and was well tolerated [<xref rid="B476-cells-09-02061" ref-type="bibr">476</xref>]. An example for an oncolytic vaccinia virus in clinical studies is pexastimogene devacirepvec (Pexa-Vec, JX-594), which bears a mutation in the TK gene for cancer cell targeting and an inserted GM-CSF gene to enhance immune stimulation [<xref rid="B456-cells-09-02061" ref-type="bibr">456</xref>,<xref rid="B482-cells-09-02061" ref-type="bibr">482</xref>,<xref rid="B486-cells-09-02061" ref-type="bibr">486</xref>,<xref rid="B487-cells-09-02061" ref-type="bibr">487</xref>,<xref rid="B488-cells-09-02061" ref-type="bibr">488</xref>]. In a phase III clinical trial, Pexa-Vec is currently evaluated in combination with the multi tyrosine kinase inhibitor sorafenib in patients with advanced hepatocellular carcinoma without prior systemic therapy [<xref rid="B482-cells-09-02061" ref-type="bibr">482</xref>].</p><p>Reolysin<sup>&#174;</sup> (pelareorep) is a wild-type oncolytic RNA virus (type 3 Dearing (T3D) strain reovirus) [<xref rid="B457-cells-09-02061" ref-type="bibr">457</xref>,<xref rid="B489-cells-09-02061" ref-type="bibr">489</xref>], which is extensively studied in clinical trials [<xref rid="B456-cells-09-02061" ref-type="bibr">456</xref>,<xref rid="B472-cells-09-02061" ref-type="bibr">472</xref>]. In phase II and III clinical trials, Reolysin<sup>&#174;</sup> showed encouraging clinical efficacy, especially in combination with chemotherapeutics (e.g., carboplatin and paclitaxel) in patients with advanced malignancies [<xref rid="B472-cells-09-02061" ref-type="bibr">472</xref>,<xref rid="B473-cells-09-02061" ref-type="bibr">473</xref>].</p><p>Despite rapid progress in oncolytic virotherapy and encouraging results in clinical trials, there are still some obstacles [<xref rid="B457-cells-09-02061" ref-type="bibr">457</xref>]. One shortcoming is the small genomic capacity of some oncolytic viruses [<xref rid="B460-cells-09-02061" ref-type="bibr">460</xref>]. Moreover, deletion of pathogenic genes to reduce toxicity might also reduce oncolytic activity [<xref rid="B490-cells-09-02061" ref-type="bibr">490</xref>]. Efficacy may be enhanced for instance by insertion of transgenes or combination with other therapies. In case of the latter, optimal therapy regimens and schedules have to be evaluated in terms of dosage, application routes, and timing [<xref rid="B457-cells-09-02061" ref-type="bibr">457</xref>]. Therefore, further investigations in clinical trials are needed.</p></sec><sec id="sec5dot4-cells-09-02061"><title>5.4. Nucleic Acid-Based TLR Agonists to Boost Anti-Tumor Immune Response</title><p>PAMPs and other danger signals are recognized by the innate immune system via pattern recognition receptors such as TLRs [<xref rid="B491-cells-09-02061" ref-type="bibr">491</xref>,<xref rid="B492-cells-09-02061" ref-type="bibr">492</xref>]. Subsequently, pro-inflammatory pathways and the innate immune system are activated to eradicate pathogens. The anti-tumor immune response can be augmented by mimicking PAMPs. Monophosphoryl lipid A, a modified lipopolysaccharide derivative that triggers TLR4, is used as the adjuvant component in the prophylactic cervix cancer vaccine Cervarix<sup>&#174;</sup> [<xref rid="B493-cells-09-02061" ref-type="bibr">493</xref>]. The successful application of this TLR ligand also reinforced further research in immunostimulatory nucleic acids like double-stranded RNA (dsRNA) or single-stranded DNA (ssDNA) for cancer immunotherapy.</p><p>Poly(I:C) is an artificial dsRNA analog that acts as a potent TLR3 agonist [<xref rid="B491-cells-09-02061" ref-type="bibr">491</xref>,<xref rid="B494-cells-09-02061" ref-type="bibr">494</xref>]. Besides enhancement of the anti-tumor immune response, mainly by induction of IFN type I and chemokines especially in immune cells, poly(I:C) also directly induces apoptosis in cancer cells [<xref rid="B495-cells-09-02061" ref-type="bibr">495</xref>,<xref rid="B496-cells-09-02061" ref-type="bibr">496</xref>,<xref rid="B497-cells-09-02061" ref-type="bibr">497</xref>]. However, early clinical trials conducted in the 1970s using poly(I:C) for cancer treatment did not prove any clinical benefit [<xref rid="B491-cells-09-02061" ref-type="bibr">491</xref>,<xref rid="B498-cells-09-02061" ref-type="bibr">498</xref>,<xref rid="B499-cells-09-02061" ref-type="bibr">499</xref>,<xref rid="B500-cells-09-02061" ref-type="bibr">500</xref>], most likely because of its fast degradation prior to cellular uptake [<xref rid="B501-cells-09-02061" ref-type="bibr">501</xref>,<xref rid="B502-cells-09-02061" ref-type="bibr">502</xref>]. Consequently, a stabilized version of poly(I:C), polyriboinosinic:polyribocytidylic acid-polylysine carboxymethylcellulose (poly-ICLC, Hiltonol<sup>&#174;</sup>), has been developed [<xref rid="B502-cells-09-02061" ref-type="bibr">502</xref>,<xref rid="B503-cells-09-02061" ref-type="bibr">503</xref>]. However, toxicity was a big issue in early rounds of clinical testing, which could be reduced by administration of lower intravenous doses and by local application [<xref rid="B491-cells-09-02061" ref-type="bibr">491</xref>]. Nowadays, poly-ICLC is intensively evaluated in phase I and II clinical trials, especially in combination with cancer vaccines and radiotherapy [<xref rid="B491-cells-09-02061" ref-type="bibr">491</xref>,<xref rid="B492-cells-09-02061" ref-type="bibr">492</xref>,<xref rid="B495-cells-09-02061" ref-type="bibr">495</xref>,<xref rid="B504-cells-09-02061" ref-type="bibr">504</xref>,<xref rid="B505-cells-09-02061" ref-type="bibr">505</xref>]. Another concept to increase the stability and to improve the toxicity profile of TLR3 agonists is the employment of particulate formulations [<xref rid="B506-cells-09-02061" ref-type="bibr">506</xref>]. Shir et al. designed poly(I:C) polyplexes using a polymer conjugate consisting of branched PEI, PEG, EGF for EGFR-targeting, and lytic melittin for improved endosomal escape [<xref rid="B507-cells-09-02061" ref-type="bibr">507</xref>,<xref rid="B508-cells-09-02061" ref-type="bibr">508</xref>]. Complete tumor elimination could be achieved via intratumoral application in three different tumor mouse models (glioblastoma, breast cancer, adenocarcinoma) [<xref rid="B507-cells-09-02061" ref-type="bibr">507</xref>], and in a disseminated EGFR overexpressing tumor mouse model [<xref rid="B508-cells-09-02061" ref-type="bibr">508</xref>]. In the latter study, polyplexes were administered intravenously, followed by intraperitoneal injection of peripheral blood mononuclear cells into tumor bearing immune-deficient SCID mice. Tumor-targeted poly(I:C) mediated induction of chemokines and inflammatory cytokines selectively within the tumor tissue. This led to tumor homing of the injected immune cells as well as a strong anti-tumor and bystander killing effect. The latter might be advantageous in view of the heterogeneous tumor tissue. In this study, complete curation was achieved without adverse side effects [<xref rid="B508-cells-09-02061" ref-type="bibr">508</xref>]. Schaffert et al. optimized the nano-carrier by using linear instead of branched PEI [<xref rid="B509-cells-09-02061" ref-type="bibr">509</xref>]. The improved carrier was effective even without the lytic melittin unit. In a follow-up study, GE11 peptide was used for EGFR targeting [<xref rid="B510-cells-09-02061" ref-type="bibr">510</xref>]. In contrast to EGF, GE11 does not activate EGFR, and thus mitogenic activity of the tumor cells should be much lower. This could be an advantage in terms of clinical use. Other types of poly(I:C) polyplexes were formulated by L&#228;chelt et al. [<xref rid="B511-cells-09-02061" ref-type="bibr">511</xref>] using sequence-defined oligo(ethanamino)amides modified with PEG and the anti-folate drug methotrexate (MTX) with varying degrees of polyglutamylation. MTX exhibits dual function by serving as ligand targeting the folate receptor and by exerting cytotoxic effects in the cytosol. The extent of polyplex uptake as well as MTX and poly(I:C) toxicities correlated with increasing amounts of glutamic acid. A synergism of the combined cytotoxic agents was observed.</p><p>CpG ODNs are another class of TLR agonists that imitate bacterial/viral genomic sequences, and are recognized by TLR9 trough their unmethylated cytosine-guanine dinucleotide motif [<xref rid="B87-cells-09-02061" ref-type="bibr">87</xref>,<xref rid="B512-cells-09-02061" ref-type="bibr">512</xref>,<xref rid="B513-cells-09-02061" ref-type="bibr">513</xref>,<xref rid="B514-cells-09-02061" ref-type="bibr">514</xref>]. TLR9 signaling results in the secretion of pro-inflammatory cytokines and the activation of APC and CTL. To improve the in vivo stability of CpG ODNs in most cases the phosphodiester backbone is replaced (at least in part) by a nuclease-resistant phosphorothioate backbone [<xref rid="B513-cells-09-02061" ref-type="bibr">513</xref>,<xref rid="B515-cells-09-02061" ref-type="bibr">515</xref>]. Encouraging results in preclinical studies led to a series of clinical trials in the mid-2000s, testing CpG ODNs alone, in combination with cancer vaccines, or with chemo- and radiotherapy [<xref rid="B18-cells-09-02061" ref-type="bibr">18</xref>,<xref rid="B514-cells-09-02061" ref-type="bibr">514</xref>,<xref rid="B515-cells-09-02061" ref-type="bibr">515</xref>]. However, the clinical outcome fell far short of the hopes and expectations, especially in case of CpG ODN monotherapies, but safety and good tolerability were proven. Subsequent studies showed that TLR9 signaling was negatively influenced at several levels by the immunosuppressive TME [<xref rid="B514-cells-09-02061" ref-type="bibr">514</xref>]. Consequently, CpG ODNs in combination with immune checkpoint inhibitors are currently evaluated in phase I and II clinical trials for treatment of advanced solid tumors like metastatic melanoma [<xref rid="B514-cells-09-02061" ref-type="bibr">514</xref>]. Another dual immunotherapy strategy are conjugates of CpG ODN and either STAT3 siRNA or a STAT3 decoy ODN, respectively [<xref rid="B514-cells-09-02061" ref-type="bibr">514</xref>,<xref rid="B516-cells-09-02061" ref-type="bibr">516</xref>], as STAT3 is an oncogenic transcription factor that interferes with TLR9 signaling. Furthermore, NPs that deliver CpG ODN are under intensive investigation in several preclinical and also some clinical studies [<xref rid="B513-cells-09-02061" ref-type="bibr">513</xref>]. The goal of all these NP-based approaches is to enhance the therapeutic efficacy of CpG ODNs by increasing their stability and protection against nucleases as well as to improve the uptake of CpG ODNs by target cells. In addition, NPs allow to use phosphodiesters instead of the commonly used phosphorothioate backbone [<xref rid="B513-cells-09-02061" ref-type="bibr">513</xref>]. This may improve safety, as phosphorothioates are known to cause various adverse effects, especially in case of systemic application at higher doses [<xref rid="B513-cells-09-02061" ref-type="bibr">513</xref>,<xref rid="B514-cells-09-02061" ref-type="bibr">514</xref>]. By now, several types of NPs have been evaluated for CpG ODN delivery [<xref rid="B18-cells-09-02061" ref-type="bibr">18</xref>,<xref rid="B513-cells-09-02061" ref-type="bibr">513</xref>]. Preclinical studies are conducted inter alia with polymeric NPs formed with polymers like poly(lactic-co-glycolic acid) or PEI [<xref rid="B517-cells-09-02061" ref-type="bibr">517</xref>,<xref rid="B518-cells-09-02061" ref-type="bibr">518</xref>], liposomal formulations [<xref rid="B519-cells-09-02061" ref-type="bibr">519</xref>,<xref rid="B520-cells-09-02061" ref-type="bibr">520</xref>,<xref rid="B521-cells-09-02061" ref-type="bibr">521</xref>], carbon nanotubes [<xref rid="B522-cells-09-02061" ref-type="bibr">522</xref>,<xref rid="B523-cells-09-02061" ref-type="bibr">523</xref>], gold [<xref rid="B524-cells-09-02061" ref-type="bibr">524</xref>,<xref rid="B525-cells-09-02061" ref-type="bibr">525</xref>], and silica mesoporous NPs [<xref rid="B526-cells-09-02061" ref-type="bibr">526</xref>], as well as DNA-based carriers [<xref rid="B527-cells-09-02061" ref-type="bibr">527</xref>,<xref rid="B528-cells-09-02061" ref-type="bibr">528</xref>]. Near-infrared light responsive nanomaterials like copper sulfide, graphene oxide, or gold nanorods can be used for photothermal enhancing of CpG ODN immunogenicity [<xref rid="B529-cells-09-02061" ref-type="bibr">529</xref>,<xref rid="B530-cells-09-02061" ref-type="bibr">530</xref>,<xref rid="B531-cells-09-02061" ref-type="bibr">531</xref>]. Besides these preclinical studies, CpG ODN-loaded virus-like particles are already investigated in a phase I/II clinical trial [<xref rid="B532-cells-09-02061" ref-type="bibr">532</xref>]. Furthermore, CpG ODNs can also be conjugated with antigen (peptide/protein) or human immunodeficiency virus-derived Tat-peptide [<xref rid="B533-cells-09-02061" ref-type="bibr">533</xref>,<xref rid="B534-cells-09-02061" ref-type="bibr">534</xref>]. Self-assembled CpG ODNs like MGN1703 are another example, already tested in phase I and II clinical trials, for treatment of e.g., metastatic colorectal carcinomas [<xref rid="B535-cells-09-02061" ref-type="bibr">535</xref>,<xref rid="B536-cells-09-02061" ref-type="bibr">536</xref>,<xref rid="B537-cells-09-02061" ref-type="bibr">537</xref>].</p></sec><sec id="sec5dot5-cells-09-02061"><title>5.5. Tumor Suppression by RNA Interference</title><p>The discovery of RNAi in 1998 [<xref rid="B538-cells-09-02061" ref-type="bibr">538</xref>] led to a better understanding of gene regulation mechanisms [<xref rid="B103-cells-09-02061" ref-type="bibr">103</xref>]. RNAi in humans and animals is mediated by miRNA [<xref rid="B539-cells-09-02061" ref-type="bibr">539</xref>] (<xref ref-type="fig" rid="cells-09-02061-f002">Figure 2</xref>). miRNAs influence many cellular functions like proliferation, differentiation, apoptosis, oncogenesis, and drug sensitivity [<xref rid="B540-cells-09-02061" ref-type="bibr">540</xref>,<xref rid="B541-cells-09-02061" ref-type="bibr">541</xref>,<xref rid="B542-cells-09-02061" ref-type="bibr">542</xref>,<xref rid="B543-cells-09-02061" ref-type="bibr">543</xref>]. Dysregulated miRNA expression is associated with the development and progress of various diseases [<xref rid="B539-cells-09-02061" ref-type="bibr">539</xref>,<xref rid="B543-cells-09-02061" ref-type="bibr">543</xref>,<xref rid="B544-cells-09-02061" ref-type="bibr">544</xref>]. Calin et al. were the first to report involvement of miRNA in cancer progression [<xref rid="B545-cells-09-02061" ref-type="bibr">545</xref>]. miRNAs can be used as diagnostic and prognostic biomarkers [<xref rid="B546-cells-09-02061" ref-type="bibr">546</xref>]. For cancer therapy, oncogenic miRNAs can be blocked by antisense molecules (antagomirs), while attenuated levels of tumor suppressor miRNAs can be substituted by pre-miRNAs or miRNA mimics [<xref rid="B539-cells-09-02061" ref-type="bibr">539</xref>,<xref rid="B543-cells-09-02061" ref-type="bibr">543</xref>,<xref rid="B547-cells-09-02061" ref-type="bibr">547</xref>,<xref rid="B548-cells-09-02061" ref-type="bibr">548</xref>].</p><p>The major challenge in clinical translation of miRNA therapeutics is to ensure their efficient, specific, and safe delivery to the tumor [<xref rid="B539-cells-09-02061" ref-type="bibr">539</xref>,<xref rid="B543-cells-09-02061" ref-type="bibr">543</xref>,<xref rid="B546-cells-09-02061" ref-type="bibr">546</xref>,<xref rid="B549-cells-09-02061" ref-type="bibr">549</xref>]. Chemical modifications can increase resistance of RNA to enzymatic degradation by nucleases. Examples for such structural alterations are modifications of the ribose 2&#8242;-OH group, the use of phosphorothioate instead of phosphodiester bonds, peptide nucleic acids, locked nucleic acids as well as conjugation with other moieties (e.g., cholesterol, antibodies, or membrane translocation peptides) [<xref rid="B103-cells-09-02061" ref-type="bibr">103</xref>,<xref rid="B539-cells-09-02061" ref-type="bibr">539</xref>,<xref rid="B550-cells-09-02061" ref-type="bibr">550</xref>,<xref rid="B551-cells-09-02061" ref-type="bibr">551</xref>,<xref rid="B552-cells-09-02061" ref-type="bibr">552</xref>].</p><p>For example, Cheng et al. conjugated peptide nucleic acid-based anti-miR-155 to a pH-sensitive membrane translocation peptide via a disulfide link [<xref rid="B103-cells-09-02061" ref-type="bibr">103</xref>,<xref rid="B552-cells-09-02061" ref-type="bibr">552</xref>]. In the acidic tumor tissue, the conformational change in this peptide promoted internalization of the antagomir, which was released intracellularly upon disulfide cleavage due to increased glutathione levels. In a lymphoma model, cell targeting, a significant inhibition of lymphoma proliferation as well as a good tolerability were demonstrated. It is also worth noting that the neutral charge of the peptide nucleic acid was decisive for success.</p><p>Viral as well as non-viral delivery systems such as liposomal or polymeric NPs are under investigation to prevent degradation of miRNA and to promote their targeted delivery [<xref rid="B539-cells-09-02061" ref-type="bibr">539</xref>,<xref rid="B546-cells-09-02061" ref-type="bibr">546</xref>,<xref rid="B551-cells-09-02061" ref-type="bibr">551</xref>]. Loss of miR-200c expression is known to promote tumorigenic processes like tumor cell proliferation, EMT, migration, and chemoresistance [<xref rid="B539-cells-09-02061" ref-type="bibr">539</xref>,<xref rid="B553-cells-09-02061" ref-type="bibr">553</xref>,<xref rid="B554-cells-09-02061" ref-type="bibr">554</xref>,<xref rid="B555-cells-09-02061" ref-type="bibr">555</xref>,<xref rid="B556-cells-09-02061" ref-type="bibr">556</xref>,<xref rid="B557-cells-09-02061" ref-type="bibr">557</xref>,<xref rid="B558-cells-09-02061" ref-type="bibr">558</xref>]. M&#252;ller et al. tested a cationic oligo(ethanamino)amide structure with T-shape topology, terminal cysteines, and a dioleyl motif, post-functionalized with PEG-GE11 for shielding and EGFR targeting for delivery of a mimic of the tumor suppressor miR-200c [<xref rid="B559-cells-09-02061" ref-type="bibr">559</xref>]. In two different human tumor cell lines, these EGFR-targeting miRNA polyplexes conferred selective, enhanced delivery of miRNA-200c, leading to various anti-tumor effects, including decreased tumor cell proliferation and migration, and enhanced sensitivity towards doxorubicin.</p><p>Altogether, miRNA therapeutics hold great potential for efficient and safe cancer treatment, especially as multi-functional nano formulations, paving the way towards clinical translation. A liposomal formulation of miR-34a mimic (MRX34) for treatment of patients with advanced solid tumors was the first miRNA therapeutic entering phase I clinical studies in 2013, but was accompanied by severe immune-mediated adverse effects (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01829971">NCT01829971</ext-link>) [<xref rid="B560-cells-09-02061" ref-type="bibr">560</xref>,<xref rid="B561-cells-09-02061" ref-type="bibr">561</xref>]. Nevertheless, the observed dose-dependent modulation of relevant target gene expression provided a proof-of-concept for miRNA-based cancer therapy [<xref rid="B561-cells-09-02061" ref-type="bibr">561</xref>]. This raises hope that miRNA therapeutics will make the leap towards clinical application. Therefore, further optimization of cargo and delivery systems to improve clinical efficacy and toxicity profiles is necessary.</p></sec></sec><sec sec-type="conclusions" id="sec6-cells-09-02061"><title>6. Conclusions</title><p>Until a few years ago, nucleic acid-based immunotherapeutics have proven successful in preclinical studies, but largely fell short of expectations when evaluated for therapeutic efficacy in clinical trials [<xref rid="B57-cells-09-02061" ref-type="bibr">57</xref>,<xref rid="B61-cells-09-02061" ref-type="bibr">61</xref>]. One major limit has been the lack of appropriate delivery systems required to prevent degradation of pDNA/mRNA, and to enable cell type-specific delivery [<xref rid="B125-cells-09-02061" ref-type="bibr">125</xref>,<xref rid="B126-cells-09-02061" ref-type="bibr">126</xref>]. Insofar, it is not surprising that by now virus-based gene therapies including oncolytic viruses [<xref rid="B471-cells-09-02061" ref-type="bibr">471</xref>,<xref rid="B474-cells-09-02061" ref-type="bibr">474</xref>,<xref rid="B475-cells-09-02061" ref-type="bibr">475</xref>,<xref rid="B477-cells-09-02061" ref-type="bibr">477</xref>,<xref rid="B478-cells-09-02061" ref-type="bibr">478</xref>], and cell-based immunotherapeutics, namely CAR-T cell therapies [<xref rid="B28-cells-09-02061" ref-type="bibr">28</xref>,<xref rid="B277-cells-09-02061" ref-type="bibr">277</xref>,<xref rid="B562-cells-09-02061" ref-type="bibr">562</xref>,<xref rid="B563-cells-09-02061" ref-type="bibr">563</xref>,<xref rid="B564-cells-09-02061" ref-type="bibr">564</xref>], demonstrated more successful for tumor therapy, and have been approved for clinical treatment. However, in the last years, the development of biocompatible, cell targeting NPs, especially of liposomal carriers [<xref rid="B565-cells-09-02061" ref-type="bibr">565</xref>], has strongly improved the efficacy of e.g., mRNA-based anti-tumor vaccines [<xref rid="B71-cells-09-02061" ref-type="bibr">71</xref>,<xref rid="B72-cells-09-02061" ref-type="bibr">72</xref>]. Additionally, in case of CAR-T as an ex vivo gene therapy approach non-viral delivery is currently tested [<xref rid="B566-cells-09-02061" ref-type="bibr">566</xref>]. These developments, in combination with structural improvements in particular of gene encoding pDNA [<xref rid="B567-cells-09-02061" ref-type="bibr">567</xref>], and the proper choice of individual tumor-specific neoantigens for individualized vaccination [<xref rid="B79-cells-09-02061" ref-type="bibr">79</xref>], are important factors to overcome the low therapeutic efficacy of most nucleic acid immunotherapeutics tested so far. Furthermore, as numerous clinical trials have repetitively shown, nucleic acid-based therapeutics were more efficient when co-applied with agents that act on other levels like immune checkpoint inhibitors [<xref rid="B70-cells-09-02061" ref-type="bibr">70</xref>,<xref rid="B79-cells-09-02061" ref-type="bibr">79</xref>] or chemotherapeutics [<xref rid="B474-cells-09-02061" ref-type="bibr">474</xref>], and radiotherapy [<xref rid="B568-cells-09-02061" ref-type="bibr">568</xref>]. Moreover, first preclinical studies have shown that also different kinds of nucleic acids that act on distinct levels of cancer treatment may be combined to yield synergistic effects. For example, co-administration of the adjuvant poly(I:C) enhanced the anti-tumor efficacy of CAR-T cells [<xref rid="B569-cells-09-02061" ref-type="bibr">569</xref>]. Similarly, co-application of an oncolytic adenovirus and of CAR-T cells improved anti-tumor responses as compared to monotherapy [<xref rid="B570-cells-09-02061" ref-type="bibr">570</xref>].</p><p>Altogether, ongoing developments indicate that nucleic acid-based therapeutics will become essential tools for successful tumor therapy as part of combination therapies, comprising the induction of tumor antigen-specific immune reactions [<xref rid="B79-cells-09-02061" ref-type="bibr">79</xref>], the enhancement of anti-tumor responses [<xref rid="B514-cells-09-02061" ref-type="bibr">514</xref>], the inhibition or reprograming of regulatory immune cells [<xref rid="B256-cells-09-02061" ref-type="bibr">256</xref>], the generation of tumor killing immune cells (CAR) [<xref rid="B284-cells-09-02061" ref-type="bibr">284</xref>], and direct killing of tumor cells [<xref rid="B482-cells-09-02061" ref-type="bibr">482</xref>]. The versatility of nucleic acids as a therapeutic mean is underscored by the fact that these can exert either of the aforementioned functions by serving as gene expression units in pDNA/mRNA vaccines, conferring RNAi (siRNA, miRNA), and adjuvant activity (e.g., CpG ODN), and can be easily produced under GMP conditions [<xref rid="B571-cells-09-02061" ref-type="bibr">571</xref>]. Therefore, it is conceivable that in the future nucleic acid-based therapeutics that act on different levels of cancer treatment will be part of combination therapies involving either also conventional therapeutics or distinct types of nucleic acids.</p></sec></body><back><notes><title>Author Contributions</title><p>Each author has substantially contributed to drafting this review. S.H., E.W. and M.B. conceptualized the review topic. S.H., F.J.F., E.W., and M.B. wrote the manuscript draft and S.H., E.W., and M.B. revised it. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was funded by the Deutsche Forschungsgemeinschaft (SFB1066, project B05).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><p>A2AR: adenosine A2A receptor; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; APC: antigen presenting cell; ASO: antisense oligonucleotide; AVET: adenovirus-enhanced transferrinfection; CAR: chimeric antigen receptor; BCG: Bacillus Calmette&#8211;Guerin; CAF: cancer-associated fibroblast; cAMP: cyclic adenosine monophosphate; CCL: C-C motif chemokine ligand; CLL: chronic lymphocytic leukemia; CLR: C-type lectin receptor; CPP: cell penetrating peptide; CEA: carcinoembryonic antigen; CSC: cancer stem cell; CTL: cytotoxic T lymphocyte; CTLA-4: CTL-associated protein 4; CXCL12: C-X-C motif chemokine 12; CXCR4: C-X-C motif chemokine receptor 4; DC: dendritic cell; DOPE: dioleoyl phosphatidylethanolamine; DOTAP: N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride; DOTMA: 1,2-di-O-octadecenyl-3-trimethylammonium propane; DSPE: distearoylphosphatidylethanolamine; dsRNA: double-stranded RNA; ECHO-7: enteric cytopathogenic human orphan 7; ECM: extracellular matrix; EGFR: epidermal growth factor receptor; EMA: European Medicines Agency; EMT: epithelial&#8211;mesenchymal transition; ENO1: &#945;-enolase; EPR: enhanced permeation and retention; FDA: united states food and drug administration; GM-CSF: granulocyte macrophage colony-stimulating factor; HD: hexanediol diacrylate; HSV: herpes simplex virus; IFN-&#945;: interferon alpha; IL: interleukin; IRAK1: IL-1 receptor-associated kinase; JNK: c-Jun N-terminal kinase; KC: Kupffer cell; mcDNA: mini-circle DNA; LAMP: lysosomal-associated membrane protein; LSEC: liver sinusoidal endothelial cell; MHC: major histocompatibility complex; MDSC: myeloid-derived suppressor cell; MMP: matrix metalloprotease; MTX: methotrexate; NK: natural killer cell; NLS: nuclear localization signal; NP: nanoparticle; NHL: non-Hodgkin lymphoma; ODN: oligodeoxynucleotides; OEI: oligoethylenimine; PD-1: programmed cell death protein 1; PD-L1: PD ligand 1; PEG: polyethylene glycol; PEI: polyethylenimine; Pexa-Vec: pexastimogene devacirepvec; PLGA: poly-D,L-lactic-co-glycolic acid; Poly(I:C): polyriboinosinic:polyribocytidylic acid; poly-ICLC: polyriboinosinic:polyribocytidylic acid-polylysine carboxymethylcellulose; RNAi: RNA interference; ROS: reactive oxygen species; SCF: stem cell factor; scFv: single chain fragment variable; ssDNA: single-stranded DNA; STAT: signal transducer and activator of transcription; STING: stimulator of IFN genes; SV40: simian virus 40; T-Vec: talminogene laherparepvec; T3D: type 3 Dearing; TAA: tumor-associated antigen; TAM: tumor-associated macrophage; TCR: T cell receptor; Teff: effector T cell; TGF-&#946;: transforming growth factor beta; Th: T helper cell; TIL: tumor-infiltrating lymphocyte; TK: thymidine kinase; TLR: toll-like receptor; TNF-&#945;: tumor necrosis factor alpha; TRAF6: tumor necrosis factor receptor-associated factor 6; Treg: regulatory T cell; iTreg: induced Treg; tTreg: thymic Treg; VEGF: vascular endothelial growth factor; VEGFR: VEGF receptor; WT1: Wilms&#8217; tumor 1.</p></glossary><ref-list><title>References</title><ref id="B1-cells-09-02061"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics, 2019</article-title><source>CA Cancer J. Clin.</source><year>2019</year><volume>69</volume><fpage>7</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.3322/caac.21551</pub-id><pub-id pub-id-type="pmid">30620402</pub-id></element-citation></ref><ref id="B2-cells-09-02061"><label>2.</label><element-citation publication-type="journal"><article-title>Think globally about cancer</article-title><source>Nat. Med.</source><year>2019</year><volume>25</volume><fpage>351</fpage><pub-id pub-id-type="doi">10.1038/s41591-019-0402-x</pub-id><pub-id pub-id-type="pmid">30842673</pub-id></element-citation></ref><ref id="B3-cells-09-02061"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Colombet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mathers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Parkin</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Pi&#241;eros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Znaor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name></person-group><article-title>Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods</article-title><source>Int. J. Cancer</source><year>2019</year><volume>144</volume><fpage>1941</fpage><lpage>1953</lpage><pub-id pub-id-type="doi">10.1002/ijc.31937</pub-id><pub-id pub-id-type="pmid">30350310</pub-id></element-citation></ref><ref id="B4-cells-09-02061"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Colombet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dyba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Randi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bettio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gavin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Visser</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name></person-group><article-title>Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018</article-title><source>Eur. J. Cancer</source><year>2018</year><volume>103</volume><fpage>356</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2018.07.005</pub-id><pub-id pub-id-type="pmid">30100160</pub-id></element-citation></ref><ref id="B5-cells-09-02061"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Torre</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J. Clin.</source><year>2018</year><volume>68</volume><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref><ref id="B6-cells-09-02061"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>H.C.</given-names></name></person-group><article-title>The molecular mechanisms of chemoresistance in cancers</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>59950</fpage><lpage>59964</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.19048</pub-id><pub-id pub-id-type="pmid">28938696</pub-id><pub-id pub-id-type="pmcid">PMC5601792</pub-id></element-citation></ref><ref id="B7-cells-09-02061"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>D.</given-names></name></person-group><article-title>Factors involved in cancer metastasis: A better understanding to &#8220;seed and soil&#8221; hypothesis</article-title><source>Mol. Cancer</source><year>2017</year><volume>16</volume><fpage>176</fpage><pub-id pub-id-type="doi">10.1186/s12943-017-0742-4</pub-id><pub-id pub-id-type="pmid">29197379</pub-id><pub-id pub-id-type="pmcid">PMC5712107</pub-id></element-citation></ref><ref id="B8-cells-09-02061"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schirrmacher</surname><given-names>V.</given-names></name></person-group><article-title>From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)</article-title><source>Int. J. Oncol.</source><year>2019</year><volume>54</volume><fpage>407</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.3892/ijo.2018.4661</pub-id><pub-id pub-id-type="pmid">30570109</pub-id><pub-id pub-id-type="pmcid">PMC6317661</pub-id></element-citation></ref><ref id="B9-cells-09-02061"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>S.A.</given-names></name></person-group><article-title>A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens</article-title><source>Immunity</source><year>1999</year><volume>10</volume><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80028-X</pub-id><pub-id pub-id-type="pmid">10204484</pub-id></element-citation></ref><ref id="B10-cells-09-02061"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zugazagoitia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guedes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ponce</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Molina-Pinelo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paz-Ares</surname><given-names>L.</given-names></name></person-group><article-title>Current Challenges in Cancer Treatment</article-title><source>Clin. Ther.</source><year>2016</year><volume>38</volume><fpage>1551</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2016.03.026</pub-id><pub-id pub-id-type="pmid">27158009</pub-id></element-citation></ref><ref id="B11-cells-09-02061"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tariman</surname><given-names>J.D.</given-names></name></person-group><article-title>Changes in Cancer Treatment: Mabs, Mibs, Mids, Nabs, and Nibs</article-title><source>Nurs. Clin. North Am.</source><year>2017</year><volume>52</volume><fpage>65</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.cnur.2016.10.004</pub-id><pub-id pub-id-type="pmid">28189167</pub-id></element-citation></ref><ref id="B12-cells-09-02061"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farkona</surname><given-names>S.</given-names></name><name name-style="western"><surname>Diamandis</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Blasutig</surname><given-names>I.M.</given-names></name></person-group><article-title>Cancer immunotherapy: The beginning of the end of cancer?</article-title><source>BMC Med.</source><year>2016</year><volume>14</volume><elocation-id>73</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-016-0623-5</pub-id><pub-id pub-id-type="pmid">27151159</pub-id><pub-id pub-id-type="pmcid">PMC4858828</pub-id></element-citation></ref><ref id="B13-cells-09-02061"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saleh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shojaosadati</surname><given-names>S.A.</given-names></name></person-group><article-title>Multifunctional nanoparticles for cancer immunotherapy</article-title><source>Hum. Vaccin. Immunother.</source><year>2016</year><volume>12</volume><fpage>1863</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1147635</pub-id><pub-id pub-id-type="pmid">26901287</pub-id><pub-id pub-id-type="pmcid">PMC4964832</pub-id></element-citation></ref><ref id="B14-cells-09-02061"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ogris</surname><given-names>M.</given-names></name></person-group><article-title>Biopharmaceuticals and gene vectors opening new avenues in cancer immune therapy</article-title><source>Ther. Deliv.</source><year>2016</year><volume>7</volume><fpage>419</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.4155/tde-2016-0032</pub-id><pub-id pub-id-type="pmid">27403627</pub-id></element-citation></ref><ref id="B15-cells-09-02061"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emens</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Ascierto</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Darcy</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Demaria</surname><given-names>S.</given-names></name><name name-style="western"><surname>Eggermont</surname><given-names>A.M.M.</given-names></name><name name-style="western"><surname>Redmond</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Seliger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marincola</surname><given-names>F.M.</given-names></name></person-group><article-title>Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape</article-title><source>Eur. J. Cancer</source><year>2017</year><volume>81</volume><fpage>116</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2017.01.035</pub-id><pub-id pub-id-type="pmid">28623775</pub-id></element-citation></ref><ref id="B16-cells-09-02061"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rangel-Sosa</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Aguilar-C&#243;rdova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rojas-Mart&#237;nez</surname><given-names>A.</given-names></name></person-group><article-title>Immunotherapy and gene therapy as novel treatments for cancer</article-title><source>Colomb. Med. (Cali)</source><year>2017</year><volume>48</volume><fpage>138</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.25100/cm.v48i3.2997</pub-id><pub-id pub-id-type="pmid">29213157</pub-id><pub-id pub-id-type="pmcid">PMC5687866</pub-id></element-citation></ref><ref id="B17-cells-09-02061"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>W.</given-names></name><name name-style="western"><surname>Musetti</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Nanomaterials for cancer immunotherapy</article-title><source>Biomaterials</source><year>2017</year><volume>148</volume><fpage>16</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.09.017</pub-id><pub-id pub-id-type="pmid">28961532</pub-id><pub-id pub-id-type="pmcid">PMC5762124</pub-id></element-citation></ref><ref id="B18-cells-09-02061"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy</article-title><source>ACS Nano</source><year>2018</year><volume>12</volume><fpage>11740</fpage><lpage>11755</lpage><pub-id pub-id-type="doi">10.1021/acsnano.8b05893</pub-id><pub-id pub-id-type="pmid">30508378</pub-id></element-citation></ref><ref id="B19-cells-09-02061"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alsaab</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Bhise</surname><given-names>K.</given-names></name><name name-style="western"><surname>Alzhrani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nabil</surname><given-names>G.</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>A.K.</given-names></name></person-group><article-title>Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment</article-title><source>J. Controlled Release</source><year>2018</year><volume>274</volume><fpage>24</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.01.028</pub-id><pub-id pub-id-type="pmcid">PMC5847475</pub-id><pub-id pub-id-type="pmid">29391232</pub-id></element-citation></ref><ref id="B20-cells-09-02061"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name></person-group><article-title>Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy</article-title><source>Int. J. Pharm.</source><year>2019</year><volume>570</volume><fpage>118636</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.118636</pub-id><pub-id pub-id-type="pmid">31446027</pub-id></element-citation></ref><ref id="B21-cells-09-02061"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>M.</given-names></name></person-group><article-title>Emerging strategies in cancer therapy combining chemotherapy with immunotherapy</article-title><source>Cancer Lett.</source><year>2019</year><volume>454</volume><fpage>191</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2019.04.017</pub-id><pub-id pub-id-type="pmid">30998963</pub-id></element-citation></ref><ref id="B22-cells-09-02061"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvioni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rizzuto</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Bertolini</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Pandolfi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prosperi</surname><given-names>D.</given-names></name></person-group><article-title>Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope</article-title><source>Cancers</source><year>2019</year><volume>11</volume><elocation-id>1855</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11121855</pub-id><pub-id pub-id-type="pmid">31769416</pub-id><pub-id pub-id-type="pmcid">PMC6966668</pub-id></element-citation></ref><ref id="B23-cells-09-02061"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lammers</surname><given-names>T.</given-names></name></person-group><article-title>Combining Nanomedicine and Immunotherapy</article-title><source>Acc. Chem. Res.</source><year>2019</year><volume>52</volume><fpage>1543</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.9b00148</pub-id><pub-id pub-id-type="pmid">31120725</pub-id><pub-id pub-id-type="pmcid">PMC7115879</pub-id></element-citation></ref><ref id="B24-cells-09-02061"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>L.</given-names></name></person-group><article-title>Advances in the techniques and methodologies of cancer gene therapy</article-title><source>Discov. Med.</source><year>2019</year><volume>27</volume><fpage>45</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">30721651</pub-id></element-citation></ref><ref id="B25-cells-09-02061"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hargadon</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C.J.</given-names></name></person-group><article-title>Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors</article-title><source>Int. Immunopharmacol.</source><year>2018</year><volume>62</volume><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2018.06.001</pub-id><pub-id pub-id-type="pmid">29990692</pub-id></element-citation></ref><ref id="B26-cells-09-02061"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilky</surname><given-names>B.A.</given-names></name></person-group><article-title>Immune checkpoint inhibitors: The linchpins of modern immunotherapy</article-title><source>Immunol. Rev.</source><year>2019</year><volume>290</volume><fpage>6</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1111/imr.12766</pub-id><pub-id pub-id-type="pmid">31355494</pub-id></element-citation></ref><ref id="B27-cells-09-02061"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name></person-group><article-title>Delivery Strategies for Immune Checkpoint Blockade</article-title><source>Adv. Healthc. Mater.</source><year>2018</year><volume>7</volume><fpage>e1800424</fpage><pub-id pub-id-type="doi">10.1002/adhm.201800424</pub-id><pub-id pub-id-type="pmid">29978565</pub-id></element-citation></ref><ref id="B28-cells-09-02061"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sermer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brentjens</surname><given-names>R.</given-names></name></person-group><article-title>CAR T-cell therapy: Full speed ahead</article-title><source>Hematol. Oncol.</source><year>2019</year><volume>37</volume><fpage>95</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1002/hon.2591</pub-id><pub-id pub-id-type="pmid">31187533</pub-id></element-citation></ref><ref id="B29-cells-09-02061"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Fry</surname><given-names>T.J.</given-names></name></person-group><article-title>Mechanisms of resistance to CAR T cell therapy</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2019</year><volume>16</volume><fpage>372</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1038/s41571-019-0184-6</pub-id><pub-id pub-id-type="pmid">30837712</pub-id><pub-id pub-id-type="pmcid">PMC8214555</pub-id></element-citation></ref><ref id="B30-cells-09-02061"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ginn</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Amaya</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Edelstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abedi</surname><given-names>M.R.</given-names></name></person-group><article-title>Gene therapy clinical trials worldwide to 2017: An update</article-title><source>J. Gene Med.</source><year>2018</year><volume>20</volume><fpage>e3015</fpage><pub-id pub-id-type="doi">10.1002/jgm.3015</pub-id><pub-id pub-id-type="pmid">29575374</pub-id></element-citation></ref><ref id="B31-cells-09-02061"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hobernik</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M.</given-names></name></person-group><article-title>DNA Vaccines&#8212;How Far From Clinical Use?</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>3605</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19113605</pub-id><pub-id pub-id-type="pmid">30445702</pub-id><pub-id pub-id-type="pmcid">PMC6274812</pub-id></element-citation></ref><ref id="B32-cells-09-02061"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nabel</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Plautz</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>A.E.</given-names></name></person-group><article-title>Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans</article-title><source>Proc. Natl. Acad. Sci.</source><year>1993</year><volume>90</volume><fpage>11307</fpage><pub-id pub-id-type="doi">10.1073/pnas.90.23.11307</pub-id><pub-id pub-id-type="pmid">8248244</pub-id><pub-id pub-id-type="pmcid">PMC47971</pub-id></element-citation></ref><ref id="B33-cells-09-02061"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldberg</surname><given-names>M.S.</given-names></name></person-group><article-title>Improving cancer immunotherapy through nanotechnology</article-title><source>Nat. Rev. Cancer</source><year>2019</year><volume>19</volume><fpage>587</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0186-9</pub-id><pub-id pub-id-type="pmid">31492927</pub-id></element-citation></ref><ref id="B34-cells-09-02061"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shae</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baljon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wehbe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Sheehy</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.T.</given-names></name></person-group><article-title>At the bench: Engineering the next generation of cancer vaccines</article-title><source>J. Leukoc. Biol.</source><year>2019</year><pub-id pub-id-type="doi">10.1002/JLB.5BT0119-016R</pub-id><pub-id pub-id-type="pmid">31430398</pub-id></element-citation></ref><ref id="B35-cells-09-02061"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadeghzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bornehdeli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mohahammadrezakhani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Abolghasemi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Poursaei</surname><given-names>E.</given-names></name><name name-style="western"><surname>Asadi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zafari</surname><given-names>V.</given-names></name><name name-style="western"><surname>Aghebati-Maleki</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shanehbandi</surname><given-names>D.</given-names></name></person-group><article-title>Dendritic cell therapy in cancer treatment; The state-of-the-art</article-title><source>Life Sci.</source><year>2020</year><volume>254</volume><fpage>117580</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.117580</pub-id><pub-id pub-id-type="pmid">32205087</pub-id></element-citation></ref><ref id="B36-cells-09-02061"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastola</surname><given-names>R.</given-names></name><name name-style="western"><surname>Noh</surname><given-names>G.</given-names></name><name name-style="western"><surname>Keum</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bashyal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name></person-group><article-title>Vaccine adjuvants: Smart components to boost the immune system</article-title><source>Arch. Pharm. Res.</source><year>2017</year><volume>40</volume><fpage>1238</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1007/s12272-017-0969-z</pub-id><pub-id pub-id-type="pmid">29027637</pub-id></element-citation></ref><ref id="B37-cells-09-02061"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scuderi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Provenzano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bartoccioni</surname><given-names>E.</given-names></name></person-group><article-title>Skeletal muscle cells: From local inflammatory response to active immunity</article-title><source>Gene ther.</source><year>2011</year><volume>18</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1038/gt.2010.124</pub-id><pub-id pub-id-type="pmid">20927136</pub-id></element-citation></ref><ref id="B38-cells-09-02061"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hengge</surname><given-names>U.R.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>J.C.</given-names></name></person-group><article-title>Cytokine gene expression in epidermis with biological effects following injection of naked DNA</article-title><source>Nat. Genet.</source><year>1995</year><volume>10</volume><fpage>161</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1038/ng0695-161</pub-id><pub-id pub-id-type="pmid">7545056</pub-id></element-citation></ref><ref id="B39-cells-09-02061"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kessler</surname><given-names>J.A.</given-names></name></person-group><article-title>Design, Assembly, Production, and Transfection of Synthetic Modified mRNA</article-title><source>Methods</source><year>2018</year><volume>133</volume><fpage>29</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2017.10.008</pub-id><pub-id pub-id-type="pmid">29080741</pub-id><pub-id pub-id-type="pmcid">PMC5807177</pub-id></element-citation></ref><ref id="B40-cells-09-02061"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lester</surname><given-names>G.M.S.</given-names></name><name name-style="western"><surname>Petishnok</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>D.A.</given-names></name></person-group><article-title>Cytoplasmic transport and nuclear import of plasmid DNA</article-title><source>Biosci. Rep.</source><year>2017</year><volume>37</volume><pub-id pub-id-type="doi">10.1042/BSR20160616</pub-id><pub-id pub-id-type="pmcid">PMC5705778</pub-id><pub-id pub-id-type="pmid">29054961</pub-id></element-citation></ref><ref id="B41-cells-09-02061"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazzaro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giovani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mangiavacchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Magini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maione</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baudner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Geall</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name><name name-style="western"><surname>D&#8217;Oro</surname><given-names>U.</given-names></name><name name-style="western"><surname>Buonsanti</surname><given-names>C.</given-names></name></person-group><article-title>CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes</article-title><source>Immunology</source><year>2015</year><volume>146</volume><fpage>312</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1111/imm.12505</pub-id><pub-id pub-id-type="pmid">26173587</pub-id><pub-id pub-id-type="pmcid">PMC4582972</pub-id></element-citation></ref><ref id="B42-cells-09-02061"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sudowe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dominitzki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Montermann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grabbe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reske-Kunz</surname><given-names>A.B.</given-names></name></person-group><article-title>Uptake and presentation of exogenous antigen and presentation of endogenously produced antigen by skin dendritic cells represent equivalent pathways for the priming of cellular immune responses following biolistic DNA immunization</article-title><source>Immunology</source><year>2009</year><volume>128</volume><fpage>e193</fpage><lpage>e205</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2008.02947.x</pub-id><pub-id pub-id-type="pmid">18800984</pub-id><pub-id pub-id-type="pmcid">PMC2753911</pub-id></element-citation></ref><ref id="B43-cells-09-02061"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huyan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cacalano</surname><given-names>N.A.</given-names></name></person-group><article-title>Exosomes: Versatile Nano Mediators of Immune Regulation</article-title><source>Cancers</source><year>2019</year><volume>11</volume><elocation-id>1557</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11101557</pub-id><pub-id pub-id-type="pmid">31615107</pub-id><pub-id pub-id-type="pmcid">PMC6826959</pub-id></element-citation></ref><ref id="B44-cells-09-02061"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Larregina</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Morelli</surname><given-names>A.E.</given-names></name></person-group><article-title>Impact of extracellular vesicles on innate immunity</article-title><source>Curr. Opin. Organ. Transplant.</source><year>2019</year><volume>24</volume><fpage>670</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1097/MOT.0000000000000701</pub-id><pub-id pub-id-type="pmid">31592838</pub-id><pub-id pub-id-type="pmcid">PMC7328797</pub-id></element-citation></ref><ref id="B45-cells-09-02061"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Den Haan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Arens</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Zelm</surname><given-names>M.C.</given-names></name></person-group><article-title>The activation of the adaptive immune system: Cross-talk between antigen-presenting cells, T cells and B cells</article-title><source>Immunol. Lett.</source><year>2014</year><volume>162</volume><fpage>103</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2014.10.011</pub-id><pub-id pub-id-type="pmid">25455596</pub-id></element-citation></ref><ref id="B46-cells-09-02061"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dumont</surname><given-names>C.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Mintern</surname><given-names>J.D.</given-names></name></person-group><article-title>Targeting dendritic cells: A promising strategy to improve vaccine effectiveness</article-title><source>Clin. Transl. Immunol.</source><year>2016</year><volume>5</volume><fpage>e66</fpage><pub-id pub-id-type="doi">10.1038/cti.2016.6</pub-id><pub-id pub-id-type="pmcid">PMC4815026</pub-id><pub-id pub-id-type="pmid">27217957</pub-id></element-citation></ref><ref id="B47-cells-09-02061"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porgador</surname><given-names>A.</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Germain</surname><given-names>R.N.</given-names></name></person-group><article-title>Predominant role for directly transfected dendritic cells in antigen presentation to CD8<sup>+</sup> T cells after gene gun immunization</article-title><source>J. Exp. Med.</source><year>1998</year><volume>188</volume><fpage>1075</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1084/jem.188.6.1075</pub-id><pub-id pub-id-type="pmid">9743526</pub-id><pub-id pub-id-type="pmcid">PMC2212529</pub-id></element-citation></ref><ref id="B48-cells-09-02061"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coban</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kobiyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jounai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tozuka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name></person-group><article-title>DNA vaccines: A simple DNA sensing matter?</article-title><source>Hum. Vaccin. Immunother.</source><year>2013</year><volume>9</volume><fpage>2216</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.4161/hv.25893</pub-id><pub-id pub-id-type="pmid">23912600</pub-id><pub-id pub-id-type="pmcid">PMC3906407</pub-id></element-citation></ref><ref id="B49-cells-09-02061"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joffre</surname><given-names>O.</given-names></name><name name-style="western"><surname>Nolte</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Sporri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reis e Sousa</surname><given-names>C.</given-names></name></person-group><article-title>Inflammatory signals in dendritic cell activation and the induction of adaptive immunity</article-title><source>Immunol. Rev.</source><year>2009</year><volume>227</volume><fpage>234</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00718.x</pub-id><pub-id pub-id-type="pmid">19120488</pub-id></element-citation></ref><ref id="B50-cells-09-02061"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maecker</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Umetsu</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>DeKruyff</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>S.</given-names></name></person-group><article-title>Cytotoxic T cell responses to DNA vaccination: Dependence on antigen presentation via class II MHC</article-title><source>J. Immunol. (Baltimore, Md.: 1950)</source><year>1998</year><volume>161</volume><fpage>6532</fpage><lpage>6536</lpage><pub-id pub-id-type="pmid">9862678</pub-id></element-citation></ref><ref id="B51-cells-09-02061"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aloulou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fazilleau</surname><given-names>N.</given-names></name></person-group><article-title>Regulation of B cell responses by distinct populations of CD4 T cells</article-title><source>Biomed. J.</source><year>2019</year><volume>42</volume><fpage>243</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.bj.2019.06.002</pub-id><pub-id pub-id-type="pmid">31627866</pub-id><pub-id pub-id-type="pmcid">PMC6818157</pub-id></element-citation></ref><ref id="B52-cells-09-02061"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Chien</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Sytwu</surname><given-names>H.K.</given-names></name></person-group><article-title>Interplay between Cytokine Circuitry and Transcriptional Regulation Shaping Helper T Cell Pathogenicity and Plasticity in Inflammatory Bowel Disease</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>3379</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21093379</pub-id><pub-id pub-id-type="pmid">32403220</pub-id><pub-id pub-id-type="pmcid">PMC7247009</pub-id></element-citation></ref><ref id="B53-cells-09-02061"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farhood</surname><given-names>B.</given-names></name><name name-style="western"><surname>Najafi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mortezaee</surname><given-names>K.</given-names></name></person-group><article-title>CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review</article-title><source>J. Cell. Physiol.</source><year>2019</year><volume>234</volume><fpage>8509</fpage><lpage>8521</lpage><pub-id pub-id-type="doi">10.1002/jcp.27782</pub-id><pub-id pub-id-type="pmid">30520029</pub-id></element-citation></ref><ref id="B54-cells-09-02061"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tagawa</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Snively</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boswell</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ounpraseuth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hickingbottom</surname><given-names>B.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>J.S.</given-names></name></person-group><article-title>Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma</article-title><source>Cancer</source><year>2003</year><volume>98</volume><fpage>144</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1002/cncr.11462</pub-id><pub-id pub-id-type="pmid">12833467</pub-id></element-citation></ref><ref id="B55-cells-09-02061"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proudfoot</surname><given-names>O.</given-names></name><name name-style="western"><surname>Apostolopoulos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pietersz</surname><given-names>G.A.</given-names></name></person-group><article-title>Receptor-mediated delivery of antigens to dendritic cells: Anticancer applications</article-title><source>Mol. Pharm.</source><year>2007</year><volume>4</volume><fpage>58</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1021/mp0601087</pub-id><pub-id pub-id-type="pmid">17228857</pub-id></element-citation></ref><ref id="B56-cells-09-02061"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steele</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marsden</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Berhane</surname><given-names>S.</given-names></name><name name-style="western"><surname>Billingham</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>N.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Uppal</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma</article-title><source>Gene Ther.</source><year>2011</year><volume>18</volume><fpage>584</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1038/gt.2011.1</pub-id><pub-id pub-id-type="pmid">21307889</pub-id></element-citation></ref><ref id="B57-cells-09-02061"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vandermeulen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pr&#233;at</surname><given-names>V.</given-names></name></person-group><article-title>Cancer DNA vaccines: Current preclinical and clinical developments and future perspectives</article-title><source>J.Exp. Clin. Cancer Res.</source><year>2019</year><volume>38</volume><fpage>146</fpage><pub-id pub-id-type="doi">10.1186/s13046-019-1154-7</pub-id><pub-id pub-id-type="pmid">30953535</pub-id><pub-id pub-id-type="pmcid">PMC6449928</pub-id></element-citation></ref><ref id="B58-cells-09-02061"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCann</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Mander</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cazaly</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chudley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stasakova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thirdborough</surname><given-names>S.</given-names></name><name name-style="western"><surname>King</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lloyd-Evans</surname><given-names>P.</given-names></name><name name-style="western"><surname>Buxton</surname><given-names>E.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes</article-title><source>Clin. Cancer Res.</source><year>2016</year><volume>22</volume><fpage>4827</fpage><lpage>4836</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2507</pub-id><pub-id pub-id-type="pmid">27091407</pub-id><pub-id pub-id-type="pmcid">PMC5330406</pub-id></element-citation></ref><ref id="B59-cells-09-02061"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNeel</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Eickhoff</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Wargowski</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zahm</surname><given-names>C.</given-names></name><name name-style="western"><surname>Staab</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Straus</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name></person-group><article-title>Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>25586</fpage><lpage>25596</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.25387</pub-id><pub-id pub-id-type="pmid">29876010</pub-id><pub-id pub-id-type="pmcid">PMC5986652</pub-id></element-citation></ref><ref id="B60-cells-09-02061"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tosch</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bastien</surname><given-names>B.</given-names></name><name name-style="western"><surname>Barraud</surname><given-names>L.</given-names></name><name name-style="western"><surname>Grellier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nourtier</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gantzer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Limacher</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Quemeneur</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bendjama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pr&#233;ville</surname><given-names>X.</given-names></name></person-group><article-title>Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC</article-title><source>J. Immunother. Cancer</source><year>2017</year><volume>5</volume><fpage>70</fpage><pub-id pub-id-type="doi">10.1186/s40425-017-0274-x</pub-id><pub-id pub-id-type="pmid">28923084</pub-id><pub-id pub-id-type="pmcid">PMC5604422</pub-id></element-citation></ref><ref id="B61-cells-09-02061"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#246;rrie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schaft</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schuler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schuler-Thurner</surname><given-names>B.</given-names></name></person-group><article-title>Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>92</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12020092</pub-id><pub-id pub-id-type="pmid">31979205</pub-id><pub-id pub-id-type="pmcid">PMC7076681</pub-id></element-citation></ref><ref id="B62-cells-09-02061"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Tendeloo</surname><given-names>V.F.</given-names></name><name name-style="western"><surname>Van de Velde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Driessche</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cools</surname><given-names>N.</given-names></name><name name-style="western"><surname>Anguille</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ladell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gostick</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pieters</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nijs</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Induction of complete and molecular remissions in acute myeloid leukemia by Wilms&#8217; tumor 1 antigen-targeted dendritic cell vaccination</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>13824</fpage><lpage>13829</lpage><pub-id pub-id-type="doi">10.1073/pnas.1008051107</pub-id><pub-id pub-id-type="pmid">20631300</pub-id><pub-id pub-id-type="pmcid">PMC2922237</pub-id></element-citation></ref><ref id="B63-cells-09-02061"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anguille</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van de Velde</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Smits</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Van Tendeloo</surname><given-names>V.F.</given-names></name><name name-style="western"><surname>Juliusson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cools</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nijs</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lion</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van Driessche</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia</article-title><source>Blood</source><year>2017</year><volume>130</volume><fpage>1713</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-04-780155</pub-id><pub-id pub-id-type="pmid">28830889</pub-id><pub-id pub-id-type="pmcid">PMC5649080</pub-id></element-citation></ref><ref id="B64-cells-09-02061"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Vieweg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weizer</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Dahm</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yancey</surname><given-names>D.</given-names></name><name name-style="western"><surname>Turaga</surname><given-names>V.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boczkowski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gilboa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dannull</surname><given-names>J.</given-names></name></person-group><article-title>Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product</article-title><source>Cancer Res.</source><year>2002</year><volume>62</volume><fpage>5041</fpage><lpage>5048</lpage><pub-id pub-id-type="pmid">12208759</pub-id></element-citation></ref><ref id="B65-cells-09-02061"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khoury</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>R.H.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Blum</surname><given-names>W.</given-names></name><name name-style="western"><surname>Stiff</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Elias</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lebkowski</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nishimoto</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Sen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>E.D.</given-names><suffix>III</suffix></name><etal/></person-group><article-title>Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia</article-title><source>Cancer</source><year>2017</year><volume>123</volume><fpage>3061</fpage><lpage>3072</lpage><pub-id pub-id-type="doi">10.1002/cncr.30696</pub-id><pub-id pub-id-type="pmid">28411378</pub-id></element-citation></ref><ref id="B66-cells-09-02061"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vik-Mo</surname><given-names>E.O.</given-names></name><name name-style="western"><surname>Nyakas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mikkelsen</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Moe</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Due-T&#248;nnesen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Suso</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>S&#230;b&#248;e-Larssen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sandberg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brinchmann</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Helseth</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma</article-title><source>Cancer Immunol. Immunother.</source><year>2013</year><volume>62</volume><fpage>1499</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1007/s00262-013-1453-3</pub-id><pub-id pub-id-type="pmid">23817721</pub-id><pub-id pub-id-type="pmcid">PMC3755221</pub-id></element-citation></ref><ref id="B67-cells-09-02061"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batich</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Reap</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Sanchez-Perez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Schmittling</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Norberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W.</given-names></name><name name-style="western"><surname>Herndon</surname><given-names>J.E.</given-names><suffix>II</suffix></name><name name-style="western"><surname>Healy</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination</article-title><source>Clin. Cancer Res.</source><year>2017</year><volume>23</volume><fpage>1898</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-2057</pub-id><pub-id pub-id-type="pmid">28411277</pub-id><pub-id pub-id-type="pmcid">PMC5559300</pub-id></element-citation></ref><ref id="B68-cells-09-02061"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dastmalchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Karachi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>D.</given-names></name></person-group><article-title>The role of CMV in glioblastoma and implications for immunotherapeutic strategies</article-title><source>Oncoimmunology</source><year>2019</year><volume>8</volume><fpage>e1514921</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2018.1514921</pub-id><pub-id pub-id-type="pmid">30546954</pub-id><pub-id pub-id-type="pmcid">PMC6287786</pub-id></element-citation></ref><ref id="B69-cells-09-02061"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilgenhof</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corthals</surname><given-names>J.</given-names></name><name name-style="western"><surname>Van Nuffel</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Benteyn</surname><given-names>D.</given-names></name><name name-style="western"><surname>Heirman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bonehill</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thielemans</surname><given-names>K.</given-names></name><name name-style="western"><surname>Neyns</surname><given-names>B.</given-names></name></person-group><article-title>Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases</article-title><source>Cancer Immunol. Immunother.</source><year>2015</year><volume>64</volume><fpage>381</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1007/s00262-014-1642-8</pub-id><pub-id pub-id-type="pmid">25548092</pub-id><pub-id pub-id-type="pmcid">PMC11029539</pub-id></element-citation></ref><ref id="B70-cells-09-02061"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilgenhof</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corthals</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heirman</surname><given-names>C.</given-names></name><name name-style="western"><surname>van Baren</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kvistborg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thielemans</surname><given-names>K.</given-names></name><name name-style="western"><surname>Neyns</surname><given-names>B.</given-names></name></person-group><article-title>Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma</article-title><source>J. Clin. Oncol.</source><year>2016</year><volume>34</volume><fpage>1330</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.63.4121</pub-id><pub-id pub-id-type="pmid">26926680</pub-id></element-citation></ref><ref id="B71-cells-09-02061"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grabbe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>H.</given-names></name><name name-style="western"><surname>Diken</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kranz</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Langguth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>U.</given-names></name></person-group><article-title>Translating nanoparticulate-personalized cancer vaccines into clinical applications: Case study with RNA-lipoplexes for the treatment of melanoma</article-title><source>Nanomedicine (London, England)</source><year>2016</year><volume>11</volume><fpage>2723</fpage><lpage>2734</lpage><pub-id pub-id-type="doi">10.2217/nnm-2016-0275</pub-id><pub-id pub-id-type="pmid">27700619</pub-id></element-citation></ref><ref id="B72-cells-09-02061"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kranz</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Diken</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kreiter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loquai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vascotto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hefesha</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy</article-title><source>Nature</source><year>2016</year><volume>534</volume><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1038/nature18300</pub-id><pub-id pub-id-type="pmid">27281205</pub-id></element-citation></ref><ref id="B73-cells-09-02061"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nazarkina Zh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Khar&#8217;kova</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Antonets</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Morozkin</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Bazhan</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Karpenko</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Vlasov</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Ilyichev</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Laktionov</surname><given-names>P.P.</given-names></name></person-group><article-title>Design of Polyepitope DNA Vaccine against Breast Carcinoma Cells and Analysis of Its Expression in Dendritic Cells</article-title><source>Bull. Exp. Biol. Med.</source><year>2016</year><volume>160</volume><fpage>486</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1007/s10517-016-3203-y</pub-id><pub-id pub-id-type="pmid">26915653</pub-id></element-citation></ref><ref id="B74-cells-09-02061"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirayama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>Y.</given-names></name></person-group><article-title>The present status and future prospects of peptide-based cancer vaccines</article-title><source>Int. Immunol.</source><year>2016</year><volume>28</volume><fpage>319</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxw027</pub-id><pub-id pub-id-type="pmid">27235694</pub-id></element-citation></ref><ref id="B75-cells-09-02061"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brennick</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>George</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Corwin</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Ebrahimi-Nik</surname><given-names>H.</given-names></name></person-group><article-title>Neoepitopes as cancer immunotherapy targets: Key challenges and opportunities</article-title><source>Immunotherapy</source><year>2017</year><volume>9</volume><fpage>361</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.2217/imt-2016-0146</pub-id><pub-id pub-id-type="pmid">28303769</pub-id></element-citation></ref><ref id="B76-cells-09-02061"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiyotani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>Y.</given-names></name></person-group><article-title>Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens</article-title><source>Cancer Sci.</source><year>2018</year><volume>109</volume><fpage>542</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1111/cas.13498</pub-id><pub-id pub-id-type="pmid">29288513</pub-id><pub-id pub-id-type="pmcid">PMC5834780</pub-id></element-citation></ref><ref id="B77-cells-09-02061"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sultan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Trillo-Tinoco</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Celis</surname><given-names>E.</given-names></name></person-group><article-title>Effective antitumor peptide vaccines can induce severe autoimmune pathology</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>70317</fpage><lpage>70331</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.19688</pub-id><pub-id pub-id-type="pmid">29050282</pub-id><pub-id pub-id-type="pmcid">PMC5642557</pub-id></element-citation></ref><ref id="B78-cells-09-02061"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Crystal</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>El-Gamil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>C.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Samuels</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions</article-title><source>Clin. Cancer Res.</source><year>2014</year><volume>20</volume><fpage>3401</fpage><lpage>3410</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0433</pub-id><pub-id pub-id-type="pmid">24987109</pub-id><pub-id pub-id-type="pmcid">PMC4083471</pub-id></element-citation></ref><ref id="B79-cells-09-02061"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U.</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kloke</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>P.</given-names></name><name name-style="western"><surname>L&#246;wer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bukur</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tadmor</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Luxemburger</surname><given-names>U.</given-names></name><name name-style="western"><surname>Schr&#246;rs</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</article-title><source>Nature</source><year>2017</year><volume>547</volume><fpage>222</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1038/nature23003</pub-id><pub-id pub-id-type="pmid">28678784</pub-id></element-citation></ref><ref id="B80-cells-09-02061"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bins</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Wolkers</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>van den Boom</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Haanen</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>T.N.</given-names></name></person-group><article-title>In vivo antigen stability affects DNA vaccine immunogenicity</article-title><source>J. Immunol. (Baltimore, Md.: 1950)</source><year>2007</year><volume>179</volume><fpage>2126</fpage><lpage>2133</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.4.2126</pub-id><pub-id pub-id-type="pmid">17675471</pub-id></element-citation></ref><ref id="B81-cells-09-02061"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoppes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Oostvogels</surname><given-names>R.</given-names></name><name name-style="western"><surname>Luimstra</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wals</surname><given-names>K.</given-names></name><name name-style="western"><surname>Toebes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bies</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ekkebus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rijal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Celie</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Altered peptide ligands revisited: Vaccine design through chemically modified HLA-A2-restricted T cell epitopes</article-title><source>J. Immunol.</source><year>2014</year><volume>193</volume><fpage>4803</fpage><lpage>4813</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1400800</pub-id><pub-id pub-id-type="pmid">25311806</pub-id><pub-id pub-id-type="pmcid">PMC4226423</pub-id></element-citation></ref><ref id="B82-cells-09-02061"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seledtsova</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Shishkov</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Kaschenko</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Goncharov</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Gazatova</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Seledtsov</surname><given-names>V.I.</given-names></name></person-group><article-title>Xenogeneic cell-based vaccine therapy for stage III melanoma: Safety, immune-mediated responses and survival benefits</article-title><source>Eur. J. Dermatol.</source><year>2016</year><volume>26</volume><fpage>138</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1684/ejd.2016.2733</pub-id><pub-id pub-id-type="pmid">27026566</pub-id></element-citation></ref><ref id="B83-cells-09-02061"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sponaas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carstens</surname><given-names>C.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>N.</given-names></name></person-group><article-title>C-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells</article-title><source>Gene Ther.</source><year>1999</year><volume>6</volume><fpage>1826</fpage><lpage>1834</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3301021</pub-id><pub-id pub-id-type="pmid">10602378</pub-id></element-citation></ref><ref id="B84-cells-09-02061"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tudor</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dubuquoy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gaboriau</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>F.</given-names></name><name name-style="western"><surname>Charley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Riffault</surname><given-names>S.</given-names></name></person-group><article-title>TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>1258</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.09.001</pub-id><pub-id pub-id-type="pmid">15652668</pub-id></element-citation></ref><ref id="B85-cells-09-02061"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suschak</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name></person-group><article-title>A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines</article-title><source>J. Immunol.</source><year>2016</year><volume>196</volume><fpage>310</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1501836</pub-id><pub-id pub-id-type="pmid">26590319</pub-id><pub-id pub-id-type="pmcid">PMC4685033</pub-id></element-citation></ref><ref id="B86-cells-09-02061"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larregina</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Erdos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Storkus</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Beer Stolz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Falo</surname><given-names>L.D.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Direct transfection and activation of human cutaneous dendritic cells</article-title><source>Gene Ther.</source><year>2001</year><volume>8</volume><fpage>608</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3301404</pub-id><pub-id pub-id-type="pmid">11320407</pub-id></element-citation></ref><ref id="B87-cells-09-02061"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemmi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kaisho</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sanjo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hoshino</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A Toll-like receptor recognizes bacterial DNA</article-title><source>Nature</source><year>2000</year><volume>408</volume><fpage>740</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1038/35047123</pub-id><pub-id pub-id-type="pmid">11130078</pub-id></element-citation></ref><ref id="B88-cells-09-02061"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheiermann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D.M.</given-names></name></person-group><article-title>Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>6377</fpage><lpage>6389</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.06.065</pub-id><pub-id pub-id-type="pmid">24975812</pub-id><pub-id pub-id-type="pmcid">PMC4252359</pub-id></element-citation></ref><ref id="B89-cells-09-02061"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>R.</given-names></name></person-group><article-title>Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD50 rabies challenge virus standard strain</article-title><source>Mol. Immunol.</source><year>2017</year><volume>85</volume><fpage>166</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2017.02.011</pub-id><pub-id pub-id-type="pmid">28267643</pub-id></element-citation></ref><ref id="B90-cells-09-02061"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shedlock</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Tingey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mahadevan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hutnick</surname><given-names>N.</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Kudchodkar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Flingai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Ugen</surname><given-names>K.E.</given-names></name><etal/></person-group><article-title>Co-Administration of Molecular Adjuvants Expressing NF-Kappa B Subunit p65/RelA or Type-1 Transactivator T-bet Enhance Antigen Specific DNA Vaccine-Induced Immunity</article-title><source>Vaccines</source><year>2014</year><volume>2</volume><fpage>196</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.3390/vaccines2020196</pub-id><pub-id pub-id-type="pmid">26344618</pub-id><pub-id pub-id-type="pmcid">PMC4494262</pub-id></element-citation></ref><ref id="B91-cells-09-02061"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfeiffer</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Hoyer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gerer</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Voll</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Knippertz</surname><given-names>I.</given-names></name><name name-style="western"><surname>G&#252;ckel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schuler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schaft</surname><given-names>N.</given-names></name><name name-style="western"><surname>D&#246;rrie</surname><given-names>J.</given-names></name></person-group><article-title>Triggering of NF-&#954;B in cytokine-matured human DCs generates superior DCs for T-cell priming in cancer immunotherapy</article-title><source>Eur. J. Immunol.</source><year>2014</year><volume>44</volume><fpage>3413</fpage><lpage>3428</lpage><pub-id pub-id-type="doi">10.1002/eji.201344417</pub-id><pub-id pub-id-type="pmid">25100611</pub-id></element-citation></ref><ref id="B92-cells-09-02061"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosch</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Voll</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Voskens</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seliger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schuler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schaft</surname><given-names>N.</given-names></name><name name-style="western"><surname>D&#246;rrie</surname><given-names>J.</given-names></name></person-group><article-title>NF-&#954;B activation triggers NK-cell stimulation by monocyte-derived dendritic cells</article-title><source>Ther. Adv. Med. Oncol.</source><year>2019</year><volume>11</volume><fpage>1758835919891622</fpage><pub-id pub-id-type="doi">10.1177/1758835919891622</pub-id><pub-id pub-id-type="pmid">31853267</pub-id><pub-id pub-id-type="pmcid">PMC6909276</pub-id></element-citation></ref><ref id="B93-cells-09-02061"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amara</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Yeow</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Pitha</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>H.L.</given-names></name></person-group><article-title>Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors</article-title><source>J. Virol.</source><year>2002</year><volume>76</volume><fpage>6652</fpage><lpage>6659</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.13.6652-6659.2002</pub-id><pub-id pub-id-type="pmid">12050378</pub-id><pub-id pub-id-type="pmcid">PMC136278</pub-id></element-citation></ref><ref id="B94-cells-09-02061"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bontkes</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ruizendaal</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Hooijberg</surname><given-names>E.</given-names></name></person-group><article-title>Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells</article-title><source>Clin. Immunol.</source><year>2008</year><volume>127</volume><fpage>375</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2008.02.001</pub-id><pub-id pub-id-type="pmid">18358784</pub-id></element-citation></ref><ref id="B95-cells-09-02061"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Kochar</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Elizaga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hay</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>De Rosa</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ota-Setlik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>D.</given-names></name><etal/></person-group><article-title>DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8(+) T-Cell Responses by Interleukin-12 Plasmid DNA</article-title><source>Clin. Vaccine Immunol.</source><year>2017</year><volume>24</volume><pub-id pub-id-type="doi">10.1128/CVI.00263-17</pub-id><pub-id pub-id-type="pmcid">PMC5674193</pub-id><pub-id pub-id-type="pmid">28931520</pub-id></element-citation></ref><ref id="B96-cells-09-02061"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name></person-group><article-title>Novel adjuvant for immunization against tuberculosis: DNA vaccine expressing Mycobacterium tuberculosis antigen 85A and interleukin-15 fusion product elicits strong immune responses in mice</article-title><source>Biotechnol. Lett.</source><year>2017</year><volume>39</volume><fpage>1159</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1007/s10529-017-2342-1</pub-id><pub-id pub-id-type="pmid">28470626</pub-id></element-citation></ref><ref id="B97-cells-09-02061"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>F.</given-names></name></person-group><article-title>Mutual enhancement of IL-2 and IL-7 on DNA vaccine immunogenicity mainly involves regulations on their receptor expression and receptor-expressing lymphocyte generation</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>3480</fpage><lpage>3487</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.05.068</pub-id><pub-id pub-id-type="pmid">26055295</pub-id></element-citation></ref><ref id="B98-cells-09-02061"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name></person-group><article-title>Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo</article-title><source>Biomaterials</source><year>2015</year><volume>38</volume><fpage>50</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.10.050</pub-id><pub-id pub-id-type="pmid">25457983</pub-id></element-citation></ref><ref id="B99-cells-09-02061"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer</article-title><source>Int. J. Nanomed.</source><year>2017</year><volume>12</volume><fpage>5331</fpage><lpage>5343</lpage><pub-id pub-id-type="doi">10.2147/IJN.S137245</pub-id><pub-id pub-id-type="pmcid">PMC5536232</pub-id><pub-id pub-id-type="pmid">28794626</pub-id></element-citation></ref><ref id="B100-cells-09-02061"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Self-Fordham</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Naqvi</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Uttamani</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nares</surname><given-names>S.</given-names></name></person-group><article-title>MicroRNA: Dynamic Regulators of Macrophage Polarization and Plasticity</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1062</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01062</pub-id><pub-id pub-id-type="pmid">28912781</pub-id><pub-id pub-id-type="pmcid">PMC5583156</pub-id></element-citation></ref><ref id="B101-cells-09-02061"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Migault</surname><given-names>M.</given-names></name><name name-style="western"><surname>Donnou-Fournet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Galibert</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Gilot</surname><given-names>D.</given-names></name></person-group><article-title>Definition and identification of small RNA sponges: Focus on miRNA sequestration</article-title><source>Methods</source><year>2017</year><volume>117</volume><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2016.11.012</pub-id><pub-id pub-id-type="pmid">27876678</pub-id></element-citation></ref><ref id="B102-cells-09-02061"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lima</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Cerqueira</surname><given-names>L.</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>C.</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>N.F.</given-names></name></person-group><article-title>Anti-miRNA oligonucleotides: A comprehensive guide for design</article-title><source>RNA Biol.</source><year>2018</year><volume>15</volume><fpage>338</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1080/15476286.2018.1445959</pub-id><pub-id pub-id-type="pmid">29570036</pub-id><pub-id pub-id-type="pmcid">PMC5927725</pub-id></element-citation></ref><ref id="B103-cells-09-02061"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>Tumor-targeted Delivery of Anti-microRNA for Cancer Therapy: pHLIP is Key</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2015</year><volume>54</volume><fpage>5824</fpage><lpage>5826</lpage><pub-id pub-id-type="doi">10.1002/anie.201502146</pub-id><pub-id pub-id-type="pmid">25892205</pub-id></element-citation></ref><ref id="B104-cells-09-02061"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vargas</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Salton</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sodre de Castro Laino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pires</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Bonamino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lenz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Delgado-Canedo</surname><given-names>A.</given-names></name></person-group><article-title>pLR: A lentiviral backbone series to stable transduction of bicistronic genes and exchange of promoters</article-title><source>Plasmid</source><year>2012</year><volume>68</volume><fpage>179</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.plasmid.2012.06.001</pub-id><pub-id pub-id-type="pmid">22728068</pub-id></element-citation></ref><ref id="B105-cells-09-02061"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terenin</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Smirnova</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Andreev</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Dmitriev</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Shatsky</surname><given-names>I.N.</given-names></name></person-group><article-title>A researcher&#8217;s guide to the galaxy of IRESs</article-title><source>Cell. Mol. Life Sci.</source><year>2017</year><volume>74</volume><fpage>1431</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1007/s00018-016-2409-5</pub-id><pub-id pub-id-type="pmid">27853833</pub-id><pub-id pub-id-type="pmcid">PMC11107752</pub-id></element-citation></ref><ref id="B106-cells-09-02061"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Youn</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>J.H.</given-names></name></person-group><article-title>Development of an RNA Expression Platform Controlled by Viral Internal Ribosome Entry Sites</article-title><source>J. Microbiol. Biotechnol.</source><year>2019</year><volume>29</volume><fpage>127</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.4014/jmb.1811.11019</pub-id><pub-id pub-id-type="pmid">30518020</pub-id></element-citation></ref><ref id="B107-cells-09-02061"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hoi</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Gagnon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells</article-title><source>mAbs</source><year>2015</year><volume>7</volume><fpage>403</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1080/19420862.2015.1008351</pub-id><pub-id pub-id-type="pmid">25621616</pub-id><pub-id pub-id-type="pmcid">PMC4622431</pub-id></element-citation></ref><ref id="B108-cells-09-02061"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.Y.</given-names></name></person-group><article-title>High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice</article-title><source>PloS ONE</source><year>2011</year><volume>6</volume><elocation-id>e18556</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0018556</pub-id><pub-id pub-id-type="pmid">21602908</pub-id><pub-id pub-id-type="pmcid">PMC3084703</pub-id></element-citation></ref><ref id="B109-cells-09-02061"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gracey Maniar</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Maniar</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fire</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Kay</surname><given-names>M.A.</given-names></name></person-group><article-title>Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level</article-title><source>Mol. Ther.</source><year>2013</year><volume>21</volume><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1038/mt.2012.244</pub-id><pub-id pub-id-type="pmid">23183534</pub-id><pub-id pub-id-type="pmcid">PMC3538319</pub-id></element-citation></ref><ref id="B110-cells-09-02061"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blomberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C.I.</given-names></name></person-group><article-title>Safety and efficacy of DNA vaccines: Plasmids vs. minicircles</article-title><source>Hum. Vaccin. Immunother.</source><year>2014</year><volume>10</volume><fpage>1306</fpage><lpage>1308</lpage><pub-id pub-id-type="doi">10.4161/hv.28077</pub-id><pub-id pub-id-type="pmid">24553064</pub-id><pub-id pub-id-type="pmcid">PMC4896608</pub-id></element-citation></ref><ref id="B111-cells-09-02061"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lechardeur</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lukacs</surname><given-names>G.L.</given-names></name></person-group><article-title>Nucleocytoplasmic transport of plasmid DNA: A perilous journey from the cytoplasm to the nucleus</article-title><source>Hum. Gene Ther.</source><year>2006</year><volume>17</volume><fpage>882</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1089/hum.2006.17.882</pub-id><pub-id pub-id-type="pmid">16972756</pub-id></element-citation></ref><ref id="B112-cells-09-02061"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dean</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>L.C.</given-names></name></person-group><article-title>Sequence requirements for plasmid nuclear import</article-title><source>Exp. Cell. Res.</source><year>1999</year><volume>253</volume><fpage>713</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1006/excr.1999.4716</pub-id><pub-id pub-id-type="pmid">10585295</pub-id><pub-id pub-id-type="pmcid">PMC4152905</pub-id></element-citation></ref><ref id="B113-cells-09-02061"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanazawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takashima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>H.</given-names></name></person-group><article-title>Versatile nuclear localization signal-based oligopeptide as a gene vector</article-title><source>Biol. Pharm. Bull.</source><year>2015</year><volume>38</volume><fpage>559</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1248/bpb.b14-00706</pub-id><pub-id pub-id-type="pmid">25832636</pub-id></element-citation></ref><ref id="B114-cells-09-02061"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grubor-Bauk</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wijesundara</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gummow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garrod</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Voskoboinik</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gowans</surname><given-names>E.J.</given-names></name></person-group><article-title>Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs</article-title><source>Gene Ther.</source><year>2016</year><volume>23</volume><fpage>26</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1038/gt.2015.86</pub-id><pub-id pub-id-type="pmid">26262584</pub-id></element-citation></ref><ref id="B115-cells-09-02061"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krinner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heitzer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Asbach</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>R.</given-names></name></person-group><article-title>Interplay of Promoter Usage and Intragenic CpG Content: Impact on GFP Reporter Gene Expression</article-title><source>Hum. Gene Ther.</source><year>2015</year><volume>26</volume><fpage>826</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1089/hum.2015.075</pub-id><pub-id pub-id-type="pmid">26414116</pub-id></element-citation></ref><ref id="B116-cells-09-02061"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yagi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miyamoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Toyama</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suda</surname><given-names>T.</given-names></name></person-group><article-title>Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells</article-title><source>J. Bone Miner. Metab.</source><year>2006</year><volume>24</volume><fpage>355</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1007/s00774-006-0697-9</pub-id><pub-id pub-id-type="pmid">16937266</pub-id></element-citation></ref><ref id="B117-cells-09-02061"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dresch</surname><given-names>C.</given-names></name><name name-style="western"><surname>Edelmann</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Marconi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Brocker</surname><given-names>T.</given-names></name></person-group><article-title>Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo</article-title><source>J. Immunol.</source><year>2008</year><volume>181</volume><fpage>4495</fpage><lpage>4506</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.7.4495</pub-id><pub-id pub-id-type="pmid">18802052</pub-id></element-citation></ref><ref id="B118-cells-09-02061"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonkobara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zukas</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Shikano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>P.D.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Ariizumi</surname><given-names>K.</given-names></name></person-group><article-title>Epidermal Langerhans cell-targeted gene expression by a dectin-2 promoter</article-title><source>J. Immunol.</source><year>2001</year><volume>167</volume><fpage>6893</fpage><lpage>6900</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.167.12.6893</pub-id><pub-id pub-id-type="pmid">11739507</pub-id></element-citation></ref><ref id="B119-cells-09-02061"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vanvarenberg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Preat</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vandermeulen</surname><given-names>G.</given-names></name></person-group><article-title>Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 Mastocytoma</article-title><source>Mol. Ther. Nucleic Acids</source><year>2017</year><volume>8</volume><fpage>404</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2017.07.011</pub-id><pub-id pub-id-type="pmid">28918040</pub-id><pub-id pub-id-type="pmcid">PMC5537203</pub-id></element-citation></ref><ref id="B120-cells-09-02061"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sudowe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beisner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Ludwig-Portugall</surname><given-names>I.</given-names></name><name name-style="western"><surname>Steitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tuting</surname><given-names>T.</given-names></name><name name-style="western"><surname>Knop</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reske-Kunz</surname><given-names>A.B.</given-names></name></person-group><article-title>Transcriptional targeting of dendritic cells for gene therapy using the promoter of the cytoskeletal protein fascin</article-title><source>Gene Ther.</source><year>2003</year><volume>10</volume><fpage>1035</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3301968</pub-id><pub-id pub-id-type="pmid">12776161</pub-id></element-citation></ref><ref id="B121-cells-09-02061"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Pautz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reske-Kunz</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>R.</given-names></name></person-group><article-title>The human fascin gene promoter is highly active in mature dendritic cells due to a stage-specific enhancer</article-title><source>J. Immunol.</source><year>2003</year><volume>171</volume><fpage>1825</fpage><lpage>1834</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.4.1825</pub-id><pub-id pub-id-type="pmid">12902483</pub-id></element-citation></ref><ref id="B122-cells-09-02061"><label>122.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Raker</surname><given-names>V.</given-names></name><name name-style="western"><surname>Maxeiner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reske-Kunz</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Sudowe</surname><given-names>S.</given-names></name></person-group><article-title>Efficiency of biolistic DNA vaccination in experimental type I allergy</article-title><source>Biolistic DNA Delivery: Methods in Molecular Biology</source><person-group person-group-type="editor"><name name-style="western"><surname>Sudowe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reske-Kunz</surname><given-names>A.</given-names></name></person-group><publisher-name>Humana Press</publisher-name><publisher-loc>Totowa, NJ, USA</publisher-loc><year>2013</year><fpage>357</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1007/978-1-62703-110-3_26</pub-id><pub-id pub-id-type="pmid">23104354</pub-id></element-citation></ref><ref id="B123-cells-09-02061"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castor</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yogev</surname><given-names>N.</given-names></name><name name-style="western"><surname>Blank</surname><given-names>T.</given-names></name><name name-style="western"><surname>Barwig</surname><given-names>C.</given-names></name><name name-style="western"><surname>Prinz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Waisman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reske-Kunz</surname><given-names>A.B.</given-names></name></person-group><article-title>Inhibition of experimental autoimmune encephalomyelitis by tolerance-promoting DNA vaccination focused to dendritic cells</article-title><source>PloS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0191927</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0191927</pub-id><pub-id pub-id-type="pmid">29408931</pub-id><pub-id pub-id-type="pmcid">PMC5800700</pub-id></element-citation></ref><ref id="B124-cells-09-02061"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sudowe</surname><given-names>S.</given-names></name><name name-style="western"><surname>H&#246;hn</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Renzing</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maxeiner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Montermann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Habermeier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Closs</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reske-Kunz</surname><given-names>A.B.</given-names></name></person-group><article-title>Inhibition of antigen-specific immune responses by co-application of an indoleamine 2,3-dioxygenase (IDO)-encoding vector requires antigen transgene expression focused on dendritic cells</article-title><source>Amino Acids</source><year>2020</year><volume>52</volume><fpage>411</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1007/s00726-020-02817-4</pub-id><pub-id pub-id-type="pmid">32008091</pub-id></element-citation></ref><ref id="B125-cells-09-02061"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>DNA Nanotechnology for Precise Control over Drug Delivery and Gene Therapy</article-title><source>Small (Weinheim an der Bergstrasse, Germany)</source><year>2016</year><volume>12</volume><fpage>1117</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1002/smll.201502167</pub-id><pub-id pub-id-type="pmid">26725041</pub-id></element-citation></ref><ref id="B126-cells-09-02061"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Menezes</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Emdad</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>P.B.</given-names></name></person-group><article-title>Gene Therapies for Cancer: Strategies, Challenges and Successes</article-title><source>J. Cell. Physiol.</source><year>2015</year><volume>230</volume><fpage>259</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1002/jcp.24791</pub-id><pub-id pub-id-type="pmid">25196387</pub-id><pub-id pub-id-type="pmcid">PMC4363073</pub-id></element-citation></ref><ref id="B127-cells-09-02061"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Combinatorial Nano-Bio Interfaces</article-title><source>ACS Nano</source><year>2018</year><pub-id pub-id-type="doi">10.1021/acsnano.8b03285</pub-id><pub-id pub-id-type="pmid">29883094</pub-id></element-citation></ref><ref id="B128-cells-09-02061"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Houseley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tollervey</surname><given-names>D.</given-names></name></person-group><article-title>The many pathways of RNA degradation</article-title><source>Cell</source><year>2009</year><volume>136</volume><fpage>763</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.01.019</pub-id><pub-id pub-id-type="pmid">19239894</pub-id></element-citation></ref><ref id="B129-cells-09-02061"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name></person-group><article-title>Nanoscale platforms for messenger RNA delivery</article-title><source>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</source><year>2019</year><volume>11</volume><fpage>e1530</fpage><pub-id pub-id-type="doi">10.1002/wnan.1530</pub-id><pub-id pub-id-type="pmid">29726120</pub-id><pub-id pub-id-type="pmcid">PMC6443240</pub-id></element-citation></ref><ref id="B130-cells-09-02061"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Midoux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pichon</surname><given-names>C.</given-names></name></person-group><article-title>Lipid-based mRNA vaccine delivery systems</article-title><source>Expert. Rev. Vaccines</source><year>2015</year><volume>14</volume><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1586/14760584.2015.986104</pub-id><pub-id pub-id-type="pmid">25540984</pub-id></element-citation></ref><ref id="B131-cells-09-02061"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foged</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brodin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Frokjaer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sundblad</surname><given-names>A.</given-names></name></person-group><article-title>Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model</article-title><source>Int. J. Pharm.</source><year>2005</year><volume>298</volume><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2005.03.035</pub-id><pub-id pub-id-type="pmid">15961266</pub-id></element-citation></ref><ref id="B132-cells-09-02061"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Scholzen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Minigo</surname><given-names>G.</given-names></name><name name-style="western"><surname>David</surname><given-names>C.</given-names></name><name name-style="western"><surname>Apostolopoulos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mottram</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Plebanski</surname><given-names>M.</given-names></name></person-group><article-title>Pathogen recognition and development of particulate vaccines: Does size matter?</article-title><source>Methods</source><year>2006</year><volume>40</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2006.05.016</pub-id><pub-id pub-id-type="pmid">16997708</pub-id></element-citation></ref><ref id="B133-cells-09-02061"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niikura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsunaga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Orba</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kajino</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ninomiya</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Gold nanoparticles as a vaccine platform: Influence of size and shape on immunological responses in vitro and in vivo</article-title><source>ACS Nano</source><year>2013</year><volume>7</volume><fpage>3926</fpage><lpage>3938</lpage><pub-id pub-id-type="doi">10.1021/nn3057005</pub-id><pub-id pub-id-type="pmid">23631767</pub-id></element-citation></ref><ref id="B134-cells-09-02061"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radis-Baptista</surname><given-names>G.</given-names></name><name name-style="western"><surname>Campelo</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Morlighem</surname><given-names>J.R.L.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>V.J.F.</given-names></name></person-group><article-title>Cell-penetrating peptides (CPPs): From delivery of nucleic acids and antigens to transduction of engineered nucleases for application in transgenesis</article-title><source>J. Biotechnol.</source><year>2017</year><volume>252</volume><fpage>15</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2017.05.002</pub-id><pub-id pub-id-type="pmid">28479163</pub-id></element-citation></ref><ref id="B135-cells-09-02061"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falanga</surname><given-names>A.</given-names></name><name name-style="western"><surname>Galdiero</surname><given-names>S.</given-names></name></person-group><article-title>Peptide chemistry encounters nanomedicine: Recent applications and upcoming scenarios in cancer</article-title><source>Future. Med. Chem.</source><year>2018</year><volume>10</volume><fpage>1877</fpage><lpage>1880</lpage><pub-id pub-id-type="doi">10.4155/fmc-2018-0182</pub-id><pub-id pub-id-type="pmid">29921135</pub-id></element-citation></ref><ref id="B136-cells-09-02061"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dane</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Nembrini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tomei</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Eby</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>O&#8217;Neil</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Velluto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Inverardi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>J.A.</given-names></name></person-group><article-title>Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival</article-title><source>J. Controlled Release</source><year>2011</year><volume>156</volume><fpage>154</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2011.08.009</pub-id><pub-id pub-id-type="pmid">21864593</pub-id></element-citation></ref><ref id="B137-cells-09-02061"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.S.</given-names></name></person-group><article-title>Subcutaneous administration of liposomes: A comparison with the intravenous and intraperitoneal routes of injection</article-title><source>Biochim. Biophys. Acta</source><year>1993</year><volume>1150</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/0005-2736(93)90115-G</pub-id><pub-id pub-id-type="pmid">8334142</pub-id></element-citation></ref><ref id="B138-cells-09-02061"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Longmire</surname><given-names>M.</given-names></name><name name-style="western"><surname>Choyke</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>H.</given-names></name></person-group><article-title>Clearance properties of nano-sized particles and molecules as imaging agents: Considerations and caveats</article-title><source>Nanomedicine (London, England)</source><year>2008</year><volume>3</volume><fpage>703</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.2217/17435889.3.5.703</pub-id><pub-id pub-id-type="pmcid">PMC3407669</pub-id><pub-id pub-id-type="pmid">18817471</pub-id></element-citation></ref><ref id="B139-cells-09-02061"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>G.</given-names></name></person-group><article-title>Long circulating polymeric nanoparticles for gene/drug delivery</article-title><source>Curr. Drug Metab.</source><year>2018</year><volume>19</volume><fpage>723</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.2174/1389200219666171207120643</pub-id><pub-id pub-id-type="pmid">29219050</pub-id></element-citation></ref><ref id="B140-cells-09-02061"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C.</given-names></name></person-group><article-title>Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles</article-title><source>Biomaterials</source><year>2010</year><volume>31</volume><fpage>3657</fpage><lpage>3666</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.01.065</pub-id><pub-id pub-id-type="pmid">20138662</pub-id></element-citation></ref><ref id="B141-cells-09-02061"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fogli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Montis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paccosi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Silvano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Michelucci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Berti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bosi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parenti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Romagnoli</surname><given-names>P.</given-names></name></person-group><article-title>Inorganic nanoparticles as potential regulators of immune response in dendritic cells</article-title><source>Nanomedicine (London, England)</source><year>2017</year><volume>12</volume><fpage>1647</fpage><lpage>1660</lpage><pub-id pub-id-type="doi">10.2217/nnm-2017-0061</pub-id><pub-id pub-id-type="pmid">28635380</pub-id></element-citation></ref><ref id="B142-cells-09-02061"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svoboda</surname><given-names>O.</given-names></name><name name-style="western"><surname>Fohlerova</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Baiazitova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mlynek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Samouylov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Provaznik</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hubalek</surname><given-names>J.</given-names></name></person-group><article-title>Transfection by Polyethyleneimine-Coated Magnetic Nanoparticles: Fine-Tuning the Condition for Electrophysiological Experiments</article-title><source>J. Biomed. Nanotechnol.</source><year>2018</year><volume>14</volume><fpage>1505</fpage><lpage>1514</lpage><pub-id pub-id-type="doi">10.1166/jbn.2018.2602</pub-id><pub-id pub-id-type="pmid">29903065</pub-id></element-citation></ref><ref id="B143-cells-09-02061"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>S.Z.</given-names></name></person-group><article-title>A mesoporous organosilica nano-bowl with high DNA loading capacity - a potential gene delivery carrier</article-title><source>Nanoscale</source><year>2016</year><volume>8</volume><fpage>17446</fpage><lpage>17450</lpage><pub-id pub-id-type="doi">10.1039/C6NR06777H</pub-id><pub-id pub-id-type="pmid">27714117</pub-id></element-citation></ref><ref id="B144-cells-09-02061"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Herrera</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name></person-group><article-title>Graphene oxide: An efficient material and recent approach for biotechnological and biomedical applications</article-title><source>Mater. Sci. Eng. C Mater. Biol. App.</source><year>2018</year><volume>86</volume><fpage>173</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2018.01.004</pub-id><pub-id pub-id-type="pmid">29525091</pub-id></element-citation></ref><ref id="B145-cells-09-02061"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.J.</given-names></name></person-group><article-title>Stimuli-Regulated Enzymatically Degradable Smart Graphene-Oxide-Polymer Nanocarrier Facilitating Photothermal Gene Delivery</article-title><source>Adv. Healthc. Mater.</source><year>2016</year><volume>5</volume><fpage>1918</fpage><lpage>1930</lpage><pub-id pub-id-type="doi">10.1002/adhm.201600246</pub-id><pub-id pub-id-type="pmid">27185583</pub-id></element-citation></ref><ref id="B146-cells-09-02061"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yue</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>D.</given-names></name></person-group><article-title>Graphene oxide-mediated Cas9/sgRNA delivery for efficient genome editing</article-title><source>Nanoscale</source><year>2018</year><volume>10</volume><fpage>1063</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1039/C7NR07999K</pub-id><pub-id pub-id-type="pmid">29266160</pub-id></element-citation></ref><ref id="B147-cells-09-02061"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quader</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>K.</given-names></name></person-group><article-title>Nanomaterial-Enabled Cancer Therapy</article-title><source>Mol. Ther.</source><year>2017</year><volume>25</volume><fpage>1501</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.04.026</pub-id><pub-id pub-id-type="pmid">28532763</pub-id><pub-id pub-id-type="pmcid">PMC5498831</pub-id></element-citation></ref><ref id="B148-cells-09-02061"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.Y.</given-names></name></person-group><article-title>Carbon Dioxide-Generating PLG Nanoparticles for Controlled Anti-Cancer Drug Delivery</article-title><source>Pharm. Res.</source><year>2018</year><volume>35</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.1007/s11095-018-2359-8</pub-id><pub-id pub-id-type="pmid">29427239</pub-id></element-citation></ref><ref id="B149-cells-09-02061"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>F.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name></person-group><article-title>Surface-functionalized, pH-responsive poly(lactic-co-glycolic acid)-based microparticles for intranasal vaccine delivery: Effect of surface modification with chitosan and mannan</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2016</year><volume>109</volume><fpage>24</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2016.08.012</pub-id><pub-id pub-id-type="pmid">27569030</pub-id></element-citation></ref><ref id="B150-cells-09-02061"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Itaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Harada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamasaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>K.</given-names></name></person-group><article-title>In situ single cell observation by fluorescence resonance energy transfer reveals fast intra-cytoplasmic delivery and easy release of plasmid DNA complexed with linear polyethylenimine</article-title><source>J. Gene Med.</source><year>2004</year><volume>6</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1002/jgm.470</pub-id><pub-id pub-id-type="pmid">14716679</pub-id></element-citation></ref><ref id="B151-cells-09-02061"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name></person-group><article-title>Dual-responsive polyplexes with enhanced disassembly and endosomal escape for efficient delivery of siRNA</article-title><source>Biomaterials</source><year>2018</year><volume>162</volume><fpage>47</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.01.042</pub-id><pub-id pub-id-type="pmid">29432988</pub-id></element-citation></ref><ref id="B152-cells-09-02061"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name></person-group><article-title>Polyethylenimine-based Formulations for Delivery of Oligonucleotides</article-title><source>Curr. Med. Chem.</source><year>2019</year><volume>26</volume><fpage>2264</fpage><lpage>2284</lpage><pub-id pub-id-type="doi">10.2174/0929867325666181031094759</pub-id><pub-id pub-id-type="pmid">30378483</pub-id></element-citation></ref><ref id="B153-cells-09-02061"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erbacher</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bettinger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Steffan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Remy</surname><given-names>J.S.</given-names></name></person-group><article-title>Chitosan-based vector/DNA complexes for gene delivery: Biophysical characteristics and transfection ability</article-title><source>Pharm. Res.</source><year>1998</year><volume>15</volume><fpage>1332</fpage><lpage>1339</lpage><pub-id pub-id-type="doi">10.1023/A:1011981000671</pub-id><pub-id pub-id-type="pmid">9755882</pub-id></element-citation></ref><ref id="B154-cells-09-02061"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name></person-group><article-title>pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response</article-title><source>ACS Nano</source><year>2015</year><volume>9</volume><fpage>4925</fpage><lpage>4938</lpage><pub-id pub-id-type="doi">10.1021/nn5066793</pub-id><pub-id pub-id-type="pmid">25898266</pub-id></element-citation></ref><ref id="B155-cells-09-02061"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slutter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Plapied</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fievez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sande</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>des Rieux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Van Riet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name><name name-style="western"><surname>Preat</surname><given-names>V.</given-names></name></person-group><article-title>Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination</article-title><source>J. Controlled Release</source><year>2009</year><volume>138</volume><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2009.05.011</pub-id><pub-id pub-id-type="pmid">19445980</pub-id></element-citation></ref><ref id="B156-cells-09-02061"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lohcharoenkal</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Rojanasakul</surname><given-names>Y.</given-names></name></person-group><article-title>Protein nanoparticles as drug delivery carriers for cancer therapy</article-title><source>BioMed Res. Int.</source><year>2014</year><volume>2014</volume><fpage>180549</fpage><pub-id pub-id-type="doi">10.1155/2014/180549</pub-id><pub-id pub-id-type="pmid">24772414</pub-id><pub-id pub-id-type="pmcid">PMC3977416</pub-id></element-citation></ref><ref id="B157-cells-09-02061"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moran</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Rosell</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ruano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Busquets</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Vinardell</surname><given-names>M.P.</given-names></name></person-group><article-title>Gelatin-based nanoparticles as DNA delivery systems: Synthesis, physicochemical and biocompatible characterization</article-title><source>Colloids Surf. B.</source><year>2015</year><volume>134</volume><fpage>156</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2015.07.009</pub-id><pub-id pub-id-type="pmid">26188853</pub-id></element-citation></ref><ref id="B158-cells-09-02061"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.C.</given-names></name></person-group><article-title>Efficient gene delivery by oligochitosan conjugated serum albumin: Facile synthesis, polyplex stability, and transfection</article-title><source>Carbohydr. Polym.</source><year>2018</year><volume>183</volume><fpage>37</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2017.11.013</pub-id><pub-id pub-id-type="pmid">29352891</pub-id></element-citation></ref><ref id="B159-cells-09-02061"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer</article-title><source>Small (Weinheim an der Bergstrasse, Germany)</source><year>2014</year><volume>10</volume><fpage>524</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1002/smll.201301992</pub-id><pub-id pub-id-type="pmid">24106138</pub-id></element-citation></ref><ref id="B160-cells-09-02061"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rezaee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oskuee</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Nassirli</surname><given-names>H.</given-names></name><name name-style="western"><surname>Malaekeh-Nikouei</surname><given-names>B.</given-names></name></person-group><article-title>Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems</article-title><source>J. Controlled Release</source><year>2016</year><volume>236</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.06.023</pub-id><pub-id pub-id-type="pmid">27317365</pub-id></element-citation></ref><ref id="B161-cells-09-02061"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Felgner</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Gadek</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Holm</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Wenz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Northrop</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Ringold</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Danielsen</surname><given-names>M.</given-names></name></person-group><article-title>Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1987</year><volume>84</volume><fpage>7413</fpage><lpage>7417</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.21.7413</pub-id><pub-id pub-id-type="pmid">2823261</pub-id><pub-id pub-id-type="pmcid">PMC299306</pub-id></element-citation></ref><ref id="B162-cells-09-02061"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mevel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haudebourg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Colombani</surname><given-names>T.</given-names></name><name name-style="western"><surname>Peuziat</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dallet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chatin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>O.</given-names></name><name name-style="western"><surname>Berchel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montier</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jaffres</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>Important role of phosphoramido linkage in imidazole-based dioleyl helper lipids for liposome stability and primary cell transfection</article-title><source>J. Gene Med.</source><year>2016</year><volume>18</volume><fpage>3</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1002/jgm.2869</pub-id><pub-id pub-id-type="pmid">26519353</pub-id></element-citation></ref><ref id="B163-cells-09-02061"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bahreman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Daudey</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bussmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Olsthoorn</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Kros</surname><given-names>A.</given-names></name></person-group><article-title>Drug Delivery via Cell Membrane Fusion Using Lipopeptide Modified Liposomes</article-title><source>ACS Cent. Sci.</source><year>2016</year><volume>2</volume><fpage>621</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.6b00172</pub-id><pub-id pub-id-type="pmid">27725960</pub-id><pub-id pub-id-type="pmcid">PMC5043431</pub-id></element-citation></ref><ref id="B164-cells-09-02061"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glass</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kent</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>De Rose</surname><given-names>R.</given-names></name></person-group><article-title>Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination</article-title><source>Expert Rev. Vaccines</source><year>2016</year><volume>15</volume><fpage>719</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1586/14760584.2016.1141054</pub-id><pub-id pub-id-type="pmid">26783186</pub-id></element-citation></ref><ref id="B165-cells-09-02061"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagener</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krumb</surname><given-names>M.</given-names></name><name name-style="western"><surname>Langhanki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pektor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Worm</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schinnerer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montermann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Miederer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Targeting of Immune Cells with Trimannosylated Liposomes</article-title><source>Adv. Ther.</source><year>2020</year><volume>3</volume><fpage>1900185</fpage><pub-id pub-id-type="doi">10.1002/adtp.201900185</pub-id></element-citation></ref><ref id="B166-cells-09-02061"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lind&#233;n</surname><given-names>M.</given-names></name></person-group><article-title>Biodistribution and Excretion of Intravenously Injected Mesoporous Silica Nanoparticles: Implications for Drug Delivery Efficiency and Safety</article-title><source>Enzymes</source><year>2018</year><volume>43</volume><fpage>155</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/bs.enz.2018.07.007</pub-id><pub-id pub-id-type="pmid">30244806</pub-id></element-citation></ref><ref id="B167-cells-09-02061"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Multi-functionalized chitosan nanoparticles for enhanced chemotherapy in lung cancer</article-title><source>Carbohydr. Polym.</source><year>2018</year><volume>195</volume><fpage>311</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2018.04.087</pub-id><pub-id pub-id-type="pmid">29804982</pub-id></element-citation></ref><ref id="B168-cells-09-02061"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Walking the line: The fate of nanomaterials at biological barriers</article-title><source>Biomaterials</source><year>2018</year><volume>174</volume><fpage>41</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.04.056</pub-id><pub-id pub-id-type="pmid">29778981</pub-id><pub-id pub-id-type="pmcid">PMC5984195</pub-id></element-citation></ref><ref id="B169-cells-09-02061"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tavares</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>McGilvray</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W.C.W.</given-names></name></person-group><article-title>Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination</article-title><source>J. Controlled Release</source><year>2016</year><volume>240</volume><fpage>332</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.01.020</pub-id><pub-id pub-id-type="pmid">26774224</pub-id></element-citation></ref><ref id="B170-cells-09-02061"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>He</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>J.</given-names></name></person-group><article-title>The role of Kupffer cells in hepatic diseases</article-title><source>Mol. immunol.</source><year>2017</year><volume>85</volume><fpage>222</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2017.02.018</pub-id><pub-id pub-id-type="pmid">28314211</pub-id></element-citation></ref><ref id="B171-cells-09-02061"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sago</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Krupczak</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Lokugamage</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dahlman</surname><given-names>J.E.</given-names></name></person-group><article-title>Cell Subtypes Within the Liver Microenvironment Differentially Interact with Lipid Nanoparticles</article-title><source>Cell. Mol. Bioeng.</source><year>2019</year><volume>12</volume><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1007/s12195-019-00573-4</pub-id><pub-id pub-id-type="pmid">31719922</pub-id><pub-id pub-id-type="pmcid">PMC6816632</pub-id></element-citation></ref><ref id="B172-cells-09-02061"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pustylnikov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sagar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>Z.K.</given-names></name></person-group><article-title>Targeting the C-type lectins-mediated host-pathogen interactions with dextran</article-title><source>J. Pharm. Sci.</source><year>2014</year><volume>17</volume><fpage>371</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.18433/J3N590</pub-id><pub-id pub-id-type="pmid">25224349</pub-id><pub-id pub-id-type="pmcid">PMC5553543</pub-id></element-citation></ref><ref id="B173-cells-09-02061"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elvevold</surname><given-names>K.</given-names></name><name name-style="western"><surname>Simon-Santamaria</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hasvold</surname><given-names>H.</given-names></name><name name-style="western"><surname>McCourt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Smedsr&#248;d</surname><given-names>B.</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>K.K.</given-names></name></person-group><article-title>Liver sinusoidal endothelial cells depend on mannose receptor-mediated recruitment of lysosomal enzymes for normal degradation capacity</article-title><source>Hepatology</source><year>2008</year><volume>48</volume><fpage>2007</fpage><lpage>2015</lpage><pub-id pub-id-type="doi">10.1002/hep.22527</pub-id><pub-id pub-id-type="pmid">19026003</pub-id></element-citation></ref><ref id="B174-cells-09-02061"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S.</given-names></name></person-group><article-title>Murine macrophage scavenger receptor: In vivo expression and function as receptor for macrophage adhesion in lymphoid and non-lymphoid organs</article-title><source>Eur. J. Immunol.</source><year>1995</year><volume>25</volume><fpage>466</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1002/eji.1830250224</pub-id><pub-id pub-id-type="pmid">7875210</pub-id></element-citation></ref><ref id="B175-cells-09-02061"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poisson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lemoinne</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boulanger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Durand</surname><given-names>F.</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>R.</given-names></name><name name-style="western"><surname>Valla</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rautou</surname><given-names>P.E.</given-names></name></person-group><article-title>Liver sinusoidal endothelial cells: Physiology and role in liver diseases</article-title><source>J. Hepatol.</source><year>2017</year><volume>66</volume><fpage>212</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.07.009</pub-id><pub-id pub-id-type="pmid">27423426</pub-id></element-citation></ref><ref id="B176-cells-09-02061"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#252;l</surname><given-names>N.</given-names></name><name name-style="western"><surname>Babes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Siegmund</surname><given-names>K.</given-names></name><name name-style="western"><surname>Korthouwer</surname><given-names>R.</given-names></name><name name-style="western"><surname>B&#246;gels</surname><given-names>M.</given-names></name><name name-style="western"><surname>Braster</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vidarsson</surname><given-names>G.</given-names></name><name name-style="western"><surname>ten Hagen</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Kubes</surname><given-names>P.</given-names></name><name name-style="western"><surname>van Egmond</surname><given-names>M.</given-names></name></person-group><article-title>Macrophages eliminate circulating tumor cells after monoclonal antibody therapy</article-title><source>J. Clin. Invest.</source><year>2014</year><volume>124</volume><fpage>812</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1172/JCI66776</pub-id><pub-id pub-id-type="pmid">24430180</pub-id><pub-id pub-id-type="pmcid">PMC3904600</pub-id></element-citation></ref><ref id="B177-cells-09-02061"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganesan</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mohanty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Birmingham</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.L.</given-names></name></person-group><article-title>Fc&#947;RIIb on liver sinusoidal endothelium clears small immune complexes</article-title><source>J. Immunol.</source><year>2012</year><volume>189</volume><fpage>4981</fpage><lpage>4988</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202017</pub-id><pub-id pub-id-type="pmid">23053513</pub-id><pub-id pub-id-type="pmcid">PMC4381350</pub-id></element-citation></ref><ref id="B178-cells-09-02061"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hinglais</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kazatchkine</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Mandet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Appay</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Bariety</surname><given-names>J.</given-names></name></person-group><article-title>Human liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. An immunohistochemical study</article-title><source>Lab. Invest.</source><year>1989</year><volume>61</volume><fpage>509</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">2478758</pub-id></element-citation></ref><ref id="B179-cells-09-02061"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nuhn</surname><given-names>L.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moll</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mailander</surname><given-names>V.</given-names></name><name name-style="western"><surname>Landfester</surname><given-names>K.</given-names></name><name name-style="western"><surname>Grabbe</surname><given-names>S.</given-names></name></person-group><article-title>The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1760</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01760</pub-id><pub-id pub-id-type="pmid">30116246</pub-id><pub-id pub-id-type="pmcid">PMC6082927</pub-id></element-citation></ref><ref id="B180-cells-09-02061"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tenzer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Storck</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hobernik</surname><given-names>D.</given-names></name><name name-style="western"><surname>Raker</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Decker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dzionek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krauthauser</surname><given-names>S.</given-names></name><name name-style="western"><surname>Diken</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Protein corona-mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses</article-title><source>J. Allergy Clin. Immunol.</source><year>2018</year><pub-id pub-id-type="doi">10.1016/j.jaci.2017.08.049</pub-id><pub-id pub-id-type="pmid">29382591</pub-id></element-citation></ref><ref id="B181-cells-09-02061"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name></person-group><article-title>The Blood Clearance Kinetics and Pathway of Polymeric Micelles in Cancer Drug Delivery</article-title><source>ACS Nano</source><year>2018</year><volume>12</volume><fpage>6179</fpage><lpage>6192</lpage><pub-id pub-id-type="doi">10.1021/acsnano.8b02830</pub-id><pub-id pub-id-type="pmid">29847730</pub-id></element-citation></ref><ref id="B182-cells-09-02061"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arhontoulis</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Bowne</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>H.</given-names></name></person-group><article-title>Dense and Dynamic Polyethylene Glycol Shells Cloak Nanoparticles from Uptake by Liver Endothelial Cells for Long Blood Circulation</article-title><source>ACS Nano</source><year>2018</year><volume>12</volume><fpage>10130</fpage><lpage>10141</lpage><pub-id pub-id-type="doi">10.1021/acsnano.8b04947</pub-id><pub-id pub-id-type="pmid">30117736</pub-id><pub-id pub-id-type="pmcid">PMC6349371</pub-id></element-citation></ref><ref id="B183-cells-09-02061"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayat</surname><given-names>S.M.G.</given-names></name><name name-style="western"><surname>Jaafari</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Hatamipour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Penson</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A.</given-names></name></person-group><article-title>Liposome Circulation Time is Prolonged by CD47 Coating</article-title><source>Protein Pept. Lett.</source><year>2020</year><pub-id pub-id-type="doi">10.2174/0929866527666200413100120</pub-id><pub-id pub-id-type="pmid">32282292</pub-id></element-citation></ref><ref id="B184-cells-09-02061"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gulla</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Moku</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jinka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nimmu</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Khalid</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patra</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Chaudhuri</surname><given-names>A.</given-names></name></person-group><article-title>In vivo targeting of DNA vaccines to dendritic cells using functionalized gold nanoparticles</article-title><source>Biomater. Sci.</source><year>2019</year><volume>7</volume><fpage>773</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1039/C8BM01272E</pub-id><pub-id pub-id-type="pmid">30601510</pub-id></element-citation></ref><ref id="B185-cells-09-02061"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wi</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>Byeon</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Won</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Sood</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Han</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.M.</given-names></name></person-group><article-title>Selective Tumor-Specific Antigen Delivery to Dendritic Cells Using Mannose-Labeled Poly(d, l-lactide-co-glycolide) Nanoparticles for Cancer Immunotherapy</article-title><source>J. Biomed. Nanotechnol.</source><year>2020</year><volume>16</volume><fpage>201</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1166/jbn.2020.2883</pub-id><pub-id pub-id-type="pmid">32252881</pub-id></element-citation></ref><ref id="B186-cells-09-02061"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Silvers</surname><given-names>W.K.</given-names></name></person-group><article-title>Distribution of ATPase-positive Langerhans cells in normal adult human skin</article-title><source>Br. J. Dermatol.</source><year>1985</year><volume>113</volume><fpage>707</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.1985.tb02406.x</pub-id><pub-id pub-id-type="pmid">2420351</pub-id></element-citation></ref><ref id="B187-cells-09-02061"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nitschke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Halin</surname><given-names>C.</given-names></name></person-group><article-title>Dendritic cell interactions with lymphatic endothelium</article-title><source>Lymphatic Research and Biology</source><year>2013</year><volume>11</volume><fpage>172</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1089/lrb.2013.0008</pub-id><pub-id pub-id-type="pmid">24044757</pub-id><pub-id pub-id-type="pmcid">PMC3780311</pub-id></element-citation></ref><ref id="B188-cells-09-02061"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernando</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Haigh</surname><given-names>O.L.</given-names></name><name name-style="western"><surname>Yukiko</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Kendall</surname><given-names>M.A.</given-names></name></person-group><article-title>Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8(+) T cell responses</article-title><source>J. Controlled Release</source><year>2016</year><volume>237</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.06.045</pub-id><pub-id pub-id-type="pmid">27381247</pub-id></element-citation></ref><ref id="B189-cells-09-02061"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambracht-Washington</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frost</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>R.N.</given-names></name></person-group><article-title>Evaluation of a DNA A&#946;42 vaccine in adult rhesus monkeys (Macaca mulatta): Antibody kinetics and immune profile after intradermal immunization with full-length DNA A&#946;42 trimer</article-title><source>Alzheimers Res. Ther.</source><year>2017</year><volume>9</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1186/s13195-017-0257-7</pub-id><pub-id pub-id-type="pmid">28441965</pub-id><pub-id pub-id-type="pmcid">PMC5405538</pub-id></element-citation></ref><ref id="B190-cells-09-02061"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarez</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Huh</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>L.S.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Conner</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Sauter</surname><given-names>E.</given-names></name><name name-style="western"><surname>Paradis</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3)</article-title><source>Gynecol. Oncol.</source><year>2016</year><volume>140</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2015.11.026</pub-id><pub-id pub-id-type="pmid">26616223</pub-id><pub-id pub-id-type="pmcid">PMC4724445</pub-id></element-citation></ref><ref id="B191-cells-09-02061"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duong</surname><given-names>H.T.T.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Thambi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Giang Phan</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.S.</given-names></name></person-group><article-title>Smart vaccine delivery based on microneedle arrays decorated with ultra-pH-responsive copolymers for cancer immunotherapy</article-title><source>Biomaterials</source><year>2018</year><volume>185</volume><fpage>13</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.09.008</pub-id><pub-id pub-id-type="pmid">30216806</pub-id></element-citation></ref><ref id="B192-cells-09-02061"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cole</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>McErlean</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mulholland</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Short</surname><given-names>A.</given-names></name><name name-style="western"><surname>McCrudden</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>McCaffrey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Robson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kett</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Coulter</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen</article-title><source>Acta Biomater.</source><year>2019</year><volume>96</volume><fpage>480</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2019.07.003</pub-id><pub-id pub-id-type="pmid">31299353</pub-id></element-citation></ref><ref id="B193-cells-09-02061"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samuels</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marijne Heeren</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zijlmans</surname><given-names>H.</given-names></name><name name-style="western"><surname>Welters</surname><given-names>M.J.P.</given-names></name><name name-style="western"><surname>van den Berg</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Philips</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kvistborg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ehsan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Scholl</surname><given-names>S.M.E.</given-names></name><name name-style="western"><surname>Nuijen</surname><given-names>B.</given-names></name><etal/></person-group><article-title>HPV16 E7 DNA tattooing: Safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia</article-title><source>Cancer Immunol. Immunother.</source><year>2017</year><volume>66</volume><fpage>1163</fpage><lpage>1173</lpage><pub-id pub-id-type="doi">10.1007/s00262-017-2006-y</pub-id><pub-id pub-id-type="pmid">28451790</pub-id><pub-id pub-id-type="pmcid">PMC11028457</pub-id></element-citation></ref><ref id="B194-cells-09-02061"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernelin-Cottet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Urien</surname><given-names>C.</given-names></name><name name-style="western"><surname>McCaffrey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>D.</given-names></name><name name-style="western"><surname>Donadei</surname><given-names>A.</given-names></name><name name-style="western"><surname>McDaid</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jakob</surname><given-names>V.</given-names></name><name name-style="western"><surname>Barnier-Quer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Collin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bouguyon</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Electroporation of a nanoparticle-associated DNA vaccine induces higher inflammation and immunity compared to its delivery with microneedle patches in pigs</article-title><source>J. Controlled Release</source><year>2019</year><volume>308</volume><fpage>14</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.06.041</pub-id><pub-id pub-id-type="pmid">31265882</pub-id></element-citation></ref><ref id="B195-cells-09-02061"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schultheis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>T.R.F.</given-names></name><name name-style="western"><surname>Kiosses</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Kraynyak</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Broderick</surname><given-names>K.E.</given-names></name></person-group><article-title>Delineating the Cellular Mechanisms Associated with Skin Electroporation</article-title><source>Hum. Gene. Ther. Methods</source><year>2018</year><volume>29</volume><fpage>177</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1089/hgtb.2017.105</pub-id><pub-id pub-id-type="pmid">29953259</pub-id><pub-id pub-id-type="pmcid">PMC6421993</pub-id></element-citation></ref><ref id="B196-cells-09-02061"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamolinara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stramucci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hysi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iezzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marchini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mariotti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amici</surname><given-names>A.</given-names></name><name name-style="western"><surname>Curcio</surname><given-names>C.</given-names></name></person-group><article-title>Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor</article-title><source>J. Immunol. Res.</source><year>2015</year><volume>2015</volume><fpage>159145</fpage><pub-id pub-id-type="doi">10.1155/2015/159145</pub-id><pub-id pub-id-type="pmid">26247038</pub-id><pub-id pub-id-type="pmcid">PMC4515534</pub-id></element-citation></ref><ref id="B197-cells-09-02061"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Danishmalik</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Sin</surname><given-names>J.I.</given-names></name></person-group><article-title>DNA vaccines, electroporation and their applications in cancer treatment</article-title><source>Hum. Vaccin. Immunother.</source><year>2015</year><volume>11</volume><fpage>1889</fpage><lpage>1900</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1035502</pub-id><pub-id pub-id-type="pmid">25984993</pub-id><pub-id pub-id-type="pmcid">PMC4635908</pub-id></element-citation></ref><ref id="B198-cells-09-02061"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katz</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Fargnoli</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Gubara</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Fish</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bridges</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Hajjar</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>K.</given-names></name></person-group><article-title>Targeted Gene Delivery through the Respiratory System: Rationale for Intratracheal Gene Transfer</article-title><source>J. Cardiovasc. Dev. Dis.</source><year>2019</year><volume>6</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.3390/jcdd6010008</pub-id><pub-id pub-id-type="pmcid">PMC6462990</pub-id><pub-id pub-id-type="pmid">30781363</pub-id></element-citation></ref><ref id="B199-cells-09-02061"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Nunez-Alonso</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>McLachlan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hyde</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>D.R.</given-names></name></person-group><article-title>Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy</article-title><source>Human Gene Ther. Clinical Develop.</source><year>2014</year><volume>25</volume><fpage>97</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1089/humc.2014.019</pub-id><pub-id pub-id-type="pmid">24865497</pub-id></element-citation></ref><ref id="B200-cells-09-02061"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Diaz-Arevalo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>M.</given-names></name></person-group><article-title>Noninvasive vaccination against infectious diseases</article-title><source>Hum. Vaccin. Immunother.</source><year>2018</year><volume>14</volume><fpage>1717</fpage><lpage>1733</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1461296</pub-id><pub-id pub-id-type="pmid">29624470</pub-id><pub-id pub-id-type="pmcid">PMC6067898</pub-id></element-citation></ref><ref id="B201-cells-09-02061"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mortimer</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Butcher</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Musumeci</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Minchin</surname><given-names>R.F.</given-names></name></person-group><article-title>Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials</article-title><source>ACS Nano</source><year>2014</year><volume>8</volume><fpage>3357</fpage><lpage>3366</lpage><pub-id pub-id-type="doi">10.1021/nn405830g</pub-id><pub-id pub-id-type="pmid">24617595</pub-id></element-citation></ref><ref id="B202-cells-09-02061"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name></person-group><article-title>Application of dextran as nanoscale drug carriers</article-title><source>Nanomedicine (London, England)</source><year>2018</year><volume>13</volume><fpage>3149</fpage><lpage>3158</lpage><pub-id pub-id-type="doi">10.2217/nnm-2018-0331</pub-id><pub-id pub-id-type="pmid">30516091</pub-id></element-citation></ref><ref id="B203-cells-09-02061"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalil</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name></person-group><article-title>An efficient PEGylated gene delivery system with improved targeting: Synergism between octaarginine and a fusogenic peptide</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>538</volume><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.01.007</pub-id><pub-id pub-id-type="pmid">29341911</pub-id></element-citation></ref><ref id="B204-cells-09-02061"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation</article-title><source>J. Controlled Release</source><year>2016</year><volume>244</volume><fpage>184</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.06.040</pub-id><pub-id pub-id-type="pmid">27369864</pub-id><pub-id pub-id-type="pmcid">PMC5747248</pub-id></element-citation></ref><ref id="B205-cells-09-02061"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frenz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Grabski</surname><given-names>E.</given-names></name><name name-style="western"><surname>Duran</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hozsa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stepczynska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Furch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gieseler</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Kalinke</surname><given-names>U.</given-names></name></person-group><article-title>Antigen presenting cell-selective drug delivery by glycan-decorated nanocarriers</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2015</year><volume>95</volume><fpage>13</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2015.02.008</pub-id><pub-id pub-id-type="pmid">25701806</pub-id></element-citation></ref><ref id="B206-cells-09-02061"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgdorf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lukacs-Kornek</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kurts</surname><given-names>C.</given-names></name></person-group><article-title>The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation</article-title><source>J. Immunol.</source><year>2006</year><volume>176</volume><fpage>6770</fpage><lpage>6776</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.11.6770</pub-id><pub-id pub-id-type="pmid">16709836</pub-id></element-citation></ref><ref id="B207-cells-09-02061"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Appelmelk</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>van Die</surname><given-names>I.</given-names></name><name name-style="western"><surname>van Vliet</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Vandenbroucke-Grauls</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Geijtenbeek</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>van Kooyk</surname><given-names>Y.</given-names></name></person-group><article-title>Cutting edge: Carbohydrate profiling identifies new pathogens that interact with dendritic cell-specific ICAM-3-grabbing nonintegrin on dendritic cells</article-title><source>J. Immunol.</source><year>2003</year><volume>170</volume><fpage>1635</fpage><lpage>1639</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.4.1635</pub-id><pub-id pub-id-type="pmid">12574325</pub-id></element-citation></ref><ref id="B208-cells-09-02061"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Enhanced non-inflammasome mediated immune responses by mannosylated zwitterionic-based cationic liposomes for HIV DNA vaccines</article-title><source>Biomaterials</source><year>2016</year><volume>85</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.01.054</pub-id><pub-id pub-id-type="pmid">26851653</pub-id></element-citation></ref><ref id="B209-cells-09-02061"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.G.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.F.</given-names></name></person-group><article-title>DC targeting DNA vaccines induce protective and therapeutic antitumor immunity in mice</article-title><source>Int. J. Clin. Exp. Med.</source><year>2015</year><volume>8</volume><fpage>17565</fpage><lpage>17577</lpage><pub-id pub-id-type="pmid">26770347</pub-id><pub-id pub-id-type="pmcid">PMC4694247</pub-id></element-citation></ref><ref id="B210-cells-09-02061"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Iyoda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>S.I.</given-names></name></person-group><article-title>Immune suppression and reversal of the suppressive tumor microenvironment</article-title><source>Int. Immunol.</source><year>2018</year><volume>30</volume><fpage>445</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxy042</pub-id><pub-id pub-id-type="pmid">29939325</pub-id></element-citation></ref><ref id="B211-cells-09-02061"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nagibin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Groth</surname><given-names>C.</given-names></name><name name-style="western"><surname>Altevogt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Utikal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Umansky</surname><given-names>V.</given-names></name></person-group><article-title>Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1310</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01310</pub-id><pub-id pub-id-type="pmid">29942309</pub-id><pub-id pub-id-type="pmcid">PMC6004385</pub-id></element-citation></ref><ref id="B212-cells-09-02061"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahrends</surname><given-names>T.</given-names></name><name name-style="western"><surname>Borst</surname><given-names>J.</given-names></name></person-group><article-title>The opposing roles of CD4(+) T cells in anti-tumour immunity</article-title><source>Immunology</source><year>2018</year><pub-id pub-id-type="doi">10.1111/imm.12941</pub-id><pub-id pub-id-type="pmid">29700809</pub-id><pub-id pub-id-type="pmcid">PMC6050207</pub-id></element-citation></ref><ref id="B213-cells-09-02061"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hippen</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Loschi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nicholls</surname><given-names>J.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>K.P.A.</given-names></name><name name-style="western"><surname>Blazar</surname><given-names>B.R.</given-names></name></person-group><article-title>Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00057</pub-id><pub-id pub-id-type="pmid">29445371</pub-id><pub-id pub-id-type="pmcid">PMC5797736</pub-id></element-citation></ref><ref id="B214-cells-09-02061"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name></person-group><article-title>Epigenetics in myeloid derived suppressor cells: A sheathed sword towards cancer</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>57452</fpage><lpage>57463</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.10767</pub-id><pub-id pub-id-type="pmid">27458169</pub-id><pub-id pub-id-type="pmcid">PMC5303001</pub-id></element-citation></ref><ref id="B215-cells-09-02061"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>24506</fpage><pub-id pub-id-type="doi">10.1038/srep24506</pub-id><pub-id pub-id-type="pmid">27074905</pub-id><pub-id pub-id-type="pmcid">PMC4830950</pub-id></element-citation></ref><ref id="B216-cells-09-02061"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name></person-group><article-title>The Regulatory T Cell in Active Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-Analysis</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>159</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00159</pub-id><pub-id pub-id-type="pmid">30833946</pub-id><pub-id pub-id-type="pmcid">PMC6387904</pub-id></element-citation></ref><ref id="B217-cells-09-02061"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bacher</surname><given-names>P.</given-names></name><name name-style="western"><surname>Scheffold</surname><given-names>A.</given-names></name></person-group><article-title>Antigen-specific regulatory T-cell responses against aeroantigens and their role in allergy</article-title><source>Mucosal Immunol.</source><year>2018</year><volume>11</volume><fpage>1537</fpage><lpage>1550</lpage><pub-id pub-id-type="doi">10.1038/s41385-018-0038-z</pub-id><pub-id pub-id-type="pmid">29858582</pub-id></element-citation></ref><ref id="B218-cells-09-02061"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Najafi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farhood</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mortezaee</surname><given-names>K.</given-names></name></person-group><article-title>Contribution of regulatory T cells to cancer: A review</article-title><source>J. Cell. Physiol.</source><year>2019</year><volume>234</volume><fpage>7983</fpage><lpage>7993</lpage><pub-id pub-id-type="doi">10.1002/jcp.27553</pub-id><pub-id pub-id-type="pmid">30317612</pub-id></element-citation></ref><ref id="B219-cells-09-02061"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attias</surname><given-names>M.</given-names></name><name name-style="western"><surname>Al-Aubodah</surname><given-names>T.</given-names></name><name name-style="western"><surname>Piccirillo</surname><given-names>C.A.</given-names></name></person-group><article-title>Mechanisms of human FoxP3(+) T(reg) cell development and function in health and disease</article-title><source>Clin. Exp. Immunol.</source><year>2019</year><volume>197</volume><fpage>36</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1111/cei.13290</pub-id><pub-id pub-id-type="pmid">30864147</pub-id><pub-id pub-id-type="pmcid">PMC6591147</pub-id></element-citation></ref><ref id="B220-cells-09-02061"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>June</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.G.</given-names></name></person-group><article-title>Differential roles of TNF&#945;-TNFR1 and TNF&#945;-TNFR2 in the differentiation and function of CD4(+)Foxp3(+) induced Treg cells in vitro and in vivo periphery in autoimmune diseases</article-title><source>Cell Death Dis.</source><year>2019</year><volume>10</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1038/s41419-018-1266-6</pub-id><pub-id pub-id-type="pmid">30631042</pub-id><pub-id pub-id-type="pmcid">PMC6328545</pub-id></element-citation></ref><ref id="B221-cells-09-02061"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Su</surname><given-names>D.M.</given-names></name></person-group><article-title>Capacity of tTreg generation is not impaired in the atrophied thymus</article-title><source>PLoS Biol.</source><year>2017</year><volume>15</volume><elocation-id>e2003352</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.2003352</pub-id><pub-id pub-id-type="pmid">29117183</pub-id><pub-id pub-id-type="pmcid">PMC5695848</pub-id></element-citation></ref><ref id="B222-cells-09-02061"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>TGF-&#946;-Induced CD8(+)CD103(+) Regulatory T Cells Show Potent Therapeutic Effect on Chronic Graft-versus-Host Disease Lupus by Suppressing B Cells</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00035</pub-id><pub-id pub-id-type="pmid">29441062</pub-id><pub-id pub-id-type="pmcid">PMC5797539</pub-id></element-citation></ref><ref id="B223-cells-09-02061"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devi</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Anandasabapathy</surname><given-names>N.</given-names></name></person-group><article-title>The origin of DCs and capacity for immunologic tolerance in central and peripheral tissues</article-title><source>Semin. Immunopathol.</source><year>2017</year><volume>39</volume><fpage>137</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1007/s00281-016-0602-0</pub-id><pub-id pub-id-type="pmid">27888331</pub-id><pub-id pub-id-type="pmcid">PMC5296242</pub-id></element-citation></ref><ref id="B224-cells-09-02061"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takenaka</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Quintana</surname><given-names>F.J.</given-names></name></person-group><article-title>Tolerogenic dendritic cells</article-title><source>Semin. Immunopathol.</source><year>2017</year><volume>39</volume><fpage>113</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1007/s00281-016-0587-8</pub-id><pub-id pub-id-type="pmid">27646959</pub-id><pub-id pub-id-type="pmcid">PMC5296314</pub-id></element-citation></ref><ref id="B225-cells-09-02061"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Plain</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hodgkinson</surname><given-names>S.J.</given-names></name></person-group><article-title>Changes in Reactivity In Vitro of CD4(+)CD25(+) and CD4(+)CD25(-) T Cell Subsets in Transplant Tolerance</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>994</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00994</pub-id><pub-id pub-id-type="pmid">28878770</pub-id><pub-id pub-id-type="pmcid">PMC5572370</pub-id></element-citation></ref><ref id="B226-cells-09-02061"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name></person-group><article-title>Analysis of murine and human Treg subsets in inflammatory bowel disease</article-title><source>Mol. Med. Rep.</source><year>2017</year><volume>16</volume><fpage>2893</fpage><lpage>2898</lpage><pub-id pub-id-type="doi">10.3892/mmr.2017.6912</pub-id><pub-id pub-id-type="pmid">28677759</pub-id></element-citation></ref><ref id="B227-cells-09-02061"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>Y.Z.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.W.</given-names></name></person-group><article-title>Cancer-associated fibroblast-derived interleukin-1&#946; activates protumor C-C motif chemokine ligand 22 signaling in head and neck cancer</article-title><source>Cancer Sci.</source><year>2019</year><volume>110</volume><fpage>2783</fpage><lpage>2793</lpage><pub-id pub-id-type="doi">10.1111/cas.14135</pub-id><pub-id pub-id-type="pmid">31325403</pub-id><pub-id pub-id-type="pmcid">PMC6726685</pub-id></element-citation></ref><ref id="B228-cells-09-02061"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siede</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fr&#246;hlich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Datsi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hegazy</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Varga</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Holecska</surname><given-names>V.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakae</surname><given-names>S.</given-names></name><name name-style="western"><surname>L&#246;hning</surname><given-names>M.</given-names></name></person-group><article-title>IL-33 Receptor-Expressing Regulatory T Cells Are Highly Activated, Th2 Biased and Suppress CD4 T Cell Proliferation through IL-10 and TGF&#946; Release</article-title><source>PloS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0161507</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0161507</pub-id><pub-id pub-id-type="pmid">27548066</pub-id><pub-id pub-id-type="pmcid">PMC4993514</pub-id></element-citation></ref><ref id="B229-cells-09-02061"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S.</given-names></name></person-group><article-title>Targeting Treg cells in cancer immunotherapy</article-title><source>Eur. J. Immunol.</source><year>2019</year><volume>49</volume><fpage>1140</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1002/eji.201847659</pub-id><pub-id pub-id-type="pmid">31257581</pub-id></element-citation></ref><ref id="B230-cells-09-02061"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conroy</surname><given-names>H.</given-names></name><name name-style="western"><surname>Galvin</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.</given-names></name></person-group><article-title>Gene silencing of TGF-&#946;1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells</article-title><source>Cancer Immunol. Immunother.</source><year>2012</year><volume>61</volume><fpage>425</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1007/s00262-011-1188-y</pub-id><pub-id pub-id-type="pmid">22193988</pub-id><pub-id pub-id-type="pmcid">PMC11029020</pub-id></element-citation></ref><ref id="B231-cells-09-02061"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masjedi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malakotikhah</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nabi Afjadi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Irandoust</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karoon Kiani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Heydarzadeh Asl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Atyabi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hassannia</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy</article-title><source>Nanomedicine</source><year>2020</year><volume>29</volume><fpage>102240</fpage><pub-id pub-id-type="doi">10.1016/j.nano.2020.102240</pub-id><pub-id pub-id-type="pmid">32553948</pub-id></element-citation></ref><ref id="B232-cells-09-02061"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Fei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.S.</given-names></name></person-group><article-title>Specific suppression in regulatory T cells by Foxp3 siRNA contributes to enhance the in vitro anti-tumor immune response in hepatocellular carcinoma patients</article-title><source>Beijing Da Xue Xue Bao Yi Xue Ban</source><year>2009</year><volume>41</volume><fpage>313</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">19727215</pub-id></element-citation></ref><ref id="B233-cells-09-02061"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>R.</given-names></name></person-group><article-title>Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets</article-title><source>Immunobiology</source><year>2010</year><volume>215</volume><fpage>153</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2009.03.001</pub-id><pub-id pub-id-type="pmid">19450895</pub-id></element-citation></ref><ref id="B234-cells-09-02061"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jebbawi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fayyad-Kazan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Merimi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lewalle</surname><given-names>P.</given-names></name><name name-style="western"><surname>Verougstraete</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Leo</surname><given-names>O.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>P.</given-names></name><name name-style="western"><surname>Burny</surname><given-names>A.</given-names></name><name name-style="western"><surname>Badran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Martiat</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A microRNA profile of human CD8(+) regulatory T cells and characterization of the effects of microRNAs on Treg cell-associated genes</article-title><source>J. Transl. Med.</source><year>2014</year><volume>12</volume><fpage>218</fpage><pub-id pub-id-type="doi">10.1186/s12967-014-0218-x</pub-id><pub-id pub-id-type="pmid">25090912</pub-id><pub-id pub-id-type="pmcid">PMC4440568</pub-id></element-citation></ref><ref id="B235-cells-09-02061"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jonuleit</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bopp</surname><given-names>T.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>C.</given-names></name></person-group><article-title>Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy</article-title><source>Nanomedicine (London, England)</source><year>2016</year><volume>11</volume><fpage>2699</fpage><lpage>2709</lpage><pub-id pub-id-type="doi">10.2217/nnm-2016-0197</pub-id><pub-id pub-id-type="pmid">27654070</pub-id></element-citation></ref><ref id="B236-cells-09-02061"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naghavian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ghaedi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kiani-Esfahani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ganjalikhani-Hakemi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Etemadifar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nasr-Esfahani</surname><given-names>M.H.</given-names></name></person-group><article-title>miR-141 and miR-200a, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis</article-title><source>PloS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0124555</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0124555</pub-id><pub-id pub-id-type="pmid">25938517</pub-id><pub-id pub-id-type="pmcid">PMC4418573</pub-id></element-citation></ref><ref id="B237-cells-09-02061"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Exosomes Released from Tumor-Associated Macrophages Transfer miRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer</article-title><source>Cancer Immunol. Res.</source><year>2018</year><volume>6</volume><fpage>1578</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-17-0479</pub-id><pub-id pub-id-type="pmid">30396909</pub-id></element-citation></ref><ref id="B238-cells-09-02061"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bopp</surname><given-names>T.</given-names></name></person-group><article-title>Cyclic AMP Represents a Crucial Component of Treg Cell-Mediated Immune Regulation</article-title><source>Front. Immunol.</source><year>2016</year><volume>7</volume><fpage>315</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2016.00315</pub-id><pub-id pub-id-type="pmid">27621729</pub-id><pub-id pub-id-type="pmcid">PMC5002888</pub-id></element-citation></ref><ref id="B239-cells-09-02061"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frick</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Domogalla</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Baier</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wurm</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Mail&#228;nder</surname><given-names>V.</given-names></name><name name-style="western"><surname>Landfester</surname><given-names>K.</given-names></name><name name-style="western"><surname>Steinbrink</surname><given-names>K.</given-names></name></person-group><article-title>Interleukin-2 Functionalized Nanocapsules for T Cell-Based Immunotherapy</article-title><source>ACS Nano</source><year>2016</year><volume>10</volume><fpage>9216</fpage><lpage>9226</lpage><pub-id pub-id-type="doi">10.1021/acsnano.5b07973</pub-id><pub-id pub-id-type="pmid">27723299</pub-id></element-citation></ref><ref id="B240-cells-09-02061"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woller</surname><given-names>N.</given-names></name><name name-style="western"><surname>Knocke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mundt</surname><given-names>B.</given-names></name><name name-style="western"><surname>G&#252;rlevik</surname><given-names>E.</given-names></name><name name-style="western"><surname>Str&#252;ver</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kloos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boozari</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schache</surname><given-names>P.</given-names></name><name name-style="western"><surname>Manns</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Malek</surname><given-names>N.P.</given-names></name><etal/></person-group><article-title>Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice</article-title><source>J. Clin. Invest.</source><year>2011</year><volume>121</volume><fpage>2570</fpage><lpage>2582</lpage><pub-id pub-id-type="doi">10.1172/JCI45585</pub-id><pub-id pub-id-type="pmid">21646722</pub-id><pub-id pub-id-type="pmcid">PMC3223834</pub-id></element-citation></ref><ref id="B241-cells-09-02061"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Sayed</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Amrein</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>B&#252;hrer</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Huguenin</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Radpour</surname><given-names>R.</given-names></name><name name-style="western"><surname>Riether</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ochsenbein</surname><given-names>A.F.</given-names></name></person-group><article-title>T-cell-Secreted TNF&#945; Induces Emergency Myelopoiesis and Myeloid-Derived Suppressor Cell Differentiation in Cancer</article-title><source>Cancer Res.</source><year>2019</year><volume>79</volume><fpage>346</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-3026</pub-id><pub-id pub-id-type="pmid">30389698</pub-id></element-citation></ref><ref id="B242-cells-09-02061"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keskinov</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Shurin</surname><given-names>M.R.</given-names></name></person-group><article-title>Myeloid regulatory cells in tumor spreading and metastasis</article-title><source>Immunobiology</source><year>2015</year><volume>220</volume><fpage>236</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2014.07.017</pub-id><pub-id pub-id-type="pmid">25178934</pub-id></element-citation></ref><ref id="B243-cells-09-02061"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salminen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kauppinen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaarniranta</surname><given-names>K.</given-names></name></person-group><article-title>AMPK activation inhibits the functions of myeloid-derived suppressor cells (MDSC): Impact on cancer and aging</article-title><source>J. Mol. Med. (Berl.)</source><year>2019</year><volume>97</volume><fpage>1049</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1007/s00109-019-01795-9</pub-id><pub-id pub-id-type="pmid">31129755</pub-id><pub-id pub-id-type="pmcid">PMC6647228</pub-id></element-citation></ref><ref id="B244-cells-09-02061"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruger</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Dorhoi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Esendagli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Barczyk-Kahlert</surname><given-names>K.</given-names></name><name name-style="western"><surname>van der Bruggen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lipoldova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perecko</surname><given-names>T.</given-names></name><name name-style="western"><surname>Santibanez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saraiva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Ginderachter</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>How to measure the immunosuppressive activity of MDSC: Assays, problems and potential solutions</article-title><source>Cancer Immunol. Immunother.</source><year>2019</year><volume>68</volume><fpage>631</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1007/s00262-018-2170-8</pub-id><pub-id pub-id-type="pmid">29785656</pub-id><pub-id pub-id-type="pmcid">PMC11028070</pub-id></element-citation></ref><ref id="B245-cells-09-02061"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stokes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Schmelz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Proytcheva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chernoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Katsanis</surname><given-names>E.</given-names></name></person-group><article-title>Pak2 regulates myeloid-derived suppressor cell development in mice</article-title><source>Blood Adv.</source><year>2017</year><volume>1</volume><fpage>1923</fpage><lpage>1933</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2017007435</pub-id><pub-id pub-id-type="pmid">29296839</pub-id><pub-id pub-id-type="pmcid">PMC5728145</pub-id></element-citation></ref><ref id="B246-cells-09-02061"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleet</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Burcham</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Calvert</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Elzey</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Ratliff</surname><given-names>T.L.</given-names></name></person-group><article-title>1&#945;, 25 Dihydroxyvitamin D (1,25(OH)(2)D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC)</article-title><source>J. Steroid Biochem. Mol. Biol.</source><year>2020</year><volume>198</volume><fpage>105557</fpage><pub-id pub-id-type="doi">10.1016/j.jsbmb.2019.105557</pub-id><pub-id pub-id-type="pmid">31783150</pub-id><pub-id pub-id-type="pmcid">PMC8041088</pub-id></element-citation></ref><ref id="B247-cells-09-02061"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finn</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>Ochoa</surname><given-names>A.C.</given-names></name></person-group><article-title>Editorial: Myeloid Derived Suppressor Cells as Disease Modulators</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>90</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.00090</pub-id><pub-id pub-id-type="pmid">32082331</pub-id><pub-id pub-id-type="pmcid">PMC7005921</pub-id></element-citation></ref><ref id="B248-cells-09-02061"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boros</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ochando</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zeher</surname><given-names>M.</given-names></name></person-group><article-title>Myeloid derived suppressor cells and autoimmunity</article-title><source>Hum. Immunol.</source><year>2016</year><volume>77</volume><fpage>631</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2016.05.024</pub-id><pub-id pub-id-type="pmid">27240453</pub-id></element-citation></ref><ref id="B249-cells-09-02061"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hartl</surname><given-names>D.</given-names></name></person-group><article-title>Myeloid-Derived Suppressor Cells in Infection: A General Overview</article-title><source>J. Innate Immun.</source><year>2018</year><volume>10</volume><fpage>407</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1159/000489830</pub-id><pub-id pub-id-type="pmid">29945134</pub-id><pub-id pub-id-type="pmcid">PMC6784037</pub-id></element-citation></ref><ref id="B250-cells-09-02061"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Garstka</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.F.</given-names></name></person-group><article-title>Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor</article-title><source>Mol. Immunol.</source><year>2020</year><volume>117</volume><fpage>201</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2019.11.014</pub-id><pub-id pub-id-type="pmid">31835202</pub-id></element-citation></ref><ref id="B251-cells-09-02061"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouzounova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Piranlioglu</surname><given-names>R.</given-names></name><name name-style="western"><surname>El Andaloussi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kolhe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Demirci</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Marasco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Asm</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chadli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>K.A.</given-names></name><etal/></person-group><article-title>Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>14979</fpage><pub-id pub-id-type="doi">10.1038/ncomms14979</pub-id><pub-id pub-id-type="pmid">28382931</pub-id><pub-id pub-id-type="pmcid">PMC5384228</pub-id></element-citation></ref><ref id="B252-cells-09-02061"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veglia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Perego</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gabrilovich</surname><given-names>D.</given-names></name></person-group><article-title>Myeloid-derived suppressor cells coming of age</article-title><source>Nat. Immunol.</source><year>2018</year><volume>19</volume><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1038/s41590-017-0022-x</pub-id><pub-id pub-id-type="pmid">29348500</pub-id><pub-id pub-id-type="pmcid">PMC5854158</pub-id></element-citation></ref><ref id="B253-cells-09-02061"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boldin</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Taganov</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Kalwani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garcia-Flores</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Devrekanli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice</article-title><source>J. Exp. Med.</source><year>2011</year><volume>208</volume><fpage>1189</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1084/jem.20101823</pub-id><pub-id pub-id-type="pmid">21555486</pub-id><pub-id pub-id-type="pmcid">PMC3173243</pub-id></element-citation></ref><ref id="B254-cells-09-02061"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Min</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>miR-223 suppresses differentiation of tumor-induced CD11b<sup>+</sup> Gr1<sup>+</sup> myeloid-derived suppressor cells from bone marrow cells</article-title><source>Int. J. Cancer</source><year>2011</year><volume>129</volume><fpage>2662</fpage><lpage>2673</lpage><pub-id pub-id-type="doi">10.1002/ijc.25921</pub-id><pub-id pub-id-type="pmid">21213211</pub-id></element-citation></ref><ref id="B255-cells-09-02061"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Muroski</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Miska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee-Chang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rashidi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lopez-Rosas</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Repolarization of myeloid derived suppressor cells via magnetic nanoparticles to promote radiotherapy for glioma treatment</article-title><source>Nanomedicine</source><year>2019</year><volume>16</volume><fpage>126</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2018.11.015</pub-id><pub-id pub-id-type="pmid">30553919</pub-id></element-citation></ref><ref id="B256-cells-09-02061"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirota</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tross</surname><given-names>D.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D.M.</given-names></name></person-group><article-title>CpG Oligonucleotides as Cancer Vaccine Adjuvants</article-title><source>Vaccines</source><year>2015</year><volume>3</volume><fpage>390</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.3390/vaccines3020390</pub-id><pub-id pub-id-type="pmid">26343193</pub-id><pub-id pub-id-type="pmcid">PMC4494345</pub-id></element-citation></ref><ref id="B257-cells-09-02061"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>H.Y.</given-names></name></person-group><article-title>Stem cell factor produced by tumor cells expands myeloid-derived suppressor cells in mice</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>11257</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-68061-8</pub-id><pub-id pub-id-type="pmid">32647215</pub-id><pub-id pub-id-type="pmcid">PMC7347545</pub-id></element-citation></ref><ref id="B258-cells-09-02061"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Eisenstein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sikora</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.H.</given-names></name></person-group><article-title>Targeting immune suppressing myeloid-derived suppressor cells in oncology</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>2011</year><volume>77</volume><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2010.02.004</pub-id><pub-id pub-id-type="pmid">20304669</pub-id><pub-id pub-id-type="pmcid">PMC2927714</pub-id></element-citation></ref><ref id="B259-cells-09-02061"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>T.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Inhibition of A20 expression in tumor microenvironment exerts anti-tumor effect through inducing myeloid-derived suppressor cells apoptosis</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>16437</fpage><pub-id pub-id-type="doi">10.1038/srep16437</pub-id><pub-id pub-id-type="pmid">26561336</pub-id><pub-id pub-id-type="pmcid">PMC4642332</pub-id></element-citation></ref><ref id="B260-cells-09-02061"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujii</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shin-Ya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mukai</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adachi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akiyoshi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mazda</surname><given-names>O.</given-names></name></person-group><article-title>Cycloamylose-nanogel drug delivery system-mediated intratumor silencing of the vascular endothelial growth factor regulates neovascularization in tumor microenvironment</article-title><source>Cancer Sci.</source><year>2014</year><volume>105</volume><fpage>1616</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1111/cas.12547</pub-id><pub-id pub-id-type="pmid">25283373</pub-id><pub-id pub-id-type="pmcid">PMC4317968</pub-id></element-citation></ref><ref id="B261-cells-09-02061"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>J.</given-names></name><name name-style="western"><surname>Galani</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Cerwenka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schirrmacher</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fournier</surname><given-names>P.</given-names></name></person-group><article-title>Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>1185</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.12.005</pub-id><pub-id pub-id-type="pmid">21172381</pub-id></element-citation></ref><ref id="B262-cells-09-02061"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Principe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ceruti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>N.Y.</given-names></name><name name-style="western"><surname>Chattaragada</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Rolla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Conti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bestagno</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zentilin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Migliorini</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>11098</fpage><lpage>11113</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3572</pub-id><pub-id pub-id-type="pmid">25860938</pub-id><pub-id pub-id-type="pmcid">PMC4484442</pub-id></element-citation></ref><ref id="B263-cells-09-02061"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cappello</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rolla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chiarle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Principe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cavallo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Perconti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Feo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giovarelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Novelli</surname><given-names>F.</given-names></name></person-group><article-title>Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer</article-title><source>Gastroenterology</source><year>2013</year><volume>144</volume><fpage>1098</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2013.01.020</pub-id><pub-id pub-id-type="pmid">23333712</pub-id></element-citation></ref><ref id="B264-cells-09-02061"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arndt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bergmann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Berndt</surname><given-names>N.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koristka</surname><given-names>S.</given-names></name></person-group><article-title>Theranostic CAR T cell targeting: A brief review</article-title><source>J. Labelled Comp. Radiopharm.</source><year>2019</year><volume>62</volume><fpage>533</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1002/jlcr.3727</pub-id><pub-id pub-id-type="pmid">30889625</pub-id></element-citation></ref><ref id="B265-cells-09-02061"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newick</surname><given-names>K.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>V.</given-names></name><name name-style="western"><surname>Maceyko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pur&#233;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Albelda</surname><given-names>S.M.</given-names></name></person-group><article-title>Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization</article-title><source>Cancer Immunol. Res.</source><year>2016</year><volume>4</volume><fpage>541</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-15-0263</pub-id><pub-id pub-id-type="pmid">27045023</pub-id><pub-id pub-id-type="pmcid">PMC4891259</pub-id></element-citation></ref><ref id="B266-cells-09-02061"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darowski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jost</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stubenrauch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wessels</surname><given-names>U.</given-names></name><name name-style="western"><surname>Benz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ehler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Freimoser-Grundschober</surname><given-names>A.</given-names></name><name name-style="western"><surname>Br&#252;nker</surname><given-names>P.</given-names></name><name name-style="western"><surname>M&#246;ssner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Uma&#241;a</surname><given-names>P.</given-names></name><etal/></person-group><article-title>P329G-CAR-J: A novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation</article-title><source>Protein Eng. Des. Sel.</source><year>2019</year><volume>32</volume><fpage>207</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1093/protein/gzz027</pub-id><pub-id pub-id-type="pmid">31504896</pub-id></element-citation></ref><ref id="B267-cells-09-02061"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Koffman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Turtle</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Maloney</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Acharya</surname><given-names>U.H.</given-names></name></person-group><article-title>Not so crystal clear: Observations from a case of crystalline arthritis with cytokine release syndrome (CRS) after chimeric antigen receptor (CAR)-T cell therapy</article-title><source>Bone Marrow Transplant.</source><year>2019</year><volume>54</volume><fpage>632</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/s41409-018-0357-4</pub-id><pub-id pub-id-type="pmid">30291306</pub-id></element-citation></ref><ref id="B268-cells-09-02061"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohrs</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Siegler</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Finley</surname><given-names>S.D.</given-names></name></person-group><article-title>ERK Activation in CAR T Cells Is Amplified by CD28-Mediated Increase in CD3&#950; Phosphorylation</article-title><source>iScience</source><year>2020</year><volume>23</volume><fpage>101023</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2020.101023</pub-id><pub-id pub-id-type="pmid">32325413</pub-id><pub-id pub-id-type="pmcid">PMC7178546</pub-id></element-citation></ref><ref id="B269-cells-09-02061"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kintz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nylen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>A.</given-names></name></person-group><article-title>Inclusion of Dap10 or 4&#8211;1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma</article-title><source>Cell Immunol.</source><year>2020</year><volume>351</volume><fpage>104069</fpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2020.104069</pub-id><pub-id pub-id-type="pmid">32106933</pub-id></element-citation></ref><ref id="B270-cells-09-02061"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hermanson</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Moriarity</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>D.S.</given-names></name></person-group><article-title>Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity</article-title><source>Cell Stem Cell</source><year>2018</year><volume>23</volume><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.06.002</pub-id><pub-id pub-id-type="pmid">30082067</pub-id><pub-id pub-id-type="pmcid">PMC6084450</pub-id></element-citation></ref><ref id="B271-cells-09-02061"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strohl</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Naso</surname><given-names>M.</given-names></name></person-group><article-title>Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells</article-title><source>Antibodies</source><year>2019</year><volume>8</volume><elocation-id>41</elocation-id><pub-id pub-id-type="doi">10.3390/antib8030041</pub-id><pub-id pub-id-type="pmcid">PMC6784091</pub-id><pub-id pub-id-type="pmid">31544847</pub-id></element-citation></ref><ref id="B272-cells-09-02061"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oelsner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Friede</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Badura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bader</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ullrich</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ottmann</surname><given-names>O.G.</given-names></name><name name-style="western"><surname>Klingemann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tonn</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma</article-title><source>Cytotherapy</source><year>2017</year><volume>19</volume><fpage>235</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/j.jcyt.2016.10.009</pub-id><pub-id pub-id-type="pmid">27887866</pub-id></element-citation></ref><ref id="B273-cells-09-02061"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1205</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01205</pub-id><pub-id pub-id-type="pmid">31214177</pub-id><pub-id pub-id-type="pmcid">PMC6554437</pub-id></element-citation></ref><ref id="B274-cells-09-02061"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oberschmidt</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kloess</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koehl</surname><given-names>U.</given-names></name></person-group><article-title>Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an &#8220;Off-the-Shelf Immunotherapy&#8221; for Improvement in Cancer Treatment</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>654</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00654</pub-id><pub-id pub-id-type="pmid">28649246</pub-id><pub-id pub-id-type="pmcid">PMC5465249</pub-id></element-citation></ref><ref id="B275-cells-09-02061"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sievers</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>D&#246;rrie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schaft</surname><given-names>N.</given-names></name></person-group><article-title>CARs: Beyond T Cells and T Cell-Derived Signaling Domains</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>3525</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21103525</pub-id><pub-id pub-id-type="pmcid">PMC7279007</pub-id><pub-id pub-id-type="pmid">32429316</pub-id></element-citation></ref><ref id="B276-cells-09-02061"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirayama</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Turtle</surname><given-names>C.J.</given-names></name></person-group><article-title>Toxicities of CD19 CAR-T cell immunotherapy</article-title><source>Am. J. Hematol.</source><year>2019</year><volume>94</volume><fpage>S42</fpage><lpage>S49</lpage><pub-id pub-id-type="doi">10.1002/ajh.25445</pub-id><pub-id pub-id-type="pmid">30784102</pub-id></element-citation></ref><ref id="B277-cells-09-02061"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maude</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Laetsch</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Buechner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rives</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bittencourt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bader</surname><given-names>P.</given-names></name><name name-style="western"><surname>Verneris</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Stefanski</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>G.D.</given-names></name><etal/></person-group><article-title>Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>378</volume><fpage>439</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1709866</pub-id><pub-id pub-id-type="pmid">29385370</pub-id><pub-id pub-id-type="pmcid">PMC5996391</pub-id></element-citation></ref><ref id="B278-cells-09-02061"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Locke</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Neelapu</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Siddiqi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chavez</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Hosing</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ghobadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Budde</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Bot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma</article-title><source>Mol. Ther.</source><year>2017</year><volume>25</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2016.10.020</pub-id><pub-id pub-id-type="pmid">28129122</pub-id><pub-id pub-id-type="pmcid">PMC5363293</pub-id></element-citation></ref><ref id="B279-cells-09-02061"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belay</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yirdaw</surname><given-names>K.</given-names></name><name name-style="western"><surname>Enawgaw</surname><given-names>B.</given-names></name></person-group><article-title>Tumor Lysis Syndrome in Patients with Hematological Malignancies</article-title><source>J. Oncol.</source><year>2017</year><volume>2017</volume><fpage>9684909</fpage><pub-id pub-id-type="doi">10.1155/2017/9684909</pub-id><pub-id pub-id-type="pmid">29230244</pub-id><pub-id pub-id-type="pmcid">PMC5688348</pub-id></element-citation></ref><ref id="B280-cells-09-02061"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimabukuro-Vornhagen</surname><given-names>A.</given-names></name><name name-style="western"><surname>G&#246;del</surname><given-names>P.</given-names></name><name name-style="western"><surname>Subklewe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stemmler</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Schl&#246;&#223;er</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Schlaak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kochanek</surname><given-names>M.</given-names></name><name name-style="western"><surname>B&#246;ll</surname><given-names>B.</given-names></name><name name-style="western"><surname>von Bergwelt-Baildon</surname><given-names>M.S.</given-names></name></person-group><article-title>Cytokine release syndrome</article-title><source>J. Immunother. Cancer</source><year>2018</year><volume>6</volume><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/s40425-018-0343-9</pub-id><pub-id pub-id-type="pmid">29907163</pub-id><pub-id pub-id-type="pmcid">PMC6003181</pub-id></element-citation></ref><ref id="B281-cells-09-02061"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giavridis</surname><given-names>T.</given-names></name><name name-style="western"><surname>van der Stegen</surname><given-names>S.J.C.</given-names></name><name name-style="western"><surname>Eyquem</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hamieh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Piersigilli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sadelain</surname><given-names>M.</given-names></name></person-group><article-title>CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade</article-title><source>Nat. Med.</source><year>2018</year><volume>24</volume><fpage>731</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0041-7</pub-id><pub-id pub-id-type="pmid">29808005</pub-id><pub-id pub-id-type="pmcid">PMC6410714</pub-id></element-citation></ref><ref id="B282-cells-09-02061"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cervantes</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Spitler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>K.</given-names></name><name name-style="western"><surname>Davila</surname><given-names>M.L.</given-names></name></person-group><article-title>MDSC Suppression of CAR T Cells Can be Reduced By Targeted Signaling Disruption</article-title><source>Blood</source><year>2019</year><volume>134</volume><fpage>4438</fpage><pub-id pub-id-type="doi">10.1182/blood-2019-122752</pub-id></element-citation></ref><ref id="B283-cells-09-02061"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burga</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Thorn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Point</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Guha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Licata</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>DeMatteo</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Ayala</surname><given-names>A.</given-names></name><name name-style="western"><surname>Joseph Espat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Junghans</surname><given-names>R.P.</given-names></name><etal/></person-group><article-title>Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T</article-title><source>Cancer Immunol. Immunother.</source><year>2015</year><volume>64</volume><fpage>817</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1007/s00262-015-1692-6</pub-id><pub-id pub-id-type="pmid">25850344</pub-id><pub-id pub-id-type="pmcid">PMC4485571</pub-id></element-citation></ref><ref id="B284-cells-09-02061"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name></person-group><article-title>MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>4760</fpage><lpage>4769</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.6734</pub-id><pub-id pub-id-type="pmid">26716894</pub-id><pub-id pub-id-type="pmcid">PMC4826241</pub-id></element-citation></ref><ref id="B285-cells-09-02061"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crotti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Agape</surname><given-names>E.</given-names></name><name name-style="western"><surname>Becciolini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Biggioggero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Favalli</surname><given-names>E.G.</given-names></name></person-group><article-title>Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects</article-title><source>Drugs</source><year>2019</year><volume>79</volume><fpage>1741</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.1007/s40265-019-01192-z</pub-id><pub-id pub-id-type="pmid">31486005</pub-id></element-citation></ref><ref id="B286-cells-09-02061"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsaab</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Sau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alzhrani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tatiparti</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bhise</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kashaw</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>A.K.</given-names></name></person-group><article-title>PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome</article-title><source>Front. Pharmacol.</source><year>2017</year><volume>8</volume><fpage>561</fpage><pub-id pub-id-type="doi">10.3389/fphar.2017.00561</pub-id><pub-id pub-id-type="pmid">28878676</pub-id><pub-id pub-id-type="pmcid">PMC5572324</pub-id></element-citation></ref><ref id="B287-cells-09-02061"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fultang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Panetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P.</given-names></name><name name-style="western"><surname>Graef</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rizkalla</surname><given-names>N.</given-names></name><name name-style="western"><surname>Booth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lenton</surname><given-names>R.</given-names></name><name name-style="western"><surname>Noyvert</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shannon-Lowe</surname><given-names>C.</given-names></name><etal/></person-group><article-title>MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers</article-title><source>EBioMedicine</source><year>2019</year><volume>47</volume><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2019.08.025</pub-id><pub-id pub-id-type="pmid">31462392</pub-id><pub-id pub-id-type="pmcid">PMC6796554</pub-id></element-citation></ref><ref id="B288-cells-09-02061"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Du</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J.</given-names></name></person-group><article-title>Minicircle DNA-Mediated CAR T Cells Targeting CD44 Suppressed Hepatocellular Carcinoma Both in vitro and in vivo</article-title><source>Onco Targets Ther.</source><year>2020</year><volume>13</volume><fpage>3703</fpage><lpage>3716</lpage><pub-id pub-id-type="doi">10.2147/OTT.S247836</pub-id><pub-id pub-id-type="pmid">32440140</pub-id><pub-id pub-id-type="pmcid">PMC7210041</pub-id></element-citation></ref><ref id="B289-cells-09-02061"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name></person-group><article-title>Tumor microenvironment and therapeutic response</article-title><source>Cancer Lett.</source><year>2017</year><volume>387</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2016.01.043</pub-id><pub-id pub-id-type="pmid">26845449</pub-id></element-citation></ref><ref id="B290-cells-09-02061"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanahan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Coussens</surname><given-names>L.M.</given-names></name></person-group><article-title>Accessories to the crime: Functions of cells recruited to the tumor microenvironment</article-title><source>Cancer Cell</source><year>2012</year><volume>21</volume><fpage>309</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.02.022</pub-id><pub-id pub-id-type="pmid">22439926</pub-id></element-citation></ref><ref id="B291-cells-09-02061"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Mellman</surname><given-names>I.</given-names></name></person-group><article-title>Elements of cancer immunity and the cancer-immune set point</article-title><source>Nature</source><year>2017</year><volume>541</volume><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/nature21349</pub-id><pub-id pub-id-type="pmid">28102259</pub-id></element-citation></ref><ref id="B292-cells-09-02061"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beatty</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Gladney</surname><given-names>W.L.</given-names></name></person-group><article-title>Immune Escape Mechanisms as a Guide for Cancer Immunotherapy</article-title><source>Clin. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>687</fpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1860</pub-id><pub-id pub-id-type="pmid">25501578</pub-id><pub-id pub-id-type="pmcid">PMC4334715</pub-id></element-citation></ref><ref id="B293-cells-09-02061"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#214;stman</surname><given-names>A.</given-names></name></person-group><article-title>The tumor microenvironment controls drug sensitivity</article-title><source>Nat. Med.</source><year>2012</year><volume>18</volume><fpage>1332</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1038/nm.2938</pub-id><pub-id pub-id-type="pmid">22961158</pub-id></element-citation></ref><ref id="B294-cells-09-02061"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>E.</given-names></name></person-group><article-title>Turning foes to friends: Targeting cancer-associated fibroblasts</article-title><source>Nat. Rev. Drug Discov.</source><year>2019</year><volume>18</volume><fpage>99</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1038/s41573-018-0004-1</pub-id><pub-id pub-id-type="pmid">30470818</pub-id></element-citation></ref><ref id="B295-cells-09-02061"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>B.-Z.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>J.W.</given-names></name></person-group><article-title>Macrophage Diversity Enhances Tumor Progression and Metastasis</article-title><source>Cell</source><year>2010</year><volume>141</volume><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.03.014</pub-id><pub-id pub-id-type="pmid">20371344</pub-id><pub-id pub-id-type="pmcid">PMC4994190</pub-id></element-citation></ref><ref id="B296-cells-09-02061"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pathria</surname><given-names>P.</given-names></name><name name-style="western"><surname>Louis</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Varner</surname><given-names>J.A.</given-names></name></person-group><article-title>Targeting Tumor-Associated Macrophages in Cancer</article-title><source>Trends Immunol.</source><year>2019</year><volume>40</volume><fpage>310</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.it.2019.02.003</pub-id><pub-id pub-id-type="pmid">30890304</pub-id></element-citation></ref><ref id="B297-cells-09-02061"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prenen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mazzone</surname><given-names>M.</given-names></name></person-group><article-title>Tumor-associated macrophages: A short compendium</article-title><source>Cell. Mol. Life Sci.</source><year>2019</year><volume>76</volume><fpage>1447</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1007/s00018-018-2997-3</pub-id><pub-id pub-id-type="pmid">30747250</pub-id><pub-id pub-id-type="pmcid">PMC11105658</pub-id></element-citation></ref><ref id="B298-cells-09-02061"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swiecki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Colonna</surname><given-names>M.</given-names></name></person-group><article-title>The multifaceted biology of plasmacytoid dendritic cells</article-title><source>Nat. Rev. Immunol.</source><year>2015</year><volume>15</volume><fpage>471</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1038/nri3865</pub-id><pub-id pub-id-type="pmid">26160613</pub-id><pub-id pub-id-type="pmcid">PMC4808588</pub-id></element-citation></ref><ref id="B299-cells-09-02061"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Stromnes</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>P.D.</given-names></name></person-group><article-title>Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies</article-title><source>Cancer Cell</source><year>2017</year><volume>31</volume><fpage>311</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.02.008</pub-id><pub-id pub-id-type="pmid">28292435</pub-id><pub-id pub-id-type="pmcid">PMC5423788</pub-id></element-citation></ref><ref id="B300-cells-09-02061"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badalamenti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fanale</surname><given-names>D.</given-names></name><name name-style="western"><surname>Incorvaia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Barraco</surname><given-names>N.</given-names></name><name name-style="western"><surname>List&#236;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maragliano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vincenzi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cal&#242;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Iovanna</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Bazan</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?</article-title><source>Cell Immunol.</source><year>2019</year><volume>343</volume><fpage>103753</fpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2018.01.013</pub-id><pub-id pub-id-type="pmid">29395859</pub-id></element-citation></ref><ref id="B301-cells-09-02061"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warburg</surname><given-names>O.</given-names></name></person-group><article-title>The Metabolism of Carcinoma Cells</article-title><source>J. Cancer Res.</source><year>1925</year><volume>9</volume><fpage>148</fpage><pub-id pub-id-type="doi">10.1158/jcr.1925.148</pub-id></element-citation></ref><ref id="B302-cells-09-02061"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>L.M.R.</given-names></name></person-group><article-title>Cancer metabolism: The Warburg effect today</article-title><source>Exp. Mol. Pathol.</source><year>2010</year><volume>89</volume><fpage>372</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/j.yexmp.2010.08.006</pub-id><pub-id pub-id-type="pmid">20804748</pub-id></element-citation></ref><ref id="B303-cells-09-02061"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Hay</surname><given-names>M.P.</given-names></name></person-group><article-title>Targeting hypoxia in cancer therapy</article-title><source>Nat. Rev. Cancer</source><year>2011</year><volume>11</volume><fpage>393</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1038/nrc3064</pub-id><pub-id pub-id-type="pmid">21606941</pub-id></element-citation></ref><ref id="B304-cells-09-02061"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gialeli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Theocharis</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Karamanos</surname><given-names>N.K.</given-names></name></person-group><article-title>Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting</article-title><source>FEBS J.</source><year>2011</year><volume>278</volume><fpage>16</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2010.07919.x</pub-id><pub-id pub-id-type="pmid">21087457</pub-id></element-citation></ref><ref id="B305-cells-09-02061"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuppusamy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ilangovan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cardounel</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Zweier</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krishna</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>J.B.</given-names></name></person-group><article-title>Noninvasive Imaging of Tumor Redox Status and Its Modification by Tissue Glutathione Levels</article-title><source>Cancer Res.</source><year>2002</year><volume>62</volume><fpage>307</fpage><pub-id pub-id-type="pmid">11782393</pub-id></element-citation></ref><ref id="B306-cells-09-02061"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reuter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Chaturvedi</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Oxidative stress, inflammation, and cancer: How are they linked?</article-title><source>Free Radic. Biol. Med.</source><year>2010</year><volume>49</volume><fpage>1603</fpage><lpage>1616</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2010.09.006</pub-id><pub-id pub-id-type="pmid">20840865</pub-id><pub-id pub-id-type="pmcid">PMC2990475</pub-id></element-citation></ref><ref id="B307-cells-09-02061"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hager</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>Bioresponsive polyplexes - chemically programmed for nucleic acid delivery</article-title><source>Expert Opin. Drug Deliv.</source><year>2018</year><volume>15</volume><fpage>1067</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1080/17425247.2018.1526922</pub-id><pub-id pub-id-type="pmid">30247975</pub-id></element-citation></ref><ref id="B308-cells-09-02061"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>H.</given-names></name></person-group><article-title>Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity</article-title><source>Adv. Drug Deliv. Rev.</source><year>2015</year><volume>91</volume><fpage>3</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2015.01.002</pub-id><pub-id pub-id-type="pmid">25579058</pub-id></element-citation></ref><ref id="B309-cells-09-02061"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruoslahti</surname><given-names>E.</given-names></name></person-group><article-title>Peptides as targeting elements and tissue penetration devices for nanoparticles</article-title><source>Adv. Mater.</source><year>2012</year><volume>24</volume><fpage>3747</fpage><lpage>3756</lpage><pub-id pub-id-type="doi">10.1002/adma.201200454</pub-id><pub-id pub-id-type="pmid">22550056</pub-id><pub-id pub-id-type="pmcid">PMC3947925</pub-id></element-citation></ref><ref id="B310-cells-09-02061"><label>310.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruoslahti</surname><given-names>E.</given-names></name></person-group><article-title>Tumor penetrating peptides for improved drug delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2017</year><volume>110&#8211;111</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2016.03.008</pub-id><pub-id pub-id-type="pmcid">PMC5045823</pub-id><pub-id pub-id-type="pmid">27040947</pub-id></element-citation></ref><ref id="B311-cells-09-02061"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramsey</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>N.H.</given-names></name></person-group><article-title>Cell-penetrating peptides transport therapeutics into cells</article-title><source>Pharmacol. Ther.</source><year>2015</year><volume>154</volume><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2015.07.003</pub-id><pub-id pub-id-type="pmid">26210404</pub-id></element-citation></ref><ref id="B312-cells-09-02061"><label>312.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#228;chelt</surname><given-names>U.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond)</article-title><source>Chem. Rev.</source><year>2015</year><volume>115</volume><fpage>11043</fpage><lpage>11078</lpage><pub-id pub-id-type="doi">10.1021/cr5006793</pub-id><pub-id pub-id-type="pmid">25872804</pub-id></element-citation></ref><ref id="B313-cells-09-02061"><label>313.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berraondo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sanmamed</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Ochoa</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Etxeberria</surname><given-names>I.</given-names></name><name name-style="western"><surname>Aznar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>P&#233;rez-Gracia</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Ruiz</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Ponz-Sarvise</surname><given-names>M.</given-names></name><name name-style="western"><surname>Casta&#241;&#243;n</surname><given-names>E.</given-names></name><name name-style="western"><surname>Melero</surname><given-names>I.</given-names></name></person-group><article-title>Cytokines in clinical cancer immunotherapy</article-title><source>Br. J. Cancer</source><year>2019</year><volume>120</volume><fpage>6</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41416-018-0328-y</pub-id><pub-id pub-id-type="pmid">30413827</pub-id><pub-id pub-id-type="pmcid">PMC6325155</pub-id></element-citation></ref><ref id="B314-cells-09-02061"><label>314.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kulmburg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Veelken</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mackensen</surname><given-names>A.</given-names></name><name name-style="western"><surname>M&#233;zes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lindemann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mertelsmann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>F.M.</given-names></name></person-group><article-title>Cytokine gene transfer in cancer therapy</article-title><source>Stem Cells</source><year>1998</year><volume>16</volume><fpage>251</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1002/stem.5530160831</pub-id><pub-id pub-id-type="pmid">11012169</pub-id></element-citation></ref><ref id="B315-cells-09-02061"><label>315.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parmiani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rivoltini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Andreola</surname><given-names>G.</given-names></name><name name-style="western"><surname>Carrabba</surname><given-names>M.</given-names></name></person-group><article-title>Cytokines in cancer therapy</article-title><source>Immunol. Lett.</source><year>2000</year><volume>74</volume><fpage>41</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/S0165-2478(00)00247-9</pub-id><pub-id pub-id-type="pmid">10996626</pub-id></element-citation></ref><ref id="B316-cells-09-02061"><label>316.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conlon</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Miljkovic</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Waldmann</surname><given-names>T.A.</given-names></name></person-group><article-title>Cytokines in the Treatment of Cancer</article-title><source>J. Interferon Cytokine Res.</source><year>2019</year><volume>39</volume><fpage>6</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1089/jir.2018.0019</pub-id><pub-id pub-id-type="pmid">29889594</pub-id><pub-id pub-id-type="pmcid">PMC6350412</pub-id></element-citation></ref><ref id="B317-cells-09-02061"><label>317.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golomb</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fefer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ozer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Portlock</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ratain</surname><given-names>M.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vardiman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J.S.</given-names></name></person-group><article-title>Alpha-2 interferon therapy of hairy-cell leukemia: A multicenter study of 64 patients</article-title><source>J. Clin. Oncol.</source><year>1986</year><volume>4</volume><fpage>900</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1200/JCO.1986.4.6.900</pub-id><pub-id pub-id-type="pmid">3519880</pub-id></element-citation></ref><ref id="B318-cells-09-02061"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antony</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Dudek</surname><given-names>A.Z.</given-names></name></person-group><article-title>Interleukin 2 in Cancer Therapy</article-title><source>Curr. Med. Chem.</source><year>2010</year><volume>17</volume><fpage>3297</fpage><lpage>3302</lpage><pub-id pub-id-type="doi">10.2174/092986710793176410</pub-id><pub-id pub-id-type="pmid">20712575</pub-id></element-citation></ref><ref id="B319-cells-09-02061"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schreiber</surname><given-names>S.</given-names></name><name name-style="western"><surname>K&#228;mpgen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pirkhammer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Trcka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Korschan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lindemann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dorffner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kittler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kasteliz</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study</article-title><source>Hum. Gene Ther.</source><year>1999</year><volume>10</volume><fpage>983</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1089/10430349950018382</pub-id><pub-id pub-id-type="pmid">10223732</pub-id></element-citation></ref><ref id="B320-cells-09-02061"><label>320.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gansbacher</surname><given-names>B.</given-names></name><name name-style="western"><surname>Houghton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>P.</given-names></name><name name-style="western"><surname>Minasian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gilboa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Oettgen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Steffens</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name></person-group><article-title>A Pilot Study of Immunization with HLA-A2 Matched Allogeneic Melanoma Cells That Secrete Interleukin-2 in Patients with Metastatic Melanoma</article-title><source>Hum. Gene Ther.</source><year>1992</year><volume>3</volume><fpage>677</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1089/hum.1992.3.6-677</pub-id><pub-id pub-id-type="pmid">1482708</pub-id></element-citation></ref><ref id="B321-cells-09-02061"><label>321.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osanto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brouwenst&#255;n</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vaessen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Figdor</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Melief</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Schrier</surname><given-names>P.I.</given-names></name></person-group><article-title>Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma</article-title><source>Hum. Gene Ther.</source><year>1993</year><volume>4</volume><fpage>323</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1089/hum.1993.4.3-323</pub-id><pub-id pub-id-type="pmid">8338879</pub-id></element-citation></ref><ref id="B322-cells-09-02061"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowman</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Grossmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rill</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>B.</given-names></name><name name-style="western"><surname>Leimig</surname><given-names>T.</given-names></name><name name-style="western"><surname>Coustan-Smith</surname><given-names>E.</given-names></name><name name-style="western"><surname>Campana</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma</article-title><source>Hum. Gene Ther.</source><year>1998</year><volume>9</volume><fpage>1303</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1089/hum.1998.9.9-1303</pub-id><pub-id pub-id-type="pmid">9650615</pub-id></element-citation></ref><ref id="B323-cells-09-02061"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kali</surname><given-names>A.</given-names></name></person-group><article-title>TNFerade, an innovative cancer immunotherapeutic</article-title><source>Indian J. Pharmacol.</source><year>2015</year><volume>47</volume><fpage>479</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.4103/0253-7613.165190</pub-id><pub-id pub-id-type="pmid">26600634</pub-id><pub-id pub-id-type="pmcid">PMC4621666</pub-id></element-citation></ref><ref id="B324-cells-09-02061"><label>324.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kircheis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>Technology evaluation: TNFerade, GenVec</article-title><source>Curr. Opin. Mol. Ther.</source><year>2003</year><volume>5</volume><fpage>437</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">14513689</pub-id></element-citation></ref><ref id="B325-cells-09-02061"><label>325.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiocca</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Lukas</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Ligon</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Triggs</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Reardon</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stopa</surname><given-names>B.M.</given-names></name><etal/></person-group><article-title>Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial</article-title><source>Sci. Transl. Med.</source><year>2019</year><volume>11</volume><pub-id pub-id-type="doi">10.1126/scitranslmed.aaw5680</pub-id><pub-id pub-id-type="pmid">31413142</pub-id><pub-id pub-id-type="pmcid">PMC7286430</pub-id></element-citation></ref><ref id="B326-cells-09-02061"><label>326.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Uram</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Sugar</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Onners</surname><given-names>B.</given-names></name><name name-style="western"><surname>Solt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>L.A.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Donehower</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Jaffee</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer</article-title><source>J. Immunother.</source><year>2013</year><volume>36</volume><fpage>382</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e31829fb7a2</pub-id><pub-id pub-id-type="pmid">23924790</pub-id><pub-id pub-id-type="pmcid">PMC3779664</pub-id></element-citation></ref><ref id="B327-cells-09-02061"><label>327.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Wang-Gillam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Picozzi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Greten</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Crocenzi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Springett</surname><given-names>G.</given-names></name><name name-style="western"><surname>Morse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fine</surname><given-names>R.L.</given-names></name><etal/></person-group><article-title>Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer</article-title><source>J. Clin. Oncol.</source><year>2015</year><volume>33</volume><fpage>1325</fpage><lpage>1333</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.57.4244</pub-id><pub-id pub-id-type="pmid">25584002</pub-id><pub-id pub-id-type="pmcid">PMC4397277</pub-id></element-citation></ref><ref id="B328-cells-09-02061"><label>328.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Picozzi</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Wainberg</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Kindler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang-Gillam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oberstein</surname><given-names>P.</given-names></name><name name-style="western"><surname>Morse</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Zeh</surname><given-names>H.J.</given-names><suffix>III</suffix></name><name name-style="western"><surname>Weekes</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)</article-title><source>Clin. Cancer Res.</source><year>2019</year><volume>25</volume><fpage>5493</fpage><lpage>5502</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2992</pub-id><pub-id pub-id-type="pmid">31126960</pub-id><pub-id pub-id-type="pmcid">PMC7376746</pub-id></element-citation></ref><ref id="B329-cells-09-02061"><label>329.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsujikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Crocenzi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Durham</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Sugar</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Onners</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nauroth</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Anders</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Fertig</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Laheru</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer</article-title><source>Clin. Cancer Res.</source><year>2020</year><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-3978</pub-id><pub-id pub-id-type="pmcid">PMC7727397</pub-id><pub-id pub-id-type="pmid">32273276</pub-id></element-citation></ref><ref id="B330-cells-09-02061"><label>330.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duplisea</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Mokkapati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Plote</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schluns</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>McConkey</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Yla-Herttuala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Dinney</surname><given-names>C.P.</given-names></name></person-group><article-title>The development of interferon-based gene therapy for BCG unresponsive bladder cancer: From bench to bedside</article-title><source>World J. Urol.</source><year>2019</year><volume>37</volume><fpage>2041</fpage><lpage>2049</lpage><pub-id pub-id-type="doi">10.1007/s00345-018-2553-7</pub-id><pub-id pub-id-type="pmid">30415317</pub-id><pub-id pub-id-type="pmcid">PMC6511323</pub-id></element-citation></ref><ref id="B331-cells-09-02061"><label>331.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nemunaitis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dillman</surname><given-names>R.O.</given-names></name><name name-style="western"><surname>Schwarzenberger</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Senzer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pappen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer</article-title><source>J. Clin. Oncol.</source><year>2006</year><volume>24</volume><fpage>4721</fpage><lpage>4730</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.05.5335</pub-id><pub-id pub-id-type="pmid">16966690</pub-id></element-citation></ref><ref id="B332-cells-09-02061"><label>332.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nemunaitis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nemunaitis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Senzer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Snitz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bedell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pappen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Maples</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Shawler</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fakhrai</surname><given-names>H.</given-names></name></person-group><article-title>Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients</article-title><source>Cancer Gene Ther.</source><year>2009</year><volume>16</volume><fpage>620</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1038/cgt.2009.15</pub-id><pub-id pub-id-type="pmid">19287371</pub-id></element-citation></ref><ref id="B333-cells-09-02061"><label>333.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giaccone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bazhenova</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Nemunaitis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Juh&#225;sz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ramlau</surname><given-names>R.</given-names></name><name name-style="western"><surname>van den Heuvel</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kloecker</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>K.D.</given-names></name><etal/></person-group><article-title>A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer</article-title><source>Eur. J. Cancer</source><year>2015</year><volume>51</volume><fpage>2321</fpage><lpage>2329</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2015.07.035</pub-id><pub-id pub-id-type="pmid">26283035</pub-id></element-citation></ref><ref id="B334-cells-09-02061"><label>334.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name></person-group><article-title>New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases</article-title><source>Int. Immunopharmacol.</source><year>2019</year><volume>72</volume><fpage>322</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2019.03.064</pub-id><pub-id pub-id-type="pmid">31005777</pub-id></element-citation></ref><ref id="B335-cells-09-02061"><label>335.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kircheis</surname><given-names>R.</given-names></name><name name-style="western"><surname>K&#252;pc&#252;</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wallner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma</article-title><source>Cytokines Cell. Mol. Ther.</source><year>1998</year><volume>4</volume><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">9681248</pub-id></element-citation></ref><ref id="B336-cells-09-02061"><label>336.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Blaese</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Ettinghausen</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Hwu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Karp</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Kasid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mule</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Parkinson</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Salo</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Immunization of Cancer Patients Using Autologous Cancer Cells Modified by Insertion of the Gene for Interleukin-2 (National Institutes of Health)</article-title><source>Hum. Gene Ther.</source><year>1992</year><volume>3</volume><fpage>75</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1089/hum.1992.3.1-75</pub-id><pub-id pub-id-type="pmid">1562642</pub-id></element-citation></ref><ref id="B337-cells-09-02061"><label>337.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kircheis</surname><given-names>R.</given-names></name><name name-style="western"><surname>K&#252;pc&#252;</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wallner</surname><given-names>G.</given-names></name><name name-style="western"><surname>R&#246;ssler</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schweighoffer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice</article-title><source>Cancer Gene Ther.</source><year>2000</year><volume>7</volume><fpage>870</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1038/sj.cgt.7700183</pub-id><pub-id pub-id-type="pmid">10880017</pub-id></element-citation></ref><ref id="B338-cells-09-02061"><label>338.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zatloukal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cotten</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kirlappos</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mechtler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Curiel</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Birnstiel</surname><given-names>M.L.</given-names></name></person-group><article-title>Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1992</year><volume>89</volume><fpage>6099</fpage><lpage>6103</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.13.6099</pub-id><pub-id pub-id-type="pmid">1631096</pub-id><pub-id pub-id-type="pmcid">PMC49445</pub-id></element-citation></ref><ref id="B339-cells-09-02061"><label>339.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vile</surname><given-names>R.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chernajovsky</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>I.</given-names></name></person-group><article-title>A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes</article-title><source>Gene Ther.</source><year>1994</year><volume>1</volume><fpage>307</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">7584096</pub-id></element-citation></ref><ref id="B340-cells-09-02061"><label>340.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.K.</given-names></name></person-group><article-title>The targeted expression of the human interleukin-2/interferon alpha2b fused gene in alpha-fetoprotein-expressing hepatocellular carcinoma cells</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>1999</year><volume>125</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s004320050245</pub-id><pub-id pub-id-type="pmid">10190313</pub-id><pub-id pub-id-type="pmcid">PMC12199870</pub-id></element-citation></ref><ref id="B341-cells-09-02061"><label>341.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaurasiya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hew</surname><given-names>P.</given-names></name><name name-style="western"><surname>Crosley</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sharon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Potts</surname><given-names>K.</given-names></name><name name-style="western"><surname>Agopsowicz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Long</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hitt</surname><given-names>M.M.</given-names></name></person-group><article-title>Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences</article-title><source>Cancer Gene Ther.</source><year>2016</year><volume>23</volume><fpage>178</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1038/cgt.2016.18</pub-id><pub-id pub-id-type="pmid">27151235</pub-id></element-citation></ref><ref id="B342-cells-09-02061"><label>342.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Donehower</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Pawlik</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: Final results</article-title><source>J. Clin. Oncol.</source><year>2013</year><volume>31</volume><fpage>886</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.44.7516</pub-id><pub-id pub-id-type="pmid">23341531</pub-id><pub-id pub-id-type="pmcid">PMC4820756</pub-id></element-citation></ref><ref id="B343-cells-09-02061"><label>343.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bottermann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Foss</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Tienen</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Vaysburd</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cruickshank</surname><given-names>J.</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mayes</surname><given-names>K.</given-names></name><name name-style="western"><surname>Higginson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hirst</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>10440</fpage><lpage>10445</lpage><pub-id pub-id-type="doi">10.1073/pnas.1806314115</pub-id><pub-id pub-id-type="pmid">30209217</pub-id><pub-id pub-id-type="pmcid">PMC6187179</pub-id></element-citation></ref><ref id="B344-cells-09-02061"><label>344.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kircheis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ostermann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wolschek</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Lichtenberger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Magin-Lachmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wightman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kursa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>Tumor-targeted gene delivery of tumor necrosis factor-&#945; induces tumor necrosis and tumor regression without systemic toxicity</article-title><source>Cancer Gene Ther.</source><year>2002</year><volume>9</volume><fpage>673</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/sj.cgt.7700487</pub-id><pub-id pub-id-type="pmid">12136428</pub-id></element-citation></ref><ref id="B345-cells-09-02061"><label>345.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cengizeroglu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Farkasova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Viola</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Anton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ellwart</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Haase</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ogris</surname><given-names>M.</given-names></name></person-group><article-title>Systemic TNF&#945; Gene Therapy Synergizes With Liposomal Doxorubicine in the Treatment of Metastatic Cancer</article-title><source>Mol. Ther.</source><year>2013</year><volume>21</volume><fpage>300</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1038/mt.2012.229</pub-id><pub-id pub-id-type="pmid">23299796</pub-id><pub-id pub-id-type="pmcid">PMC3594014</pub-id></element-citation></ref><ref id="B346-cells-09-02061"><label>346.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russ</surname><given-names>V.</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>M.</given-names></name><name name-style="western"><surname>Halama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ogris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>Oligoethylenimine-grafted polypropylenimine dendrimers as degradable and biocompatible synthetic vectors for gene delivery</article-title><source>J. Controlled Release</source><year>2008</year><volume>132</volume><fpage>131</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2008.09.003</pub-id><pub-id pub-id-type="pmid">18812195</pub-id></element-citation></ref><ref id="B347-cells-09-02061"><label>347.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#228;fer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pahnke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schaffert</surname><given-names>D.</given-names></name><name name-style="western"><surname>van Weerden</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>de Ridder</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>R&#246;dl</surname><given-names>W.</given-names></name><name name-style="western"><surname>Vetter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Spitzweg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kraaij</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: A fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation</article-title><source>Hum. Gene Ther.</source><year>2011</year><volume>22</volume><fpage>1463</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.1089/hum.2010.231</pub-id><pub-id pub-id-type="pmid">21644815</pub-id><pub-id pub-id-type="pmcid">PMC3237691</pub-id></element-citation></ref><ref id="B348-cells-09-02061"><label>348.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tandle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lorang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hajitou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moya</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Pasqualini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Arap</surname><given-names>W.</given-names></name><name name-style="western"><surname>Adem</surname><given-names>A.</given-names></name><name name-style="western"><surname>Starker</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hewitt</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Tumor vasculature-targeted delivery of tumor necrosis factor-&#945;*</article-title><source>Cancer</source><year>2009</year><volume>115</volume><fpage>128</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1002/cncr.24001</pub-id><pub-id pub-id-type="pmid">19090007</pub-id><pub-id pub-id-type="pmcid">PMC8385542</pub-id></element-citation></ref><ref id="B349-cells-09-02061"><label>349.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Syrkin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Adem</surname><given-names>A.</given-names></name><name name-style="western"><surname>Geha</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pastoriza</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vrikshajanani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>T.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Alemu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-&#945; leads to synergistic antitumor activity</article-title><source>Cancer Gene Ther.</source><year>2013</year><volume>20</volume><fpage>46</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/cgt.2012.83</pub-id><pub-id pub-id-type="pmid">23154431</pub-id><pub-id pub-id-type="pmcid">PMC3534156</pub-id></element-citation></ref><ref id="B350-cells-09-02061"><label>350.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quinn</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Healy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Claros</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Kabarriti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scandiuzzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gorecka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adem</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Preclinical evaluation of radiation and systemic, RGD-targeted, adeno-associated virus phage-TNF gene therapy in a mouse model of spontaneously metastatic melanoma</article-title><source>Cancer Gene Ther.</source><year>2017</year><volume>24</volume><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1038/cgt.2016.70</pub-id><pub-id pub-id-type="pmid">27934883</pub-id></element-citation></ref><ref id="B351-cells-09-02061"><label>351.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lasek</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zago&#380;d&#380;on</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jakobisiak</surname><given-names>M.</given-names></name></person-group><article-title>Interleukin 12: Still a promising candidate for tumor immunotherapy?</article-title><source>Cancer Immunol. Immunother.</source><year>2014</year><volume>63</volume><fpage>419</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1007/s00262-014-1523-1</pub-id><pub-id pub-id-type="pmid">24514955</pub-id><pub-id pub-id-type="pmcid">PMC3994286</pub-id></element-citation></ref><ref id="B352-cells-09-02061"><label>352.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voest</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Kenyon</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>O&#8217;Reilly</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Truitt</surname><given-names>G.</given-names></name><name name-style="western"><surname>D&#8217;Amato</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Folkman</surname><given-names>J.</given-names></name></person-group><article-title>Inhibition of angiogenesis in vivo by interleukin 12</article-title><source>J. Natl. Cancer Inst.</source><year>1995</year><volume>87</volume><fpage>581</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1093/jnci/87.8.581</pub-id><pub-id pub-id-type="pmid">7538593</pub-id></element-citation></ref><ref id="B353-cells-09-02061"><label>353.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dias</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>R.</given-names></name><name name-style="western"><surname>Balkwill</surname><given-names>F.</given-names></name></person-group><article-title>IL-12 regulates VEGF and MMPs in a murine breast cancer model</article-title><source>Int. J. Cancer</source><year>1998</year><volume>78</volume><fpage>361</fpage><lpage>365</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-0215(19981029)78:3&amp;#x0003c;361::AID-IJC17&amp;#x0003e;3.0.CO;2-9</pub-id><pub-id pub-id-type="pmid">9766572</pub-id></element-citation></ref><ref id="B354-cells-09-02061"><label>354.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Vecchio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bajetta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Canova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lotze</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Wesa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parmiani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Anichini</surname><given-names>A.</given-names></name></person-group><article-title>Interleukin-12: Biological properties and clinical application</article-title><source>Clin. Cancer Res.</source><year>2007</year><volume>13</volume><fpage>4677</fpage><lpage>4685</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0776</pub-id><pub-id pub-id-type="pmid">17699845</pub-id></element-citation></ref><ref id="B355-cells-09-02061"><label>355.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>J.</given-names></name></person-group><article-title>IL-12 Deaths: Explanation and a Puzzle</article-title><source>Science</source><year>1995</year><volume>270</volume><fpage>908</fpage><pub-id pub-id-type="doi">10.1126/science.270.5238.908a</pub-id><pub-id pub-id-type="pmid">7481785</pub-id></element-citation></ref><ref id="B356-cells-09-02061"><label>356.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonard</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Sosman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Dutcher</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Vogelzang</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>J.L.</given-names></name></person-group><article-title>Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production</article-title><source>Blood</source><year>1997</year><volume>90</volume><fpage>2541</fpage><lpage>2548</lpage><pub-id pub-id-type="pmid">9326219</pub-id></element-citation></ref><ref id="B357-cells-09-02061"><label>357.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasche</surname><given-names>N.</given-names></name><name name-style="western"><surname>Neri</surname><given-names>D.</given-names></name></person-group><article-title>Immunocytokines: A novel class of potent armed antibodies</article-title><source>Drug Discov. Today</source><year>2012</year><volume>17</volume><fpage>583</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2012.01.007</pub-id><pub-id pub-id-type="pmid">22289353</pub-id></element-citation></ref><ref id="B358-cells-09-02061"><label>358.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudman</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Jameson</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>McKeage</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Savage</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jodrell</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Harries</surname><given-names>M.</given-names></name><name name-style="western"><surname>Acton</surname><given-names>G.</given-names></name><name name-style="western"><surname>Erlandsson</surname><given-names>F.</given-names></name><name name-style="western"><surname>Spicer</surname><given-names>J.F.</given-names></name></person-group><article-title>A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma</article-title><source>Clin. Cancer. Res.</source><year>2011</year><volume>17</volume><fpage>1998</fpage><lpage>2005</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2490</pub-id><pub-id pub-id-type="pmid">21447719</pub-id><pub-id pub-id-type="pmcid">PMC3071333</pub-id></element-citation></ref><ref id="B359-cells-09-02061"><label>359.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez-Alcoceba</surname><given-names>R.</given-names></name><name name-style="western"><surname>Poutou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ballesteros-Briones</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Smerdou</surname><given-names>C.</given-names></name></person-group><article-title>Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12</article-title><source>Immunotherapy</source><year>2016</year><volume>8</volume><fpage>179</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.2217/imt.15.109</pub-id><pub-id pub-id-type="pmid">26786809</pub-id></element-citation></ref><ref id="B360-cells-09-02061"><label>360.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tugues</surname><given-names>S.</given-names></name><name name-style="western"><surname>Burkhard</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Ohs</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vrohlings</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nussbaum</surname><given-names>K.</given-names></name><name name-style="western"><surname>vom Berg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kulig</surname><given-names>P.</given-names></name><name name-style="western"><surname>Becher</surname><given-names>B.</given-names></name></person-group><article-title>New insights into IL-12-mediated tumor suppression</article-title><source>Cell Death Differ.</source><year>2015</year><volume>22</volume><fpage>237</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1038/cdd.2014.134</pub-id><pub-id pub-id-type="pmid">25190142</pub-id><pub-id pub-id-type="pmcid">PMC4291488</pub-id></element-citation></ref><ref id="B361-cells-09-02061"><label>361.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sangro</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mazzolini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Herraiz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Quiroga</surname><given-names>J.</given-names></name><name name-style="western"><surname>Herrero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Benito</surname><given-names>A.</given-names></name><name name-style="western"><surname>Larrache</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pueyo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Subtil</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors</article-title><source>J. Clin. Oncol.</source><year>2004</year><volume>22</volume><fpage>1389</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.04.059</pub-id><pub-id pub-id-type="pmid">15084613</pub-id></element-citation></ref><ref id="B362-cells-09-02061"><label>362.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Triozzi</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Strong</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Bucy</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>K.O.</given-names></name><name name-style="western"><surname>Carlisle</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Lobuglio</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Conry</surname><given-names>R.M.</given-names></name></person-group><article-title>Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma</article-title><source>Hum. Gene Ther.</source><year>2005</year><volume>16</volume><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1089/hum.2005.16.91</pub-id><pub-id pub-id-type="pmid">15703492</pub-id></element-citation></ref><ref id="B363-cells-09-02061"><label>363.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Triozzi</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>K.O.</given-names></name><name name-style="western"><surname>Carlisle</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>M.</given-names></name><name name-style="western"><surname>LoBuglio</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Conry</surname><given-names>R.M.</given-names></name></person-group><article-title>Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma</article-title><source>Clin. Cancer. Res.</source><year>2005</year><volume>11</volume><fpage>4168</fpage><lpage>4175</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2283</pub-id><pub-id pub-id-type="pmid">15930353</pub-id></element-citation></ref><ref id="B364-cells-09-02061"><label>364.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linette</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Hamid</surname><given-names>O.</given-names></name><name name-style="western"><surname>Whitman</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Nemunaitis</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Chesney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Agarwala</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Starodub</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martell</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>A phase I open-label study of Ad-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unresectable stage III/IV melanoma</article-title><source>J. Clin. Oncol.</source><year>2013</year><volume>31</volume><fpage>3022</fpage><pub-id pub-id-type="doi">10.1200/jco.2013.31.15_suppl.3022</pub-id></element-citation></ref><ref id="B365-cells-09-02061"><label>365.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quetglas</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Labiano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aznar</surname><given-names>M.&#193;.</given-names></name><name name-style="western"><surname>Bola&#241;os</surname><given-names>E.</given-names></name><name name-style="western"><surname>Azpilikueta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Casales</surname><given-names>E.</given-names></name><name name-style="western"><surname>S&#225;nchez-Paulete</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Segura</surname><given-names>V.</given-names></name><name name-style="western"><surname>Smerdou</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Virotherapy with a Semliki Forest Virus&#8211;Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade</article-title><source>Cancer Immunol. Res.</source><year>2015</year><volume>3</volume><fpage>449</fpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0216</pub-id><pub-id pub-id-type="pmid">25691326</pub-id></element-citation></ref><ref id="B366-cells-09-02061"><label>366.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name></person-group><article-title>Lentiviral delivery of novel fusion protein IL12/FasTI for cancer immune/gene therapy</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0201100</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0201100</pub-id><pub-id pub-id-type="pmid">30044833</pub-id><pub-id pub-id-type="pmcid">PMC6059467</pub-id></element-citation></ref><ref id="B367-cells-09-02061"><label>367.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucas</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Heller</surname><given-names>L.</given-names></name><name name-style="western"><surname>Coppola</surname><given-names>D.</given-names></name><name name-style="western"><surname>Heller</surname><given-names>R.</given-names></name></person-group><article-title>IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma</article-title><source>Mol. Ther.</source><year>2002</year><volume>5</volume><fpage>668</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1006/mthe.2002.0601</pub-id><pub-id pub-id-type="pmid">12027550</pub-id></element-citation></ref><ref id="B368-cells-09-02061"><label>368.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinzerling</surname><given-names>L.</given-names></name><name name-style="western"><surname>Burg</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dummer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oberholzer</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Elzaouk</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pavlovic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moelling</surname><given-names>K.</given-names></name></person-group><article-title>Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: Clinical efficacy</article-title><source>Hum. Gene Ther.</source><year>2005</year><volume>16</volume><fpage>35</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1089/hum.2005.16.35</pub-id><pub-id pub-id-type="pmid">15703487</pub-id></element-citation></ref><ref id="B369-cells-09-02061"><label>369.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahvi</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Albertini</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meredith</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schalch</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rakhmilevich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hank</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sondel</surname><given-names>P.</given-names></name></person-group><article-title>Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial</article-title><source>Cancer Gene Ther.</source><year>2007</year><volume>14</volume><fpage>717</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1038/sj.cgt.7701064</pub-id><pub-id pub-id-type="pmid">17557109</pub-id></element-citation></ref><ref id="B370-cells-09-02061"><label>370.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daud</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>DeConti</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>S.</given-names></name><name name-style="western"><surname>Urbas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Riker</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Sondak</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Munster</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Ugen</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Messina</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma</article-title><source>J. Clin. Oncol.</source><year>2008</year><volume>26</volume><fpage>5896</fpage><lpage>5903</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.15.6794</pub-id><pub-id pub-id-type="pmid">19029422</pub-id><pub-id pub-id-type="pmcid">PMC2645111</pub-id></element-citation></ref><ref id="B371-cells-09-02061"><label>371.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cutrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>King</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kicenuik</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gumpel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name></person-group><article-title>Safety and efficacy of tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions</article-title><source>Curr. Gene Ther.</source><year>2015</year><volume>15</volume><fpage>44</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.2174/1566523214666141127093654</pub-id><pub-id pub-id-type="pmid">25429465</pub-id><pub-id pub-id-type="pmcid">PMC4280356</pub-id></element-citation></ref><ref id="B372-cells-09-02061"><label>372.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cemazar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ambrozic Avgustin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pavlin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sersa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Poli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krhac Levacic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tesic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lampreht Tratar</surname><given-names>U.</given-names></name><name name-style="western"><surname>Rak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tozon</surname><given-names>N.</given-names></name></person-group><article-title>Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours</article-title><source>Vet. Comp. Oncol.</source><year>2017</year><volume>15</volume><fpage>641</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1111/vco.12208</pub-id><pub-id pub-id-type="pmid">26840222</pub-id></element-citation></ref><ref id="B373-cells-09-02061"><label>373.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cicchelero</surname><given-names>L.</given-names></name><name name-style="western"><surname>Denies</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haers</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vanderperren</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stock</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van Brantegem</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Rooster</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>N.N.</given-names></name></person-group><article-title>Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer</article-title><source>Vet. Comp. Oncol.</source><year>2017</year><volume>15</volume><fpage>1187</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1111/vco.12255</pub-id><pub-id pub-id-type="pmid">27506827</pub-id></element-citation></ref><ref id="B374-cells-09-02061"><label>374.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigo-Garz&#243;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>Berraondo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ochoa</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zulueta</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Aseguinolaza</surname><given-names>G.</given-names></name></person-group><article-title>Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis</article-title><source>Cancer Gene Ther.</source><year>2010</year><volume>17</volume><fpage>20</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1038/cgt.2009.45</pub-id><pub-id pub-id-type="pmid">19575045</pub-id></element-citation></ref><ref id="B375-cells-09-02061"><label>375.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anwer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Fewell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>R.D.</given-names></name></person-group><article-title>Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer</article-title><source>Gene Ther.</source><year>2010</year><volume>17</volume><fpage>360</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1038/gt.2009.159</pub-id><pub-id pub-id-type="pmid">20033066</pub-id></element-citation></ref><ref id="B376-cells-09-02061"><label>376.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anwer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fewell</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>R.D.</given-names></name></person-group><article-title>Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer</article-title><source>Gynecol. Oncol.</source><year>2013</year><volume>131</volume><fpage>169</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2013.07.081</pub-id><pub-id pub-id-type="pmid">23863356</pub-id></element-citation></ref><ref id="B377-cells-09-02061"><label>377.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Men</surname><given-names>K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>X.</given-names></name></person-group><article-title>Local and Systemic Delivery of Interleukin-12 Gene by Cationic Micelles for Cancer Immunogene Therapy</article-title><source>J. Biomed. Nanotechnol.</source><year>2018</year><volume>14</volume><fpage>1719</fpage><lpage>1730</lpage><pub-id pub-id-type="doi">10.1166/jbn.2018.2593</pub-id><pub-id pub-id-type="pmid">30041719</pub-id></element-citation></ref><ref id="B378-cells-09-02061"><label>378.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chmielewski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abken</surname><given-names>H.</given-names></name></person-group><article-title>CAR T cells transform to trucks: Chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer</article-title><source>Cancer Immunol. Immunother.</source><year>2012</year><volume>61</volume><fpage>1269</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1007/s00262-012-1202-z</pub-id><pub-id pub-id-type="pmid">22274776</pub-id><pub-id pub-id-type="pmcid">PMC11029721</pub-id></element-citation></ref><ref id="B379-cells-09-02061"><label>379.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodi</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>U.N.</given-names></name><name name-style="western"><surname>Butterfield</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Tarhini</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Leming</surname><given-names>P.</given-names></name><name name-style="western"><surname>Puzanov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kirkwood</surname><given-names>J.M.</given-names></name></person-group><article-title>Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial</article-title><source>JAMA</source><year>2014</year><volume>312</volume><fpage>1744</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.13943</pub-id><pub-id pub-id-type="pmid">25369488</pub-id><pub-id pub-id-type="pmcid">PMC4336189</pub-id></element-citation></ref><ref id="B380-cells-09-02061"><label>380.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sterner</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Sakemura</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kenderian</surname><given-names>S.S.</given-names></name></person-group><article-title>Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells</article-title><source>J. Vis. Exp.</source><year>2019</year><pub-id pub-id-type="doi">10.3791/59629</pub-id><pub-id pub-id-type="pmid">31380838</pub-id></element-citation></ref><ref id="B381-cells-09-02061"><label>381.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teicher</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Fricker</surname><given-names>S.P.</given-names></name></person-group><article-title>CXCL12 (SDF-1)/CXCR4 pathway in cancer</article-title><source>Clin. Cancer Res.</source><year>2010</year><volume>16</volume><fpage>2927</fpage><lpage>2931</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-2329</pub-id><pub-id pub-id-type="pmid">20484021</pub-id></element-citation></ref><ref id="B382-cells-09-02061"><label>382.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>The role of CXCL12 in tumor microenvironment</article-title><source>Gene</source><year>2018</year><volume>641</volume><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2017.10.015</pub-id><pub-id pub-id-type="pmid">29017963</pub-id></element-citation></ref><ref id="B383-cells-09-02061"><label>383.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feig</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Kraman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Deonarine</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Connell</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Caballero</surname><given-names>O.L.</given-names></name><etal/></person-group><article-title>Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>20212</fpage><lpage>20217</lpage><pub-id pub-id-type="doi">10.1073/pnas.1320318110</pub-id><pub-id pub-id-type="pmid">24277834</pub-id><pub-id pub-id-type="pmcid">PMC3864274</pub-id></element-citation></ref><ref id="B384-cells-09-02061"><label>384.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ultsch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coons</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>N.Y.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>S.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Development and preclinical characterization of a humanized antibody targeting CXCL12</article-title><source>Clin. Cancer Res.</source><year>2013</year><volume>19</volume><fpage>4433</fpage><lpage>4445</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-0943</pub-id><pub-id pub-id-type="pmid">23812669</pub-id></element-citation></ref><ref id="B385-cells-09-02061"><label>385.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodwin</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Musetti</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Local and transient gene expression primes the liver to resist cancer metastasis</article-title><source>Sci. Transl. Med.</source><year>2016</year><volume>8</volume><fpage>364ra153</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aag2306</pub-id><pub-id pub-id-type="pmid">27831902</pub-id><pub-id pub-id-type="pmcid">PMC5512420</pub-id></element-citation></ref><ref id="B386-cells-09-02061"><label>386.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Das</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Dorosheva</surname><given-names>O.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer</article-title><source>ACS Nano</source><year>2017</year><volume>11</volume><fpage>8690</fpage><lpage>8706</lpage><pub-id pub-id-type="doi">10.1021/acsnano.7b01786</pub-id><pub-id pub-id-type="pmid">28809532</pub-id><pub-id pub-id-type="pmcid">PMC5961942</pub-id></element-citation></ref><ref id="B387-cells-09-02061"><label>387.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>A highly efficient synthetic vector: Nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo</article-title><source>ACS Nano</source><year>2013</year><volume>7</volume><fpage>5376</fpage><lpage>5384</lpage><pub-id pub-id-type="doi">10.1021/nn4012384</pub-id><pub-id pub-id-type="pmid">23647441</pub-id><pub-id pub-id-type="pmcid">PMC3718078</pub-id></element-citation></ref><ref id="B388-cells-09-02061"><label>388.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weis</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Cheresh</surname><given-names>D.A.</given-names></name></person-group><article-title>Tumor angiogenesis: Molecular pathways and therapeutic targets</article-title><source>Nat. Med.</source><year>2011</year><volume>17</volume><fpage>1359</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1038/nm.2537</pub-id><pub-id pub-id-type="pmid">22064426</pub-id></element-citation></ref><ref id="B389-cells-09-02061"><label>389.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ott</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Hodi</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Buchbinder</surname><given-names>E.I.</given-names></name></person-group><article-title>Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data</article-title><source>Front. Oncol.</source><year>2015</year><volume>5</volume><fpage>202</fpage><pub-id pub-id-type="doi">10.3389/fonc.2015.00202</pub-id><pub-id pub-id-type="pmid">26442214</pub-id><pub-id pub-id-type="pmcid">PMC4585112</pub-id></element-citation></ref><ref id="B390-cells-09-02061"><label>390.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lockhart</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Rothenberg</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Dupont</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chevalier</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sternas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buzenet</surname><given-names>G.</given-names></name><name name-style="western"><surname>Koehler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sosman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>L.H.</given-names></name><etal/></person-group><article-title>Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors</article-title><source>J. Clin. Oncol.</source><year>2009</year><volume>28</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.22.9237</pub-id><pub-id pub-id-type="pmid">19949018</pub-id><pub-id pub-id-type="pmcid">PMC2815710</pub-id></element-citation></ref><ref id="B391-cells-09-02061"><label>391.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarhini</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Frankel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Margolin</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ruel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shipe-Spotloe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gandara</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kirkwood</surname><given-names>J.M.</given-names></name></person-group><article-title>Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin</article-title><source>Clin. Cancer Res.</source><year>2011</year><volume>17</volume><fpage>6574</fpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1463</pub-id><pub-id pub-id-type="pmid">21880788</pub-id><pub-id pub-id-type="pmcid">PMC3196047</pub-id></element-citation></ref><ref id="B392-cells-09-02061"><label>392.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hillan</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Novotny</surname><given-names>W.</given-names></name></person-group><article-title>Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2005</year><volume>333</volume><fpage>328</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.05.132</pub-id><pub-id pub-id-type="pmid">15961063</pub-id></element-citation></ref><ref id="B393-cells-09-02061"><label>393.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melosky</surname><given-names>B.</given-names></name><name name-style="western"><surname>Reardon</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Nixon</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bair</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>I.</given-names></name></person-group><article-title>Bevacizumab biosimilars: Scientific justification for extrapolation of indications</article-title><source>Future Oncol.</source><year>2018</year><volume>14</volume><fpage>2507</fpage><lpage>2520</lpage><pub-id pub-id-type="doi">10.2217/fon-2018-0051</pub-id><pub-id pub-id-type="pmid">29690784</pub-id></element-citation></ref><ref id="B394-cells-09-02061"><label>394.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vennepureddy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rastogi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Atallah</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Terjanian</surname><given-names>T.</given-names></name></person-group><article-title>Evolution of ramucirumab in the treatment of cancer - A review of literature</article-title><source>J. Oncol. Pharm. Pract.</source><year>2017</year><volume>23</volume><fpage>525</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1177/1078155216655474</pub-id><pub-id pub-id-type="pmid">27306885</pub-id></element-citation></ref><ref id="B395-cells-09-02061"><label>395.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tekade</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Tekade</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kesharwani</surname><given-names>P.</given-names></name><name name-style="western"><surname>D&#8217;Emanuele</surname><given-names>A.</given-names></name></person-group><article-title>RNAi-combined nano-chemotherapeutics to tackle resistant tumors</article-title><source>Drug Discov. Today</source><year>2016</year><volume>21</volume><fpage>1761</fpage><lpage>1774</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2016.06.029</pub-id><pub-id pub-id-type="pmid">27380716</pub-id></element-citation></ref><ref id="B396-cells-09-02061"><label>396.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanazawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sugawara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Horiuchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takashima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>H.</given-names></name></person-group><article-title>Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG-PCL nanomicelles</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2012</year><volume>81</volume><fpage>470</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2012.04.021</pub-id><pub-id pub-id-type="pmid">22579732</pub-id></element-citation></ref><ref id="B397-cells-09-02061"><label>397.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egorova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shubina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sokolov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Selkov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baranov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kiselev</surname><given-names>A.</given-names></name></person-group><article-title>CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery</article-title><source>Int. J. Pharm.</source><year>2016</year><volume>515</volume><fpage>431</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.10.049</pub-id><pub-id pub-id-type="pmid">27789364</pub-id></element-citation></ref><ref id="B398-cells-09-02061"><label>398.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Ul Ain</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.H.</given-names></name></person-group><article-title>Enhanced Systemic Anti-Angiogenic siVEGF Delivery Using PEGylated Oligo-d-arginine</article-title><source>Mol. Pharm.</source><year>2017</year><volume>14</volume><fpage>3059</fpage><lpage>3068</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00282</pub-id><pub-id pub-id-type="pmid">28704054</pub-id></element-citation></ref><ref id="B399-cells-09-02061"><label>399.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>Y.E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.C.</given-names></name></person-group><article-title>VEGF siRNA Delivery by a Cancer-Specific Cell-Penetrating Peptide</article-title><source>J. Microbiol. Biotechnol.</source><year>2018</year><volume>28</volume><fpage>367</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.4014/jmb.1711.11025</pub-id><pub-id pub-id-type="pmid">29316746</pub-id></element-citation></ref><ref id="B400-cells-09-02061"><label>400.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiffelers</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Storm</surname><given-names>G.</given-names></name><name name-style="western"><surname>Molema</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Scaria</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Woodle</surname><given-names>M.C.</given-names></name></person-group><article-title>Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle</article-title><source>Nucleic Acids Res.</source><year>2004</year><volume>32</volume><fpage>e149</fpage><pub-id pub-id-type="doi">10.1093/nar/gnh140</pub-id><pub-id pub-id-type="pmid">15520458</pub-id><pub-id pub-id-type="pmcid">PMC528817</pub-id></element-citation></ref><ref id="B401-cells-09-02061"><label>401.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>T.G.</given-names></name></person-group><article-title>Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer</article-title><source>J. Controlled Release</source><year>2008</year><volume>129</volume><fpage>107</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2008.03.008</pub-id><pub-id pub-id-type="pmid">18486981</pub-id></element-citation></ref><ref id="B402-cells-09-02061"><label>402.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>S.K.</given-names></name></person-group><article-title>Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis</article-title><source>Mol. Pharm.</source><year>2009</year><volume>6</volume><fpage>727</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1021/mp800176t</pub-id><pub-id pub-id-type="pmid">19178144</pub-id></element-citation></ref><ref id="B403-cells-09-02061"><label>403.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barve</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K.</given-names></name></person-group><article-title>Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>4508</fpage><lpage>4524</lpage><pub-id pub-id-type="doi">10.7150/thno.34314</pub-id><pub-id pub-id-type="pmid">31285776</pub-id><pub-id pub-id-type="pmcid">PMC6599648</pub-id></element-citation></ref><ref id="B404-cells-09-02061"><label>404.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Yhee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J.H.</given-names></name></person-group><article-title>Synergistic anti-tumor effects of bevacizumab and tumor targeted polymerized VEGF siRNA nanoparticles</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2017</year><volume>489</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.05.103</pub-id><pub-id pub-id-type="pmid">28533089</pub-id></element-citation></ref><ref id="B405-cells-09-02061"><label>405.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z.Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.Z.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>X.R.</given-names></name></person-group><article-title>Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>5226</fpage><lpage>5239</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.03.017</pub-id><pub-id pub-id-type="pmid">24695093</pub-id></element-citation></ref><ref id="B406-cells-09-02061"><label>406.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>You</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.T.</given-names></name><etal/></person-group><article-title>Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect via Multi-functional Nanoparticles for Orthotopic Non-Small Cell Lung Cancer Treatment</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>5886</fpage><lpage>5898</lpage><pub-id pub-id-type="doi">10.7150/thno.32416</pub-id><pub-id pub-id-type="pmid">31534526</pub-id><pub-id pub-id-type="pmcid">PMC6735374</pub-id></element-citation></ref><ref id="B407-cells-09-02061"><label>407.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conde</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>D.</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Artzi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>F.</given-names></name></person-group><article-title>Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells</article-title><source>Adv. Funct. Mater.</source><year>2015</year><volume>25</volume><fpage>4183</fpage><lpage>4194</lpage><pub-id pub-id-type="doi">10.1002/adfm.201501283</pub-id><pub-id pub-id-type="pmid">27340392</pub-id><pub-id pub-id-type="pmcid">PMC4914053</pub-id></element-citation></ref><ref id="B408-cells-09-02061"><label>408.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo</article-title><source>Int. J. Nanomed.</source><year>2018</year><volume>13</volume><fpage>3713</fpage><lpage>3728</lpage><pub-id pub-id-type="doi">10.2147/IJN.S162939</pub-id><pub-id pub-id-type="pmcid">PMC6028351</pub-id><pub-id pub-id-type="pmid">29983564</pub-id></element-citation></ref><ref id="B409-cells-09-02061"><label>409.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akhurst</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Hata</surname><given-names>A.</given-names></name></person-group><article-title>Targeting the TGF&#946; signalling pathway in disease</article-title><source>Nat. Rev. Drug Discov.</source><year>2012</year><volume>11</volume><fpage>790</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1038/nrd3810</pub-id><pub-id pub-id-type="pmid">23000686</pub-id><pub-id pub-id-type="pmcid">PMC3520610</pub-id></element-citation></ref><ref id="B410-cells-09-02061"><label>410.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J.C.</given-names></name></person-group><article-title>Transforming growth factor-&#946;: A therapeutic target for cancer</article-title><source>Hum. Vaccin. Immunother.</source><year>2017</year><volume>13</volume><fpage>1741</fpage><lpage>1750</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1327107</pub-id><pub-id pub-id-type="pmid">28575585</pub-id><pub-id pub-id-type="pmcid">PMC5557219</pub-id></element-citation></ref><ref id="B411-cells-09-02061"><label>411.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Najafi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farhood</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mortezaee</surname><given-names>K.</given-names></name></person-group><article-title>Transforming growth factor-&#946; signaling: Tumorigenesis and targeting for cancer therapy</article-title><source>J. Cell. Physiol.</source><year>2019</year><volume>234</volume><fpage>12173</fpage><lpage>12187</lpage><pub-id pub-id-type="doi">10.1002/jcp.27955</pub-id><pub-id pub-id-type="pmid">30537043</pub-id></element-citation></ref><ref id="B412-cells-09-02061"><label>412.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Nanoparticle-delivered transforming growth factor-&#946; siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment</article-title><source>ACS Nano</source><year>2014</year><volume>8</volume><fpage>3636</fpage><lpage>3645</lpage><pub-id pub-id-type="doi">10.1021/nn500216y</pub-id><pub-id pub-id-type="pmid">24580381</pub-id><pub-id pub-id-type="pmcid">PMC4004320</pub-id></element-citation></ref><ref id="B413-cells-09-02061"><label>413.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2017</year><volume>36</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/s13046-017-0499-z</pub-id><pub-id pub-id-type="pmid">28193228</pub-id><pub-id pub-id-type="pmcid">PMC5307754</pub-id></element-citation></ref><ref id="B414-cells-09-02061"><label>414.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shu</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>S.S.</given-names></name><etal/></person-group><article-title>MicroRNA-29c-5p suppresses gallbladder carcinoma progression by directly targeting CPEB4 and inhibiting the MAPK pathway</article-title><source>Cell Death Differ.</source><year>2017</year><volume>24</volume><fpage>445</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1038/cdd.2016.146</pub-id><pub-id pub-id-type="pmid">28060377</pub-id><pub-id pub-id-type="pmcid">PMC5344207</pub-id></element-citation></ref><ref id="B415-cells-09-02061"><label>415.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name></person-group><article-title>miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-&#946;RI signaling pathway</article-title><source>Cell Death Dis.</source><year>2018</year><volume>9</volume><fpage>395</fpage><pub-id pub-id-type="doi">10.1038/s41419-018-0431-2</pub-id><pub-id pub-id-type="pmid">29531222</pub-id><pub-id pub-id-type="pmcid">PMC5847584</pub-id></element-citation></ref><ref id="B416-cells-09-02061"><label>416.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlingensiepen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goldbrunner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Szyrach</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Stauder</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jachimczak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bogdahn</surname><given-names>U.</given-names></name><name name-style="western"><surname>Schulmeyer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hau</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schlingensiepen</surname><given-names>K.H.</given-names></name></person-group><article-title>Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: Toxicology and safety</article-title><source>Oligonucleotides</source><year>2005</year><volume>15</volume><fpage>94</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1089/oli.2005.15.94</pub-id><pub-id pub-id-type="pmid">15989424</pub-id></element-citation></ref><ref id="B417-cells-09-02061"><label>417.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlingensiepen</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Schlingensiepen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Steinbrecher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hau</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bogdahn</surname><given-names>U.</given-names></name><name name-style="western"><surname>Fischer-Blass</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jachimczak</surname><given-names>P.</given-names></name></person-group><article-title>Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009</article-title><source>Cytokine Growth Factor Rev.</source><year>2006</year><volume>17</volume><fpage>129</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2005.09.002</pub-id><pub-id pub-id-type="pmid">16377233</pub-id></element-citation></ref><ref id="B418-cells-09-02061"><label>418.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlingensiepen</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Jaschinski</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Moser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Geissler</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Schlitt</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kielmanowicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>A.</given-names></name></person-group><article-title>Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer</article-title><source>Cancer Sci.</source><year>2011</year><volume>102</volume><fpage>1193</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2011.01917.x</pub-id><pub-id pub-id-type="pmid">21366804</pub-id></element-citation></ref><ref id="B419-cells-09-02061"><label>419.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hau</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jachimczak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schlingensiepen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schulmeyer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jauch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Steinbrecher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brawanski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Proescholdt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schlaier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Buchroithner</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: From preclinical to phase I/II studies</article-title><source>Oligonucleotides</source><year>2007</year><volume>17</volume><fpage>201</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1089/oli.2006.0053</pub-id><pub-id pub-id-type="pmid">17638524</pub-id></element-citation></ref><ref id="B420-cells-09-02061"><label>420.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagaraj</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>P.K.</given-names></name></person-group><article-title>Targeting the transforming growth factor-beta signaling pathway in human cancer</article-title><source>Expert Opin. Investig. Drugs</source><year>2010</year><volume>19</volume><fpage>77</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1517/13543780903382609</pub-id><pub-id pub-id-type="pmcid">PMC2796203</pub-id><pub-id pub-id-type="pmid">20001556</pub-id></element-citation></ref><ref id="B421-cells-09-02061"><label>421.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bogdahn</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hau</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stockhammer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Venkataramana</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Mahapatra</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Suri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Balasubramaniam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oliushine</surname><given-names>V.</given-names></name><name name-style="western"><surname>Parfenov</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Targeted therapy for high-grade glioma with the TGF-&#946;2 inhibitor trabedersen: Results of a randomized and controlled phase IIb study</article-title><source>Neuro Oncol.</source><year>2011</year><volume>13</volume><fpage>132</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noq142</pub-id><pub-id pub-id-type="pmid">20980335</pub-id><pub-id pub-id-type="pmcid">PMC3018908</pub-id></element-citation></ref><ref id="B422-cells-09-02061"><label>422.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Varikuti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Satoskar</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy</article-title><source>JCI Insight</source><year>2018</year><volume>3</volume><pub-id pub-id-type="doi">10.1172/jci.insight.98745</pub-id><pub-id pub-id-type="pmid">29618655</pub-id><pub-id pub-id-type="pmcid">PMC5928864</pub-id></element-citation></ref><ref id="B423-cells-09-02061"><label>423.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashimoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>R.</given-names></name><name name-style="western"><surname>Narumi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Heike</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>K.</given-names></name></person-group><article-title>Type I IFN gene delivery suppresses regulatory T cells within tumors</article-title><source>Cancer Gene Ther.</source><year>2014</year><volume>21</volume><fpage>532</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1038/cgt.2014.60</pub-id><pub-id pub-id-type="pmid">25430879</pub-id></element-citation></ref><ref id="B424-cells-09-02061"><label>424.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirata</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shibasaki</surname><given-names>C.</given-names></name><name name-style="western"><surname>Narumi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>K.</given-names></name></person-group><article-title>Intratumoral IFN-&#945; gene delivery reduces tumor-infiltrating regulatory T cells through the downregulation of tumor CCL17 expression</article-title><source>Cancer Gene Ther.</source><year>2019</year><volume>26</volume><fpage>334</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/s41417-018-0059-5</pub-id><pub-id pub-id-type="pmid">30420718</pub-id></element-citation></ref><ref id="B425-cells-09-02061"><label>425.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name><name name-style="western"><surname>Lederer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>G.C.</given-names></name></person-group><article-title>Targeting Regulatory T Cells in Cancer</article-title><source>Cancer Res.</source><year>2011</year><volume>71</volume><fpage>6915</fpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1156</pub-id><pub-id pub-id-type="pmid">22068034</pub-id><pub-id pub-id-type="pmcid">PMC4287207</pub-id></element-citation></ref><ref id="B426-cells-09-02061"><label>426.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobs</surname><given-names>J.F.M.</given-names></name><name name-style="western"><surname>Nierkens</surname><given-names>S.</given-names></name><name name-style="western"><surname>Figdor</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>I.J.M.</given-names></name><name name-style="western"><surname>Adema</surname><given-names>G.J.</given-names></name></person-group><article-title>Regulatory T cells in melanoma: The final hurdle towards effective immunotherapy?</article-title><source>Lancet Oncol.</source><year>2012</year><volume>13</volume><fpage>e32</fpage><lpage>e42</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(11)70155-3</pub-id><pub-id pub-id-type="pmid">22225723</pub-id></element-citation></ref><ref id="B427-cells-09-02061"><label>427.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfeffer</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Dinarello</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Herberman</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>B.R.G.</given-names></name><name name-style="western"><surname>Borden</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Bordens</surname><given-names>R.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Nagabhushan</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Trotta</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Pestka</surname><given-names>S.</given-names></name></person-group><article-title>Biological Properties of Recombinant &#945;-Interferons: 40th Anniversary of the Discovery of Interferons</article-title><source>Cancer Res.</source><year>1998</year><volume>58</volume><fpage>2489</fpage><pub-id pub-id-type="pmid">9635566</pub-id></element-citation></ref><ref id="B428-cells-09-02061"><label>428.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iqbal Ahmed</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Demers</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Engler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Howe</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Wills</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Shinoda</surname><given-names>J.</given-names></name><name name-style="western"><surname>Beltran</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nodelman</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers</article-title><source>Cancer Gene Ther.</source><year>2001</year><volume>8</volume><fpage>788</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1038/sj.cgt.7700364</pub-id><pub-id pub-id-type="pmid">11687902</pub-id></element-citation></ref><ref id="B429-cells-09-02061"><label>429.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardoll</surname><given-names>D.M.</given-names></name></person-group><article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title><source>Nat. Rev. Cancer</source><year>2012</year><volume>12</volume><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nrc3239</pub-id><pub-id pub-id-type="pmid">22437870</pub-id><pub-id pub-id-type="pmcid">PMC4856023</pub-id></element-citation></ref><ref id="B430-cells-09-02061"><label>430.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadreddini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baradaran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Aghebati-Maleki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sadreddini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shanehbandi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fotouhi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aghebati-Maleki</surname><given-names>L.</given-names></name></person-group><article-title>Immune checkpoint blockade opens a new way to cancer immunotherapy</article-title><source>J. Cell. Physiol.</source><year>2019</year><volume>234</volume><fpage>8541</fpage><lpage>8549</lpage><pub-id pub-id-type="doi">10.1002/jcp.27816</pub-id><pub-id pub-id-type="pmid">30511409</pub-id></element-citation></ref><ref id="B431-cells-09-02061"><label>431.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunet</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Denizot</surname><given-names>F.</given-names></name><name name-style="western"><surname>Luciani</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Roux-Dosseto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suzan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mattei</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Golstein</surname><given-names>P.</given-names></name></person-group><article-title>A new member of the immunoglobulin superfamily--CTLA-4</article-title><source>Nature</source><year>1987</year><volume>328</volume><fpage>267</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1038/328267a0</pub-id><pub-id pub-id-type="pmid">3496540</pub-id></element-citation></ref><ref id="B432-cells-09-02061"><label>432.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Agata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shibahara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Honjo</surname><given-names>T.</given-names></name></person-group><article-title>Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death</article-title><source>EMBO J.</source><year>1992</year><volume>11</volume><fpage>3887</fpage><lpage>3895</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1992.tb05481.x</pub-id><pub-id pub-id-type="pmid">1396582</pub-id><pub-id pub-id-type="pmcid">PMC556898</pub-id></element-citation></ref><ref id="B433-cells-09-02061"><label>433.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taams</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>de Gruijl</surname><given-names>T.D.</given-names></name></person-group><article-title>Immune checkpoint inhibition: From molecules to clinical application</article-title><source>Clin. Exp. Immunol.</source><year>2020</year><volume>200</volume><fpage>105</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1111/cei.13434</pub-id><pub-id pub-id-type="pmid">32297327</pub-id><pub-id pub-id-type="pmcid">PMC7160649</pub-id></element-citation></ref><ref id="B434-cells-09-02061"><label>434.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>P.-L.</given-names></name><name name-style="western"><surname>Roh</surname><given-names>W.</given-names></name><name name-style="western"><surname>Reuben</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Prieto</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Bassett</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Gopalakrishnan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wani</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade</article-title><source>Cancer Discov.</source><year>2016</year><volume>6</volume><fpage>827</fpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-1545</pub-id><pub-id pub-id-type="pmid">27301722</pub-id><pub-id pub-id-type="pmcid">PMC5082984</pub-id></element-citation></ref><ref id="B435-cells-09-02061"><label>435.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Barbie</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Flaherty</surname><given-names>K.T.</given-names></name></person-group><article-title>Mechanisms of resistance to immune checkpoint inhibitors</article-title><source>Br. J. Cancer</source><year>2018</year><volume>118</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/bjc.2017.434</pub-id><pub-id pub-id-type="pmid">29319049</pub-id><pub-id pub-id-type="pmcid">PMC5765236</pub-id></element-citation></ref><ref id="B436-cells-09-02061"><label>436.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrueto</surname><given-names>L.</given-names></name><name name-style="western"><surname>Caminero</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cash</surname><given-names>L.</given-names></name><name name-style="western"><surname>Makris</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lamichhane</surname><given-names>P.</given-names></name><name name-style="western"><surname>Deshmukh</surname><given-names>R.R.</given-names></name></person-group><article-title>Resistance to Checkpoint Inhibition in Cancer Immunotherapy</article-title><source>Transl. Oncol.</source><year>2020</year><volume>13</volume><fpage>100738</fpage><pub-id pub-id-type="doi">10.1016/j.tranon.2019.12.010</pub-id><pub-id pub-id-type="pmid">32114384</pub-id><pub-id pub-id-type="pmcid">PMC7047187</pub-id></element-citation></ref><ref id="B437-cells-09-02061"><label>437.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalbasi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name></person-group><article-title>Tumour-intrinsic resistance to immune checkpoint blockade</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>25</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0218-4</pub-id><pub-id pub-id-type="pmid">31570880</pub-id><pub-id pub-id-type="pmcid">PMC8499690</pub-id></element-citation></ref><ref id="B438-cells-09-02061"><label>438.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Elsas</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>van Hall</surname><given-names>T.</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>S.H.</given-names></name></person-group><article-title>Future Challenges in Cancer Resistance to Immunotherapy</article-title><source>Cancers</source><year>2020</year><volume>12</volume><elocation-id>935</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12040935</pub-id><pub-id pub-id-type="pmcid">PMC7226490</pub-id><pub-id pub-id-type="pmid">32290124</pub-id></element-citation></ref><ref id="B439-cells-09-02061"><label>439.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>R.-R.</given-names></name><name name-style="western"><surname>Chasalow</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hamid</surname><given-names>O.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cogswell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alaparthy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jure-Kunkel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Siemers</surname><given-names>N.O.</given-names></name><etal/></person-group><article-title>An immune-active tumor microenvironment favors clinical response to ipilimumab</article-title><source>Cancer Immunol. Immunother.</source><year>2012</year><volume>61</volume><fpage>1019</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1007/s00262-011-1172-6</pub-id><pub-id pub-id-type="pmid">22146893</pub-id><pub-id pub-id-type="pmcid">PMC11028506</pub-id></element-citation></ref><ref id="B440-cells-09-02061"><label>440.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tumeh</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Harview</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Yearley</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Shintaku</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>E.J.M.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chmielowski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Spasic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ciobanu</surname><given-names>V.</given-names></name><etal/></person-group><article-title>PD-1 blockade induces responses by inhibiting adaptive immune resistance</article-title><source>Nature</source><year>2014</year><volume>515</volume><fpage>568</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/nature13954</pub-id><pub-id pub-id-type="pmid">25428505</pub-id><pub-id pub-id-type="pmcid">PMC4246418</pub-id></element-citation></ref><ref id="B441-cells-09-02061"><label>441.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granier</surname><given-names>C.</given-names></name><name name-style="western"><surname>De Guillebon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Blanc</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roussel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Badoual</surname><given-names>C.</given-names></name><name name-style="western"><surname>Colin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Saldmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oudard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tartour</surname><given-names>E.</given-names></name></person-group><article-title>Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer</article-title><source>ESMO Open</source><year>2017</year><volume>2</volume><fpage>e000213</fpage><pub-id pub-id-type="doi">10.1136/esmoopen-2017-000213</pub-id><pub-id pub-id-type="pmid">28761757</pub-id><pub-id pub-id-type="pmcid">PMC5518304</pub-id></element-citation></ref><ref id="B442-cells-09-02061"><label>442.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamichhane</surname><given-names>P.</given-names></name><name name-style="western"><surname>Amin</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lamichhane</surname><given-names>N.</given-names></name></person-group><article-title>Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?</article-title><source>Medicines</source><year>2018</year><volume>5</volume><elocation-id>114</elocation-id><pub-id pub-id-type="doi">10.3390/medicines5040114</pub-id><pub-id pub-id-type="pmid">30360504</pub-id><pub-id pub-id-type="pmcid">PMC6313567</pub-id></element-citation></ref><ref id="B443-cells-09-02061"><label>443.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>J.-E.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Menzer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beckermann</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis</article-title><source>JAMA Oncol.</source><year>2018</year><volume>4</volume><fpage>1721</fpage><lpage>1728</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2018.3923</pub-id><pub-id pub-id-type="pmid">30242316</pub-id><pub-id pub-id-type="pmcid">PMC6440712</pub-id></element-citation></ref><ref id="B444-cells-09-02061"><label>444.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urwyler</surname><given-names>P.</given-names></name><name name-style="western"><surname>Earnshaw</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bermudez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perucha</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>S.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>L.</given-names></name><name name-style="western"><surname>Karagiannis</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Taams</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Mechanisms of checkpoint inhibition-induced adverse events</article-title><source>Clin. Exp. Immunol.</source><year>2020</year><volume>200</volume><fpage>141</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1111/cei.13421</pub-id><pub-id pub-id-type="pmid">31989585</pub-id><pub-id pub-id-type="pmcid">PMC7160658</pub-id></element-citation></ref><ref id="B445-cells-09-02061"><label>445.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pruitt</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Boczkowski</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Rosa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Haley</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Morse</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Tyler</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Dannull</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.</given-names></name></person-group><article-title>Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells</article-title><source>Eur. J. Immunol.</source><year>2011</year><volume>41</volume><fpage>3553</fpage><lpage>3563</lpage><pub-id pub-id-type="doi">10.1002/eji.201141383</pub-id><pub-id pub-id-type="pmid">22028176</pub-id><pub-id pub-id-type="pmcid">PMC3594439</pub-id></element-citation></ref><ref id="B446-cells-09-02061"><label>446.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodwin</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dorosheva</surname><given-names>O.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival</article-title><source>Biomaterials</source><year>2017</year><volume>141</volume><fpage>260</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.07.007</pub-id><pub-id pub-id-type="pmid">28700955</pub-id><pub-id pub-id-type="pmcid">PMC5557391</pub-id></element-citation></ref><ref id="B447-cells-09-02061"><label>447.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dorosheva</surname><given-names>O.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>2237</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-04605-x</pub-id><pub-id pub-id-type="pmid">29884866</pub-id><pub-id pub-id-type="pmcid">PMC5993831</pub-id></element-citation></ref><ref id="B448-cells-09-02061"><label>448.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teo</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Whilding</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Parente-Pereira</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Maher</surname><given-names>J.</given-names></name><name name-style="western"><surname>George</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Hedrick</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Ghaem-Maghami</surname><given-names>S.</given-names></name></person-group><article-title>Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: Strategies to enhance T cell killing</article-title><source>Adv. Healthc. Mater.</source><year>2015</year><volume>4</volume><fpage>1180</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1002/adhm.201500089</pub-id><pub-id pub-id-type="pmid">25866054</pub-id></element-citation></ref><ref id="B449-cells-09-02061"><label>449.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy</article-title><source>Nano Lett.</source><year>2016</year><volume>16</volume><fpage>5503</fpage><lpage>5513</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.6b01994</pub-id><pub-id pub-id-type="pmid">27525587</pub-id></element-citation></ref><ref id="B450-cells-09-02061"><label>450.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwak</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>I.C.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>Y.</given-names></name></person-group><article-title>Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth</article-title><source>ACS Nano</source><year>2017</year><volume>11</volume><fpage>10135</fpage><lpage>10146</lpage><pub-id pub-id-type="doi">10.1021/acsnano.7b04717</pub-id><pub-id pub-id-type="pmid">28985469</pub-id><pub-id pub-id-type="pmcid">PMC5697980</pub-id></element-citation></ref><ref id="B451-cells-09-02061"><label>451.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name></person-group><article-title>Dual-Blockade Immune Checkpoint for Breast Cancer Treatment Based on a Tumor-Penetrating Peptide Assembling Nanoparticle</article-title><source>ACS Appl. Mater. Interfaces</source><year>2019</year><volume>11</volume><fpage>39513</fpage><lpage>39524</lpage><pub-id pub-id-type="doi">10.1021/acsami.9b13354</pub-id><pub-id pub-id-type="pmid">31599562</pub-id></element-citation></ref><ref id="B452-cells-09-02061"><label>452.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>You</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.N.</given-names></name></person-group><article-title>Stimuli-responsive nanoparticles for the codelivery of chemotherapeutic agents doxorubicin and siPD-L1 to enhance the antitumor effect</article-title><source>J. Biomed. Mater. Res. B Appl. Biomater.</source><year>2020</year><volume>108</volume><fpage>1710</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1002/jbm.b.34516</pub-id><pub-id pub-id-type="pmid">31746127</pub-id></element-citation></ref><ref id="B453-cells-09-02061"><label>453.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rupp</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Schumann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roybal</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Gate</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Marson</surname><given-names>A.</given-names></name></person-group><article-title>CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>737</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-00462-8</pub-id><pub-id pub-id-type="pmid">28389661</pub-id><pub-id pub-id-type="pmcid">PMC5428439</pub-id></element-citation></ref><ref id="B454-cells-09-02061"><label>454.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Niedermann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Firat</surname><given-names>E.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name></person-group><article-title>Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells</article-title><source>Hum. Gene. Ther.</source><year>2019</year><volume>30</volume><fpage>446</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1089/hum.2017.234</pub-id><pub-id pub-id-type="pmid">29706119</pub-id></element-citation></ref><ref id="B455-cells-09-02061"><label>455.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wing</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Tay</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S.</given-names></name></person-group><article-title>Control of Regulatory T Cells by Co-signal Molecules</article-title><source>Adv. Exp. Med. Biol.</source><year>2019</year><volume>1189</volume><fpage>179</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1007/978-981-32-9717-3_7</pub-id><pub-id pub-id-type="pmid">31758535</pub-id></element-citation></ref><ref id="B456-cells-09-02061"><label>456.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukuhara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ino</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Todo</surname><given-names>T.</given-names></name></person-group><article-title>Oncolytic virus therapy: A new era of cancer treatment at dawn</article-title><source>Cancer Sci.</source><year>2016</year><volume>107</volume><fpage>1373</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1111/cas.13027</pub-id><pub-id pub-id-type="pmid">27486853</pub-id><pub-id pub-id-type="pmcid">PMC5084676</pub-id></element-citation></ref><ref id="B457-cells-09-02061"><label>457.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name></person-group><article-title>Development of oncolytic virotherapy: From genetic modification to combination therapy</article-title><source>Front. Med.</source><year>2020</year><volume>14</volume><fpage>160</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1007/s11684-020-0750-4</pub-id><pub-id pub-id-type="pmid">32146606</pub-id><pub-id pub-id-type="pmcid">PMC7101593</pub-id></element-citation></ref><ref id="B458-cells-09-02061"><label>458.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Kohlhapp</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Zloza</surname><given-names>A.</given-names></name></person-group><article-title>Oncolytic viruses: A new class of immunotherapy drugs</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>642</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1038/nrd4663</pub-id><pub-id pub-id-type="pmid">26323545</pub-id><pub-id pub-id-type="pmcid">PMC7097180</pub-id></element-citation></ref><ref id="B459-cells-09-02061"><label>459.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Rommelaere</surname><given-names>J.</given-names></name></person-group><article-title>Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade</article-title><source>Viruses</source><year>2016</year><volume>8</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.3390/v8010009</pub-id><pub-id pub-id-type="pmid">26751469</pub-id><pub-id pub-id-type="pmcid">PMC4728569</pub-id></element-citation></ref><ref id="B460-cells-09-02061"><label>460.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bommareddy</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Shettigar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>H.L.</given-names></name></person-group><article-title>Integrating oncolytic viruses in combination cancer immunotherapy</article-title><source>Nat. Rev. Immunol.</source><year>2018</year><volume>18</volume><fpage>498</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1038/s41577-018-0014-6</pub-id><pub-id pub-id-type="pmid">29743717</pub-id></element-citation></ref><ref id="B461-cells-09-02061"><label>461.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wakimoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rabkin</surname><given-names>S.D.</given-names></name></person-group><article-title>Oncolytic herpes simplex virus interactions with the host immune system</article-title><source>Curr. Opin. Virol.</source><year>2016</year><volume>21</volume><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2016.07.007</pub-id><pub-id pub-id-type="pmid">27497296</pub-id><pub-id pub-id-type="pmcid">PMC5138121</pub-id></element-citation></ref><ref id="B462-cells-09-02061"><label>462.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martuza</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Malick</surname><given-names>A.</given-names></name><name name-style="western"><surname>Markert</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ruffner</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Coen</surname><given-names>D.M.</given-names></name></person-group><article-title>Experimental therapy of human glioma by means of a genetically engineered virus mutant</article-title><source>Science</source><year>1991</year><volume>252</volume><fpage>854</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1126/science.1851332</pub-id><pub-id pub-id-type="pmid">1851332</pub-id></element-citation></ref><ref id="B463-cells-09-02061"><label>463.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganly</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kirn</surname><given-names>D.</given-names></name><name name-style="western"><surname>Eckhardt</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Soutar</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Otto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Park</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gulley</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer</article-title><source>Clin. Cancer Res.</source><year>2000</year><volume>6</volume><fpage>798</fpage><pub-id pub-id-type="pmid">10741699</pub-id></element-citation></ref><ref id="B464-cells-09-02061"><label>464.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aghi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martuza</surname><given-names>R.L.</given-names></name></person-group><article-title>Oncolytic viral therapies - the clinical experience</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>7802</fpage><lpage>7816</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209037</pub-id><pub-id pub-id-type="pmid">16299539</pub-id></element-citation></ref><ref id="B465-cells-09-02061"><label>465.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vacchelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Eggermont</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saut&#232;s-Fridman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Galon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name></person-group><article-title>Trial watch</article-title><source>OncoImmunology</source><year>2013</year><volume>2</volume><fpage>e24612</fpage><pub-id pub-id-type="doi">10.4161/onci.24612</pub-id><pub-id pub-id-type="pmid">23894720</pub-id><pub-id pub-id-type="pmcid">PMC3716755</pub-id></element-citation></ref><ref id="B466-cells-09-02061"><label>466.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miest</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Cattaneo</surname><given-names>R.</given-names></name></person-group><article-title>New viruses for cancer therapy: Meeting clinical needs</article-title><source>Nat. Rev. Microbiol.</source><year>2014</year><volume>12</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3140</pub-id><pub-id pub-id-type="pmid">24292552</pub-id><pub-id pub-id-type="pmcid">PMC4002503</pub-id></element-citation></ref><ref id="B467-cells-09-02061"><label>467.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>K.-W.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.C.</given-names></name></person-group><article-title>Oncolytic virotherapy</article-title><source>Nat. Biotechnol.</source><year>2012</year><volume>30</volume><fpage>658</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1038/nbt.2287</pub-id><pub-id pub-id-type="pmid">22781695</pub-id><pub-id pub-id-type="pmcid">PMC3888062</pub-id></element-citation></ref><ref id="B468-cells-09-02061"><label>468.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rabkin</surname><given-names>S.D.</given-names></name></person-group><article-title>Designing Herpes Viruses as Oncolytics</article-title><source>Mol. Ther. Oncolytics</source><year>2015</year><volume>2</volume><fpage>15010</fpage><pub-id pub-id-type="doi">10.1038/mto.2015.10</pub-id><pub-id pub-id-type="pmid">26462293</pub-id><pub-id pub-id-type="pmcid">PMC4599707</pub-id></element-citation></ref><ref id="B469-cells-09-02061"><label>469.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Achard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Surendran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wedge</surname><given-names>M.-E.</given-names></name><name name-style="western"><surname>Ungerechts</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ilkow</surname><given-names>C.S.</given-names></name></person-group><article-title>Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy</article-title><source>EBioMedicine</source><year>2018</year><volume>31</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.04.020</pub-id><pub-id pub-id-type="pmid">29724655</pub-id><pub-id pub-id-type="pmcid">PMC6013846</pub-id></element-citation></ref><ref id="B470-cells-09-02061"><label>470.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemay</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Edge</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Abei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.C.</given-names></name></person-group><article-title>Oncolytic Viruses: The Best is Yet to Come</article-title><source>Curr. Cancer Drug Targets</source><year>2018</year><volume>18</volume><fpage>109</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.2174/1568009617666170206111609</pub-id><pub-id pub-id-type="pmid">28176648</pub-id></element-citation></ref><ref id="B471-cells-09-02061"><label>471.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alberts</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tilgase</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rasa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bandere</surname><given-names>K.</given-names></name><name name-style="western"><surname>Venskus</surname><given-names>D.</given-names></name></person-group><article-title>The advent of oncolytic virotherapy in oncology: The Rigvir<sup>&#174;</sup> story</article-title><source>Eur. J. Pharmacol.</source><year>2018</year><volume>837</volume><fpage>117</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2018.08.042</pub-id><pub-id pub-id-type="pmid">30179611</pub-id></element-citation></ref><ref id="B472-cells-09-02061"><label>472.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sachdev</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mita</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Mita</surname><given-names>M.M.</given-names></name></person-group><article-title>Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity</article-title><source>World J. Methodol.</source><year>2016</year><volume>6</volume><fpage>25</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.5662/wjm.v6.i1.25</pub-id><pub-id pub-id-type="pmid">27019795</pub-id><pub-id pub-id-type="pmcid">PMC4804250</pub-id></element-citation></ref><ref id="B473-cells-09-02061"><label>473.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahalingam</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fountzilas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moseley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Noronha</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chakrabarty</surname><given-names>R.</given-names></name><name name-style="western"><surname>Selvaggi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Coffey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sarantopoulos</surname><given-names>J.</given-names></name></person-group><article-title>A phase II study of REOLYSIN(<sup>&#174;</sup>) (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma</article-title><source>Cancer Chemother. Pharmacol.</source><year>2017</year><volume>79</volume><fpage>697</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1007/s00280-017-3260-6</pub-id><pub-id pub-id-type="pmid">28289863</pub-id></element-citation></ref><ref id="B474-cells-09-02061"><label>474.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.Q.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Z.Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.Q.</given-names></name><etal/></person-group><article-title>Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus</article-title><source>Ai Zheng</source><year>2004</year><volume>23</volume><fpage>1666</fpage><lpage>1670</lpage><pub-id pub-id-type="pmid">15601557</pub-id></element-citation></ref><ref id="B475-cells-09-02061"><label>475.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>M.</given-names></name></person-group><article-title>Oncorine, the World First Oncolytic Virus Medicine and its Update in China</article-title><source>Curr. Cancer Drug Targets</source><year>2018</year><volume>18</volume><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.2174/1568009618666171129221503</pub-id><pub-id pub-id-type="pmid">29189159</pub-id></element-citation></ref><ref id="B476-cells-09-02061"><label>476.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Packiam Vignesh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Campanile Alexa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Barocas Daniel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chamie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>I.I.I.R.L.</given-names></name><name name-style="western"><surname>Kader</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Lamm Donald</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yeung Alex</surname><given-names>W.</given-names></name><name name-style="western"><surname>Steinberg Gary</surname><given-names>D.</given-names></name></person-group><article-title>MP13&#8211;19 a phase II/III trial of CG0070, an oncolytic adenovirus, for BCG-refractory non-muscle-invasive bladder cancer (NMIBC)</article-title><source>J. Urol.</source><year>2016</year><volume>195</volume><fpage>e142</fpage><pub-id pub-id-type="doi">10.1016/j.juro.2016.02.2500</pub-id></element-citation></ref><ref id="B477-cells-09-02061"><label>477.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andtbacka</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Collichio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Amatruda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Senzer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chesney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Delman</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Spitler</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Puzanov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Agarwala</surname><given-names>S.S.</given-names></name><etal/></person-group><article-title>Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma</article-title><source>J. Clin. Oncol.</source><year>2015</year><volume>33</volume><fpage>2780</fpage><lpage>2788</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.58.3377</pub-id><pub-id pub-id-type="pmid">26014293</pub-id></element-citation></ref><ref id="B478-cells-09-02061"><label>478.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrington</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Puzanov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Hodi</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Murugappan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>H.L.</given-names></name></person-group><article-title>Clinical development of talimogene laherparepvec (T-VEC): A modified herpes simplex virus type-1-derived oncolytic immunotherapy</article-title><source>Expert Rev. Anticancer Ther.</source><year>2015</year><volume>15</volume><fpage>1389</fpage><lpage>1403</lpage><pub-id pub-id-type="doi">10.1586/14737140.2015.1115725</pub-id><pub-id pub-id-type="pmid">26558498</pub-id></element-citation></ref><ref id="B479-cells-09-02061"><label>479.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Foreman</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Nabors</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Riley</surname><given-names>K.O.</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Markert</surname><given-names>J.M.</given-names></name></person-group><article-title>Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma</article-title><source>Hum. Gene Ther. Clin. Dev.</source><year>2016</year><volume>27</volume><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1089/humc.2016.031</pub-id><pub-id pub-id-type="pmid">27314913</pub-id><pub-id pub-id-type="pmcid">PMC4932657</pub-id></element-citation></ref><ref id="B480-cells-09-02061"><label>480.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Todo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Martuza</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Rabkin</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>P.A.</given-names></name></person-group><article-title>Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>6396</fpage><lpage>6401</lpage><pub-id pub-id-type="doi">10.1073/pnas.101136398</pub-id><pub-id pub-id-type="pmid">11353831</pub-id><pub-id pub-id-type="pmcid">PMC33479</pub-id></element-citation></ref><ref id="B481-cells-09-02061"><label>481.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ino</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Todo</surname><given-names>T.</given-names></name></person-group><article-title>CLINICAL DEVELOPMENT OF A THIRD-GENERATION ONCOLYTIC HSV-1 (G47&#916;) FOR MALIGNANT GLIOMA</article-title><source>Gene Ther. Regul.</source><year>2010</year><volume>05</volume><fpage>101</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1142/S1568558610000185</pub-id></element-citation></ref><ref id="B482-cells-09-02061"><label>482.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abou-Alfa</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Galle</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Borad</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Luca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pelusio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agathon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lusky</surname><given-names>M.</given-names></name><etal/></person-group><article-title>PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy</article-title><source>J. Clin. Oncol.</source><year>2016</year><volume>34</volume><fpage>TPS4146</fpage><pub-id pub-id-type="doi">10.1200/JCO.2016.34.15_suppl.TPS4146</pub-id></element-citation></ref><ref id="B483-cells-09-02061"><label>483.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martuza</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Rabkin</surname><given-names>S.D.</given-names></name></person-group><article-title>Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma</article-title><source>Immunotherapy</source><year>2018</year><volume>10</volume><fpage>779</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.2217/imt-2018-0009</pub-id><pub-id pub-id-type="pmid">30008259</pub-id><pub-id pub-id-type="pmcid">PMC6275562</pub-id></element-citation></ref><ref id="B484-cells-09-02061"><label>484.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niemann</surname><given-names>J.</given-names></name><name name-style="western"><surname>K&#252;hnel</surname><given-names>F.</given-names></name></person-group><article-title>Oncolytic viruses: Adenoviruses</article-title><source>Virus Genes</source><year>2017</year><volume>53</volume><fpage>700</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1007/s11262-017-1488-1</pub-id><pub-id pub-id-type="pmid">28702840</pub-id></element-citation></ref><ref id="B485-cells-09-02061"><label>485.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name></person-group><article-title>Progress in gene therapy using oncolytic vaccinia virus as vectors</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>2018</year><volume>144</volume><fpage>2433</fpage><lpage>2440</lpage><pub-id pub-id-type="doi">10.1007/s00432-018-2762-x</pub-id><pub-id pub-id-type="pmid">30293118</pub-id><pub-id pub-id-type="pmcid">PMC11813313</pub-id></element-citation></ref><ref id="B486-cells-09-02061"><label>486.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>T.-H.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Breitbach</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Daneshmand</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Silva</surname><given-names>N.</given-names></name><name name-style="western"><surname>Parato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Diallo</surname><given-names>J.-S.</given-names></name><etal/></person-group><article-title>A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma</article-title><source>Mol. Ther.</source><year>2011</year><volume>19</volume><fpage>1913</fpage><lpage>1922</lpage><pub-id pub-id-type="doi">10.1038/mt.2011.132</pub-id><pub-id pub-id-type="pmid">21772252</pub-id><pub-id pub-id-type="pmcid">PMC3188739</pub-id></element-citation></ref><ref id="B487-cells-09-02061"><label>487.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breitbach</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Kirn</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J.</given-names></name></person-group><article-title>The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)</article-title><source>Oncolytic Virother.</source><year>2015</year><volume>4</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.2147/OV.S59640</pub-id><pub-id pub-id-type="pmid">27512667</pub-id><pub-id pub-id-type="pmcid">PMC4918374</pub-id></element-citation></ref><ref id="B488-cells-09-02061"><label>488.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breitbach</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Parato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Kirn</surname><given-names>D.H.</given-names></name></person-group><article-title>Pexa-Vec double agent engineered vaccinia: Oncolytic and active immunotherapeutic</article-title><source>Curr. Opin. Virol.</source><year>2015</year><volume>13</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2015.03.016</pub-id><pub-id pub-id-type="pmid">25900822</pub-id></element-citation></ref><ref id="B489-cells-09-02061"><label>489.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourhill</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rancourt</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Shmulevitz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>R.N.</given-names></name></person-group><article-title>Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection</article-title><source>Viruses</source><year>2018</year><volume>10</volume><elocation-id>421</elocation-id><pub-id pub-id-type="doi">10.3390/v10080421</pub-id><pub-id pub-id-type="pmcid">PMC6116061</pub-id><pub-id pub-id-type="pmid">30103501</pub-id></element-citation></ref><ref id="B490-cells-09-02061"><label>490.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdullahi</surname><given-names>S.</given-names></name><name name-style="western"><surname>J&#228;kel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Behrend</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Steiger</surname><given-names>K.</given-names></name><name name-style="western"><surname>Topping</surname><given-names>G.</given-names></name><name name-style="western"><surname>Krabbe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sandig</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schiergens</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Thasler</surname><given-names>W.E.</given-names></name><etal/></person-group><article-title>A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><pub-id pub-id-type="doi">10.1128/JVI.01386-18</pub-id><pub-id pub-id-type="pmcid">PMC6232488</pub-id><pub-id pub-id-type="pmid">30232179</pub-id></element-citation></ref><ref id="B491-cells-09-02061"><label>491.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ammi</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>J.</given-names></name><name name-style="western"><surname>Willemen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Van Brussel</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schrijvers</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Lion</surname><given-names>E.</given-names></name><name name-style="western"><surname>Smits</surname><given-names>E.L.</given-names></name></person-group><article-title>Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs</article-title><source>Pharmacol. Ther.</source><year>2015</year><volume>146</volume><fpage>120</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2014.09.010</pub-id><pub-id pub-id-type="pmid">25281915</pub-id></element-citation></ref><ref id="B492-cells-09-02061"><label>492.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-Mart&#237;nez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pitter</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Fucikova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Spisek</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name></person-group><article-title>Trial Watch: Toll-like receptor agonists in cancer immunotherapy</article-title><source>Oncoimmunology</source><year>2018</year><volume>7</volume><fpage>e1526250</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2018.1526250</pub-id><pub-id pub-id-type="pmid">30524908</pub-id><pub-id pub-id-type="pmcid">PMC6279325</pub-id></element-citation></ref><ref id="B493-cells-09-02061"><label>493.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>T.F.</given-names></name></person-group><article-title>Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix</article-title><source>Adv. Ther.</source><year>2009</year><volume>26</volume><fpage>983</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1007/s12325-009-0079-5</pub-id><pub-id pub-id-type="pmid">20024678</pub-id></element-citation></ref><ref id="B494-cells-09-02061"><label>494.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#8216;Mac&#8217; Cheever</surname><given-names>M.A.</given-names></name></person-group><article-title>Twelve immunotherapy drugs that could cure cancers</article-title><source>Immunol. Rev.</source><year>2008</year><volume>222</volume><fpage>357</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00604.x</pub-id><pub-id pub-id-type="pmid">18364014</pub-id></element-citation></ref><ref id="B495-cells-09-02061"><label>495.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pretto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tagliabue</surname><given-names>E.</given-names></name><name name-style="western"><surname>Balsari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sfondrini</surname><given-names>L.</given-names></name></person-group><article-title>Exploiting poly(I:C) to induce cancer cell apoptosis</article-title><source>Cancer Biol. Ther.</source><year>2017</year><volume>18</volume><fpage>747</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1080/15384047.2017.1373220</pub-id><pub-id pub-id-type="pmid">28881163</pub-id><pub-id pub-id-type="pmcid">PMC5678690</pub-id></element-citation></ref><ref id="B496-cells-09-02061"><label>496.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salaun</surname><given-names>B.</given-names></name><name name-style="western"><surname>Coste</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rissoan</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Lebecque</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Renno</surname><given-names>T.</given-names></name></person-group><article-title>TLR3 can directly trigger apoptosis in human cancer cells</article-title><source>J. Immunol.</source><year>2006</year><volume>176</volume><fpage>4894</fpage><lpage>4901</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.8.4894</pub-id><pub-id pub-id-type="pmid">16585585</pub-id></element-citation></ref><ref id="B497-cells-09-02061"><label>497.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estornes</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Toscano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Virard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jacquemin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pierrot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vanbervliet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bonnin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lalaoui</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mercier-Gouy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pach&#233;co</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8</article-title><source>Cell Death Differ.</source><year>2012</year><volume>19</volume><fpage>1482</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1038/cdd.2012.22</pub-id><pub-id pub-id-type="pmid">22421964</pub-id><pub-id pub-id-type="pmcid">PMC3422471</pub-id></element-citation></ref><ref id="B498-cells-09-02061"><label>498.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Darlington</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.K.</given-names></name></person-group><article-title>Evaluation of Topical Polyinosinic Acid-Polycytidylic Acid in Treatment of Localized Herpes Zoster in Children with Cancer: A Randomized, Double-Blind Controlled Study</article-title><source>Antimicrob. Agents Chemother.</source><year>1975</year><volume>8</volume><fpage>289</fpage><pub-id pub-id-type="doi">10.1128/AAC.8.3.289</pub-id><pub-id pub-id-type="pmid">1101820</pub-id><pub-id pub-id-type="pmcid">PMC429308</pub-id></element-citation></ref><ref id="B499-cells-09-02061"><label>499.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>DeVita</surname><given-names>V.T.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Baron</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>A.S.</given-names></name></person-group><article-title>A Phase I&#8211;II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors</article-title><source>J. Natl. Cancer Inst.</source><year>1976</year><volume>57</volume><fpage>599</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1093/jnci/57.3.599</pub-id><pub-id pub-id-type="pmid">978771</pub-id></element-citation></ref><ref id="B500-cells-09-02061"><label>500.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herr</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Kemeny</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yagoda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>W.F.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Poly I:C immunotherapy in patients with papillomas or superficial carcinomas of the bladder</article-title><source>Natl. Cancer Inst. Monogr.</source><year>1978</year><fpage>325</fpage><pub-id pub-id-type="pmid">372823</pub-id></element-citation></ref><ref id="B501-cells-09-02061"><label>501.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nordlund</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>H.B.</given-names></name></person-group><article-title>Inhibition of biologic activity of poly I: Poly C by human plasma</article-title><source>Proc. Soc. Exp. Biol. Med.</source><year>1970</year><volume>133</volume><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.3181/00379727-133-34492</pub-id><pub-id pub-id-type="pmid">5461121</pub-id></element-citation></ref><ref id="B502-cells-09-02061"><label>502.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Baer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baron</surname><given-names>S.</given-names></name><name name-style="western"><surname>Buckler</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Iadarola</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>London</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>J.</given-names></name></person-group><article-title>A Modified Polyriboinosinic-Polyribocytidylic Acid Complex That Induces Interferon in Primates</article-title><source>J. Infect. Dis.</source><year>1975</year><volume>132</volume><fpage>434</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1093/infdis/132.4.434</pub-id><pub-id pub-id-type="pmid">810520</pub-id></element-citation></ref><ref id="B503-cells-09-02061"><label>503.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Sivulich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wiernik</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>H.B.</given-names></name></person-group><article-title>Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer</article-title><source>Cancer Res.</source><year>1979</year><volume>39</volume><fpage>1645</fpage><lpage>1650</lpage><pub-id pub-id-type="pmid">371793</pub-id></element-citation></ref><ref id="B504-cells-09-02061"><label>504.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patchett</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Tovar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corcoran</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Lyons</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>G.M.</given-names></name></person-group><article-title>The toll-like receptor ligands Hiltonol<sup>&#174;</sup> (polyICLC) and imiquimod effectively activate antigen-specific immune responses in Tasmanian devils (Sarcophilus harrisii)</article-title><source>Dev. Comp. Immunol.</source><year>2017</year><volume>76</volume><fpage>352</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/j.dci.2017.07.004</pub-id><pub-id pub-id-type="pmid">28689773</pub-id></element-citation></ref><ref id="B505-cells-09-02061"><label>505.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#237;guez-Ruiz</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Perez-Gracia</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alfaro</surname><given-names>C.</given-names></name><name name-style="western"><surname>O&#241;ate</surname><given-names>C.</given-names></name><name name-style="western"><surname>P&#233;rez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gil-Bazo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Benito</surname><given-names>A.</given-names></name><name name-style="western"><surname>Inog&#233;s</surname><given-names>S.</given-names></name><name name-style="western"><surname>L&#243;pez-Diaz de Cerio</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients</article-title><source>Ann. Oncol.</source><year>2018</year><volume>29</volume><fpage>1312</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy089</pub-id><pub-id pub-id-type="pmid">29554212</pub-id></element-citation></ref><ref id="B506-cells-09-02061"><label>506.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hafner</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Corth&#233;sy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Merkle</surname><given-names>H.P.</given-names></name></person-group><article-title>Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant</article-title><source>Adv. Drug Deliv. Rev.</source><year>2013</year><volume>65</volume><fpage>1386</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2013.05.013</pub-id><pub-id pub-id-type="pmid">23751781</pub-id></element-citation></ref><ref id="B507-cells-09-02061"><label>507.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ogris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Levitzki</surname><given-names>A.</given-names></name></person-group><article-title>EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice</article-title><source>PLoS Med.</source><year>2006</year><volume>3</volume><elocation-id>e6</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0030006</pub-id><pub-id pub-id-type="pmid">16318410</pub-id><pub-id pub-id-type="pmcid">PMC1298941</pub-id></element-citation></ref><ref id="B508-cells-09-02061"><label>508.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ogris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roedl</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Levitzki</surname><given-names>A.</given-names></name></person-group><article-title>EGFR-Homing dsRNA Activates Cancer-Targeted Immune Response and Eliminates Disseminated EGFR-Overexpressing Tumors in Mice</article-title><source>Clin. Cancer Res.</source><year>2011</year><volume>17</volume><fpage>1033</fpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1140</pub-id><pub-id pub-id-type="pmid">21196415</pub-id><pub-id pub-id-type="pmcid">PMC3079342</pub-id></element-citation></ref><ref id="B509-cells-09-02061"><label>509.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaffert</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kiss</surname><given-names>M.</given-names></name><name name-style="western"><surname>R&#246;dl</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Levitzki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ogris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier</article-title><source>Pharm. Res.</source><year>2011</year><volume>28</volume><fpage>731</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1007/s11095-010-0225-4</pub-id><pub-id pub-id-type="pmid">20694527</pub-id></element-citation></ref><ref id="B510-cells-09-02061"><label>510.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abourbeh</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mishani</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ogris</surname><given-names>M.</given-names></name><name name-style="western"><surname>R&#246;dl</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Levitzki</surname><given-names>A.</given-names></name></person-group><article-title>PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors</article-title><source>IUBMB Life</source><year>2012</year><volume>64</volume><fpage>324</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1002/iub.1002</pub-id><pub-id pub-id-type="pmid">22362419</pub-id><pub-id pub-id-type="pmcid">PMC3711802</pub-id></element-citation></ref><ref id="B511-cells-09-02061"><label>511.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#228;chelt</surname><given-names>U.</given-names></name><name name-style="western"><surname>Wittmann</surname><given-names>V.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>K.</given-names></name><name name-style="western"><surname>Edinger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kos</surname><given-names>P.</given-names></name><name name-style="western"><surname>H&#246;hn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>Synthetic polyglutamylation of dual-functional MTX ligands for enhanced combined cytotoxicity of poly(I:C) nanoplexes</article-title><source>Mol. Pharm.</source><year>2014</year><volume>11</volume><fpage>2631</fpage><lpage>2639</lpage><pub-id pub-id-type="doi">10.1021/mp500017u</pub-id><pub-id pub-id-type="pmid">24754871</pub-id></element-citation></ref><ref id="B512-cells-09-02061"><label>512.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krieg</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Matson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Waldschmidt</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Teasdale</surname><given-names>R.</given-names></name><name name-style="western"><surname>Koretzky</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D.M.</given-names></name></person-group><article-title>CpG motifs in bacterial DNA trigger direct B-cell activation</article-title><source>Nature</source><year>1995</year><volume>374</volume><fpage>546</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1038/374546a0</pub-id><pub-id pub-id-type="pmid">7700380</pub-id></element-citation></ref><ref id="B513-cells-09-02061"><label>513.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanagata</surname><given-names>N.</given-names></name></person-group><article-title>CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies</article-title><source>Int. J. Nanomedicine</source><year>2017</year><volume>12</volume><fpage>515</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.2147/IJN.S114477</pub-id><pub-id pub-id-type="pmid">28144136</pub-id><pub-id pub-id-type="pmcid">PMC5248940</pub-id></element-citation></ref><ref id="B514-cells-09-02061"><label>514.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamus</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kortylewski</surname><given-names>M.</given-names></name></person-group><article-title>The revival of CpG oligonucleotide-based cancer immunotherapies</article-title><source>Contemp. Oncol. (Pozn)</source><year>2018</year><volume>22</volume><fpage>56</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.5114/wo.2018.73887</pub-id><pub-id pub-id-type="pmid">29628795</pub-id><pub-id pub-id-type="pmcid">PMC5885070</pub-id></element-citation></ref><ref id="B515-cells-09-02061"><label>515.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krieg</surname><given-names>A.M.</given-names></name></person-group><article-title>Development of TLR9 agonists for cancer therapy</article-title><source>J. Clin. Invest.</source><year>2007</year><volume>117</volume><fpage>1184</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1172/JCI31414</pub-id><pub-id pub-id-type="pmid">17476348</pub-id><pub-id pub-id-type="pmcid">PMC1857270</pub-id></element-citation></ref><ref id="B516-cells-09-02061"><label>516.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Duttagupta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Won</surname><given-names>H.</given-names></name><name name-style="western"><surname>Buettner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nechaev</surname><given-names>S.</given-names></name><name name-style="western"><surname>Majka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia</article-title><source>Blood</source><year>2016</year><volume>127</volume><fpage>1687</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-08-665604</pub-id><pub-id pub-id-type="pmid">26796361</pub-id><pub-id pub-id-type="pmcid">PMC4817311</pub-id></element-citation></ref><ref id="B517-cells-09-02061"><label>517.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikitczuk</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Schloss</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Yarmush</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Lattime</surname><given-names>E.C.</given-names></name></person-group><article-title>PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-&#947; response and enhances survival</article-title><source>J. Cancer Ther.</source><year>2013</year><volume>4</volume><fpage>280</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.4236/jct.2013.41035</pub-id><pub-id pub-id-type="pmid">23741626</pub-id><pub-id pub-id-type="pmcid">PMC3670804</pub-id></element-citation></ref><ref id="B518-cells-09-02061"><label>518.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>Polyethylenimine-Mediated CpG Oligodeoxynucleotide Delivery Stimulates Bifurcated Cytokine Induction</article-title><source>ACS Biomater. Sci. Eng.</source><year>2018</year><volume>4</volume><fpage>1013</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.8b00049</pub-id><pub-id pub-id-type="pmid">33418784</pub-id></element-citation></ref><ref id="B519-cells-09-02061"><label>519.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwong</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>D.J.</given-names></name></person-group><article-title>Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>5134</fpage><lpage>5147</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.03.067</pub-id><pub-id pub-id-type="pmid">21514665</pub-id><pub-id pub-id-type="pmcid">PMC3140866</pub-id></element-citation></ref><ref id="B520-cells-09-02061"><label>520.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Park</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name></person-group><article-title>Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model</article-title><source>Oncol. Rep.</source><year>2013</year><volume>29</volume><fpage>735</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.3892/or.2012.2130</pub-id><pub-id pub-id-type="pmid">23138455</pub-id></element-citation></ref><ref id="B521-cells-09-02061"><label>521.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.E.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name></person-group><article-title>Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse model</article-title><source>BMB Rep.</source><year>2014</year><volume>47</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.5483/BMBRep.2014.47.4.157</pub-id><pub-id pub-id-type="pmid">24286311</pub-id><pub-id pub-id-type="pmcid">PMC4163885</pub-id></element-citation></ref><ref id="B522-cells-09-02061"><label>522.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alizadeh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Farrukh</surname><given-names>O.</given-names></name><name name-style="western"><surname>Manuel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Badie</surname><given-names>B.</given-names></name></person-group><article-title>Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity</article-title><source>Clin. Cancer Res.</source><year>2011</year><volume>17</volume><fpage>771</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2444</pub-id><pub-id pub-id-type="pmid">21088258</pub-id><pub-id pub-id-type="pmcid">PMC3041854</pub-id></element-citation></ref><ref id="B523-cells-09-02061"><label>523.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hashida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kawakami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mihara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Umeyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Imahori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hashida</surname><given-names>M.</given-names></name></person-group><article-title>Preparation of immunostimulatory single-walled carbon nanotube/CpG DNA complexes and evaluation of their potential in cancer immunotherapy</article-title><source>Int. J. Pharm.</source><year>2014</year><volume>471</volume><fpage>214</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.05.037</pub-id><pub-id pub-id-type="pmid">24861942</pub-id></element-citation></ref><ref id="B524-cells-09-02061"><label>524.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>An</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Im</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Jon</surname><given-names>S.</given-names></name></person-group><article-title>Imageable antigen-presenting gold nanoparticle vaccines for effective cancer immunotherapy in vivo</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2012</year><volume>51</volume><fpage>8800</fpage><lpage>8805</lpage><pub-id pub-id-type="doi">10.1002/anie.201203193</pub-id><pub-id pub-id-type="pmid">22847719</pub-id></element-citation></ref><ref id="B525-cells-09-02061"><label>525.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Bear</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Drezek</surname><given-names>R.A.</given-names></name></person-group><article-title>Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e63550</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0063550</pub-id><pub-id pub-id-type="pmid">23691064</pub-id><pub-id pub-id-type="pmcid">PMC3655178</pub-id></element-citation></ref><ref id="B526-cells-09-02061"><label>526.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cha</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name></person-group><article-title>Extra-Large Pore Mesoporous Silica Nanoparticles Enabling Co-Delivery of High Amounts of Protein Antigen and Toll-like Receptor 9 Agonist for Enhanced Cancer Vaccine Efficacy</article-title><source>ACS Cent. Sci.</source><year>2018</year><volume>4</volume><fpage>484</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.8b00035</pub-id><pub-id pub-id-type="pmid">29721531</pub-id><pub-id pub-id-type="pmcid">PMC5920615</pub-id></element-citation></ref><ref id="B527-cells-09-02061"><label>527.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#252;ller</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Heidegger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sandholzer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nickels</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Suhartha</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Endres</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bourquin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liedl</surname><given-names>T.</given-names></name></person-group><article-title>Cellular immunostimulation by CpG-sequence-coated DNA origami structures</article-title><source>ACS Nano</source><year>2011</year><volume>5</volume><fpage>9696</fpage><lpage>9702</lpage><pub-id pub-id-type="doi">10.1021/nn203161y</pub-id><pub-id pub-id-type="pmid">22092186</pub-id></element-citation></ref><ref id="B528-cells-09-02061"><label>528.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name></person-group><article-title>Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody</article-title><source>Adv. Mater.</source><year>2016</year><volume>28</volume><fpage>8912</fpage><lpage>8920</lpage><pub-id pub-id-type="doi">10.1002/adma.201506312</pub-id><pub-id pub-id-type="pmid">27558441</pub-id><pub-id pub-id-type="pmcid">PMC5283805</pub-id></element-citation></ref><ref id="B529-cells-09-02061"><label>529.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zalewski</surname><given-names>O.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name></person-group><article-title>Combinatorial Photothermal and Immuno Cancer Therapy Using Chitosan-Coated Hollow Copper Sulfide Nanoparticles</article-title><source>ACS Nano</source><year>2014</year><volume>8</volume><fpage>5670</fpage><lpage>5681</lpage><pub-id pub-id-type="doi">10.1021/nn5002112</pub-id><pub-id pub-id-type="pmid">24801008</pub-id><pub-id pub-id-type="pmcid">PMC4072412</pub-id></element-citation></ref><ref id="B530-cells-09-02061"><label>530.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>X.</given-names></name></person-group><article-title>Immunostimulatory oligonucleotides-loaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal/immune cancer therapy</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>9963</fpage><lpage>9971</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.08.036</pub-id><pub-id pub-id-type="pmid">25224368</pub-id></element-citation></ref><ref id="B531-cells-09-02061"><label>531.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>X.</given-names></name></person-group><article-title>Engineered, self-assembled near-infrared photothermal agents for combined tumor immunotherapy and chemo-photothermal therapy</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>6646</fpage><lpage>6656</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.04.073</pub-id><pub-id pub-id-type="pmid">24818880</pub-id></element-citation></ref><ref id="B532-cells-09-02061"><label>532.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speiser</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Baumgaertner</surname><given-names>P.</given-names></name><name name-style="western"><surname>Manolova</surname><given-names>V.</given-names></name><name name-style="western"><surname>Devevre</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sterry</surname><given-names>W.</given-names></name><name name-style="western"><surname>Walden</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zippelius</surname><given-names>A.</given-names></name><name name-style="western"><surname>Conzett</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Senti</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients</article-title><source>J. Immunother.</source><year>2010</year><volume>33</volume><fpage>848</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e3181f1d614</pub-id><pub-id pub-id-type="pmid">20842051</pub-id></element-citation></ref><ref id="B533-cells-09-02061"><label>533.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Takabayashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Corr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tuck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raz</surname><given-names>E.</given-names></name></person-group><article-title>Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism</article-title><source>Nat. Biotechnol.</source><year>2000</year><volume>18</volume><fpage>509</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1038/75365</pub-id><pub-id pub-id-type="pmid">10802617</pub-id></element-citation></ref><ref id="B534-cells-09-02061"><label>534.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gungor</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yagci</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Tincer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bayyurt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Alpdundar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yildiz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ozcan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gursel</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gursel</surname><given-names>M.</given-names></name></person-group><article-title>CpG ODN nanorings induce IFN&#945; from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity</article-title><source>Sci Transl. Med.</source><year>2014</year><volume>6</volume><fpage>235ra261</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3007909</pub-id><pub-id pub-id-type="pmid">24807558</pub-id></element-citation></ref><ref id="B535-cells-09-02061"><label>535.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmoll</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Wittig</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>D.</given-names></name><name name-style="western"><surname>Riera-Knorrenschild</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nitsche</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kroening</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Andel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ziebermayr</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scheithauer</surname><given-names>W.</given-names></name></person-group><article-title>Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: A randomised, double-blind, placebo-controlled trial</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>2014</year><volume>140</volume><fpage>1615</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.1007/s00432-014-1682-7</pub-id><pub-id pub-id-type="pmid">24816725</pub-id><pub-id pub-id-type="pmcid">PMC4131138</pub-id></element-citation></ref><ref id="B536-cells-09-02061"><label>536.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weihrauch</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Richly</surname><given-names>H.</given-names></name><name name-style="western"><surname>von Bergwelt-Baildon</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hacker</surname><given-names>U.T.</given-names></name><name name-style="western"><surname>Shimabukuro-Vornhagen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Holtick</surname><given-names>U.</given-names></name><name name-style="western"><surname>Nokay</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schroff</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours</article-title><source>Eur. J. Cancer</source><year>2015</year><volume>51</volume><fpage>146</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2014.11.002</pub-id><pub-id pub-id-type="pmid">25480557</pub-id></element-citation></ref><ref id="B537-cells-09-02061"><label>537.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wittig</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scheithauer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Schmoll</surname><given-names>H.J.</given-names></name></person-group><article-title>MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>2015</year><volume>94</volume><fpage>31</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2014.12.002</pub-id><pub-id pub-id-type="pmid">25577571</pub-id></element-citation></ref><ref id="B538-cells-09-02061"><label>538.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fire</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Kostas</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Driver</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Mello</surname><given-names>C.C.</given-names></name></person-group><article-title>Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans</article-title><source>Nature</source><year>1998</year><volume>391</volume><fpage>806</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1038/35888</pub-id><pub-id pub-id-type="pmid">9486653</pub-id></element-citation></ref><ref id="B539-cells-09-02061"><label>539.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>RNAi-Based Nano-Oncologicals: Delivery and Clinical Applications</article-title><source>Nano-Oncologicals: New Targeting and Delivery Approaches</source><person-group person-group-type="editor"><name name-style="western"><surname>Alonso</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Garcia-Fuentes</surname><given-names>M.</given-names></name></person-group><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2014</year><fpage>245</fpage><lpage>268</lpage></element-citation></ref><ref id="B540-cells-09-02061"><label>540.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>G.J.</given-names></name></person-group><article-title>Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics</article-title><source>Mol. Cancer Ther.</source><year>2010</year><volume>9</volume><fpage>3126</fpage><lpage>3136</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-10-0397</pub-id><pub-id pub-id-type="pmid">20940321</pub-id></element-citation></ref><ref id="B541-cells-09-02061"><label>541.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Ferland-McCollough</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Bushell</surname><given-names>M.</given-names></name></person-group><article-title>microRNAs in cancer management</article-title><source>Lancet Oncol.</source><year>2012</year><volume>13</volume><fpage>e249</fpage><lpage>e258</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(12)70073-6</pub-id><pub-id pub-id-type="pmid">22652233</pub-id></element-citation></ref><ref id="B542-cells-09-02061"><label>542.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hornicek</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Z.</given-names></name></person-group><article-title>MicroRNA Involvement in Osteosarcoma</article-title><source>Sarcoma</source><year>2012</year><volume>2012</volume><fpage>359739</fpage><pub-id pub-id-type="doi">10.1155/2012/359739</pub-id><pub-id pub-id-type="pmid">22550419</pub-id><pub-id pub-id-type="pmcid">PMC3329862</pub-id></element-citation></ref><ref id="B543-cells-09-02061"><label>543.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iyer</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Amiji</surname><given-names>M.M.</given-names></name></person-group><article-title>Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors</article-title><source>Mol. Pharm.</source><year>2014</year><volume>11</volume><fpage>2511</fpage><lpage>2526</lpage><pub-id pub-id-type="doi">10.1021/mp500024p</pub-id><pub-id pub-id-type="pmid">24661041</pub-id></element-citation></ref><ref id="B544-cells-09-02061"><label>544.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Croce</surname><given-names>C.M.</given-names></name></person-group><article-title>Causes and consequences of microRNA dysregulation in cancer</article-title><source>Nat. Rev. Genet.</source><year>2009</year><volume>10</volume><fpage>704</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1038/nrg2634</pub-id><pub-id pub-id-type="pmid">19763153</pub-id><pub-id pub-id-type="pmcid">PMC3467096</pub-id></element-citation></ref><ref id="B545-cells-09-02061"><label>545.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calin</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Dumitru</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bichi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zupo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Noch</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aldler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rattan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Keating</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2002</year><volume>99</volume><fpage>15524</fpage><pub-id pub-id-type="doi">10.1073/pnas.242606799</pub-id><pub-id pub-id-type="pmid">12434020</pub-id><pub-id pub-id-type="pmcid">PMC137750</pub-id></element-citation></ref><ref id="B546-cells-09-02061"><label>546.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awasthi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rathbone</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Hansbro</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Bebawy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dua</surname><given-names>K.</given-names></name></person-group><article-title>Therapeutic prospects of microRNAs in cancer treatment through nanotechnology</article-title><source>Drug Deliv. Transl. Res.</source><year>2018</year><volume>8</volume><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1007/s13346-017-0440-1</pub-id><pub-id pub-id-type="pmid">29185148</pub-id></element-citation></ref><ref id="B547-cells-09-02061"><label>547.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bader</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>D.</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>M.</given-names></name></person-group><article-title>The promise of microRNA replacement therapy</article-title><source>Cancer Res.</source><year>2010</year><volume>70</volume><fpage>7027</fpage><lpage>7030</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2010</pub-id><pub-id pub-id-type="pmid">20807816</pub-id><pub-id pub-id-type="pmcid">PMC2940943</pub-id></element-citation></ref><ref id="B548-cells-09-02061"><label>548.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garzon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marcucci</surname><given-names>G.</given-names></name><name name-style="western"><surname>Croce</surname><given-names>C.M.</given-names></name></person-group><article-title>Targeting microRNAs in cancer: Rationale, strategies and challenges</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>775</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1038/nrd3179</pub-id><pub-id pub-id-type="pmid">20885409</pub-id><pub-id pub-id-type="pmcid">PMC3904431</pub-id></element-citation></ref><ref id="B549-cells-09-02061"><label>549.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>Biomaterials in RNAi therapeutics: Quo vadis?</article-title><source>Biomater. Sci.</source><year>2013</year><volume>1</volume><fpage>804</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1039/c3bm60071h</pub-id><pub-id pub-id-type="pmid">32481926</pub-id></element-citation></ref><ref id="B550-cells-09-02061"><label>550.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kr&#252;tzfeldt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rajewsky</surname><given-names>N.</given-names></name><name name-style="western"><surname>Braich</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rajeev</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Tuschl</surname><given-names>T.</given-names></name><name name-style="western"><surname>Manoharan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stoffel</surname><given-names>M.</given-names></name></person-group><article-title>Silencing of microRNAs in vivo with &#8216;antagomirs&#8217;</article-title><source>Nature</source><year>2005</year><volume>438</volume><fpage>685</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1038/nature04303</pub-id><pub-id pub-id-type="pmid">16258535</pub-id></element-citation></ref><ref id="B551-cells-09-02061"><label>551.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>T.M.</given-names></name></person-group><article-title>Therapeutic targeting of microRNAs: Current status and future challenges</article-title><source>Nat. Rev. Drug Discov.</source><year>2014</year><volume>13</volume><fpage>622</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1038/nrd4359</pub-id><pub-id pub-id-type="pmid">25011539</pub-id></element-citation></ref><ref id="B552-cells-09-02061"><label>552.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Bahal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Babar</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Pincus</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Barrera</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Svoronos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Braddock</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Glazer</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Engelman</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>MicroRNA silencing for cancer therapy targeted to the tumour microenvironment</article-title><source>Nature</source><year>2015</year><volume>518</volume><fpage>107</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1038/nature13905</pub-id><pub-id pub-id-type="pmid">25409146</pub-id><pub-id pub-id-type="pmcid">PMC4367962</pub-id></element-citation></ref><ref id="B553-cells-09-02061"><label>553.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guilford</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Harraway</surname><given-names>J.</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>M.</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>N.</given-names></name><name name-style="western"><surname>Harawira</surname><given-names>P.</given-names></name><name name-style="western"><surname>Taite</surname><given-names>H.</given-names></name><name name-style="western"><surname>Scoular</surname><given-names>R.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reeve</surname><given-names>A.E.</given-names></name></person-group><article-title>E-cadherin germline mutations in familial gastric cancer</article-title><source>Nature</source><year>1998</year><volume>392</volume><fpage>402</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/32918</pub-id><pub-id pub-id-type="pmid">9537325</pub-id></element-citation></ref><ref id="B554-cells-09-02061"><label>554.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregory</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Bert</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Tsykin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Farshid</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vadas</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Khew-Goodall</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Goodall</surname><given-names>G.J.</given-names></name></person-group><article-title>The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1</article-title><source>Nat. Cell Bio.</source><year>2008</year><volume>10</volume><fpage>593</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1038/ncb1722</pub-id><pub-id pub-id-type="pmid">18376396</pub-id></element-citation></ref><ref id="B555-cells-09-02061"><label>555.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howe</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Cochrane</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Richer</surname><given-names>J.K.</given-names></name></person-group><article-title>Targets of miR-200c mediate suppression of cell motility and anoikis resistance</article-title><source>Breast Cancer Res.</source><year>2011</year><volume>13</volume><fpage>R45</fpage><pub-id pub-id-type="doi">10.1186/bcr2867</pub-id><pub-id pub-id-type="pmid">21501518</pub-id><pub-id pub-id-type="pmcid">PMC3219208</pub-id></element-citation></ref><ref id="B556-cells-09-02061"><label>556.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kopp</surname><given-names>F.</given-names></name><name name-style="western"><surname>Oak</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Roidl</surname><given-names>A.</given-names></name></person-group><article-title>miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e50469</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0050469</pub-id><pub-id pub-id-type="pmid">23209748</pub-id><pub-id pub-id-type="pmcid">PMC3510180</pub-id></element-citation></ref><ref id="B557-cells-09-02061"><label>557.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kopp</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Roidl</surname><given-names>A.</given-names></name></person-group><article-title>The proto-oncogene KRAS is targeted by miR-200c</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.1427</pub-id><pub-id pub-id-type="pmid">24368337</pub-id><pub-id pub-id-type="pmcid">PMC3960200</pub-id></element-citation></ref><ref id="B558-cells-09-02061"><label>558.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mutlu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Raza</surname><given-names>U.</given-names></name><name name-style="western"><surname>Saatci</surname><given-names>&#214;.</given-names></name><name name-style="western"><surname>Ey&#252;po&#287;lu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yurdusev</surname><given-names>E.</given-names></name><name name-style="western"><surname>&#350;ahin</surname><given-names>&#214;.</given-names></name></person-group><article-title>miR-200c: A versatile watchdog in cancer progression, EMT, and drug resistance</article-title><source>J. Mol. Med.</source><year>2016</year><volume>94</volume><fpage>629</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1007/s00109-016-1420-5</pub-id><pub-id pub-id-type="pmid">27094812</pub-id></element-citation></ref><ref id="B559-cells-09-02061"><label>559.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>K.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Heissig</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roidl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>EGF receptor targeted lipo-oligocation polyplexes for antitumoral siRNA and miRNA delivery</article-title><source>Nanotechnology</source><year>2016</year><volume>27</volume><fpage>464001</fpage><pub-id pub-id-type="doi">10.1088/0957-4484/27/46/464001</pub-id><pub-id pub-id-type="pmid">27736810</pub-id></element-citation></ref><ref id="B560-cells-09-02061"><label>560.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beg</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Sachdev</surname><given-names>J.</given-names></name><name name-style="western"><surname>Borad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Stoudemire</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bader</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>D.S.</given-names></name></person-group><article-title>Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors</article-title><source>Invest. New Drugs</source><year>2017</year><volume>35</volume><fpage>180</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1007/s10637-016-0407-y</pub-id><pub-id pub-id-type="pmid">27917453</pub-id><pub-id pub-id-type="pmcid">PMC5893501</pub-id></element-citation></ref><ref id="B561-cells-09-02061"><label>561.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Borad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sachdev</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ejadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.Y.</given-names></name><etal/></person-group><article-title>Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours</article-title><source>Br. J. Cancer</source><year>2020</year><volume>122</volume><fpage>1630</fpage><lpage>1637</lpage><pub-id pub-id-type="doi">10.1038/s41416-020-0802-1</pub-id><pub-id pub-id-type="pmid">32238921</pub-id><pub-id pub-id-type="pmcid">PMC7251107</pub-id></element-citation></ref><ref id="B562-cells-09-02061"><label>562.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>June</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Kawalekar</surname><given-names>O.U.</given-names></name><name name-style="western"><surname>Ghassemi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Milone</surname><given-names>M.C.</given-names></name></person-group><article-title>CAR T cell immunotherapy for human cancer</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>1361</fpage><pub-id pub-id-type="doi">10.1126/science.aar6711</pub-id><pub-id pub-id-type="pmid">29567707</pub-id></element-citation></ref><ref id="B563-cells-09-02061"><label>563.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kjeken</surname><given-names>R.</given-names></name><name name-style="western"><surname>Niederlaender</surname><given-names>C.</given-names></name><name name-style="western"><surname>Markey</surname><given-names>G.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Opsata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moltu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bremnes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gr&#248;nevik</surname><given-names>E.</given-names></name><name name-style="western"><surname>Muusse</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma</article-title><source>Oncologist</source><year>2020</year><volume>25</volume><fpage>e321</fpage><lpage>e327</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2019-0233</pub-id><pub-id pub-id-type="pmid">32043764</pub-id><pub-id pub-id-type="pmcid">PMC7011647</pub-id></element-citation></ref><ref id="B564-cells-09-02061"><label>564.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papadouli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mueller-Berghaus</surname><given-names>J.</given-names></name><name name-style="western"><surname>Beuneu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hofner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Petavy</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tzogani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miermont</surname><given-names>A.</given-names></name><name name-style="western"><surname>Norga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kholmanskikh</surname><given-names>O.</given-names></name><etal/></person-group><article-title>EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma</article-title><source>Oncologist</source><year>2020</year><pub-id pub-id-type="doi">10.1634/theoncologist.2019-0646</pub-id><pub-id pub-id-type="pmid">32339368</pub-id><pub-id pub-id-type="pmcid">PMC7543293</pub-id></element-citation></ref><ref id="B565-cells-09-02061"><label>565.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tejeda-Mansir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garc&#237;a-Rend&#243;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guerrero-Germ&#225;n</surname><given-names>P.</given-names></name></person-group><article-title>Plasmid-DNA lipid and polymeric nanovaccines: A new strategic in vaccines development</article-title><source>Biotechnol. Genet. Eng. Rev.</source><year>2019</year><volume>35</volume><fpage>46</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1080/02648725.2018.1560552</pub-id><pub-id pub-id-type="pmid">30587085</pub-id></element-citation></ref><ref id="B566-cells-09-02061"><label>566.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caruso</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Collier</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Heimberger</surname><given-names>A.B.</given-names></name></person-group><article-title>Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function</article-title><source>J. Neurooncol.</source><year>2019</year><volume>145</volume><fpage>429</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1007/s11060-019-03311-y</pub-id><pub-id pub-id-type="pmid">31686330</pub-id></element-citation></ref><ref id="B567-cells-09-02061"><label>567.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iurescia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fioretti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rinaldi</surname><given-names>M.</given-names></name></person-group><article-title>A blueprint for DNA vaccine design</article-title><source>Methods Mol. Biol. (Clifton, N.J.)</source><year>2014</year><volume>1143</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-0410-5_1</pub-id><pub-id pub-id-type="pmid">24715278</pub-id></element-citation></ref><ref id="B568-cells-09-02061"><label>568.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guckenberger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sentman</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>P.</given-names></name></person-group><article-title>NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma</article-title><source>Cancer Res.</source><year>2018</year><volume>78</volume><fpage>1031</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-1788</pub-id><pub-id pub-id-type="pmid">29222400</pub-id></element-citation></ref><ref id="B569-cells-09-02061"><label>569.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name></person-group><article-title>Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells</article-title><source>Front. Oncol.</source><year>2019</year><volume>9</volume><fpage>241</fpage><pub-id pub-id-type="doi">10.3389/fonc.2019.00241</pub-id><pub-id pub-id-type="pmid">31058074</pub-id><pub-id pub-id-type="pmcid">PMC6481273</pub-id></element-citation></ref><ref id="B570-cells-09-02061"><label>570.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Han</surname><given-names>B.</given-names></name><name name-style="western"><surname>Seth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Oncolytic adenovirus targeting TGF-&#946; enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer</article-title><source>Cell Immunol.</source><year>2020</year><volume>348</volume><fpage>104041</fpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2020.104041</pub-id><pub-id pub-id-type="pmid">31983398</pub-id></element-citation></ref><ref id="B571-cells-09-02061"><label>571.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grunwitz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kranz</surname><given-names>L.M.</given-names></name></person-group><article-title>mRNA Cancer Vaccines-Messages that Prevail</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2017</year><volume>405</volume><fpage>145</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1007/82_2017_509</pub-id><pub-id pub-id-type="pmid">28401358</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="cells-09-02061-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Nucleic acid-based strategies for tumor therapy. Vaccination of dendritic cells (DC) aims to induce tumor-specific effector T cells (Teff), which in turn kill tumor cells. Regulatory immune cells, regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC), are induced by the tumor and other cells of the tumor microenvironment (TEM) and inhibit both DC and Teff. The expansion and suppressive activity of Treg/MDSC can be inhibited by RNA interference (RNAi) and MDSC may be reprogramed to yield antigen presenting cells by applying nucleic acid-based stimuli. Further, T cells can be transfected/transduced with chimeric antigen receptors (CAR) to gain tumor specificity. Teff are inhibited by factors within the TME. Tumor-specific delivery of nucleic acids (gene-coding or conferring RNAi) is aimed to induce apoptosis in tumor cells, and to inhibit or reprogram accessory cells within the TME, tumor-associated macrophages (TAM), and cancer-associated fibroblasts (CAF).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-09-02061-g001.jpg"/></fig><fig id="cells-09-02061-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Mechanism of RNA interference (RNAi) and options for therapeutic intervention. (1) Substitution of tumor suppressor micro-RNA (miRNA, miR) in form of pre-miRNA or miRNA mimics, thereby inducing RNAi. (2) Blocking of oncogenic miRNA by miRNA-specific antagomirs (anti-miR). This figure is reprinted with permission from [<xref rid="B103-cells-09-02061" ref-type="bibr">103</xref>]. Copyright &#169; 2020; John Wiley and Sons.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-09-02061-g002.jpg"/></fig><fig id="cells-09-02061-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Immune checkpoint inhibition mediated by nucleic acid-based strategies. (<bold>a</bold>) Besides recognition of major histocompatibility complex (MHC)-bound antigen on the surface of APC via TCR, co-stimulatory signals&#8212;inter alia interaction of CD80 (B7-1) and CD28&#8212;are required for full T cell activation. The duration and intensity of activation is regulated among other things by immune checkpoint CTLA-4 that binds with high affinity to CD80. Blocking of this interaction results in enhanced T cell activity. One therapeutic option is delivery of mRNA encoding for anti-CTLA-4 antibodies. (<bold>b</bold>) Tumor cells often upregulate PD-L1 that binds to PD-1 on effector T cells, thereby inhibiting the activity of effector T cells. Nucleic acid-based approaches for blocking this immune checkpoint comprise siRNA against PD-L1, pDNA encoding for PD-L1 trap proteins (pPD-L1-trap), and CRISPR/Cas9-mediated knock-down of PD-1 gene.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-09-02061-g003.jpg"/></fig><fig id="cells-09-02061-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Genetic modifications to enhance selectivity, safety, and efficacy of oncolytic virotherapies.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-09-02061-g004.jpg"/></fig><table-wrap id="cells-09-02061-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">cells-09-02061-t001_Table 1</object-id><label>Table 1</label><caption><p>Examples of clinical trials investigating nucleic acid-based approaches for adjusting intratumoral cytokine levels.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Signaling Molecule</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapy Strategy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Application Route</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treated Cancer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical State</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IL-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Syngeneic tumor cell vaccine modified with IL-2 gene ex vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intradermal or subcutaneous injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B319-cells-09-02061" ref-type="bibr">319</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Allogeneic tumor cell vaccine modified with IL-2 gene ex vivo</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Subcutaneous injection</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Metastatic melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pilot study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B320-cells-09-02061" ref-type="bibr">320</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I&#8211;II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B321-cells-09-02061" ref-type="bibr">321</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Allogeneic tumor cell vaccine modified with IL-2 gene ex vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Relapsed neuroblastoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B322-cells-09-02061" ref-type="bibr">322</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TNF-&#945;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TNFerade, a replication-deficient adenoviral vector encoding for TNF-&#945; under the control of a radiation inducible promotor (erg-1 gene promotor)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratumoral injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Various cancer types, e.g., advanced pancreatic cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B323-cells-09-02061" ref-type="bibr">323</xref>,<xref rid="B324-cells-09-02061" ref-type="bibr">324</xref>] </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad&#8211;RTS&#8211;hIL-12, an adenoviral vector encoding for IL-12 transgene designed with a ligand-inducible expression switch</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Injection in the resection cavity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent high-grade glioma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B325-cells-09-02061" ref-type="bibr">325</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">GM-CSF</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">GVAX, an allogeneic tumor cell vaccine modified with GM-CSF gene ex vivo,(in combination with immune checkpoint inhibitors and/or cyclophosphamide and Listeria monocytogenes-expressing mesothelin (CRS-207))</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intradermal injection</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Advanced pancreatic cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase Ib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B326-cells-09-02061" ref-type="bibr">326</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B327-cells-09-02061" ref-type="bibr">327</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase IIb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B328-cells-09-02061" ref-type="bibr">328</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B329-cells-09-02061" ref-type="bibr">329</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN-&#945;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Instiladrin<sup>&#174;</sup> (rAdIFN&#945;2b/Syn3), an IFN-&#945; encoding adenoviral vector</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravesical injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCG unresponsive bladder cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III<italic toggle="yes">&#8212;</italic>results pending (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02773849">NCT02773849</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B330-cells-09-02061" ref-type="bibr">330</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">TGF-&#946; (inhibition)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Belagenpneumatucel-L, an allogeneic tumor cell vaccine altered to express ASO directed against TGF-&#946;</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intradermal injection</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Advanced non-small cell lung cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B331-cells-09-02061" ref-type="bibr">331</xref>,<xref rid="B332-cells-09-02061" ref-type="bibr">332</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B333-cells-09-02061" ref-type="bibr">333</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="cells-09-02061-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">cells-09-02061-t002_Table 2</object-id><label>Table 2</label><caption><p>Examples of oncolytic virotherapies approved or in clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Oncolytic Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genetic Modification</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treated Cancer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical State</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Wild-Type Virus</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RIGVIR<sup>&#174;</sup> (wild-type ECHO-7; (+)ssRNA virus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved in Lativa in 2004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B471-cells-09-02061" ref-type="bibr">471</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reolysin<sup>&#174;</sup> (pelareorep, type 3 Dearing (T3D) strain reovirus; dsRNA virus)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#8211;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Many advanced malignancies (e.g., melanoma, sarcomas, non-small cell lung cancer, pancreatic adenocarcinoma)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I and II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B457-cells-09-02061" ref-type="bibr">457</xref>,<xref rid="B472-cells-09-02061" ref-type="bibr">472</xref>,<xref rid="B473-cells-09-02061" ref-type="bibr">473</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced, metastatic head and neck cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B472-cells-09-02061" ref-type="bibr">472</xref>]</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Oncolytic Adenovirus (dsDNA virus)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncorine<sup>&#174;</sup> (rAdV H101)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deletion in E1B-55K and E3 genes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nasopharyngeal carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved in China in 2005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B474-cells-09-02061" ref-type="bibr">474</xref>,<xref rid="B475-cells-09-02061" ref-type="bibr">475</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CG0070 (AdV-5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deletion in E3 gene; insertion of GM-CSF gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-muscle-invasive bladder cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II/III (BOND, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01438112">NCT01438112</ext-link>); phase II (BOND2, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02365818">NCT02365818</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B456-cells-09-02061" ref-type="bibr">456</xref>,<xref rid="B476-cells-09-02061" ref-type="bibr">476</xref>]</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Oncolytic Herpes Simplex Virus, HSV-1 (dsDNA virus)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T-Vec (talminogene laherparepvec)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deletion in ICP34.5 and ICP47 genes; insertion of GM-CSF gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved by FDA and EMA in 2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B477-cells-09-02061" ref-type="bibr">477</xref>,<xref rid="B478-cells-09-02061" ref-type="bibr">478</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M032</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deletion in ICP34.5 gene; insertion of IL-12 gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glioblastoma multiforme</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B479-cells-09-02061" ref-type="bibr">479</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G47&#916;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deletion in ICP34.5, ICP47 and ICP6 genes; insertion of GM-CSF gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent glioblastoma, castration resistant prostate cancer, recurrent olfactory neuroblastoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trials in Japan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B456-cells-09-02061" ref-type="bibr">456</xref>,<xref rid="B480-cells-09-02061" ref-type="bibr">480</xref>,<xref rid="B481-cells-09-02061" ref-type="bibr">481</xref>]</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Oncolytic Vaccinia Virus (dsDNA virus)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pexa-Vec (JX-594, pexastimogene devacirepvec)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutation in TK gene; insertion of GM-CSF gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced hepatocellular carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III (in combination with sorafenib)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B482-cells-09-02061" ref-type="bibr">482</xref>]</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>